abstract_id,sentence,entity_1_mention,entity_2_mention,entity_1_id,entity_2_id
1711760,"Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded",hypertensive,isoflurane,D006973,D007530
1711760,"Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded",isoflurane,hypertensive,D007530,D006973
1711760,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining",neuronal injury,"2,3,5-triphenyltetrazolium",D009410,C009591
1711760,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining","2,3,5-triphenyltetrazolium",neuronal injury,C009591,D009410
1711760,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",phenylephrine,neuronal dysfunction,D010656,D009410
1711760,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",phenylephrine,hypertension,D010656,D006973
1711760,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",phenylephrine,ischemic,D010656,D007511
1711760,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",phenylephrine,MCAO,D010656,D020244
1711760,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",phenylephrine,edema,D010656,D004487
1711760,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",neuronal dysfunction,phenylephrine,D009410,D010656
1711760,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",hypertension,phenylephrine,D006973,D010656
1711760,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",ischemic,phenylephrine,D007511,D010656
1711760,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",MCAO,phenylephrine,D020244,D010656
1711760,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",edema,phenylephrine,D004487,D010656
6086495,Localisation of the Becker muscular dystrophy gene on the short arm of the X chromosome by linkage to cloned DNA sequences,Becker muscular dystrophy,Becker muscular dystrophy gene,D020388,1756
6086495,Localisation of the Becker muscular dystrophy gene on the short arm of the X chromosome by linkage to cloned DNA sequences,Becker muscular dystrophy gene,Becker muscular dystrophy,1756,D020388
6086495,"A linkage study in 30 Becker muscular dystrophy (BMD) kindreds using three cloned DNA sequences from the X chromosome which demonstrate restriction fragment length polymorphisms (RFLPs), suggests that the BMD gene is located on the short arm of the X chromosome, in the p21 region",BMD,Becker muscular dystrophy,1756,D020388
6086495,"A linkage study in 30 Becker muscular dystrophy (BMD) kindreds using three cloned DNA sequences from the X chromosome which demonstrate restriction fragment length polymorphisms (RFLPs), suggests that the BMD gene is located on the short arm of the X chromosome, in the p21 region",Becker muscular dystrophy,BMD,D020388,1756
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,prolactin,hyperprolactinemia,5617,D006966
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,prolactin,luteinizing hormone-releasing hormone,5617,2796
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,prolactin,luteinizing hormone,5617,1081
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,prolactin,haloperidol,5617,D006220
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,hyperprolactinemia,prolactin,D006966,5617
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,hyperprolactinemia,luteinizing hormone-releasing hormone,D006966,2796
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,hyperprolactinemia,luteinizing hormone,D006966,1081
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,hyperprolactinemia,haloperidol,D006966,D006220
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,luteinizing hormone-releasing hormone,prolactin,2796,5617
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,luteinizing hormone-releasing hormone,hyperprolactinemia,2796,D006966
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,luteinizing hormone-releasing hormone,luteinizing hormone,2796,1081
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,luteinizing hormone-releasing hormone,haloperidol,2796,D006220
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,luteinizing hormone,prolactin,1081,5617
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,luteinizing hormone,hyperprolactinemia,1081,D006966
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,luteinizing hormone,luteinizing hormone-releasing hormone,1081,2796
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,luteinizing hormone,haloperidol,1081,D006220
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,haloperidol,prolactin,D006220,5617
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,haloperidol,hyperprolactinemia,D006220,D006966
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,haloperidol,luteinizing hormone-releasing hormone,D006220,2796
7018927,Pituitary response to luteinizing hormone-releasing hormone during haloperidol-induced hyperprolactinemia,haloperidol,luteinizing hormone,D006220,1081
7018927,The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects,luteinizing hormone,prolactin,1081,5617
7018927,The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects,luteinizing hormone,LH,1081,1081
7018927,The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects,luteinizing hormone,haloperidol,1081,D006220
7018927,The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects,prolactin,luteinizing hormone,5617,1081
7018927,The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects,prolactin,LH,5617,1081
7018927,The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects,prolactin,haloperidol,5617,D006220
7018927,The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects,LH,luteinizing hormone,1081,1081
7018927,The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects,LH,prolactin,1081,5617
7018927,The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects,LH,haloperidol,1081,D006220
7018927,The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects,haloperidol,luteinizing hormone,D006220,1081
7018927,The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects,haloperidol,prolactin,D006220,5617
7018927,The effects of a 6-hour infusion with haloperidol on serum prolactin and luteinizing hormone (LH) levels was studied in a group of male subjects,haloperidol,LH,D006220,1081
7018927,"Five hours after starting the infusions, a study of the pituitary responses to LH-releasing hormone (LH-RH) was carried out",LH-RH,LH-releasing hormone,2796,2796
7018927,"Five hours after starting the infusions, a study of the pituitary responses to LH-releasing hormone (LH-RH) was carried out",LH-RH,LH,2796,1081
7018927,"Five hours after starting the infusions, a study of the pituitary responses to LH-releasing hormone (LH-RH) was carried out",LH-releasing hormone,LH-RH,2796,2796
7018927,"Five hours after starting the infusions, a study of the pituitary responses to LH-releasing hormone (LH-RH) was carried out",LH-releasing hormone,LH,2796,1081
7018927,"Five hours after starting the infusions, a study of the pituitary responses to LH-releasing hormone (LH-RH) was carried out",LH,LH-RH,1081,2796
7018927,"Five hours after starting the infusions, a study of the pituitary responses to LH-releasing hormone (LH-RH) was carried out",LH,LH-releasing hormone,1081,2796
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",prolactin,hyperprolactinemia,5617,D006966
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",prolactin,LH,5617,1081
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",prolactin,LH-RH,5617,2796
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",prolactin,haloperidol,5617,D006220
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",hyperprolactinemia,prolactin,D006966,5617
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",hyperprolactinemia,LH,D006966,1081
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",hyperprolactinemia,LH-RH,D006966,2796
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",hyperprolactinemia,haloperidol,D006966,D006220
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",LH,prolactin,1081,5617
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",LH,hyperprolactinemia,1081,D006966
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",LH,LH-RH,1081,2796
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",LH,haloperidol,1081,D006220
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",LH-RH,prolactin,2796,5617
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",LH-RH,hyperprolactinemia,2796,D006966
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",LH-RH,LH,2796,1081
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",LH-RH,haloperidol,2796,D006220
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",haloperidol,prolactin,D006220,5617
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",haloperidol,hyperprolactinemia,D006220,D006966
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",haloperidol,LH,D006220,1081
7018927,"During the course of haloperidol infusions, significant hyperprolactinemia was found, together with an abolished pituitary response to LH-RH, as compared with responses of control subjects.",haloperidol,LH-RH,D006220,2796
7811247,"Bidirectional sequencing of the entire coding ALD gene disclosed a cytosine to guanine transversion at nucleotide 1451 in exon five, resulting in substitution of proline 484 by arginine",proline 484 by arginine,cytosine to guanine transversion at nucleotide 1451,rs128624214,rs128624214
7811247,"Bidirectional sequencing of the entire coding ALD gene disclosed a cytosine to guanine transversion at nucleotide 1451 in exon five, resulting in substitution of proline 484 by arginine",proline 484 by arginine,ALD,rs128624214,D000326
7811247,"Bidirectional sequencing of the entire coding ALD gene disclosed a cytosine to guanine transversion at nucleotide 1451 in exon five, resulting in substitution of proline 484 by arginine",cytosine to guanine transversion at nucleotide 1451,proline 484 by arginine,rs128624214,rs128624214
7811247,"Bidirectional sequencing of the entire coding ALD gene disclosed a cytosine to guanine transversion at nucleotide 1451 in exon five, resulting in substitution of proline 484 by arginine",cytosine to guanine transversion at nucleotide 1451,ALD,rs128624214,D000326
7811247,"Bidirectional sequencing of the entire coding ALD gene disclosed a cytosine to guanine transversion at nucleotide 1451 in exon five, resulting in substitution of proline 484 by arginine",ALD,proline 484 by arginine,D000326,rs128624214
7811247,"Bidirectional sequencing of the entire coding ALD gene disclosed a cytosine to guanine transversion at nucleotide 1451 in exon five, resulting in substitution of proline 484 by arginine",ALD,cytosine to guanine transversion at nucleotide 1451,D000326,rs128624214
7811247,"Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls",Addison,long chain fatty acids,D000224,D005227
7811247,"Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls",adrenomyeloneuropathy,long chain fatty acids,D000326,D005227
7811247,"Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls",long chain fatty acids,Addison,D005227,D000224
7811247,"Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls",long chain fatty acids,adrenomyeloneuropathy,D005227,D000326
7811247,"Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls",long chain fatty acids,ALD,D005227,D000326
7811247,"Five of nine siblings of the patient, comprising two cerebral ALD, one adrenomyeloneuropathy, one Addison only as well as the symptomatic mother (all accumulating very long chain fatty acids) carried this mutation, which was not found in the unaffected persons, in five unrelated ALD patients, and in twenty controls",ALD,long chain fatty acids,D000326,D005227
8944024,45-kilobases (kb) exon 11 of the hereditary breast and ovarian cancer gene BRCA1,BRCA1,breast and ovarian cancer gene,672,672
8944024,45-kilobases (kb) exon 11 of the hereditary breast and ovarian cancer gene BRCA1,breast and ovarian cancer gene,BRCA1,672,672
14510914,Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein,sodium/iodide symporter,iodide,6528,D007454
14510914,Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein,sodium/iodide symporter,Congenital hypothyroidism,6528,D003409
14510914,Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein,sodium/iodide symporter,hypothyroidism,6528,D007037
14510914,Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein,iodide,sodium/iodide symporter,D007454,6528
14510914,Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein,iodide,Congenital hypothyroidism,D007454,D003409
14510914,Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein,iodide,hypothyroidism,D007454,D007037
14510914,Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein,Congenital hypothyroidism,sodium/iodide symporter,D003409,6528
14510914,Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein,Congenital hypothyroidism,iodide,D003409,D007454
14510914,Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein,hypothyroidism,sodium/iodide symporter,D007037,6528
14510914,Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein,hypothyroidism,iodide,D007037,D007454
14510914,"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism",congenital hypothyroidism,iodide,D003409,D007454
14510914,"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism",Iodide transport defect,iodide,C564766,D007454
14510914,"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism",inability of the thyroid,iodide,D050033,D007454
14510914,"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism",ITD,iodide,C564766,D007454
14510914,"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism",iodide,congenital hypothyroidism,D007454,D003409
14510914,"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism",iodide,Iodide transport defect,D007454,C564766
14510914,"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism",iodide,inability of the thyroid,D007454,D050033
14510914,"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism",iodide,ITD,D007454,C564766
14510914,"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism",iodide,hypothyroidism,D007454,D007037
14510914,"OBJECTIVE: Iodide transport defect (ITD) is a rare disorder characterised by an inability of the thyroid to maintain an iodide gradient across the basolateral membrane of thyroid follicular cells, that often results in congenital hypothyroidism",hypothyroidism,iodide,D007037,D007454
14510914,When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium/iodide symporter (NIS),sodium/iodide symporter,iodide,6528,D007454
14510914,When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium/iodide symporter (NIS),sodium/iodide symporter,NIS,6528,6528
14510914,When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium/iodide symporter (NIS),iodide,sodium/iodide symporter,D007454,6528
14510914,When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium/iodide symporter (NIS),iodide,NIS,D007454,6528
14510914,When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium/iodide symporter (NIS),NIS,sodium/iodide symporter,6528,6528
14510914,When present the defect is also found in the salivary glands and gastric mucosa and it has been shown to arise from abnormalities of the sodium/iodide symporter (NIS),NIS,iodide,6528,D007454
14510914,"The diagnosis of ITD was suspected because of nodular goitre, and little if any iodide uptake by the thyroid and salivary glands",ITD,iodide,C564766,D007454
14510914,"The diagnosis of ITD was suspected because of nodular goitre, and little if any iodide uptake by the thyroid and salivary glands",iodide,ITD,D007454,C564766
14510914,"The diagnosis of ITD was suspected because of nodular goitre, and little if any iodide uptake by the thyroid and salivary glands",iodide,nodular goitre,D007454,D020518
14510914,"The diagnosis of ITD was suspected because of nodular goitre, and little if any iodide uptake by the thyroid and salivary glands",nodular goitre,iodide,D020518,D007454
14510914,"Treatment with iodide partially corrected the hypothyroidism; however, long-term substitution therapy with L-thyroxine was started",L-thyroxine,iodide,D013974,D007454
14510914,"Treatment with iodide partially corrected the hypothyroidism; however, long-term substitution therapy with L-thyroxine was started",L-thyroxine,hypothyroidism,D013974,D007037
14510914,"Treatment with iodide partially corrected the hypothyroidism; however, long-term substitution therapy with L-thyroxine was started",iodide,L-thyroxine,D007454,D013974
14510914,"Treatment with iodide partially corrected the hypothyroidism; however, long-term substitution therapy with L-thyroxine was started",iodide,hypothyroidism,D007454,D007037
14510914,"Treatment with iodide partially corrected the hypothyroidism; however, long-term substitution therapy with L-thyroxine was started",hypothyroidism,L-thyroxine,D007037,D013974
14510914,"Treatment with iodide partially corrected the hypothyroidism; however, long-term substitution therapy with L-thyroxine was started",hypothyroidism,iodide,D007037,D007454
14510914,MEASUREMENTS: Thyroid radioiodide uptake was only 1.4% and 0.3% at 1 and 24 h after the administration of recombinant human TSH,iodide,radioiodide,D007454,D007454
14510914,MEASUREMENTS: Thyroid radioiodide uptake was only 1.4% and 0.3% at 1 and 24 h after the administration of recombinant human TSH,iodide,TSH,D007454,7200
14510914,MEASUREMENTS: Thyroid radioiodide uptake was only 1.4% and 0.3% at 1 and 24 h after the administration of recombinant human TSH,radioiodide,iodide,D007454,D007454
14510914,MEASUREMENTS: Thyroid radioiodide uptake was only 1.4% and 0.3% at 1 and 24 h after the administration of recombinant human TSH,radioiodide,TSH,D007454,7200
14510914,MEASUREMENTS: Thyroid radioiodide uptake was only 1.4% and 0.3% at 1 and 24 h after the administration of recombinant human TSH,TSH,iodide,7200,D007454
14510914,MEASUREMENTS: Thyroid radioiodide uptake was only 1.4% and 0.3% at 1 and 24 h after the administration of recombinant human TSH,TSH,radioiodide,7200,D007454
14510914,The saliva to plasma I- ratio was 1.1 indicating that the inability of the thyroid gland to concentrate I- was also present in the salivary glands,inability of the thyroid,I-,D050033,D007454
14510914,The saliva to plasma I- ratio was 1.1 indicating that the inability of the thyroid gland to concentrate I- was also present in the salivary glands,I-,inability of the thyroid,D007454,D050033
14510914,RESULTS: Analysis of the patient's NIS gene revealed a 15 nucleotide (nt) deletion of the coding sequence (nt 1314 through nt 1328) and the insertion of 15 nt duplicating the first 15 nt of the adjacent intron,NIS,deletion of the coding sequence (nt 1314 through nt 1328),6528,c|DEL|1314_1328|
14510914,RESULTS: Analysis of the patient's NIS gene revealed a 15 nucleotide (nt) deletion of the coding sequence (nt 1314 through nt 1328) and the insertion of 15 nt duplicating the first 15 nt of the adjacent intron,NIS,insertion of 15 nt duplicating the first 15,6528,c|DUP||15
14510914,RESULTS: Analysis of the patient's NIS gene revealed a 15 nucleotide (nt) deletion of the coding sequence (nt 1314 through nt 1328) and the insertion of 15 nt duplicating the first 15 nt of the adjacent intron,deletion of the coding sequence (nt 1314 through nt 1328),NIS,c|DEL|1314_1328|,6528
14510914,RESULTS: Analysis of the patient's NIS gene revealed a 15 nucleotide (nt) deletion of the coding sequence (nt 1314 through nt 1328) and the insertion of 15 nt duplicating the first 15 nt of the adjacent intron,deletion of the coding sequence (nt 1314 through nt 1328),insertion of 15 nt duplicating the first 15,c|DEL|1314_1328|,c|DUP||15
14510914,RESULTS: Analysis of the patient's NIS gene revealed a 15 nucleotide (nt) deletion of the coding sequence (nt 1314 through nt 1328) and the insertion of 15 nt duplicating the first 15 nt of the adjacent intron,insertion of 15 nt duplicating the first 15,NIS,c|DUP||15,6528
14510914,RESULTS: Analysis of the patient's NIS gene revealed a 15 nucleotide (nt) deletion of the coding sequence (nt 1314 through nt 1328) and the insertion of 15 nt duplicating the first 15 nt of the adjacent intron,insertion of 15 nt duplicating the first 15,deletion of the coding sequence (nt 1314 through nt 1328),c|DUP||15,c|DEL|1314_1328|
14510914,"COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient",NIS,ITD,6528,C564766
14510914,"COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient",NIS,iodide,6528,D007454
14510914,"COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient",NIS,del-(439-443),6528,p|DEL|439_443|
14510914,"COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient",ITD,NIS,C564766,6528
14510914,"COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient",ITD,iodide,C564766,D007454
14510914,"COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient",ITD,del-(439-443),C564766,p|DEL|439_443|
14510914,"COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient",iodide,NIS,D007454,6528
14510914,"COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient",iodide,ITD,D007454,C564766
14510914,"COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient",iodide,del-(439-443),D007454,p|DEL|439_443|
14510914,"COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient",del-(439-443),NIS,p|DEL|439_443|,6528
14510914,"COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient",del-(439-443),ITD,p|DEL|439_443|,C564766
14510914,"COS-7 cells transfected with a vector expressing the mutant del-(439-443) NIS failed to concentrate iodide, suggesting that the mutation was the direct cause of the ITD in this patient",del-(439-443),iodide,p|DEL|439_443|,D007454
14510914,CONCLUSION: In conclusion we describe the first Italian case of congenital hypothyroidism due to a new deletion in the NIS gene.,NIS,congenital hypothyroidism,6528,D003409
14510914,CONCLUSION: In conclusion we describe the first Italian case of congenital hypothyroidism due to a new deletion in the NIS gene.,NIS,hypothyroidism,6528,D007037
14510914,CONCLUSION: In conclusion we describe the first Italian case of congenital hypothyroidism due to a new deletion in the NIS gene.,congenital hypothyroidism,NIS,D003409,6528
14510914,CONCLUSION: In conclusion we describe the first Italian case of congenital hypothyroidism due to a new deletion in the NIS gene.,hypothyroidism,NIS,D007037,6528
15041272,A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation,R1306W,type 2B von Willebrand disease,rs61749384,D056728
15041272,A first Taiwanese Chinese family of type 2B von Willebrand disease with R1306W mutation,type 2B von Willebrand disease,R1306W,D056728,rs61749384
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",ristocetin-induced platelet aggregation,von Willebrand factor,D001791,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",ristocetin-induced platelet aggregation,VWF,D001791,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",ristocetin-induced platelet aggregation,von Willerand factor,D001791,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",ristocetin-induced platelet aggregation,ristocetin,D001791,D012310
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",ristocetin-induced platelet aggregation,VIII,D001791,2157
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willebrand factor,ristocetin-induced platelet aggregation,7450,D001791
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willebrand factor,bleeding,7450,D006470
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willebrand factor,VWF,7450,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willebrand factor,von Willerand factor,7450,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willebrand factor,ristocetin,7450,D012310
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willebrand factor,VIII,7450,2157
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willebrand factor,RIPA,7450,D001791
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",bleeding,von Willebrand factor,D006470,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",bleeding,VWF,D006470,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",bleeding,von Willerand factor,D006470,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",bleeding,ristocetin,D006470,D012310
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",bleeding,VIII,D006470,2157
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VWF,ristocetin-induced platelet aggregation,7450,D001791
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VWF,von Willebrand factor,7450,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VWF,bleeding,7450,D006470
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VWF,von Willerand factor,7450,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VWF,ristocetin,7450,D012310
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VWF,VIII,7450,2157
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VWF,RIPA,7450,D001791
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willerand factor,ristocetin-induced platelet aggregation,7450,D001791
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willerand factor,von Willebrand factor,7450,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willerand factor,bleeding,7450,D006470
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willerand factor,VWF,7450,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willerand factor,ristocetin,7450,D012310
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willerand factor,VIII,7450,2157
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",von Willerand factor,RIPA,7450,D001791
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",ristocetin,ristocetin-induced platelet aggregation,D012310,D001791
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",ristocetin,von Willebrand factor,D012310,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",ristocetin,bleeding,D012310,D006470
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",ristocetin,VWF,D012310,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",ristocetin,von Willerand factor,D012310,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",ristocetin,VIII,D012310,2157
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",ristocetin,RIPA,D012310,D001791
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VIII,ristocetin-induced platelet aggregation,2157,D001791
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VIII,von Willebrand factor,2157,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VIII,bleeding,2157,D006470
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VIII,VWF,2157,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VIII,von Willerand factor,2157,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VIII,ristocetin,2157,D012310
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",VIII,RIPA,2157,D001791
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",RIPA,von Willebrand factor,D001791,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",RIPA,VWF,D001791,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",RIPA,von Willerand factor,D001791,7450
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",RIPA,ristocetin,D001791,D012310
15041272,"In proband, PT, PTT and platelet count were normal; template bleeding time was 14 min; VIII:C was 51%, von Willebrand factor antigen (VWF:Ag), 42% and von Willerand factor ristocetin-cofactor (VWF:RCo, 15%); ristocetin-induced platelet aggregation (RIPA) at 0.3 and 0.6 mg/ml of ristocetin was 16% and 68%, respectively",RIPA,VIII,D001791,2157
15041272,Analysis of von Willebrand factor (VWF) multimer of plasma but not of platelets showed absence of high-molecular weight (HMW) multimer,von Willebrand factor,VWF,7450,7450
15041272,Analysis of von Willebrand factor (VWF) multimer of plasma but not of platelets showed absence of high-molecular weight (HMW) multimer,VWF,von Willebrand factor,7450,7450
15041272,The proband and three children were all found to be heterozygous for C to T transition at nucleotide 3916 resulting in Arg 1306 Trp (R1306W) substitution,Arg 1306 Trp,R1306W,rs61749384,rs61749384
15041272,The proband and three children were all found to be heterozygous for C to T transition at nucleotide 3916 resulting in Arg 1306 Trp (R1306W) substitution,Arg 1306 Trp,C to T transition at nucleotide 3916,rs61749384,rs61749384
15041272,The proband and three children were all found to be heterozygous for C to T transition at nucleotide 3916 resulting in Arg 1306 Trp (R1306W) substitution,R1306W,Arg 1306 Trp,rs61749384,rs61749384
15041272,The proband and three children were all found to be heterozygous for C to T transition at nucleotide 3916 resulting in Arg 1306 Trp (R1306W) substitution,R1306W,C to T transition at nucleotide 3916,rs61749384,rs61749384
15041272,The proband and three children were all found to be heterozygous for C to T transition at nucleotide 3916 resulting in Arg 1306 Trp (R1306W) substitution,C to T transition at nucleotide 3916,Arg 1306 Trp,rs61749384,rs61749384
15041272,The proband and three children were all found to be heterozygous for C to T transition at nucleotide 3916 resulting in Arg 1306 Trp (R1306W) substitution,C to T transition at nucleotide 3916,R1306W,rs61749384,rs61749384
15041272,"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia",glycoprotein Ib,GPIb,2811,2811
15041272,"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia",glycoprotein Ib,thrombocytopenia,2811,D013921
15041272,"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia",glycoprotein Ib,VWF,2811,7450
15041272,"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia",GPIb,glycoprotein Ib,2811,2811
15041272,"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia",GPIb,thrombocytopenia,2811,D013921
15041272,"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia",GPIb,VWF,2811,7450
15041272,"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia",thrombocytopenia,glycoprotein Ib,D013921,2811
15041272,"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia",thrombocytopenia,GPIb,D013921,2811
15041272,"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia",thrombocytopenia,VWF,D013921,7450
15041272,"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia",VWF,glycoprotein Ib,7450,2811
15041272,"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia",VWF,GPIb,7450,2811
15041272,"This mutation in the glycoprotein Ib (GPIb)-binding site has been found to increase the affinity of plasma VWF for platelets, and thus cause loss of HMW multimers and often thrombocytopenia",VWF,thrombocytopenia,7450,D013921
15041272,"In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.",VWD,R1306W,D014842,rs61749384
15041272,"In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.",VWD,VWF,D014842,7450
15041272,"In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.",type 2B VWD,R1306W,D056728,rs61749384
15041272,"In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.",type 2B VWD,VWF,D056728,7450
15041272,"In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.",R1306W,VWD,rs61749384,D014842
15041272,"In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.",R1306W,type 2B VWD,rs61749384,D056728
15041272,"In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.",R1306W,VWF,rs61749384,7450
15041272,"In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.",VWF,VWD,7450,D014842
15041272,"In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.",VWF,type 2B VWD,7450,D056728
15041272,"In conclusion, a first report of type 2B VWD in a Taiwanese Chinese family who show R1306W mutation in VWF gene was described.",VWF,R1306W,7450,rs61749384
15096016,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias",rigidity,levodopa,D009127,D007980
15096016,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias",levodopa,rigidity,D007980,D009127
15096016,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias",levodopa,bradykinesia,D007980,D018476
15096016,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias",levodopa,dyskinesias,D007980,D004409
15096016,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias",bradykinesia,levodopa,D018476,D007980
15096016,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias",dyskinesias,levodopa,D004409,D007980
15099351,Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia,cholesterol,hypercholesterolemia,D002784,D006937
15099351,Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia,cholesterol,PCSK9,D002784,255738
15099351,Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia,cholesterol,autosomal dominant hypercholesterolemia,D002784,D006938
15099351,Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia,hypercholesterolemia,cholesterol,D006937,D002784
15099351,Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia,hypercholesterolemia,PCSK9,D006937,255738
15099351,Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia,PCSK9,cholesterol,255738,D002784
15099351,Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia,PCSK9,hypercholesterolemia,255738,D006937
15099351,Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia,PCSK9,autosomal dominant hypercholesterolemia,255738,D006938
15099351,Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia,autosomal dominant hypercholesterolemia,cholesterol,D006938,D002784
15099351,Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia,autosomal dominant hypercholesterolemia,PCSK9,D006938,255738
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",Proprotein convertase subtilisin/kexin type 9,cholesterol,255738,D002784
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",Proprotein convertase subtilisin/kexin type 9,hypercholesterolemia,255738,D006937
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",Proprotein convertase subtilisin/kexin type 9,autosomal dominant hypercholesterolemia,255738,D006938
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",Proprotein convertase subtilisin/kexin type 9,PCSK9,255738,255738
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",cholesterol,Proprotein convertase subtilisin/kexin type 9,D002784,255738
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",cholesterol,hypercholesterolemia,D002784,D006937
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",cholesterol,autosomal dominant hypercholesterolemia,D002784,D006938
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",cholesterol,PCSK9,D002784,255738
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",hypercholesterolemia,Proprotein convertase subtilisin/kexin type 9,D006937,255738
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",hypercholesterolemia,cholesterol,D006937,D002784
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",hypercholesterolemia,PCSK9,D006937,255738
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",autosomal dominant hypercholesterolemia,Proprotein convertase subtilisin/kexin type 9,D006938,255738
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",autosomal dominant hypercholesterolemia,cholesterol,D006938,D002784
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",autosomal dominant hypercholesterolemia,PCSK9,D006938,255738
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",PCSK9,Proprotein convertase subtilisin/kexin type 9,255738,255738
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",PCSK9,cholesterol,255738,D002784
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",PCSK9,hypercholesterolemia,255738,D006937
15099351,"Proprotein convertase subtilisin/kexin type 9 (PCSK9) is at a locus for autosomal dominant hypercholesterolemia, and recent data indicate that the PCSK9 gene is involved in cholesterol biosynthesis",PCSK9,autosomal dominant hypercholesterolemia,255738,D006938
15099351,Mutations within this gene have previously been found to segregate with hypercholesterolemia,cholesterol,hypercholesterolemia,D002784,D006937
15099351,Mutations within this gene have previously been found to segregate with hypercholesterolemia,hypercholesterolemia,cholesterol,D006937,D002784
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",R3500Q,cholesterol,rs5742904,D002784
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",R3500Q,hypercholesterolemia,rs5742904,D006937
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",R3500Q,familial hypercholesterolemia,rs5742904,D006937
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",R3500Q,low-density lipoprotein receptor,rs5742904,3949
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",R3500Q,PCSK9,rs5742904,255738
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",R3500Q,apolipoprotein B-100,rs5742904,338
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",cholesterol,R3500Q,D002784,rs5742904
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",cholesterol,hypercholesterolemia,D002784,D006937
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",cholesterol,familial hypercholesterolemia,D002784,D006937
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",cholesterol,low-density lipoprotein receptor,D002784,3949
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",cholesterol,PCSK9,D002784,255738
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",cholesterol,apolipoprotein B-100,D002784,338
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",hypercholesterolemia,R3500Q,D006937,rs5742904
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",hypercholesterolemia,cholesterol,D006937,D002784
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",hypercholesterolemia,low-density lipoprotein receptor,D006937,3949
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",hypercholesterolemia,PCSK9,D006937,255738
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",hypercholesterolemia,apolipoprotein B-100,D006937,338
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",familial hypercholesterolemia,R3500Q,D006937,rs5742904
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",familial hypercholesterolemia,cholesterol,D006937,D002784
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",familial hypercholesterolemia,low-density lipoprotein receptor,D006937,3949
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",familial hypercholesterolemia,PCSK9,D006937,255738
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",familial hypercholesterolemia,apolipoprotein B-100,D006937,338
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",low-density lipoprotein receptor,R3500Q,3949,rs5742904
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",low-density lipoprotein receptor,cholesterol,3949,D002784
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",low-density lipoprotein receptor,hypercholesterolemia,3949,D006937
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",low-density lipoprotein receptor,familial hypercholesterolemia,3949,D006937
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",low-density lipoprotein receptor,PCSK9,3949,255738
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",low-density lipoprotein receptor,apolipoprotein B-100,3949,338
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",PCSK9,R3500Q,255738,rs5742904
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",PCSK9,cholesterol,255738,D002784
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",PCSK9,hypercholesterolemia,255738,D006937
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",PCSK9,familial hypercholesterolemia,255738,D006937
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",PCSK9,low-density lipoprotein receptor,255738,3949
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",PCSK9,apolipoprotein B-100,255738,338
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",apolipoprotein B-100,R3500Q,338,rs5742904
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",apolipoprotein B-100,cholesterol,338,D002784
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",apolipoprotein B-100,hypercholesterolemia,338,D006937
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",apolipoprotein B-100,familial hypercholesterolemia,338,D006937
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",apolipoprotein B-100,low-density lipoprotein receptor,338,3949
15099351,"In this study, DNA sequencing of the 12 exons of the PCSK9 gene has been performed in 51 Norwegian subjects with a clinical diagnosis of familial hypercholesterolemia where mutations in the low-density lipoprotein receptor gene and mutation R3500Q in the apolipoprotein B-100 gene had been excluded",apolipoprotein B-100,PCSK9,338,255738
15099351,"Two patients were heterozygotes for D374Y, and one patient was a double heterozygote for D374Y and N157K",N157K,D374Y,rs143117125,rs137852912
15099351,"Two patients were heterozygotes for D374Y, and one patient was a double heterozygote for D374Y and N157K",D374Y,N157K,rs137852912,rs143117125
15099351,D374Y segregated with hypercholesterolemia in the two former families where family members were available for study,cholesterol,hypercholesterolemia,D002784,D006937
15099351,D374Y segregated with hypercholesterolemia in the two former families where family members were available for study,cholesterol,D374Y,D002784,rs137852912
15099351,D374Y segregated with hypercholesterolemia in the two former families where family members were available for study,hypercholesterolemia,cholesterol,D006937,D002784
15099351,D374Y segregated with hypercholesterolemia in the two former families where family members were available for study,hypercholesterolemia,D374Y,D006937,rs137852912
15099351,D374Y segregated with hypercholesterolemia in the two former families where family members were available for study,D374Y,cholesterol,rs137852912,D002784
15099351,D374Y segregated with hypercholesterolemia in the two former families where family members were available for study,D374Y,hypercholesterolemia,rs137852912,D006937
15099351,Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.,cholesterol,hypercholesterolemia,D002784,D006937
15099351,Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.,cholesterol,PCSK9,D002784,255738
15099351,Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.,cholesterol,autosomal dominant hypercholesterolemia,D002784,D006938
15099351,Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.,hypercholesterolemia,cholesterol,D006937,D002784
15099351,Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.,hypercholesterolemia,PCSK9,D006937,255738
15099351,Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.,PCSK9,cholesterol,255738,D002784
15099351,Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.,PCSK9,hypercholesterolemia,255738,D006937
15099351,Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.,PCSK9,autosomal dominant hypercholesterolemia,255738,D006938
15099351,Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.,autosomal dominant hypercholesterolemia,cholesterol,D006938,D002784
15099351,Our findings support the notion that mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia.,autosomal dominant hypercholesterolemia,PCSK9,D006938,255738
15122708,Desmin-related myopathy with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene,myopathy,selenoprotein N,D009135,57190
15122708,Desmin-related myopathy with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene,selenoprotein N,myopathy,57190,D009135
15122708,Desmin-related myopathy with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene,selenoprotein N,Desmin-related myopathy,57190,C563319
15122708,Desmin-related myopathy with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene,Desmin-related myopathy,selenoprotein N,C563319,57190
15122708,"Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin",Desmin-related myopathies,desmin,C563319,1674
15122708,"Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin",desmin,Desmin-related myopathies,1674,C563319
15122708,"Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin",desmin,DRMs,1674,C563319
15122708,"Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin",desmin,myopathies,1674,D009135
15122708,"Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin",desmin,muscle disorders,1674,D009135
15122708,"Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin",desmin,DRM,1674,C563319
15122708,"Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin",DRMs,desmin,C563319,1674
15122708,"Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin",myopathies,desmin,D009135,1674
15122708,"Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin",muscle disorders,desmin,D009135,1674
15122708,"Desmin-related myopathies (DRMs) are a heterogeneous group of muscle disorders, morphologically defined by intrasarcoplasmic aggregates of desmin",DRM,desmin,C563319,1674
15122708,Mutations in the desmin and the alpha-B crystallin genes account for approximately one third of the DRM cases,DRM,desmin,C563319,1674
15122708,Mutations in the desmin and the alpha-B crystallin genes account for approximately one third of the DRM cases,DRM,alpha-B crystallin,C563319,1410
15122708,Mutations in the desmin and the alpha-B crystallin genes account for approximately one third of the DRM cases,desmin,DRM,1674,C563319
15122708,Mutations in the desmin and the alpha-B crystallin genes account for approximately one third of the DRM cases,desmin,alpha-B crystallin,1674,1410
15122708,Mutations in the desmin and the alpha-B crystallin genes account for approximately one third of the DRM cases,alpha-B crystallin,DRM,1410,C563319
15122708,Mutations in the desmin and the alpha-B crystallin genes account for approximately one third of the DRM cases,alpha-B crystallin,desmin,1410,1674
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",SEPN-RM,selenoprotein N,D009135,57190
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",SEPN-RM,SEPN1,D009135,57190
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",selenoprotein N,SEPN-RM,57190,D009135
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",selenoprotein N,rigid spine muscular dystrophy,57190,C535683
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",selenoprotein N,myopathy,57190,D009135
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",selenoprotein N,multiminicore disease,57190,C564969
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",selenoprotein N,SEPN-related myopathy,57190,D009135
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",selenoprotein N,SEPN1,57190,57190
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",rigid spine muscular dystrophy,selenoprotein N,C535683,57190
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",rigid spine muscular dystrophy,SEPN1,C535683,57190
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",myopathy,selenoprotein N,D009135,57190
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",myopathy,SEPN1,D009135,57190
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",multiminicore disease,selenoprotein N,C564969,57190
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",multiminicore disease,SEPN1,C564969,57190
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",SEPN-related myopathy,selenoprotein N,D009135,57190
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",SEPN-related myopathy,SEPN1,D009135,57190
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",SEPN1,SEPN-RM,57190,D009135
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",SEPN1,selenoprotein N,57190,57190
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",SEPN1,rigid spine muscular dystrophy,57190,C535683
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",SEPN1,myopathy,57190,D009135
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",SEPN1,multiminicore disease,57190,C564969
15122708,"Recently, we identified the selenoprotein N gene (SEPN1) as responsible for SEPN-related myopathy (SEPN-RM), a unique early-onset myopathy formerly divided in two different nosological categories: rigid spine muscular dystrophy and the severe form of classical multiminicore disease",SEPN1,SEPN-related myopathy,57190,D009135
15122708,The finding of Mallory body-like inclusions in two cases of genetically documented SEPN-RM led us to suspect a relationship between MB-DRM and SEPN1,SEPN-RM,SEPN1,D009135,57190
15122708,The finding of Mallory body-like inclusions in two cases of genetically documented SEPN-RM led us to suspect a relationship between MB-DRM and SEPN1,SEPN1,SEPN-RM,57190,D009135
15122708,The finding of Mallory body-like inclusions in two cases of genetically documented SEPN-RM led us to suspect a relationship between MB-DRM and SEPN1,SEPN1,DRM,57190,C563319
15122708,The finding of Mallory body-like inclusions in two cases of genetically documented SEPN-RM led us to suspect a relationship between MB-DRM and SEPN1,DRM,SEPN1,C563319,57190
15122708,"In the original MB-DRM German family, we demonstrated a linkage of the disease to the SEPN1 locus (1p36), and subsequently a homozygous SEPN1 deletion (del 92 nucleotide -19/+73) in the affected patients",del 92 nucleotide -19/+73,SEPN1,c|DEL|-19_+73|92,57190
15122708,"In the original MB-DRM German family, we demonstrated a linkage of the disease to the SEPN1 locus (1p36), and subsequently a homozygous SEPN1 deletion (del 92 nucleotide -19/+73) in the affected patients",del 92 nucleotide -19/+73,DRM,c|DEL|-19_+73|92,C563319
15122708,"In the original MB-DRM German family, we demonstrated a linkage of the disease to the SEPN1 locus (1p36), and subsequently a homozygous SEPN1 deletion (del 92 nucleotide -19/+73) in the affected patients",SEPN1,del 92 nucleotide -19/+73,57190,c|DEL|-19_+73|92
15122708,"In the original MB-DRM German family, we demonstrated a linkage of the disease to the SEPN1 locus (1p36), and subsequently a homozygous SEPN1 deletion (del 92 nucleotide -19/+73) in the affected patients",SEPN1,DRM,57190,C563319
15122708,"In the original MB-DRM German family, we demonstrated a linkage of the disease to the SEPN1 locus (1p36), and subsequently a homozygous SEPN1 deletion (del 92 nucleotide -19/+73) in the affected patients",DRM,del 92 nucleotide -19/+73,C563319,c|DEL|-19_+73|92
15122708,"In the original MB-DRM German family, we demonstrated a linkage of the disease to the SEPN1 locus (1p36), and subsequently a homozygous SEPN1 deletion (del 92 nucleotide -19/+73) in the affected patients",DRM,SEPN1,C563319,57190
15188772,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose,epinephrine,left ventricular systolic and diastolic dysfunction,D004837,D018487
15188772,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose,left ventricular systolic and diastolic dysfunction,epinephrine,D018487,D004837
15188772,Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon,catecholamines,cardiomyopathy,D002395,D009202
15188772,Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon,catecholamines,Catecholamine,D002395,D002395
15188772,Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon,cardiomyopathy,catecholamines,D009202,D002395
15188772,Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon,cardiomyopathy,Catecholamine,D009202,D002395
15188772,Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon,Catecholamine,catecholamines,D002395,D002395
15188772,Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon,Catecholamine,cardiomyopathy,D002395,D009202
15188772,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis",myocardial stunning,epinephrine,D017682,D004837
15188772,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis",epinephrine,myocardial stunning,D004837,D017682
15188772,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis",epinephrine,myocardial necrosis,D004837,D009202
15188772,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis",epinephrine,left ventricular systolic and diastolic dysfunction,D004837,D018487
15188772,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis",myocardial necrosis,epinephrine,D009202,D004837
15188772,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis",left ventricular systolic and diastolic dysfunction,epinephrine,D018487,D004837
15614572,"Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats",5-HT,trazodone,D012701,D014196
15614572,"Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats",5-HT,5-HT 2A/2C receptor,D012701,"25187,29595"
15614572,"Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats",5-HT,dopamine,D012701,D004298
15614572,"Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats",trazodone,5-HT,D014196,D012701
15614572,"Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats",trazodone,5-HT 2A/2C receptor,D014196,"25187,29595"
15614572,"Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats",trazodone,dopamine,D014196,D004298
15614572,"Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats",5-HT 2A/2C receptor,5-HT,"25187,29595",D012701
15614572,"Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats",5-HT 2A/2C receptor,trazodone,"25187,29595",D014196
15614572,"Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats",5-HT 2A/2C receptor,dopamine,"25187,29595",D004298
15614572,"Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats",dopamine,5-HT,D004298,D012701
15614572,"Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats",dopamine,trazodone,D004298,D014196
15614572,"Effects of the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent behaviors in rats",dopamine,5-HT 2A/2C receptor,D004298,"25187,29595"
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-Hydroxytryptamine,5-HT 2C receptors,D012701,25187
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-Hydroxytryptamine,5-HT,D012701,D012701
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-Hydroxytryptamine,dopamine,D012701,D004298
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-Hydroxytryptamine,5-HT 2A receptors,D012701,29595
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-HT 2C receptors,5-Hydroxytryptamine,25187,D012701
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-HT 2C receptors,5-HT,25187,D012701
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-HT 2C receptors,dopamine,25187,D004298
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-HT 2C receptors,5-HT 2A receptors,25187,29595
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-HT,5-Hydroxytryptamine,D012701,D012701
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-HT,5-HT 2C receptors,D012701,25187
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-HT,dopamine,D012701,D004298
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-HT,5-HT 2A receptors,D012701,29595
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",dopamine,5-Hydroxytryptamine,D004298,D012701
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",dopamine,5-HT 2C receptors,D004298,25187
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",dopamine,5-HT,D004298,D012701
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",dopamine,5-HT 2A receptors,D004298,29595
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-HT 2A receptors,5-Hydroxytryptamine,29595,D012701
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-HT 2A receptors,5-HT 2C receptors,29595,25187
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-HT 2A receptors,5-HT,29595,D012701
15614572,"RATIONALE: 5-Hydroxytryptamine, via stimulation of 5-HT 2C receptors, exerts a tonic inhibitory influence on dopaminergic neurotransmission, whereas activation of 5-HT 2A receptors enhances stimulated DAergic neurotransmission",5-HT 2A receptors,dopamine,29595,D004298
15614572,The antidepressant trazodone is a 5-HT 2A/2C receptor antagonist,5-HT 2A/2C receptor,5-HT,"25187,29595",D012701
15614572,The antidepressant trazodone is a 5-HT 2A/2C receptor antagonist,5-HT 2A/2C receptor,trazodone,"25187,29595",D014196
15614572,The antidepressant trazodone is a 5-HT 2A/2C receptor antagonist,5-HT,5-HT 2A/2C receptor,D012701,"25187,29595"
15614572,The antidepressant trazodone is a 5-HT 2A/2C receptor antagonist,5-HT,trazodone,D012701,D014196
15614572,The antidepressant trazodone is a 5-HT 2A/2C receptor antagonist,trazodone,5-HT 2A/2C receptor,D014196,"25187,29595"
15614572,The antidepressant trazodone is a 5-HT 2A/2C receptor antagonist,trazodone,5-HT,D014196,D012701
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",fluoxetine,apomorphine,D005473,D001058
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",fluoxetine,dexamphetamine,D005473,D003913
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",fluoxetine,ergometrine,D005473,D004874
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",fluoxetine,oral stereotypies,D005473,D009062
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",fluoxetine,trazodone,D005473,D014196
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",fluoxetine,catalepsy,D005473,D002375
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",fluoxetine,haloperidol,D005473,D006220
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",apomorphine,fluoxetine,D001058,D005473
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",apomorphine,dexamphetamine,D001058,D003913
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",apomorphine,ergometrine,D001058,D004874
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",apomorphine,oral stereotypies,D001058,D009062
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",apomorphine,trazodone,D001058,D014196
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",apomorphine,catalepsy,D001058,D002375
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",apomorphine,haloperidol,D001058,D006220
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",dexamphetamine,fluoxetine,D003913,D005473
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",dexamphetamine,apomorphine,D003913,D001058
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",dexamphetamine,ergometrine,D003913,D004874
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",dexamphetamine,oral stereotypies,D003913,D009062
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",dexamphetamine,trazodone,D003913,D014196
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",dexamphetamine,catalepsy,D003913,D002375
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",dexamphetamine,haloperidol,D003913,D006220
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",ergometrine,fluoxetine,D004874,D005473
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",ergometrine,apomorphine,D004874,D001058
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",ergometrine,dexamphetamine,D004874,D003913
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",ergometrine,oral stereotypies,D004874,D009062
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",ergometrine,trazodone,D004874,D014196
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",ergometrine,catalepsy,D004874,D002375
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",ergometrine,haloperidol,D004874,D006220
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",oral stereotypies,fluoxetine,D009062,D005473
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",oral stereotypies,apomorphine,D009062,D001058
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",oral stereotypies,dexamphetamine,D009062,D003913
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",oral stereotypies,ergometrine,D009062,D004874
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",oral stereotypies,trazodone,D009062,D014196
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",oral stereotypies,haloperidol,D009062,D006220
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",trazodone,fluoxetine,D014196,D005473
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",trazodone,apomorphine,D014196,D001058
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",trazodone,dexamphetamine,D014196,D003913
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",trazodone,ergometrine,D014196,D004874
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",trazodone,oral stereotypies,D014196,D009062
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",trazodone,catalepsy,D014196,D002375
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",trazodone,haloperidol,D014196,D006220
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",catalepsy,fluoxetine,D002375,D005473
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",catalepsy,apomorphine,D002375,D001058
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",catalepsy,dexamphetamine,D002375,D003913
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",catalepsy,ergometrine,D002375,D004874
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",catalepsy,trazodone,D002375,D014196
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",catalepsy,haloperidol,D002375,D006220
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",haloperidol,fluoxetine,D006220,D005473
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",haloperidol,apomorphine,D006220,D001058
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",haloperidol,dexamphetamine,D006220,D003913
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",haloperidol,ergometrine,D006220,D004874
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",haloperidol,oral stereotypies,D006220,D009062
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",haloperidol,trazodone,D006220,D014196
15614572,"METHODS: The effect of pretreatment with trazodone on dexamphetamine- and apomorphine-induced oral stereotypies, on catalepsy induced by haloperidol and apomorphine (0.05 mg/kg, i.p.), on ergometrine-induced wet dog shake (WDS) behavior and fluoxetine-induced penile erections was studied in rats",haloperidol,catalepsy,D006220,D002375
15614572,We also investigated whether trazodone induces catalepsy in rats,catalepsy,trazodone,D002375,D014196
15614572,We also investigated whether trazodone induces catalepsy in rats,trazodone,catalepsy,D014196,D002375
15614572,"did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy",catalepsy,apomorphine,D002375,D001058
15614572,"did not induce catalepsy, and did not antagonize apomorphine (1.5 and 3 mg/kg) stereotypy and apomorphine (0.05 mg/kg)-induced catalepsy",apomorphine,catalepsy,D001058,D002375
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",fluoxetine,dexamphetamine,D005473,D003913
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",fluoxetine,ergometrine,D005473,D004874
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",fluoxetine,trazodone,D005473,D014196
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",fluoxetine,catalepsy,D005473,D002375
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",fluoxetine,haloperidol,D005473,D006220
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",dexamphetamine,fluoxetine,D003913,D005473
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",dexamphetamine,ergometrine,D003913,D004874
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",dexamphetamine,trazodone,D003913,D014196
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",dexamphetamine,catalepsy,D003913,D002375
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",dexamphetamine,haloperidol,D003913,D006220
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",ergometrine,fluoxetine,D004874,D005473
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",ergometrine,dexamphetamine,D004874,D003913
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",ergometrine,trazodone,D004874,D014196
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",ergometrine,catalepsy,D004874,D002375
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",ergometrine,haloperidol,D004874,D006220
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",trazodone,fluoxetine,D014196,D005473
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",trazodone,dexamphetamine,D014196,D003913
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",trazodone,ergometrine,D014196,D004874
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",trazodone,catalepsy,D014196,D002375
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",trazodone,haloperidol,D014196,D006220
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",catalepsy,fluoxetine,D002375,D005473
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",catalepsy,dexamphetamine,D002375,D003913
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",catalepsy,ergometrine,D002375,D004874
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",catalepsy,trazodone,D002375,D014196
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",catalepsy,haloperidol,D002375,D006220
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",haloperidol,fluoxetine,D006220,D005473
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",haloperidol,dexamphetamine,D006220,D003913
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",haloperidol,ergometrine,D006220,D004874
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",haloperidol,trazodone,D006220,D014196
15614572,"trazodone enhanced dexamphetamine stereotypy, and antagonized haloperidol catalepsy, ergometrine-induced WDS behavior and fluoxetine-induced penile erections",haloperidol,catalepsy,D006220,D002375
15614572,induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies,catalepsy,apomorphine,D002375,D001058
15614572,induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies,catalepsy,dexamphetamine,D002375,D003913
15614572,induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies,apomorphine,catalepsy,D001058,D002375
15614572,induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies,apomorphine,dexamphetamine,D001058,D003913
15614572,induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies,dexamphetamine,catalepsy,D003913,D002375
15614572,induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies,dexamphetamine,apomorphine,D003913,D001058
15614572,"CONCLUSIONS: Our results indicate that trazodone at 2.5-20 mg/kg does not block pre- and postsynaptic striatal D2 DA receptors, while at 30, 40 and 50 mg/kg it blocks postsynaptic striatal D2 DA receptors",D2 DA receptors,trazodone,24318,D014196
15614572,"CONCLUSIONS: Our results indicate that trazodone at 2.5-20 mg/kg does not block pre- and postsynaptic striatal D2 DA receptors, while at 30, 40 and 50 mg/kg it blocks postsynaptic striatal D2 DA receptors",trazodone,D2 DA receptors,D014196,24318
15614572,"Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors",5-HT 2A and 5-HT 2C receptors,5-HT 2C receptors,"25187,29595",25187
15614572,"Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors",5-HT 2A and 5-HT 2C receptors,5-HT,"25187,29595",D012701
15614572,"Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors",5-HT 2A and 5-HT 2C receptors,trazodone,"25187,29595",D014196
15614572,"Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors",5-HT 2C receptors,5-HT 2A and 5-HT 2C receptors,25187,"25187,29595"
15614572,"Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors",5-HT 2C receptors,5-HT,25187,D012701
15614572,"Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors",5-HT 2C receptors,trazodone,25187,D014196
15614572,"Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors",5-HT,5-HT 2A and 5-HT 2C receptors,D012701,"25187,29595"
15614572,"Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors",5-HT,5-HT 2C receptors,D012701,25187
15614572,"Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors",5-HT,trazodone,D012701,D014196
15614572,"Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors",trazodone,5-HT 2A and 5-HT 2C receptors,D014196,"25187,29595"
15614572,"Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors",trazodone,5-HT 2C receptors,D014196,25187
15614572,"Furthermore, at 5, 10 and 20 mg/kg, trazodone blocks 5-HT 2A and 5-HT 2C receptors",trazodone,5-HT,D014196,D012701
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",dexamphetamine,5-HT 2C receptors,D003913,25187
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",dexamphetamine,5-HT,D003913,D012701
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",dexamphetamine,trazodone,D003913,D014196
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",dexamphetamine,catalepsy,D003913,D002375
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",dexamphetamine,haloperidol,D003913,D006220
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",5-HT 2C receptors,dexamphetamine,25187,D003913
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",5-HT 2C receptors,5-HT,25187,D012701
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",5-HT 2C receptors,trazodone,25187,D014196
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",5-HT 2C receptors,catalepsy,25187,D002375
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",5-HT 2C receptors,haloperidol,25187,D006220
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",5-HT,dexamphetamine,D012701,D003913
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",5-HT,5-HT 2C receptors,D012701,25187
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",5-HT,trazodone,D012701,D014196
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",5-HT,catalepsy,D012701,D002375
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",5-HT,haloperidol,D012701,D006220
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",trazodone,dexamphetamine,D014196,D003913
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",trazodone,5-HT 2C receptors,D014196,25187
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",trazodone,5-HT,D014196,D012701
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",trazodone,catalepsy,D014196,D002375
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",trazodone,haloperidol,D014196,D006220
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",catalepsy,dexamphetamine,D002375,D003913
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",catalepsy,5-HT 2C receptors,D002375,25187
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",catalepsy,5-HT,D002375,D012701
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",catalepsy,trazodone,D002375,D014196
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",catalepsy,haloperidol,D002375,D006220
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",haloperidol,dexamphetamine,D006220,D003913
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",haloperidol,5-HT 2C receptors,D006220,25187
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",haloperidol,5-HT,D006220,D012701
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",haloperidol,trazodone,D006220,D014196
15614572,"We suggest that trazodone (5, 10 and 20 mg/kg), by blocking the 5-HT 2C receptors, releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5-HT, and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy.",haloperidol,catalepsy,D006220,D002375
15623763,TGFBI gene mutations causing lattice and granular corneal dystrophies in Indian patients,lattice and granular corneal dystrophies,TGFBI,"C537881,D003317",7045
15623763,TGFBI gene mutations causing lattice and granular corneal dystrophies in Indian patients,TGFBI,lattice and granular corneal dystrophies,7045,"C537881,D003317"
15623763,PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations,TGFBI,lattice corneal dystrophy,7045,C537881
15623763,PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations,TGFBI,GCD,7045,D003317
15623763,PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations,TGFBI,granular corneal dystrophy,7045,D003317
15623763,PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations,TGFBI,LCD,7045,C537881
15623763,PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations,lattice corneal dystrophy,TGFBI,C537881,7045
15623763,PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations,GCD,TGFBI,D003317,7045
15623763,PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations,granular corneal dystrophy,TGFBI,D003317,7045
15623763,PURPOSE: To identify mutations in the TGFBI gene in Indian patients with lattice corneal dystrophy (LCD) or granular corneal dystrophy (GCD) and to look for genotype-phenotype correlations,LCD,TGFBI,C537881,7045
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Val624-Val625del,"deletion of valine 624, valine 625",p|DEL|624_625|VV,p|DEL|624_625|VV
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Val624-Val625del,glycine-594-valine,p|DEL|624_625|VV,p|SUB|G|594|V
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Val624-Val625del,valine-539-aspartic acid,p|DEL|624_625|VV,p|SUB|V|539|D
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Val624-Val625del,Gly594Val,p|DEL|624_625|VV,p|SUB|G|594|V
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Val624-Val625del,Val539Asp,p|DEL|624_625|VV,p|SUB|V|539|D
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Val624-Val625del,LCD,p|DEL|624_625|VV,C537881
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient","deletion of valine 624, valine 625",Val624-Val625del,p|DEL|624_625|VV,p|DEL|624_625|VV
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient","deletion of valine 624, valine 625",glycine-594-valine,p|DEL|624_625|VV,p|SUB|G|594|V
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient","deletion of valine 624, valine 625",valine-539-aspartic acid,p|DEL|624_625|VV,p|SUB|V|539|D
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient","deletion of valine 624, valine 625",Gly594Val,p|DEL|624_625|VV,p|SUB|G|594|V
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient","deletion of valine 624, valine 625",Val539Asp,p|DEL|624_625|VV,p|SUB|V|539|D
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient","deletion of valine 624, valine 625",LCD,p|DEL|624_625|VV,C537881
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",glycine-594-valine,Val624-Val625del,p|SUB|G|594|V,p|DEL|624_625|VV
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",glycine-594-valine,"deletion of valine 624, valine 625",p|SUB|G|594|V,p|DEL|624_625|VV
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",glycine-594-valine,valine-539-aspartic acid,p|SUB|G|594|V,p|SUB|V|539|D
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",glycine-594-valine,Gly594Val,p|SUB|G|594|V,p|SUB|G|594|V
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",glycine-594-valine,Val539Asp,p|SUB|G|594|V,p|SUB|V|539|D
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",glycine-594-valine,LCD,p|SUB|G|594|V,C537881
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",valine-539-aspartic acid,Val624-Val625del,p|SUB|V|539|D,p|DEL|624_625|VV
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",valine-539-aspartic acid,"deletion of valine 624, valine 625",p|SUB|V|539|D,p|DEL|624_625|VV
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",valine-539-aspartic acid,glycine-594-valine,p|SUB|V|539|D,p|SUB|G|594|V
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",valine-539-aspartic acid,Gly594Val,p|SUB|V|539|D,p|SUB|G|594|V
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",valine-539-aspartic acid,Val539Asp,p|SUB|V|539|D,p|SUB|V|539|D
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",valine-539-aspartic acid,LCD,p|SUB|V|539|D,C537881
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Gly594Val,Val624-Val625del,p|SUB|G|594|V,p|DEL|624_625|VV
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Gly594Val,"deletion of valine 624, valine 625",p|SUB|G|594|V,p|DEL|624_625|VV
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Gly594Val,glycine-594-valine,p|SUB|G|594|V,p|SUB|G|594|V
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Gly594Val,valine-539-aspartic acid,p|SUB|G|594|V,p|SUB|V|539|D
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Gly594Val,Val539Asp,p|SUB|G|594|V,p|SUB|V|539|D
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Gly594Val,LCD,p|SUB|G|594|V,C537881
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Val539Asp,Val624-Val625del,p|SUB|V|539|D,p|DEL|624_625|VV
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Val539Asp,"deletion of valine 624, valine 625",p|SUB|V|539|D,p|DEL|624_625|VV
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Val539Asp,glycine-594-valine,p|SUB|V|539|D,p|SUB|G|594|V
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Val539Asp,valine-539-aspartic acid,p|SUB|V|539|D,p|SUB|V|539|D
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Val539Asp,Gly594Val,p|SUB|V|539|D,p|SUB|G|594|V
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",Val539Asp,LCD,p|SUB|V|539|D,C537881
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",LCD,Val624-Val625del,C537881,p|DEL|624_625|VV
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",LCD,"deletion of valine 624, valine 625",C537881,p|DEL|624_625|VV
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",LCD,glycine-594-valine,C537881,p|SUB|G|594|V
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",LCD,valine-539-aspartic acid,C537881,p|SUB|V|539|D
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",LCD,Gly594Val,C537881,p|SUB|G|594|V
15623763,"In LCD, three novel heterozygous mutations found were glycine-594-valine (Gly594Val) in 2 of 18 patients, valine-539-aspartic acid (Val539Asp) in 1 patient, and deletion of valine 624, valine 625 (Val624-Val625del) in 1 patient",LCD,Val539Asp,C537881,p|SUB|V|539|D
15623763,"In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients",histidine 626-to-arginine,Arg124Cys,p|SUB|H|626|R,rs121909210
15623763,"In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients",histidine 626-to-arginine,His626Arg,p|SUB|H|626|R,p|SUB|H|626|R
15623763,"In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients",histidine 626-to-arginine,arginine 124-to-cysteine,p|SUB|H|626|R,rs121909210
15623763,"In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients",Arg124Cys,histidine 626-to-arginine,rs121909210,p|SUB|H|626|R
15623763,"In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients",Arg124Cys,His626Arg,rs121909210,p|SUB|H|626|R
15623763,"In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients",Arg124Cys,arginine 124-to-cysteine,rs121909210,rs121909210
15623763,"In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients",His626Arg,histidine 626-to-arginine,p|SUB|H|626|R,p|SUB|H|626|R
15623763,"In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients",His626Arg,Arg124Cys,p|SUB|H|626|R,rs121909210
15623763,"In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients",His626Arg,arginine 124-to-cysteine,p|SUB|H|626|R,rs121909210
15623763,"In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients",arginine 124-to-cysteine,histidine 626-to-arginine,rs121909210,p|SUB|H|626|R
15623763,"In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients",arginine 124-to-cysteine,Arg124Cys,rs121909210,rs121909210
15623763,"In addition, mutation of arginine 124-to-cysteine (Arg124Cys) was found in 8 of 18 patients and histidine 626-to-arginine (His626Arg) in 2 of 18 patients",arginine 124-to-cysteine,His626Arg,rs121909210,p|SUB|H|626|R
15623763,Atypical clinical features for LCD were noted in patients with the Gly594Val and Val624-Val625del mutations,Val624-Val625del,Gly594Val,p|DEL|624_625|VV,p|SUB|G|594|V
15623763,Atypical clinical features for LCD were noted in patients with the Gly594Val and Val624-Val625del mutations,Val624-Val625del,LCD,p|DEL|624_625|VV,C537881
15623763,Atypical clinical features for LCD were noted in patients with the Gly594Val and Val624-Val625del mutations,Gly594Val,Val624-Val625del,p|SUB|G|594|V,p|DEL|624_625|VV
15623763,Atypical clinical features for LCD were noted in patients with the Gly594Val and Val624-Val625del mutations,Gly594Val,LCD,p|SUB|G|594|V,C537881
15623763,Atypical clinical features for LCD were noted in patients with the Gly594Val and Val624-Val625del mutations,LCD,Val624-Val625del,C537881,p|DEL|624_625|VV
15623763,Atypical clinical features for LCD were noted in patients with the Gly594Val and Val624-Val625del mutations,LCD,Gly594Val,C537881,p|SUB|G|594|V
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Reis-Bucklers dystrophy,arginine 555-to-tryptophan,C535476,rs121909208
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Reis-Bucklers dystrophy,Arg555Trp,C535476,rs121909208
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Reis-Bucklers dystrophy,Arg124Leu,C535476,rs121909211
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",arginine 555-to-tryptophan,Reis-Bucklers dystrophy,rs121909208,C535476
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",arginine 555-to-tryptophan,Arg555Trp,rs121909208,rs121909208
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",arginine 555-to-tryptophan,GCD,rs121909208,D003317
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",arginine 555-to-tryptophan,GCD type I,rs121909208,C537304
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",arginine 555-to-tryptophan,Arg124Leu,rs121909208,rs121909211
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",arginine 555-to-tryptophan,GCD type III,rs121909208,C535476
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Arg555Trp,Reis-Bucklers dystrophy,rs121909208,C535476
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Arg555Trp,arginine 555-to-tryptophan,rs121909208,rs121909208
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Arg555Trp,GCD,rs121909208,D003317
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Arg555Trp,GCD type I,rs121909208,C537304
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Arg555Trp,Arg124Leu,rs121909208,rs121909211
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Arg555Trp,GCD type III,rs121909208,C535476
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",GCD,arginine 555-to-tryptophan,D003317,rs121909208
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",GCD,Arg555Trp,D003317,rs121909208
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",GCD,Arg124Leu,D003317,rs121909211
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",GCD type I,arginine 555-to-tryptophan,C537304,rs121909208
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",GCD type I,Arg555Trp,C537304,rs121909208
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",GCD type I,Arg124Leu,C537304,rs121909211
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Arg124Leu,Reis-Bucklers dystrophy,rs121909211,C535476
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Arg124Leu,arginine 555-to-tryptophan,rs121909211,rs121909208
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Arg124Leu,Arg555Trp,rs121909211,rs121909208
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Arg124Leu,GCD,rs121909211,D003317
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Arg124Leu,GCD type I,rs121909211,C537304
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",Arg124Leu,GCD type III,rs121909211,C535476
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",GCD type III,arginine 555-to-tryptophan,C535476,rs121909208
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",GCD type III,Arg555Trp,C535476,rs121909208
15623763,"In GCD, 18 patients with GCD type I had a mutation of arginine 555-to-tryptophan (Arg555Trp) and 1 patient with GCD type III (Reis-Bucklers dystrophy), had the Arg124Leu mutation",GCD type III,Arg124Leu,C535476,rs121909211
15623763,"Seven novel single-nucleotide polymorphisms (SNPs) were also found, of which a change of leucine 269 to phenylalanine (Leu269Phe) was found in 12 of 18 patients with the Arg555Trp mutation",leucine 269 to phenylalanine,Arg555Trp,rs199852470,rs121909208
15623763,"Seven novel single-nucleotide polymorphisms (SNPs) were also found, of which a change of leucine 269 to phenylalanine (Leu269Phe) was found in 12 of 18 patients with the Arg555Trp mutation",leucine 269 to phenylalanine,Leu269Phe,rs199852470,rs199852470
15623763,"Seven novel single-nucleotide polymorphisms (SNPs) were also found, of which a change of leucine 269 to phenylalanine (Leu269Phe) was found in 12 of 18 patients with the Arg555Trp mutation",Arg555Trp,leucine 269 to phenylalanine,rs121909208,rs199852470
15623763,"Seven novel single-nucleotide polymorphisms (SNPs) were also found, of which a change of leucine 269 to phenylalanine (Leu269Phe) was found in 12 of 18 patients with the Arg555Trp mutation",Arg555Trp,Leu269Phe,rs121909208,rs199852470
15623763,"Seven novel single-nucleotide polymorphisms (SNPs) were also found, of which a change of leucine 269 to phenylalanine (Leu269Phe) was found in 12 of 18 patients with the Arg555Trp mutation",Leu269Phe,leucine 269 to phenylalanine,rs199852470,rs199852470
15623763,"Seven novel single-nucleotide polymorphisms (SNPs) were also found, of which a change of leucine 269 to phenylalanine (Leu269Phe) was found in 12 of 18 patients with the Arg555Trp mutation",Leu269Phe,Arg555Trp,rs199852470,rs121909208
15623763,"CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied",Arg555Trp,GCD,rs121909208,D003317
15623763,"CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied",Arg555Trp,Arg124Cys,rs121909208,rs121909210
15623763,"CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied",Arg555Trp,LCD,rs121909208,C537881
15623763,"CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied",GCD,Arg555Trp,D003317,rs121909208
15623763,"CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied",GCD,Arg124Cys,D003317,rs121909210
15623763,"CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied",Arg124Cys,Arg555Trp,rs121909210,rs121909208
15623763,"CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied",Arg124Cys,GCD,rs121909210,D003317
15623763,"CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied",Arg124Cys,LCD,rs121909210,C537881
15623763,"CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied",LCD,Arg555Trp,C537881,rs121909208
15623763,"CONCLUSIONS: Arg124Cys and Arg555Trp appear to be the predominant mutations causing LCD and GCD, respectively, in the population studied",LCD,Arg124Cys,C537881,rs121909210
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,inorganic pyrophosphate,-4-basepair G-to-A,D043564,c|SUB|G|-4|A
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,inorganic pyrophosphate,G-to-A,D043564,c|SUB|G||A
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,inorganic pyrophosphate,ANKH,D043564,56172
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,inorganic pyrophosphate,chondrocalcinosis,D043564,D002805
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,inorganic pyrophosphate,sporadic chondrocalcinosis,D043564,D002805
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,-4-basepair G-to-A,inorganic pyrophosphate,c|SUB|G|-4|A,D043564
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,-4-basepair G-to-A,G-to-A,c|SUB|G|-4|A,c|SUB|G||A
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,-4-basepair G-to-A,ANKH,c|SUB|G|-4|A,56172
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,-4-basepair G-to-A,chondrocalcinosis,c|SUB|G|-4|A,D002805
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,-4-basepair G-to-A,sporadic chondrocalcinosis,c|SUB|G|-4|A,D002805
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,G-to-A,inorganic pyrophosphate,c|SUB|G||A,D043564
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,G-to-A,-4-basepair G-to-A,c|SUB|G||A,c|SUB|G|-4|A
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,G-to-A,ANKH,c|SUB|G||A,56172
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,G-to-A,chondrocalcinosis,c|SUB|G||A,D002805
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,G-to-A,sporadic chondrocalcinosis,c|SUB|G||A,D002805
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,ANKH,inorganic pyrophosphate,56172,D043564
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,ANKH,-4-basepair G-to-A,56172,c|SUB|G|-4|A
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,ANKH,G-to-A,56172,c|SUB|G||A
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,ANKH,chondrocalcinosis,56172,D002805
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,ANKH,sporadic chondrocalcinosis,56172,D002805
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,chondrocalcinosis,inorganic pyrophosphate,D002805,D043564
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,chondrocalcinosis,-4-basepair G-to-A,D002805,c|SUB|G|-4|A
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,chondrocalcinosis,G-to-A,D002805,c|SUB|G||A
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,chondrocalcinosis,ANKH,D002805,56172
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,sporadic chondrocalcinosis,inorganic pyrophosphate,D002805,D043564
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,sporadic chondrocalcinosis,-4-basepair G-to-A,D002805,c|SUB|G|-4|A
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,sporadic chondrocalcinosis,G-to-A,D002805,c|SUB|G||A
15818664,Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate,sporadic chondrocalcinosis,ANKH,D002805,56172
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",inorganic pyrophosphate,PPi,D043564,D043564
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",inorganic pyrophosphate,familial chondrocalcinosis,D043564,D002805
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",inorganic pyrophosphate,autosomal-dominant familial chondrocalcinosis,D043564,D002805
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",inorganic pyrophosphate,ANKH,D043564,56172
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",inorganic pyrophosphate,chondrocalcinosis,D043564,D002805
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",PPi,inorganic pyrophosphate,D043564,D043564
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",PPi,familial chondrocalcinosis,D043564,D002805
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",PPi,autosomal-dominant familial chondrocalcinosis,D043564,D002805
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",PPi,ANKH,D043564,56172
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",PPi,chondrocalcinosis,D043564,D002805
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",familial chondrocalcinosis,inorganic pyrophosphate,D002805,D043564
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",familial chondrocalcinosis,PPi,D002805,D043564
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",familial chondrocalcinosis,ANKH,D002805,56172
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",autosomal-dominant familial chondrocalcinosis,inorganic pyrophosphate,D002805,D043564
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",autosomal-dominant familial chondrocalcinosis,PPi,D002805,D043564
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",autosomal-dominant familial chondrocalcinosis,ANKH,D002805,56172
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",ANKH,inorganic pyrophosphate,56172,D043564
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",ANKH,PPi,56172,D043564
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",ANKH,familial chondrocalcinosis,56172,D002805
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",ANKH,autosomal-dominant familial chondrocalcinosis,56172,D002805
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",ANKH,chondrocalcinosis,56172,D002805
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",chondrocalcinosis,inorganic pyrophosphate,D002805,D043564
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",chondrocalcinosis,PPi,D002805,D043564
15818664,"OBJECTIVE: Certain mutations in ANKH, which encodes a multiple-pass transmembrane protein that regulates inorganic pyrophosphate (PPi) transport, are linked to autosomal-dominant familial chondrocalcinosis",chondrocalcinosis,ANKH,D002805,56172
15818664,This study investigated the potential for ANKH sequence variants to promote sporadic chondrocalcinosis,ANKH,sporadic chondrocalcinosis,56172,D002805
15818664,This study investigated the potential for ANKH sequence variants to promote sporadic chondrocalcinosis,ANKH,chondrocalcinosis,56172,D002805
15818664,This study investigated the potential for ANKH sequence variants to promote sporadic chondrocalcinosis,sporadic chondrocalcinosis,ANKH,D002805,56172
15818664,This study investigated the potential for ANKH sequence variants to promote sporadic chondrocalcinosis,chondrocalcinosis,ANKH,D002805,56172
15818664,METHODS: ANKH variants identified by genomic sequencing were screened for association with chondrocalcinosis in 128 patients with severe sporadic chondrocalcinosis or pseudogout and in ethnically matched healthy controls,ANKH,chondrocalcinosis,56172,D002805
15818664,METHODS: ANKH variants identified by genomic sequencing were screened for association with chondrocalcinosis in 128 patients with severe sporadic chondrocalcinosis or pseudogout and in ethnically matched healthy controls,ANKH,pseudogout,56172,D002805
15818664,METHODS: ANKH variants identified by genomic sequencing were screened for association with chondrocalcinosis in 128 patients with severe sporadic chondrocalcinosis or pseudogout and in ethnically matched healthy controls,ANKH,sporadic chondrocalcinosis,56172,D002805
15818664,METHODS: ANKH variants identified by genomic sequencing were screened for association with chondrocalcinosis in 128 patients with severe sporadic chondrocalcinosis or pseudogout and in ethnically matched healthy controls,chondrocalcinosis,ANKH,D002805,56172
15818664,METHODS: ANKH variants identified by genomic sequencing were screened for association with chondrocalcinosis in 128 patients with severe sporadic chondrocalcinosis or pseudogout and in ethnically matched healthy controls,pseudogout,ANKH,D002805,56172
15818664,METHODS: ANKH variants identified by genomic sequencing were screened for association with chondrocalcinosis in 128 patients with severe sporadic chondrocalcinosis or pseudogout and in ethnically matched healthy controls,sporadic chondrocalcinosis,ANKH,D002805,56172
15818664,"RESULTS: Sporadic chondrocalcinosis was associated with a G-to-A transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02)",ANKH,chondrocalcinosis,56172,D002805
15818664,"RESULTS: Sporadic chondrocalcinosis was associated with a G-to-A transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02)",ANKH,Sporadic chondrocalcinosis,56172,D002805
15818664,"RESULTS: Sporadic chondrocalcinosis was associated with a G-to-A transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02)",ANKH,G-to-A,56172,c|SUB|G||A
15818664,"RESULTS: Sporadic chondrocalcinosis was associated with a G-to-A transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02)",chondrocalcinosis,ANKH,D002805,56172
15818664,"RESULTS: Sporadic chondrocalcinosis was associated with a G-to-A transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02)",chondrocalcinosis,G-to-A,D002805,c|SUB|G||A
15818664,"RESULTS: Sporadic chondrocalcinosis was associated with a G-to-A transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02)",Sporadic chondrocalcinosis,ANKH,D002805,56172
15818664,"RESULTS: Sporadic chondrocalcinosis was associated with a G-to-A transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02)",Sporadic chondrocalcinosis,G-to-A,D002805,c|SUB|G||A
15818664,"RESULTS: Sporadic chondrocalcinosis was associated with a G-to-A transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02)",G-to-A,ANKH,c|SUB|G||A,56172
15818664,"RESULTS: Sporadic chondrocalcinosis was associated with a G-to-A transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02)",G-to-A,chondrocalcinosis,c|SUB|G||A,D002805
15818664,"RESULTS: Sporadic chondrocalcinosis was associated with a G-to-A transition in the ANKH 5'-untranslated region (5'-UTR) at 4 bp upstream of the start codon (in homozygotes of the minor allele, genotype relative risk 6.0, P = 0.0006; overall genotype association P = 0.02)",G-to-A,Sporadic chondrocalcinosis,c|SUB|G||A,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",familial chondrocalcinosis,+14 bp C-to-T,D002805,c|SUB|C|14|T
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",familial chondrocalcinosis,ANKH,D002805,56172
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",familial chondrocalcinosis,GAG deletion,D002805,c|DEL||GAG
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",familial chondrocalcinosis,143-bp T-to-C,D002805,c|SUB|T|143|C
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",familial and sporadic chondrocalcinosis,+14 bp C-to-T,D002805,c|SUB|C|14|T
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",familial and sporadic chondrocalcinosis,ANKH,D002805,56172
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",familial and sporadic chondrocalcinosis,GAG deletion,D002805,c|DEL||GAG
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",familial and sporadic chondrocalcinosis,143-bp T-to-C,D002805,c|SUB|T|143|C
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",+14 bp C-to-T,familial chondrocalcinosis,c|SUB|C|14|T,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",+14 bp C-to-T,familial and sporadic chondrocalcinosis,c|SUB|C|14|T,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",+14 bp C-to-T,ANKH,c|SUB|C|14|T,56172
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",+14 bp C-to-T,GAG deletion,c|SUB|C|14|T,c|DEL||GAG
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",+14 bp C-to-T,chondrocalcinosis,c|SUB|C|14|T,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",+14 bp C-to-T,143-bp T-to-C,c|SUB|C|14|T,c|SUB|T|143|C
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",+14 bp C-to-T,sporadic chondrocalcinosis,c|SUB|C|14|T,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",ANKH,familial chondrocalcinosis,56172,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",ANKH,familial and sporadic chondrocalcinosis,56172,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",ANKH,+14 bp C-to-T,56172,c|SUB|C|14|T
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",ANKH,GAG deletion,56172,c|DEL||GAG
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",ANKH,chondrocalcinosis,56172,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",ANKH,143-bp T-to-C,56172,c|SUB|T|143|C
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",ANKH,sporadic chondrocalcinosis,56172,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",GAG deletion,familial chondrocalcinosis,c|DEL||GAG,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",GAG deletion,familial and sporadic chondrocalcinosis,c|DEL||GAG,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",GAG deletion,+14 bp C-to-T,c|DEL||GAG,c|SUB|C|14|T
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",GAG deletion,ANKH,c|DEL||GAG,56172
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",GAG deletion,chondrocalcinosis,c|DEL||GAG,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",GAG deletion,143-bp T-to-C,c|DEL||GAG,c|SUB|T|143|C
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",GAG deletion,sporadic chondrocalcinosis,c|DEL||GAG,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",chondrocalcinosis,+14 bp C-to-T,D002805,c|SUB|C|14|T
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",chondrocalcinosis,ANKH,D002805,56172
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",chondrocalcinosis,GAG deletion,D002805,c|DEL||GAG
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",chondrocalcinosis,143-bp T-to-C,D002805,c|SUB|T|143|C
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",143-bp T-to-C,familial chondrocalcinosis,c|SUB|T|143|C,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",143-bp T-to-C,familial and sporadic chondrocalcinosis,c|SUB|T|143|C,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",143-bp T-to-C,+14 bp C-to-T,c|SUB|T|143|C,c|SUB|C|14|T
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",143-bp T-to-C,ANKH,c|SUB|T|143|C,56172
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",143-bp T-to-C,GAG deletion,c|SUB|T|143|C,c|DEL||GAG
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",143-bp T-to-C,chondrocalcinosis,c|SUB|T|143|C,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",143-bp T-to-C,sporadic chondrocalcinosis,c|SUB|T|143|C,D002805
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",sporadic chondrocalcinosis,+14 bp C-to-T,D002805,c|SUB|C|14|T
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",sporadic chondrocalcinosis,ANKH,D002805,56172
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",sporadic chondrocalcinosis,GAG deletion,D002805,c|DEL||GAG
15818664,"This -4-bp transition, as well as 2 mutations previously linked with familial and sporadic chondrocalcinosis (+14 bp C-to-T and C-terminal GAG deletion, respectively), but not the French familial chondrocalcinosis kindred 143-bp T-to-C mutation, increased reticulocyte ANKH transcription/ANKH translation in vitro",sporadic chondrocalcinosis,143-bp T-to-C,D002805,c|SUB|T|143|C
15818664,"Transfection of complementary DNA for both the wild-type ANKH and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker, type X collagen",PPi,ANKH,D043564,56172
15818664,"Transfection of complementary DNA for both the wild-type ANKH and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker, type X collagen",PPi,type X collagen,D043564,1300
15818664,"Transfection of complementary DNA for both the wild-type ANKH and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker, type X collagen",PPi,hypertrophy,D043564,D006984
15818664,"Transfection of complementary DNA for both the wild-type ANKH and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker, type X collagen",ANKH,PPi,56172,D043564
15818664,"Transfection of complementary DNA for both the wild-type ANKH and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker, type X collagen",ANKH,type X collagen,56172,1300
15818664,"Transfection of complementary DNA for both the wild-type ANKH and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker, type X collagen",ANKH,hypertrophy,56172,D006984
15818664,"Transfection of complementary DNA for both the wild-type ANKH and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker, type X collagen",type X collagen,PPi,1300,D043564
15818664,"Transfection of complementary DNA for both the wild-type ANKH and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker, type X collagen",type X collagen,ANKH,1300,56172
15818664,"Transfection of complementary DNA for both the wild-type ANKH and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker, type X collagen",type X collagen,hypertrophy,1300,D006984
15818664,"Transfection of complementary DNA for both the wild-type ANKH and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker, type X collagen",hypertrophy,PPi,D006984,D043564
15818664,"Transfection of complementary DNA for both the wild-type ANKH and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker, type X collagen",hypertrophy,ANKH,D006984,56172
15818664,"Transfection of complementary DNA for both the wild-type ANKH and the -4-bp ANKH protein variant promoted increased extracellular PPi in CH-8 cells, but unexpectedly, these ANKH mutants had divergent effects on the expression of extracellular PPi and the chondrocyte hypertrophy marker, type X collagen",hypertrophy,type X collagen,D006984,1300
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,PPi,-4-bp G-to-A,D043564,c|SUB|G|-4|A
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,PPi,G-to-A,D043564,c|SUB|G||A
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,PPi,ANKH,D043564,56172
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,PPi,chondrocalcinosis,D043564,D002805
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,PPi,sporadic chondrocalcinosis,D043564,D002805
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,-4-bp G-to-A,PPi,c|SUB|G|-4|A,D043564
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,-4-bp G-to-A,G-to-A,c|SUB|G|-4|A,c|SUB|G||A
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,-4-bp G-to-A,ANKH,c|SUB|G|-4|A,56172
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,-4-bp G-to-A,chondrocalcinosis,c|SUB|G|-4|A,D002805
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,-4-bp G-to-A,sporadic chondrocalcinosis,c|SUB|G|-4|A,D002805
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,G-to-A,PPi,c|SUB|G||A,D043564
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,G-to-A,-4-bp G-to-A,c|SUB|G||A,c|SUB|G|-4|A
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,G-to-A,ANKH,c|SUB|G||A,56172
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,G-to-A,chondrocalcinosis,c|SUB|G||A,D002805
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,G-to-A,sporadic chondrocalcinosis,c|SUB|G||A,D002805
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,ANKH,PPi,56172,D043564
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,ANKH,-4-bp G-to-A,56172,c|SUB|G|-4|A
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,ANKH,G-to-A,56172,c|SUB|G||A
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,ANKH,chondrocalcinosis,56172,D002805
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,ANKH,sporadic chondrocalcinosis,56172,D002805
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,chondrocalcinosis,PPi,D002805,D043564
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,chondrocalcinosis,-4-bp G-to-A,D002805,c|SUB|G|-4|A
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,chondrocalcinosis,G-to-A,D002805,c|SUB|G||A
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,chondrocalcinosis,ANKH,D002805,56172
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,sporadic chondrocalcinosis,PPi,D002805,D043564
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,sporadic chondrocalcinosis,-4-bp G-to-A,D002805,c|SUB|G|-4|A
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,sporadic chondrocalcinosis,G-to-A,D002805,c|SUB|G||A
15818664,CONCLUSION: A subset of sporadic chondrocalcinosis appears to be heritable via a -4-bp G-to-A ANKH 5'-UTR transition that up-regulates expression of ANKH and extracellular PPi in chondrocyte cells,sporadic chondrocalcinosis,ANKH,D002805,56172
15818664,"Distinct ANKH mutations associated with heritable chondrocalcinosis may promote disease by divergent effects on extracellular PPi and chondrocyte hypertrophy, which is likely to mediate differences in the clinical phenotypes and severity of the disease.",ANKH,PPi,56172,D043564
15818664,"Distinct ANKH mutations associated with heritable chondrocalcinosis may promote disease by divergent effects on extracellular PPi and chondrocyte hypertrophy, which is likely to mediate differences in the clinical phenotypes and severity of the disease.",ANKH,chondrocalcinosis,56172,D002805
15818664,"Distinct ANKH mutations associated with heritable chondrocalcinosis may promote disease by divergent effects on extracellular PPi and chondrocyte hypertrophy, which is likely to mediate differences in the clinical phenotypes and severity of the disease.",ANKH,hypertrophy,56172,D006984
15818664,"Distinct ANKH mutations associated with heritable chondrocalcinosis may promote disease by divergent effects on extracellular PPi and chondrocyte hypertrophy, which is likely to mediate differences in the clinical phenotypes and severity of the disease.",PPi,ANKH,D043564,56172
15818664,"Distinct ANKH mutations associated with heritable chondrocalcinosis may promote disease by divergent effects on extracellular PPi and chondrocyte hypertrophy, which is likely to mediate differences in the clinical phenotypes and severity of the disease.",PPi,chondrocalcinosis,D043564,D002805
15818664,"Distinct ANKH mutations associated with heritable chondrocalcinosis may promote disease by divergent effects on extracellular PPi and chondrocyte hypertrophy, which is likely to mediate differences in the clinical phenotypes and severity of the disease.",PPi,hypertrophy,D043564,D006984
15818664,"Distinct ANKH mutations associated with heritable chondrocalcinosis may promote disease by divergent effects on extracellular PPi and chondrocyte hypertrophy, which is likely to mediate differences in the clinical phenotypes and severity of the disease.",chondrocalcinosis,ANKH,D002805,56172
15818664,"Distinct ANKH mutations associated with heritable chondrocalcinosis may promote disease by divergent effects on extracellular PPi and chondrocyte hypertrophy, which is likely to mediate differences in the clinical phenotypes and severity of the disease.",chondrocalcinosis,PPi,D002805,D043564
15818664,"Distinct ANKH mutations associated with heritable chondrocalcinosis may promote disease by divergent effects on extracellular PPi and chondrocyte hypertrophy, which is likely to mediate differences in the clinical phenotypes and severity of the disease.",hypertrophy,ANKH,D006984,56172
15818664,"Distinct ANKH mutations associated with heritable chondrocalcinosis may promote disease by divergent effects on extracellular PPi and chondrocyte hypertrophy, which is likely to mediate differences in the clinical phenotypes and severity of the disease.",hypertrophy,PPi,D006984,D043564
15824163,No Evidence for BRAF as a melanoma/nevus susceptibility gene,BRAF,melanoma,673,D008545
15824163,No Evidence for BRAF as a melanoma/nevus susceptibility gene,BRAF,nevus,673,D009506
15824163,No Evidence for BRAF as a melanoma/nevus susceptibility gene,melanoma,BRAF,D008545,673
15824163,No Evidence for BRAF as a melanoma/nevus susceptibility gene,nevus,BRAF,D009506,673
15824163,Somatic mutations of BRAF have been identified in both melanoma tumors and benign nevi,BRAF,melanoma,673,D008545
15824163,Somatic mutations of BRAF have been identified in both melanoma tumors and benign nevi,BRAF,melanoma tumors,673,D008545
15824163,Somatic mutations of BRAF have been identified in both melanoma tumors and benign nevi,BRAF,nevi,673,D009506
15824163,Somatic mutations of BRAF have been identified in both melanoma tumors and benign nevi,melanoma,BRAF,D008545,673
15824163,Somatic mutations of BRAF have been identified in both melanoma tumors and benign nevi,melanoma tumors,BRAF,D008545,673
15824163,Somatic mutations of BRAF have been identified in both melanoma tumors and benign nevi,nevi,BRAF,D009506,673
15824163,Germ line mutations in BRAF have not been identified as causal in families predisposed to melanoma,BRAF,melanoma,673,D008545
15824163,Germ line mutations in BRAF have not been identified as causal in families predisposed to melanoma,melanoma,BRAF,D008545,673
15824163,"However, a recent study suggested that a BRAF haplotype was associated with risk of sporadic melanoma in men",BRAF,melanoma,673,D008545
15824163,"However, a recent study suggested that a BRAF haplotype was associated with risk of sporadic melanoma in men",BRAF,sporadic melanoma,673,D008545
15824163,"However, a recent study suggested that a BRAF haplotype was associated with risk of sporadic melanoma in men",melanoma,BRAF,D008545,673
15824163,"However, a recent study suggested that a BRAF haplotype was associated with risk of sporadic melanoma in men",sporadic melanoma,BRAF,D008545,673
15824163,Polymorphisms or other variants in the BRAF gene may therefore act as candidate low-penetrance genes for nevus/melanoma susceptibility,BRAF,melanoma,673,D008545
15824163,Polymorphisms or other variants in the BRAF gene may therefore act as candidate low-penetrance genes for nevus/melanoma susceptibility,BRAF,nevus,673,D009506
15824163,Polymorphisms or other variants in the BRAF gene may therefore act as candidate low-penetrance genes for nevus/melanoma susceptibility,melanoma,BRAF,D008545,673
15824163,Polymorphisms or other variants in the BRAF gene may therefore act as candidate low-penetrance genes for nevus/melanoma susceptibility,nevus,BRAF,D009506,673
15824163,"Using denaturing high-pressure liquid chromatography and sequencing, we screened peripheral blood DNA from 184 familial melanoma cases for BRAF promoter variants",BRAF,familial melanoma,673,D008545
15824163,"Using denaturing high-pressure liquid chromatography and sequencing, we screened peripheral blood DNA from 184 familial melanoma cases for BRAF promoter variants",BRAF,melanoma,673,D008545
15824163,"Using denaturing high-pressure liquid chromatography and sequencing, we screened peripheral blood DNA from 184 familial melanoma cases for BRAF promoter variants",familial melanoma,BRAF,D008545,673
15824163,"Using denaturing high-pressure liquid chromatography and sequencing, we screened peripheral blood DNA from 184 familial melanoma cases for BRAF promoter variants",melanoma,BRAF,D008545,673
15824163,We identified a promoter insertion/deletion in linkage disequilibrium with the previously described BRAF polymorphism in intron 11 (rs1639679) reported to be associated with melanoma susceptibility in males,BRAF,rs1639679,673,rs1639679
15824163,We identified a promoter insertion/deletion in linkage disequilibrium with the previously described BRAF polymorphism in intron 11 (rs1639679) reported to be associated with melanoma susceptibility in males,BRAF,melanoma,673,D008545
15824163,We identified a promoter insertion/deletion in linkage disequilibrium with the previously described BRAF polymorphism in intron 11 (rs1639679) reported to be associated with melanoma susceptibility in males,rs1639679,BRAF,rs1639679,673
15824163,We identified a promoter insertion/deletion in linkage disequilibrium with the previously described BRAF polymorphism in intron 11 (rs1639679) reported to be associated with melanoma susceptibility in males,rs1639679,melanoma,rs1639679,D008545
15824163,We identified a promoter insertion/deletion in linkage disequilibrium with the previously described BRAF polymorphism in intron 11 (rs1639679) reported to be associated with melanoma susceptibility in males,melanoma,BRAF,D008545,673
15824163,We identified a promoter insertion/deletion in linkage disequilibrium with the previously described BRAF polymorphism in intron 11 (rs1639679) reported to be associated with melanoma susceptibility in males,melanoma,rs1639679,D008545,rs1639679
15824163,"We therefore investigated the contribution of this BRAF polymorphism to melanoma susceptibility in 581 consecutively recruited incident cases, 258 incident cases in a study of late relapse, 673 female general practitioner controls, and the 184 familial cases",BRAF,melanoma,673,D008545
15824163,"We therefore investigated the contribution of this BRAF polymorphism to melanoma susceptibility in 581 consecutively recruited incident cases, 258 incident cases in a study of late relapse, 673 female general practitioner controls, and the 184 familial cases",melanoma,BRAF,D008545,673
15824163,Our results therefore suggest that the BRAF polymorphism is not significantly associated with melanoma and the promoter insertion/deletion linked with the polymorphism is not a causal variant,BRAF,melanoma,673,D008545
15824163,Our results therefore suggest that the BRAF polymorphism is not significantly associated with melanoma and the promoter insertion/deletion linked with the polymorphism is not a causal variant,melanoma,BRAF,D008545,673
15824163,"In addition, we found that there was no association between the BRAF genotype and mean total number of banal or atypical nevi in either the cases or controls.",BRAF,nevi,673,D009506
15824163,"In addition, we found that there was no association between the BRAF genotype and mean total number of banal or atypical nevi in either the cases or controls.",nevi,BRAF,D009506,673
15970799,"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells",SLCO1B1,OATP-C,10599,10599
15970799,"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells",SLCO1B1,C1007G,10599,rs72559747
15970799,"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells",OATP-C,SLCO1B1,10599,10599
15970799,"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells",OATP-C,C1007G,10599,rs72559747
15970799,"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells",C1007G,SLCO1B1,rs72559747,10599
15970799,"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells",C1007G,OATP-C,rs72559747,10599
15970799,OBJECTIVES: SLCO1B1*5 and SLCO1B1*15 have been reported to reduce the clearance of pravastatin in healthy volunteers,pravastatin,SLCO1B1,D017035,10599
15970799,OBJECTIVES: SLCO1B1*5 and SLCO1B1*15 have been reported to reduce the clearance of pravastatin in healthy volunteers,SLCO1B1,pravastatin,10599,D017035
15970799,"However, there remains controversy in the effects of SLCO1B1*5 on the activity of OATP1B1 in vitro",OATP1B1,SLCO1B1,10599,10599
15970799,"However, there remains controversy in the effects of SLCO1B1*5 on the activity of OATP1B1 in vitro",SLCO1B1,OATP1B1,10599,10599
15970799,"In addition, the effect of SLCO1B1*15 on the function of OATP1B1 has not been studied using cDNA-expression systems",OATP1B1,SLCO1B1,10599,10599
15970799,"In addition, the effect of SLCO1B1*15 on the function of OATP1B1 has not been studied using cDNA-expression systems",SLCO1B1,OATP1B1,10599,10599
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",SLCO1B1,pravastatin,10599,D017035
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",SLCO1B1,OATP1B1,10599,10599
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",SLCO1B1,myopathy,10599,D009135
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",SLCO1B1,C1007G,10599,rs72559747
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",pravastatin,SLCO1B1,D017035,10599
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",pravastatin,OATP1B1,D017035,10599
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",pravastatin,myopathy,D017035,D009135
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",pravastatin,C1007G,D017035,rs72559747
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",OATP1B1,SLCO1B1,10599,10599
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",OATP1B1,pravastatin,10599,D017035
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",OATP1B1,myopathy,10599,D009135
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",OATP1B1,C1007G,10599,rs72559747
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",myopathy,SLCO1B1,D009135,10599
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",myopathy,pravastatin,D009135,D017035
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",myopathy,OATP1B1,D009135,10599
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",myopathy,C1007G,D009135,rs72559747
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",C1007G,SLCO1B1,rs72559747,10599
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",C1007G,pravastatin,rs72559747,D017035
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",C1007G,OATP1B1,rs72559747,10599
15970799,"Object of the present study was to study the influence of SLCO1B1*5, *15 and *15+C1007G, a novel haplotype found in a patient with pravastatin-induced myopathy, on the functional properties of OATP1B1 by transient expression systems of HEK293 and HeLa cells using endogenous conjugates and statins as substrates",C1007G,myopathy,rs72559747,D009135
15970799,METHODS: Transporting assays for endogenous substrates were performed using tritium labeled estradiol-17beta-D-glucuronide and estrone-3-sulfate,estradiol-17beta-D-glucuronide,tritium,C025483,D014316
15970799,METHODS: Transporting assays for endogenous substrates were performed using tritium labeled estradiol-17beta-D-glucuronide and estrone-3-sulfate,estradiol-17beta-D-glucuronide,estrone-3-sulfate,C025483,C017296
15970799,METHODS: Transporting assays for endogenous substrates were performed using tritium labeled estradiol-17beta-D-glucuronide and estrone-3-sulfate,tritium,estradiol-17beta-D-glucuronide,D014316,C025483
15970799,METHODS: Transporting assays for endogenous substrates were performed using tritium labeled estradiol-17beta-D-glucuronide and estrone-3-sulfate,tritium,estrone-3-sulfate,D014316,C017296
15970799,METHODS: Transporting assays for endogenous substrates were performed using tritium labeled estradiol-17beta-D-glucuronide and estrone-3-sulfate,estrone-3-sulfate,estradiol-17beta-D-glucuronide,C017296,C025483
15970799,METHODS: Transporting assays for endogenous substrates were performed using tritium labeled estradiol-17beta-D-glucuronide and estrone-3-sulfate,estrone-3-sulfate,tritium,C017296,D014316
15970799,"Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry",atorvastatin,pravastatin,D000069059,D017035
15970799,"Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry",atorvastatin,simvastatin,D000069059,D019821
15970799,"Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry",atorvastatin,cerivastatin,D000069059,C086276
15970799,"Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry",pravastatin,atorvastatin,D017035,D000069059
15970799,"Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry",pravastatin,simvastatin,D017035,D019821
15970799,"Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry",pravastatin,cerivastatin,D017035,C086276
15970799,"Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry",simvastatin,atorvastatin,D019821,D000069059
15970799,"Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry",simvastatin,pravastatin,D019821,D017035
15970799,"Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry",simvastatin,cerivastatin,D019821,C086276
15970799,"Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry",cerivastatin,atorvastatin,C086276,D000069059
15970799,"Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry",cerivastatin,pravastatin,C086276,D017035
15970799,"Quantitation of pravastatin, atorvastatin, cerivastatin and simvastatin were carried out using HPLC tandem mass spectrometry",cerivastatin,simvastatin,C086276,D019821
15970799,"RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin",simvastatin,C1007G,D019821,rs72559747
15970799,"RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin",simvastatin,SLCO1B1,D019821,10599
15970799,"RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin",C1007G,simvastatin,rs72559747,D019821
15970799,"RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin",C1007G,SLCO1B1,rs72559747,10599
15970799,"RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin",SLCO1B1,simvastatin,10599,D019821
15970799,"RESULTS: The transporting activities of cells expressing SLCO1B1*5, *15 and *15+C1007G decreased significantly but those of SLCO1B1*1b, *1a+C1007G and *1b+C1007G were not altered for all of the substrates tested except for simvastatin",SLCO1B1,C1007G,10599,rs72559747
15970799,"Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G",atorvastatin,pravastatin,D000069059,D017035
15970799,"Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G",atorvastatin,C1007G,D000069059,rs72559747
15970799,"Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G",atorvastatin,SLCO1B1,D000069059,10599
15970799,"Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G",pravastatin,atorvastatin,D017035,D000069059
15970799,"Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G",pravastatin,C1007G,D017035,rs72559747
15970799,"Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G",pravastatin,SLCO1B1,D017035,10599
15970799,"Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G",C1007G,atorvastatin,rs72559747,D000069059
15970799,"Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G",C1007G,pravastatin,rs72559747,D017035
15970799,"Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G",C1007G,SLCO1B1,rs72559747,10599
15970799,"Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G",SLCO1B1,atorvastatin,10599,D000069059
15970799,"Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G",SLCO1B1,pravastatin,10599,D017035
15970799,"Kinetic analysis of pravastatin and atorvastatin showed that Km values were not altered but Vmax values decreased significantly in cells expressing SLCO1B1*5, *15 and *15+C1007G",SLCO1B1,C1007G,10599,rs72559747
15970799,"Immunocytochemical study showed that SLCO1B1*5, *15 and *15+C1007G proteins are localized not only at the plasma membrane but also in the intracellular space",C1007G,SLCO1B1,rs72559747,10599
15970799,"Immunocytochemical study showed that SLCO1B1*5, *15 and *15+C1007G proteins are localized not only at the plasma membrane but also in the intracellular space",SLCO1B1,C1007G,10599,rs72559747
15970799,"CONCLUSIONS: These findings suggest that 521T>C, existing commonly in SLCO1B1*5, *15 and *15+C1007G, is the key single nucleotide polymorphism (SNP) that determines the functional properties of SLCO1B1*5, *15 and *15+C1007G allelic proteins and that decreased activities of these variant proteins are mainly caused by a sorting error produced by this SNP.",521T>C,C1007G,c|SUB|T|521|C,rs72559747
15970799,"CONCLUSIONS: These findings suggest that 521T>C, existing commonly in SLCO1B1*5, *15 and *15+C1007G, is the key single nucleotide polymorphism (SNP) that determines the functional properties of SLCO1B1*5, *15 and *15+C1007G allelic proteins and that decreased activities of these variant proteins are mainly caused by a sorting error produced by this SNP.",521T>C,SLCO1B1,c|SUB|T|521|C,10599
15970799,"CONCLUSIONS: These findings suggest that 521T>C, existing commonly in SLCO1B1*5, *15 and *15+C1007G, is the key single nucleotide polymorphism (SNP) that determines the functional properties of SLCO1B1*5, *15 and *15+C1007G allelic proteins and that decreased activities of these variant proteins are mainly caused by a sorting error produced by this SNP.",C1007G,521T>C,rs72559747,c|SUB|T|521|C
15970799,"CONCLUSIONS: These findings suggest that 521T>C, existing commonly in SLCO1B1*5, *15 and *15+C1007G, is the key single nucleotide polymorphism (SNP) that determines the functional properties of SLCO1B1*5, *15 and *15+C1007G allelic proteins and that decreased activities of these variant proteins are mainly caused by a sorting error produced by this SNP.",C1007G,SLCO1B1,rs72559747,10599
15970799,"CONCLUSIONS: These findings suggest that 521T>C, existing commonly in SLCO1B1*5, *15 and *15+C1007G, is the key single nucleotide polymorphism (SNP) that determines the functional properties of SLCO1B1*5, *15 and *15+C1007G allelic proteins and that decreased activities of these variant proteins are mainly caused by a sorting error produced by this SNP.",SLCO1B1,521T>C,10599,c|SUB|T|521|C
15970799,"CONCLUSIONS: These findings suggest that 521T>C, existing commonly in SLCO1B1*5, *15 and *15+C1007G, is the key single nucleotide polymorphism (SNP) that determines the functional properties of SLCO1B1*5, *15 and *15+C1007G allelic proteins and that decreased activities of these variant proteins are mainly caused by a sorting error produced by this SNP.",SLCO1B1,C1007G,10599,rs72559747
16001362,An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains,cerebellar ataxia,Rho guanine-nucleotide exchange-factor,D002524,9138
16001362,An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains,ataxia,Rho guanine-nucleotide exchange-factor,D001259,9138
16001362,An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains,autosomal dominant cerebellar ataxia,Rho guanine-nucleotide exchange-factor,OMIM:604121,9138
16001362,An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains,Rho guanine-nucleotide exchange-factor,cerebellar ataxia,9138,D002524
16001362,An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains,Rho guanine-nucleotide exchange-factor,ataxia,9138,D001259
16001362,An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains,Rho guanine-nucleotide exchange-factor,autosomal dominant cerebellar ataxia,9138,OMIM:604121
16001362,"After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called ""puratrophin-1"" (Purkinje cell atrophy associated protein-1)",C-->T,Purkinje cell atrophy associated protein-1,c|SUB|C||T,25894
16001362,"After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called ""puratrophin-1"" (Purkinje cell atrophy associated protein-1)",C-->T,puratrophin-1,c|SUB|C||T,25894
16001362,"After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called ""puratrophin-1"" (Purkinje cell atrophy associated protein-1)",C-->T,DKFZP434I216,c|SUB|C||T,25894
16001362,"After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called ""puratrophin-1"" (Purkinje cell atrophy associated protein-1)",Purkinje cell atrophy associated protein-1,C-->T,25894,c|SUB|C||T
16001362,"After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called ""puratrophin-1"" (Purkinje cell atrophy associated protein-1)",Purkinje cell atrophy associated protein-1,puratrophin-1,25894,25894
16001362,"After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called ""puratrophin-1"" (Purkinje cell atrophy associated protein-1)",Purkinje cell atrophy associated protein-1,DKFZP434I216,25894,25894
16001362,"After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called ""puratrophin-1"" (Purkinje cell atrophy associated protein-1)",puratrophin-1,C-->T,25894,c|SUB|C||T
16001362,"After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called ""puratrophin-1"" (Purkinje cell atrophy associated protein-1)",puratrophin-1,Purkinje cell atrophy associated protein-1,25894,25894
16001362,"After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called ""puratrophin-1"" (Purkinje cell atrophy associated protein-1)",puratrophin-1,DKFZP434I216,25894,25894
16001362,"After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called ""puratrophin-1"" (Purkinje cell atrophy associated protein-1)",DKFZP434I216,C-->T,25894,c|SUB|C||T
16001362,"After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called ""puratrophin-1"" (Purkinje cell atrophy associated protein-1)",DKFZP434I216,Purkinje cell atrophy associated protein-1,25894,25894
16001362,"After restricting the candidate region in chromosome 16q22.1 by haplotype analysis, we found that all patients from 52 unrelated Japanese families harbor a heterozygous C-->T single-nucleotide substitution, 16 nt upstream of the putative translation initiation site of the gene for a hypothetical protein DKFZP434I216, which we have called ""puratrophin-1"" (Purkinje cell atrophy associated protein-1)",DKFZP434I216,puratrophin-1,25894,25894
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",GEF,guanine-nucleotide exchange factor,9138,9138
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",GEF,actin,9138,60
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",GEF,puratrophin-1,9138,25894
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",GEF,Rho GTPases,9138,387
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",guanine-nucleotide exchange factor,GEF,9138,9138
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",guanine-nucleotide exchange factor,actin,9138,60
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",guanine-nucleotide exchange factor,puratrophin-1,9138,25894
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",guanine-nucleotide exchange factor,Rho GTPases,9138,387
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",actin,GEF,60,9138
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",actin,guanine-nucleotide exchange factor,60,9138
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",actin,puratrophin-1,60,25894
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",actin,Rho GTPases,60,387
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",puratrophin-1,GEF,25894,9138
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",puratrophin-1,guanine-nucleotide exchange factor,25894,9138
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",puratrophin-1,actin,25894,60
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",puratrophin-1,Rho GTPases,25894,387
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",Rho GTPases,GEF,387,9138
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",Rho GTPases,guanine-nucleotide exchange factor,387,9138
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",Rho GTPases,actin,387,60
16001362,"The full-length puratrophin-1 mRNA had an open reading frame of 3,576 nt, predicted to contain important domains, including the spectrin repeat and the guanine-nucleotide exchange factor (GEF) for Rho GTPases, followed by the Dbl-homologous domain, which indicates the role of puratrophin-1 in intracellular signaling and actin dynamics at the Golgi apparatus",Rho GTPases,puratrophin-1,387,25894
16001362,"Puratrophin-1--normally expressed in a wide range of cells, including epithelial hair cells in the cochlea--was aggregated in Purkinje cells of the chromosome 16q22.1-linked ADCA brains",ADCA,Puratrophin-1,OMIM:604121,25894
16001362,"Puratrophin-1--normally expressed in a wide range of cells, including epithelial hair cells in the cochlea--was aggregated in Purkinje cells of the chromosome 16q22.1-linked ADCA brains",Puratrophin-1,ADCA,25894,OMIM:604121
16001362,"The present study highlights the importance of the 5' untranslated region (UTR) in identification of genes of human disease, suggests that a single-nucleotide substitution in the 5' UTR could be associated with protein aggregation, and indicates that the GEF protein is associated with cerebellar degeneration in humans.",GEF,cerebellar degeneration,9138,D013132
16001362,"The present study highlights the importance of the 5' untranslated region (UTR) in identification of genes of human disease, suggests that a single-nucleotide substitution in the 5' UTR could be associated with protein aggregation, and indicates that the GEF protein is associated with cerebellar degeneration in humans.",cerebellar degeneration,GEF,D013132,9138
16321363,Congenital disorder of glycosylation Ic due to a de novo deletion and an hALG-6 mutation,hALG-6,Congenital disorder of glycosylation Ic,29929,C535741
16321363,Congenital disorder of glycosylation Ic due to a de novo deletion and an hALG-6 mutation,Congenital disorder of glycosylation Ic,hALG-6,C535741,29929
16321363,"Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A)",lipid-linked oligosaccharides,338G>A,C023023,rs768372697
16321363,"Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A)",lipid-linked oligosaccharides,glucose,C023023,D005947
16321363,"Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A)",lipid-linked oligosaccharides,ALG6,C023023,29929
16321363,"Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A)",338G>A,lipid-linked oligosaccharides,rs768372697,C023023
16321363,"Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A)",338G>A,glucose,rs768372697,D005947
16321363,"Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A)",338G>A,ALG6,rs768372697,29929
16321363,"Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A)",glucose,lipid-linked oligosaccharides,D005947,C023023
16321363,"Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A)",glucose,338G>A,D005947,rs768372697
16321363,"Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A)",glucose,ALG6,D005947,29929
16321363,"Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A)",ALG6,lipid-linked oligosaccharides,29929,C023023
16321363,"Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A)",ALG6,338G>A,29929,rs768372697
16321363,"Her cells accumulated lipid-linked oligosaccharides lacking three glucose residues, and sequencing of the ALG6 gene showed what initially appeared to be a homozygous novel point mutation (338G>A)",ALG6,glucose,29929,D005947
16321363,"We used high-resolution karyotyping to confirm a deletion (10-12Mb) [del(1)(p31.2p32.3)] and found no structural abnormalities in the father, suggesting a de novo event",del(1)(p31.2p32.3),deletion (10-12Mb),c|DEL|p31.2_p32.3|,c|DEL||10-12MB
16321363,"We used high-resolution karyotyping to confirm a deletion (10-12Mb) [del(1)(p31.2p32.3)] and found no structural abnormalities in the father, suggesting a de novo event",deletion (10-12Mb),del(1)(p31.2p32.3),c|DEL||10-12MB,c|DEL|p31.2_p32.3|
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",CDKN2B,MALT1,1030,10892
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",CDKN2B,BCL-2,1030,596
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",CDKN2B,CDKN2A,1030,1029
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",CDKN2B,PCLBCL,1030,D016403
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",CDKN2B,NSG-x,1030,27099
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",MALT1,CDKN2B,10892,1030
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",MALT1,BCL-2,10892,596
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",MALT1,CDKN2A,10892,1029
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",MALT1,PCLBCL,10892,D016403
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",MALT1,NSG-x,10892,27099
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",BCL-2,CDKN2B,596,1030
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",BCL-2,MALT1,596,10892
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",BCL-2,CDKN2A,596,1029
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",BCL-2,PCLBCL,596,D016403
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",BCL-2,NSG-x,596,27099
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",CDKN2A,CDKN2B,1029,1030
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",CDKN2A,MALT1,1029,10892
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",CDKN2A,BCL-2,1029,596
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",CDKN2A,PCLBCL,1029,D016403
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",CDKN2A,NSG-x,1029,27099
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",PCLBCL,CDKN2B,D016403,1030
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",PCLBCL,MALT1,D016403,10892
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",PCLBCL,BCL-2,D016403,596
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",PCLBCL,CDKN2A,D016403,1029
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",PCLBCL,NSG-x,D016403,27099
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",NSG-x,CDKN2B,27099,1030
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",NSG-x,MALT1,27099,10892
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",NSG-x,BCL-2,27099,596
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",NSG-x,CDKN2A,27099,1029
16330669,"In PCLBCL, leg type, most prominent aberrations were a high-level DNA amplification of 18q21.31-q21.33 (67%), including the BCL-2 and MALT1 genes as confirmed by FISH, and deletions of a small region within 9p21.3 containing the CDKN2A, CDKN2B, and NSG-x genes",NSG-x,PCLBCL,27099,D016403
16330669,"Complete methylation of the promoter region of the CDKN2A gene was demonstrated in one PCLBCL, leg type, patient with hemizygous deletion, in one patient without deletion, but in zero of 19 patients with PCFCL",CDKN2A,PCFCL,1029,D008224
16330669,"Complete methylation of the promoter region of the CDKN2A gene was demonstrated in one PCLBCL, leg type, patient with hemizygous deletion, in one patient without deletion, but in zero of 19 patients with PCFCL",CDKN2A,PCLBCL,1029,D016403
16330669,"Complete methylation of the promoter region of the CDKN2A gene was demonstrated in one PCLBCL, leg type, patient with hemizygous deletion, in one patient without deletion, but in zero of 19 patients with PCFCL",PCFCL,CDKN2A,D008224,1029
16330669,"Complete methylation of the promoter region of the CDKN2A gene was demonstrated in one PCLBCL, leg type, patient with hemizygous deletion, in one patient without deletion, but in zero of 19 patients with PCFCL",PCLBCL,CDKN2A,D016403,1029
16330669,"Seven of seven PCLBCL, leg type, patients with deletion of 9p21.3 and/or complete methylation of CDKN2A died as a result of their lymphoma",CDKN2A,PCLBCL,1029,D016403
16330669,"Seven of seven PCLBCL, leg type, patients with deletion of 9p21.3 and/or complete methylation of CDKN2A died as a result of their lymphoma",CDKN2A,lymphoma,1029,D008223
16330669,"Seven of seven PCLBCL, leg type, patients with deletion of 9p21.3 and/or complete methylation of CDKN2A died as a result of their lymphoma",PCLBCL,CDKN2A,D016403,1029
16330669,"Seven of seven PCLBCL, leg type, patients with deletion of 9p21.3 and/or complete methylation of CDKN2A died as a result of their lymphoma",lymphoma,CDKN2A,D008223,1029
16330669,"Inactivation of CDKN2A by either deletion or methylation of its promoter could be an important prognostic parameter for the group of PCLBCL, leg type.",CDKN2A,PCLBCL,1029,D016403
16330669,"Inactivation of CDKN2A by either deletion or methylation of its promoter could be an important prognostic parameter for the group of PCLBCL, leg type.",PCLBCL,CDKN2A,D016403,1029
16419642,"A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes",mineralocorticoid receptor,F826Y,4306,rs13306592
16419642,"A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes",mineralocorticoid receptor,hypertensive,4306,D006973
16419642,"A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes",mineralocorticoid receptor,hypertensives,4306,D006973
16419642,"A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes",F826Y,mineralocorticoid receptor,rs13306592,4306
16419642,"A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes",F826Y,hypertensive,rs13306592,D006973
16419642,"A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes",F826Y,hypertensives,rs13306592,D006973
16419642,"A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes",hypertensive,mineralocorticoid receptor,D006973,4306
16419642,"A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes",hypertensive,F826Y,D006973,rs13306592
16419642,"A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes",hypertensives,mineralocorticoid receptor,D006973,4306
16419642,"A novel missense mutation, F826Y, in the mineralocorticoid receptor gene in Japanese hypertensives: its implications for clinical phenotypes",hypertensives,F826Y,D006973,rs13306592
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",MR,S810L,4306,rs41511344
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",MR,hypertension,4306,D006973
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",MR,NR3C2,4306,4306
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",MR,mineralocorticoid receptor,4306,4306
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",S810L,MR,rs41511344,4306
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",S810L,hypertension,rs41511344,D006973
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",S810L,NR3C2,rs41511344,4306
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",S810L,mineralocorticoid receptor,rs41511344,4306
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",hypertension,MR,D006973,4306
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",hypertension,S810L,D006973,rs41511344
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",hypertension,NR3C2,D006973,4306
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",hypertension,mineralocorticoid receptor,D006973,4306
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",NR3C2,MR,4306,4306
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",NR3C2,S810L,4306,rs41511344
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",NR3C2,hypertension,4306,D006973
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",NR3C2,mineralocorticoid receptor,4306,4306
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",mineralocorticoid receptor,MR,4306,4306
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",mineralocorticoid receptor,S810L,4306,rs41511344
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",mineralocorticoid receptor,hypertension,4306,D006973
16419642,"A gain-of-function mutation resulting in the S810L amino acid substitution in the hormone-binding domain of the mineralocorticoid receptor (MR, locus symbol NR3C2) is responsible for early-onset hypertension that is exacerbated in pregnancy",mineralocorticoid receptor,NR3C2,4306,4306
16419642,"Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR",MR,S810L,4306,rs41511344
16419642,"Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR",MR,hypertension,4306,D006973
16419642,"Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR",S810L,MR,rs41511344,4306
16419642,"Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR",S810L,hypertension,rs41511344,D006973
16419642,"Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR",hypertension,MR,D006973,4306
16419642,"Here, we screened 942 Japanese patients with hypertension for the S810L mutation in exon 6 in the MR",hypertension,S810L,D006973,rs41511344
16419642,"We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese",S810L,hypertensive,rs41511344,D006973
16419642,"We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese",S810L,hypertension,rs41511344,D006973
16419642,"We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese",S810L,essential hypertension,rs41511344,D000075222
16419642,"We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese",hypertensive,S810L,D006973,rs41511344
16419642,"We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese",hypertension,S810L,D006973,rs41511344
16419642,"We did not identify the S810L mutation in our hypertensive population, indicating that S810L does not play a major role in the etiology of essential hypertension in Japanese",essential hypertension,S810L,D000075222,rs41511344
16419642,"However, we identified a novel missense mutation, F826Y, in three patients in a heterozygous state, in addition to four single nucleotide polymorphisms, including one synonymous mutation (L809L)",F826Y,L809L,rs13306592,rs145670736
16419642,"However, we identified a novel missense mutation, F826Y, in three patients in a heterozygous state, in addition to four single nucleotide polymorphisms, including one synonymous mutation (L809L)",L809L,F826Y,rs145670736,rs13306592
16419642,The F826Y mutation is present in the MR hormone-binding domain and might affect the ligand affinity,MR,F826Y,4306,rs13306592
16419642,The F826Y mutation is present in the MR hormone-binding domain and might affect the ligand affinity,F826Y,MR,rs13306592,4306
16419642,"The F826Y mutation was also identified in 13 individuals (5 hypertensives and 8 normotensives) in a Japanese general population (n=3,655)",hypertensives,F826Y,D006973,rs13306592
16419642,"The F826Y mutation was also identified in 13 individuals (5 hypertensives and 8 normotensives) in a Japanese general population (n=3,655)",F826Y,hypertensives,rs13306592,D006973
16419642,"The F826Y mutation was also identified in 13 individuals (5 hypertensives and 8 normotensives) in a Japanese general population (n=3,655)",F826Y,hypertensive,rs13306592,D006973
16419642,"The F826Y mutation was also identified in 13 individuals (5 hypertensives and 8 normotensives) in a Japanese general population (n=3,655)",hypertensive,F826Y,D006973,rs13306592
16419642,"The frequencies of the F826Y mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect hypertension",F826Y,hypertensive,rs13306592,D006973
16419642,"The frequencies of the F826Y mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect hypertension",F826Y,hypertension,rs13306592,D006973
16419642,"The frequencies of the F826Y mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect hypertension",hypertensive,F826Y,D006973,rs13306592
16419642,"The frequencies of the F826Y mutation in the hypertensive population (3/942) and in the hypertensive group (5/ 1,480) and the normotensive group (8/2,175) in the general population were not significantly different, suggesting that this mutation does not greatly affect hypertension",hypertension,F826Y,D006973,rs13306592
16419642,"Although it is unclear at present whether or not the F826Y mutation makes a substantial contribution to the mineralocorticoid receptor activity, this missense mutation may contribute, to some extent, to clinical phenotypes through its effects on MR.",MR,mineralocorticoid receptor,4306,4306
16419642,"Although it is unclear at present whether or not the F826Y mutation makes a substantial contribution to the mineralocorticoid receptor activity, this missense mutation may contribute, to some extent, to clinical phenotypes through its effects on MR.",MR,F826Y,4306,rs13306592
16419642,"Although it is unclear at present whether or not the F826Y mutation makes a substantial contribution to the mineralocorticoid receptor activity, this missense mutation may contribute, to some extent, to clinical phenotypes through its effects on MR.",mineralocorticoid receptor,MR,4306,4306
16419642,"Although it is unclear at present whether or not the F826Y mutation makes a substantial contribution to the mineralocorticoid receptor activity, this missense mutation may contribute, to some extent, to clinical phenotypes through its effects on MR.",mineralocorticoid receptor,F826Y,4306,rs13306592
16419642,"Although it is unclear at present whether or not the F826Y mutation makes a substantial contribution to the mineralocorticoid receptor activity, this missense mutation may contribute, to some extent, to clinical phenotypes through its effects on MR.",F826Y,MR,rs13306592,4306
16419642,"Although it is unclear at present whether or not the F826Y mutation makes a substantial contribution to the mineralocorticoid receptor activity, this missense mutation may contribute, to some extent, to clinical phenotypes through its effects on MR.",F826Y,mineralocorticoid receptor,rs13306592,4306
16629641,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin,ribavirin,HCV infection,D012254,D006526
16629641,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin,ribavirin,pegylated interferon,D012254,3439
16629641,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin,HCV infection,ribavirin,D006526,D012254
16629641,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin,HCV infection,pegylated interferon,D006526,3439
16629641,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin,pegylated interferon,ribavirin,3439,D012254
16629641,The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin,pegylated interferon,HCV infection,3439,D006526
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",ribavirin,renal or cardiovascular disorders,D012254,"D002318,D007674"
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",ribavirin,anemia,D012254,D000740
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",ribavirin,HCV infection,D012254,D006526
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",ribavirin,Hemoglobin,D012254,3039
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",ribavirin,hemolysis,D012254,D006461
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",renal or cardiovascular disorders,ribavirin,"D002318,D007674",D012254
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",renal or cardiovascular disorders,Hemoglobin,"D002318,D007674",3039
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",anemia,ribavirin,D000740,D012254
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",anemia,Hemoglobin,D000740,3039
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",HCV infection,ribavirin,D006526,D012254
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",HCV infection,Hemoglobin,D006526,3039
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",Hemoglobin,ribavirin,3039,D012254
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",Hemoglobin,renal or cardiovascular disorders,3039,"D002318,D007674"
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",Hemoglobin,anemia,3039,D000740
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",Hemoglobin,HCV infection,3039,D006526
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",Hemoglobin,hemolysis,3039,D006461
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",hemolysis,ribavirin,D006461,D012254
16629641,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders",hemolysis,Hemoglobin,D006461,3039
16629641,"Although ribavirin-associated anemia can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates",ribavirin,anemia,D012254,D000740
16629641,"Although ribavirin-associated anemia can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates",anemia,ribavirin,D000740,D012254
16629641,Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages,ribavirin,erythropoietin,D012254,2056
16629641,Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages,ribavirin,anemia,D012254,D000740
16629641,Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages,erythropoietin,ribavirin,2056,D012254
16629641,Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages,erythropoietin,anemia,2056,D000740
16629641,Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages,anemia,ribavirin,D000740,D012254
16629641,Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages,anemia,erythropoietin,D000740,2056
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",ribavirin,anemia,D012254,D000740
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",ribavirin,Viramidine,D012254,C026956
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",ribavirin,chronic hepatitis C,D012254,D019698
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",ribavirin,hemolytic anemia,D012254,D000743
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",anemia,ribavirin,D000740,D012254
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",anemia,Viramidine,D000740,C026956
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",Viramidine,ribavirin,C026956,D012254
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",Viramidine,anemia,C026956,D000740
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",Viramidine,chronic hepatitis C,C026956,D019698
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",Viramidine,hemolytic anemia,C026956,D000743
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",chronic hepatitis C,ribavirin,D019698,D012254
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",chronic hepatitis C,Viramidine,D019698,C026956
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",hemolytic anemia,ribavirin,D000743,D012254
16629641,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",hemolytic anemia,Viramidine,D000743,C026956
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,isoproterenol,cardiac hypertrophy,D007545,D006332
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,isoproterenol,angiotensin,D007545,24179
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,isoproterenol,angiotensinogen,D007545,24179
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,isoproterenol,hypertrophy,D007545,D006984
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,cardiac hypertrophy,isoproterenol,D006332,D007545
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,cardiac hypertrophy,angiotensin,D006332,24179
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,cardiac hypertrophy,angiotensinogen,D006332,24179
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,angiotensin,isoproterenol,24179,D007545
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,angiotensin,cardiac hypertrophy,24179,D006332
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,angiotensin,angiotensinogen,24179,24179
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,angiotensin,hypertrophy,24179,D006984
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,angiotensinogen,isoproterenol,24179,D007545
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,angiotensinogen,cardiac hypertrophy,24179,D006332
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,angiotensinogen,angiotensin,24179,24179
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,angiotensinogen,hypertrophy,24179,D006984
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,hypertrophy,isoproterenol,D006984,D007545
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,hypertrophy,angiotensin,D006984,24179
16731636,Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen,hypertrophy,angiotensinogen,D006984,24179
16731636,We have previously shown that a permanent deficiency in the brain renin-angiotensin system (RAS) may increase the sensitivity of the baroreflex control of heart rate,renin,angiotensin,24715,24179
16731636,We have previously shown that a permanent deficiency in the brain renin-angiotensin system (RAS) may increase the sensitivity of the baroreflex control of heart rate,angiotensin,renin,24179,24715
16731636,In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (beta-AR) agonist isoproterenol (Iso),isoproterenol,beta-AR,D007545,24925
16731636,In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (beta-AR) agonist isoproterenol (Iso),isoproterenol,beta-adrenoceptor,D007545,24925
16731636,In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (beta-AR) agonist isoproterenol (Iso),isoproterenol,Iso,D007545,D007545
16731636,In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (beta-AR) agonist isoproterenol (Iso),beta-AR,isoproterenol,24925,D007545
16731636,In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (beta-AR) agonist isoproterenol (Iso),beta-AR,beta-adrenoceptor,24925,24925
16731636,In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (beta-AR) agonist isoproterenol (Iso),beta-AR,Iso,24925,D007545
16731636,In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (beta-AR) agonist isoproterenol (Iso),beta-adrenoceptor,isoproterenol,24925,D007545
16731636,In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (beta-AR) agonist isoproterenol (Iso),beta-adrenoceptor,beta-AR,24925,24925
16731636,In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (beta-AR) agonist isoproterenol (Iso),beta-adrenoceptor,Iso,24925,D007545
16731636,In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (beta-AR) agonist isoproterenol (Iso),Iso,isoproterenol,D007545,D007545
16731636,In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (beta-AR) agonist isoproterenol (Iso),Iso,beta-AR,D007545,24925
16731636,In this study we aimed at studying the involvement of the brain RAS in the cardiac reactivity to the beta-adrenoceptor (beta-AR) agonist isoproterenol (Iso),Iso,beta-adrenoceptor,D007545,24925
16731636,Transgenic rats with low brain angiotensinogen (TGR) were used,angiotensinogen,angiotensin,24179,24179
16731636,Transgenic rats with low brain angiotensinogen (TGR) were used,angiotensin,angiotensinogen,24179,24179
16731636,"LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs",LV hypertrophy,Iso,D006332,D007545
16731636,"LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs",Iso,LV hypertrophy,D007545,D006332
16731636,"LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs",Iso,hypertrophy,D007545,D006984
16731636,"LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats (in g LV wt/100 g body wt, 0.28 +/- 0.004 vs",hypertrophy,Iso,D006984,D007545
16731636,The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats,LV hypertrophy,beta-AR,D006332,24925
16731636,The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats,LV hypertrophy,beta-AR kinase-1,D006332,25238
16731636,The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats,beta-AR,LV hypertrophy,24925,D006332
16731636,The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats,beta-AR,beta-AR kinase-1,24925,25238
16731636,The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats,beta-AR,hypertrophy,24925,D006984
16731636,The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats,beta-AR kinase-1,LV hypertrophy,25238,D006332
16731636,The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats,beta-AR kinase-1,beta-AR,25238,24925
16731636,The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats,beta-AR kinase-1,hypertrophy,25238,D006984
16731636,The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats,hypertrophy,beta-AR,D006984,24925
16731636,The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta-AR and upregulation of LV beta-AR kinase-1 mRNA levels compared with those in SD rats,hypertrophy,beta-AR kinase-1,D006984,25238
16731636,The decrease in the heart rate (HR) induced by the beta-AR antagonist metoprolol in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs,beta-AR,metoprolol,24925,D008790
16731636,The decrease in the heart rate (HR) induced by the beta-AR antagonist metoprolol in conscious rats was significantly attenuated in TGR compared with SD rats (-9.9 +/- 1.7% vs,metoprolol,beta-AR,D008790,24925
16731636,"These results indicate that TGR are more sensitive to beta-AR agonist-induced cardiac inotropic response and hypertrophy, possibly due to chronically low sympathetic outflow directed to the heart.",beta-AR,hypertrophy,24925,D006984
16731636,"These results indicate that TGR are more sensitive to beta-AR agonist-induced cardiac inotropic response and hypertrophy, possibly due to chronically low sympathetic outflow directed to the heart.",hypertrophy,beta-AR,D006984,24925
16737910,Identification of the nuclear localization motif in the ETV6 (TEL) protein,TEL,ETV6,2120,2120
16737910,Identification of the nuclear localization motif in the ETV6 (TEL) protein,ETV6,TEL,2120,2120
16737910,"ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer",TEL,ETV6,2120,2120
16737910,"ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer",TEL,cancer,2120,D009369
16737910,"ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer",TEL,Translocation-Ets-Leukemia,2120,2120
16737910,"ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer",ETV6,TEL,2120,2120
16737910,"ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer",ETV6,cancer,2120,D009369
16737910,"ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer",ETV6,Translocation-Ets-Leukemia,2120,2120
16737910,"ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer",cancer,TEL,D009369,2120
16737910,"ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer",cancer,ETV6,D009369,2120
16737910,"ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer",cancer,Translocation-Ets-Leukemia,D009369,2120
16737910,"ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer",Translocation-Ets-Leukemia,TEL,2120,2120
16737910,"ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer",Translocation-Ets-Leukemia,ETV6,2120,2120
16737910,"ETV6, or Translocation-Ets-Leukemia (TEL), is an ETS family transcriptional repressor that is essential for establishing hematopoiesis in neonatal bone marrow, and is frequently a target of chromosomal translocations in human cancer",Translocation-Ets-Leukemia,cancer,2120,D009369
16737910,"Furthermore, when a fragment of ETV6 comprised of amino acids 332-452 was fused to cytoplasmic beta-galactosidase protein, the fusion protein was able to enter the nucleus",beta-galactosidase,ETV6,2720,2120
16737910,"Furthermore, when a fragment of ETV6 comprised of amino acids 332-452 was fused to cytoplasmic beta-galactosidase protein, the fusion protein was able to enter the nucleus",ETV6,beta-galactosidase,2120,2720
16755009,"The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice",cholesterol,cholinesterase,D002784,12038
16755009,"The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice",cholinesterase,cholesterol,12038,D002784
16755009,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice",extract of Daucus carota seeds,DCE,D010936,D010936
16755009,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice",DCE,extract of Daucus carota seeds,D010936,D010936
16755009,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models",amnesia,scopolamine,D000647,D012601
16755009,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models",amnesia,Diazepam,D000647,D003975
16755009,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models",scopolamine,amnesia,D012601,D000647
16755009,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models",scopolamine,Diazepam,D012601,D003975
16755009,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models",Diazepam,amnesia,D003975,D000647
16755009,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models",Diazepam,scopolamine,D003975,D012601
16755009,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.)",DCE,diazepam,D010936,D003975
16755009,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.)",DCE,scopolamine,D010936,D012601
16755009,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.)",DCE,amnesia,D010936,D000647
16755009,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.)",diazepam,DCE,D003975,D010936
16755009,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.)",diazepam,scopolamine,D003975,D012601
16755009,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.)",diazepam,amnesia,D003975,D000647
16755009,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.)",scopolamine,DCE,D012601,D010936
16755009,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.)",scopolamine,diazepam,D012601,D003975
16755009,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.)",scopolamine,amnesia,D012601,D000647
16755009,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.)",amnesia,DCE,D000647,D010936
16755009,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.)",amnesia,diazepam,D000647,D003975
16755009,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.)",amnesia,scopolamine,D000647,D012601
16755009,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice",cholinesterase,cholesterol,12038,D002784
16755009,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice",cholinesterase,acetylcholinesterase,12038,11423
16755009,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice",cholinesterase,Daucus carota extract,12038,D010936
16755009,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice",cholesterol,cholinesterase,D002784,12038
16755009,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice",cholesterol,acetylcholinesterase,D002784,11423
16755009,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice",cholesterol,Daucus carota extract,D002784,D010936
16755009,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice",acetylcholinesterase,cholinesterase,11423,12038
16755009,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice",acetylcholinesterase,cholesterol,11423,D002784
16755009,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice",acetylcholinesterase,Daucus carota extract,11423,D010936
16755009,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice",Daucus carota extract,cholinesterase,D010936,12038
16755009,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice",Daucus carota extract,cholesterol,D010936,D002784
16755009,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice",Daucus carota extract,acetylcholinesterase,D010936,11423
16755009,The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg/kg was 22% in young and 19% in aged mice,DCE,cholinesterase,D010936,12038
16755009,The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg/kg was 22% in young and 19% in aged mice,cholinesterase,DCE,12038,D010936
16755009,"There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE",cholesterol,DCE,D002784,D010936
16755009,"There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE",DCE,cholesterol,D010936,D002784
16755009,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",cholesterol,DCE,D002784,D010936
16755009,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",cholesterol,cholinesterase,D002784,12038
16755009,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",cholesterol,cognitive dysfunctions,D002784,D003072
16755009,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",DCE,cholesterol,D010936,D002784
16755009,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",DCE,cholinesterase,D010936,12038
16755009,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",DCE,cognitive dysfunctions,D010936,D003072
16755009,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",cholinesterase,cholesterol,12038,D002784
16755009,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",cholinesterase,DCE,12038,D010936
16755009,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",cholinesterase,cognitive dysfunctions,12038,D003072
16755009,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",cognitive dysfunctions,cholesterol,D003072,D002784
16755009,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",cognitive dysfunctions,DCE,D003072,D010936
16755009,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",cognitive dysfunctions,cholinesterase,D003072,12038
16822828,Genotyping of five chinese patients with 17alpha-hydroxylase deficiency diagnosed through high-performance liquid chromatography serum adrenal profile: identification of two novel CYP17 mutations,CYP17,17alpha-hydroxylase deficiency,1586,C538237
16822828,Genotyping of five chinese patients with 17alpha-hydroxylase deficiency diagnosed through high-performance liquid chromatography serum adrenal profile: identification of two novel CYP17 mutations,17alpha-hydroxylase deficiency,CYP17,C538237,1586
16822828,CONTEXT: 17alpha-Hydroxylase deficiency is a rare form of congenital adrenal hyperplasia caused by CYP17 gene mutations,17alpha-Hydroxylase deficiency,CYP17,C538237,1586
16822828,CONTEXT: 17alpha-Hydroxylase deficiency is a rare form of congenital adrenal hyperplasia caused by CYP17 gene mutations,CYP17,17alpha-Hydroxylase deficiency,1586,C538237
16822828,CONTEXT: 17alpha-Hydroxylase deficiency is a rare form of congenital adrenal hyperplasia caused by CYP17 gene mutations,CYP17,congenital adrenal hyperplasia,1586,D000312
16822828,CONTEXT: 17alpha-Hydroxylase deficiency is a rare form of congenital adrenal hyperplasia caused by CYP17 gene mutations,congenital adrenal hyperplasia,CYP17,D000312,1586
16822828,"Among them, V311fs and Y329fs are two novel frame-shifting mutations",V311fs,Y329fs,p|FS|V|311||,p|FS|Y|329||
16822828,"Among them, V311fs and Y329fs are two novel frame-shifting mutations",Y329fs,V311fs,p|FS|Y|329||,p|FS|V|311||
16822828,V311fs is an 8-bp nucleotide (TTAAATGG) deletion in exon 5,8-bp nucleotide (TTAAATGG) deletion,V311fs,c|DEL||TTAAATGG,p|FS|V|311||
16822828,V311fs is an 8-bp nucleotide (TTAAATGG) deletion in exon 5,V311fs,8-bp nucleotide (TTAAATGG) deletion,p|FS|V|311||,c|DEL||TTAAATGG
16822828,Y329fs is a deletion-insertion combined mutation (TAC-->AA) at codon 329 in exon 6,(TAC-->AA) at codon 329,Y329fs,c|SUB|TAC|CODON329|AA,p|FS|Y|329||
16822828,Y329fs is a deletion-insertion combined mutation (TAC-->AA) at codon 329 in exon 6,Y329fs,(TAC-->AA) at codon 329,p|FS|Y|329||,c|SUB|TAC|CODON329|AA
16822828,Two homozygotes for Y329fs and one compound heterozygote for Y329fs and V311fs were identified from three different families,V311fs,Y329fs,p|FS|V|311||,p|FS|Y|329||
16822828,Two homozygotes for Y329fs and one compound heterozygote for Y329fs and V311fs were identified from three different families,Y329fs,V311fs,p|FS|Y|329||,p|FS|V|311||
16822828,The identification of Y329fs mutation in addition to three previously identified mutations at codon 329 suggests that codon 329 is an unstable point of the CYP17 gene,CYP17,Y329fs,1586,p|FS|Y|329||
16822828,The identification of Y329fs mutation in addition to three previously identified mutations at codon 329 suggests that codon 329 is an unstable point of the CYP17 gene,Y329fs,CYP17,p|FS|Y|329||,1586
16904497,Cauda equina syndrome after epidural steroid injection: a case report,steroid,Cauda equina syndrome,D013256,D011128
16904497,Cauda equina syndrome after epidural steroid injection: a case report,Cauda equina syndrome,steroid,D011128,D013256
16904497,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy",radiculopathy,steroid,D011843,D013256
16904497,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy",steroid,radiculopathy,D013256,D011843
16904497,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine,bupivacaine,cauda equina syndrome,D002045,D011128
16904497,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine,bupivacaine,triamcinolone,D002045,D014221
16904497,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine,cauda equina syndrome,bupivacaine,D011128,D002045
16904497,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine,cauda equina syndrome,triamcinolone,D011128,D014221
16904497,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine,triamcinolone,bupivacaine,D014221,D002045
16904497,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine,triamcinolone,cauda equina syndrome,D014221,D011128
16904497,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection,low back and right leg pain,steroid,"D010146,D017116",D013256
16904497,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection,steroid,low back and right leg pain,D013256,"D010146,D017116"
16904497,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected",triamcinolone diacetate,bupivacaine,C030262,D002045
16904497,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected",triamcinolone diacetate,triamcinolone,C030262,D014221
16904497,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected",bupivacaine,triamcinolone diacetate,D002045,C030262
16904497,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected",bupivacaine,triamcinolone,D002045,D014221
16904497,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected",triamcinolone,triamcinolone diacetate,D014221,C030262
16904497,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected",triamcinolone,bupivacaine,D014221,D002045
16904497,Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.,neurologic deterioration,steroid,D009422,D013256
16904497,Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.,steroid,neurologic deterioration,D013256,D009422
16970763,"Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity",retinopathy of prematurity,NDP,D012178,4693
16970763,"Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity",Norrie disease,NDP,C537849,4693
16970763,"Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity",NDP,retinopathy of prematurity,4693,D012178
16970763,"Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity",NDP,Norrie disease,4693,C537849
16970763,"Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity",NDP,familial exudative vitreoretinopathy,4693,D000080345
16970763,"Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity",NDP,prematurity,4693,D007235
16970763,"Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity",familial exudative vitreoretinopathy,NDP,D000080345,4693
16970763,"Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity",prematurity,NDP,D007235,4693
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",ROP,NDP,D012178,4693
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",prematurity,NDP,D007235,4693
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",retinal diseases Norrie disease,NDP,C537849,4693
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",Coat's disease,NDP,D058456,4693
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",X-linked familial exudative vitreoretinopathy,NDP,D000080345,4693
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",FEVR,NDP,D000080345,4693
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",Norrie disease,NDP,C537849,4693
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",NDP,ROP,4693,D012178
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",NDP,prematurity,4693,D007235
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",NDP,retinal diseases Norrie disease,4693,C537849
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",NDP,Coat's disease,4693,D058456
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",NDP,X-linked familial exudative vitreoretinopathy,4693,D000080345
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",NDP,FEVR,4693,D000080345
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",NDP,Norrie disease,4693,C537849
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",NDP,familial exudative vitreoretinopathy,4693,D000080345
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",NDP,retinopathy of prematurity,4693,D012178
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",familial exudative vitreoretinopathy,NDP,D000080345,4693
16970763,"BACKGROUND: To examine the contribution of mutations within the Norrie disease (NDP) gene to the clinically similar retinal diseases Norrie disease, X-linked familial exudative vitreoretinopathy (FEVR), Coat's disease and retinopathy of prematurity (ROP)",retinopathy of prematurity,NDP,D012178,4693
16970763,"METHODS: A dataset comprising 13 Norrie-FEVR, one Coat's disease, 31 ROP patients and 90 ex-premature babies of <32 weeks' gestation underwent an ophthalmologic examination and were screened for mutations within the NDP gene by direct DNA sequencing, denaturing high-performance liquid chromatography or gel electrophoresis",ROP,NDP,D012178,4693
16970763,"METHODS: A dataset comprising 13 Norrie-FEVR, one Coat's disease, 31 ROP patients and 90 ex-premature babies of <32 weeks' gestation underwent an ophthalmologic examination and were screened for mutations within the NDP gene by direct DNA sequencing, denaturing high-performance liquid chromatography or gel electrophoresis",Coat's disease,NDP,D058456,4693
16970763,"METHODS: A dataset comprising 13 Norrie-FEVR, one Coat's disease, 31 ROP patients and 90 ex-premature babies of <32 weeks' gestation underwent an ophthalmologic examination and were screened for mutations within the NDP gene by direct DNA sequencing, denaturing high-performance liquid chromatography or gel electrophoresis",Norrie-FEVR,NDP,C537849,4693
16970763,"METHODS: A dataset comprising 13 Norrie-FEVR, one Coat's disease, 31 ROP patients and 90 ex-premature babies of <32 weeks' gestation underwent an ophthalmologic examination and were screened for mutations within the NDP gene by direct DNA sequencing, denaturing high-performance liquid chromatography or gel electrophoresis",FEVR,NDP,D000080345,4693
16970763,"METHODS: A dataset comprising 13 Norrie-FEVR, one Coat's disease, 31 ROP patients and 90 ex-premature babies of <32 weeks' gestation underwent an ophthalmologic examination and were screened for mutations within the NDP gene by direct DNA sequencing, denaturing high-performance liquid chromatography or gel electrophoresis",NDP,ROP,4693,D012178
16970763,"METHODS: A dataset comprising 13 Norrie-FEVR, one Coat's disease, 31 ROP patients and 90 ex-premature babies of <32 weeks' gestation underwent an ophthalmologic examination and were screened for mutations within the NDP gene by direct DNA sequencing, denaturing high-performance liquid chromatography or gel electrophoresis",NDP,Coat's disease,4693,D058456
16970763,"METHODS: A dataset comprising 13 Norrie-FEVR, one Coat's disease, 31 ROP patients and 90 ex-premature babies of <32 weeks' gestation underwent an ophthalmologic examination and were screened for mutations within the NDP gene by direct DNA sequencing, denaturing high-performance liquid chromatography or gel electrophoresis",NDP,Norrie-FEVR,4693,C537849
16970763,"METHODS: A dataset comprising 13 Norrie-FEVR, one Coat's disease, 31 ROP patients and 90 ex-premature babies of <32 weeks' gestation underwent an ophthalmologic examination and were screened for mutations within the NDP gene by direct DNA sequencing, denaturing high-performance liquid chromatography or gel electrophoresis",NDP,FEVR,4693,D000080345
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,His43Arg,Leu103Val,p|SUB|H|43|R,p|SUB|L|103|V
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,His43Arg,FEVR,p|SUB|H|43|R,D000080345
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,His43Arg,Norrie disease,p|SUB|H|43|R,C537849
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,His43Arg,NDP,p|SUB|H|43|R,4693
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,Leu103Val,His43Arg,p|SUB|L|103|V,p|SUB|H|43|R
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,Leu103Val,FEVR,p|SUB|L|103|V,D000080345
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,Leu103Val,Norrie disease,p|SUB|L|103|V,C537849
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,Leu103Val,NDP,p|SUB|L|103|V,4693
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,FEVR,His43Arg,D000080345,p|SUB|H|43|R
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,FEVR,Leu103Val,D000080345,p|SUB|L|103|V
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,FEVR,NDP,D000080345,4693
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,Norrie disease,His43Arg,C537849,p|SUB|H|43|R
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,Norrie disease,Leu103Val,C537849,p|SUB|L|103|V
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,Norrie disease,NDP,C537849,4693
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,NDP,His43Arg,4693,p|SUB|H|43|R
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,NDP,Leu103Val,4693,p|SUB|L|103|V
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,NDP,FEVR,4693,D000080345
16970763,RESULTS: Evidence for two novel mutations in the NDP gene was presented: Leu103Val in one FEVR patient and His43Arg in monozygotic twin Norrie disease patients,NDP,Norrie disease,4693,C537849
16970763,"Furthermore, a previously described 14-bp deletion located in the 5' unstranslated region of the NDP gene was detected in three cases of regressed ROP",ROP,14-bp deletion,D012178,c|DEL||14
16970763,"Furthermore, a previously described 14-bp deletion located in the 5' unstranslated region of the NDP gene was detected in three cases of regressed ROP",ROP,NDP,D012178,4693
16970763,"Furthermore, a previously described 14-bp deletion located in the 5' unstranslated region of the NDP gene was detected in three cases of regressed ROP",14-bp deletion,ROP,c|DEL||14,D012178
16970763,"Furthermore, a previously described 14-bp deletion located in the 5' unstranslated region of the NDP gene was detected in three cases of regressed ROP",14-bp deletion,NDP,c|DEL||14,4693
16970763,"Furthermore, a previously described 14-bp deletion located in the 5' unstranslated region of the NDP gene was detected in three cases of regressed ROP",NDP,ROP,4693,D012178
16970763,"Furthermore, a previously described 14-bp deletion located in the 5' unstranslated region of the NDP gene was detected in three cases of regressed ROP",NDP,14-bp deletion,4693,c|DEL||14
16970763,"CONCLUSION: Two novel mutations within the coding region of the NDP gene were found, one associated with a severe disease phenotypes of Norrie disease and the other with FEVR",NDP,FEVR,4693,D000080345
16970763,"CONCLUSION: Two novel mutations within the coding region of the NDP gene were found, one associated with a severe disease phenotypes of Norrie disease and the other with FEVR",NDP,Norrie disease,4693,C537849
16970763,"CONCLUSION: Two novel mutations within the coding region of the NDP gene were found, one associated with a severe disease phenotypes of Norrie disease and the other with FEVR",FEVR,NDP,D000080345,4693
16970763,"CONCLUSION: Two novel mutations within the coding region of the NDP gene were found, one associated with a severe disease phenotypes of Norrie disease and the other with FEVR",Norrie disease,NDP,C537849,4693
16970763,"A deletion within the non-coding region was associated with only mild-regressed ROP, despite the presence of low birthweight, prematurity and exposure to oxygen",oxygen,ROP,D010100,D012178
16970763,"A deletion within the non-coding region was associated with only mild-regressed ROP, despite the presence of low birthweight, prematurity and exposure to oxygen",oxygen,prematurity,D010100,D007235
16970763,"A deletion within the non-coding region was associated with only mild-regressed ROP, despite the presence of low birthweight, prematurity and exposure to oxygen",ROP,oxygen,D012178,D010100
16970763,"A deletion within the non-coding region was associated with only mild-regressed ROP, despite the presence of low birthweight, prematurity and exposure to oxygen",prematurity,oxygen,D007235,D010100
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,+2740 A>G,PTPN22,rs1217412,26191
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,+2740 A>G,juvenile idiopathic arthritis,rs1217412,D001171
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,+2740 A>G,type 1 diabetes,rs1217412,D003922
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,+2740 A>G,-1123 G>C,rs1217412,rs2488457
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,PTPN22,+2740 A>G,26191,rs1217412
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,PTPN22,juvenile idiopathic arthritis,26191,D001171
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,PTPN22,type 1 diabetes,26191,D003922
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,PTPN22,-1123 G>C,26191,rs2488457
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,juvenile idiopathic arthritis,+2740 A>G,D001171,rs1217412
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,juvenile idiopathic arthritis,PTPN22,D001171,26191
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,juvenile idiopathic arthritis,-1123 G>C,D001171,rs2488457
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,type 1 diabetes,+2740 A>G,D003922,rs1217412
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,type 1 diabetes,PTPN22,D003922,26191
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,type 1 diabetes,-1123 G>C,D003922,rs2488457
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,-1123 G>C,+2740 A>G,rs2488457,rs1217412
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,-1123 G>C,PTPN22,rs2488457,26191
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,-1123 G>C,juvenile idiopathic arthritis,rs2488457,D001171
17000021,No independent role of the -1123 G>C and+2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations,-1123 G>C,type 1 diabetes,rs2488457,D003922
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",autoimmune diseases,+1858C>T,D001327,rs2476601
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",autoimmune diseases,R620W,D001327,rs2476601
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",+1858C>T,autoimmune diseases,rs2476601,D001327
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",+1858C>T,R620W,rs2476601,rs2476601
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",+1858C>T,T1D,rs2476601,D003922
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",+1858C>T,juvenile idiopathic arthritis,rs2476601,D001171
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",+1858C>T,JIA,rs2476601,D001171
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",+1858C>T,type 1 diabetes,rs2476601,D003922
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",R620W,autoimmune diseases,rs2476601,D001327
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",R620W,+1858C>T,rs2476601,rs2476601
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",R620W,T1D,rs2476601,D003922
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",R620W,juvenile idiopathic arthritis,rs2476601,D001171
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",R620W,JIA,rs2476601,D001171
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",R620W,type 1 diabetes,rs2476601,D003922
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",T1D,+1858C>T,D003922,rs2476601
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",T1D,R620W,D003922,rs2476601
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",juvenile idiopathic arthritis,+1858C>T,D001171,rs2476601
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",juvenile idiopathic arthritis,R620W,D001171,rs2476601
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",JIA,+1858C>T,D001171,rs2476601
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",JIA,R620W,D001171,rs2476601
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",type 1 diabetes,+1858C>T,D003922,rs2476601
17000021,"Its +1858C>T (R620W) polymorphism has been shown to associate with a risk for multiple autoimmune diseases, including type 1 diabetes (T1D) and juvenile idiopathic arthritis (JIA)",type 1 diabetes,R620W,D003922,rs2476601
17000021,"AIMS: We aimed to analyse the association of three PTPN22 polymorphisms in two distinct Caucasian populations, the Czechs (with T1D and with JIA) and Azeri (with T1D)",JIA,PTPN22,D001171,26191
17000021,"AIMS: We aimed to analyse the association of three PTPN22 polymorphisms in two distinct Caucasian populations, the Czechs (with T1D and with JIA) and Azeri (with T1D)",PTPN22,JIA,26191,D001171
17000021,"AIMS: We aimed to analyse the association of three PTPN22 polymorphisms in two distinct Caucasian populations, the Czechs (with T1D and with JIA) and Azeri (with T1D)",PTPN22,T1D,26191,D003922
17000021,"AIMS: We aimed to analyse the association of three PTPN22 polymorphisms in two distinct Caucasian populations, the Czechs (with T1D and with JIA) and Azeri (with T1D)",T1D,PTPN22,D003922,26191
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs2476601,rs1217412,rs2476601,rs1217412
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs2476601,R620W,rs2476601,rs2476601
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs2476601,T1D,rs2476601,D003922
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs2476601,JIA,rs2476601,D001171
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs2476601,rs2488457,rs2476601,rs2488457
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs1217412,rs2476601,rs1217412,rs2476601
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs1217412,R620W,rs1217412,rs2476601
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs1217412,T1D,rs1217412,D003922
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs1217412,JIA,rs1217412,D001171
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs1217412,rs2488457,rs1217412,rs2488457
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",R620W,rs2476601,rs2476601,rs2476601
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",R620W,rs1217412,rs2476601,rs1217412
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",R620W,T1D,rs2476601,D003922
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",R620W,JIA,rs2476601,D001171
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",R620W,rs2488457,rs2476601,rs2488457
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",T1D,rs2476601,D003922,rs2476601
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",T1D,rs1217412,D003922,rs1217412
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",T1D,R620W,D003922,rs2476601
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",T1D,rs2488457,D003922,rs2488457
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",JIA,rs2476601,D001171,rs2476601
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",JIA,rs1217412,D001171,rs1217412
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",JIA,R620W,D001171,rs2476601
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",JIA,rs2488457,D001171,rs2488457
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs2488457,rs2476601,rs2488457,rs2476601
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs2488457,rs1217412,rs2488457,rs1217412
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs2488457,R620W,rs2488457,rs2476601
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs2488457,T1D,rs2488457,D003922
17000021,"METHODS: The single nucleotide polymorphisms (SNP) at positions -1123 (rs2488457), +1858 (rs2476601, the R620W substitution), and +2740 (rs1217412) were genotyped using TaqMan assays in 372 subjects with childhood-onset T1D, 130 subjects with JIA, and 400 control subjects of Czech origin, and in 160 subjects with T1D and 271 healthy controls of Azeri origin",rs2488457,JIA,rs2488457,D001171
17000021,"Haplotype reconstruction via the expectation-maximization algorithm showed in both populations that only the haplotype containing the minor (W) allele at codon 620 was associated with T1D (OR=2.26, 95% CI 1.68-3.02 in Czechs, OR=14.8, 95% CI 2.0-651 in Azeri) or JIA (OR=2.43, 95% CI 1.66-3.56 in Czechs)",(W) allele at codon 620,JIA,rs2476601,D001171
17000021,"Haplotype reconstruction via the expectation-maximization algorithm showed in both populations that only the haplotype containing the minor (W) allele at codon 620 was associated with T1D (OR=2.26, 95% CI 1.68-3.02 in Czechs, OR=14.8, 95% CI 2.0-651 in Azeri) or JIA (OR=2.43, 95% CI 1.66-3.56 in Czechs)",(W) allele at codon 620,T1D,rs2476601,D003922
17000021,"Haplotype reconstruction via the expectation-maximization algorithm showed in both populations that only the haplotype containing the minor (W) allele at codon 620 was associated with T1D (OR=2.26, 95% CI 1.68-3.02 in Czechs, OR=14.8, 95% CI 2.0-651 in Azeri) or JIA (OR=2.43, 95% CI 1.66-3.56 in Czechs)",JIA,(W) allele at codon 620,D001171,rs2476601
17000021,"Haplotype reconstruction via the expectation-maximization algorithm showed in both populations that only the haplotype containing the minor (W) allele at codon 620 was associated with T1D (OR=2.26, 95% CI 1.68-3.02 in Czechs, OR=14.8, 95% CI 2.0-651 in Azeri) or JIA (OR=2.43, 95% CI 1.66-3.56 in Czechs)",T1D,(W) allele at codon 620,D003922,rs2476601
17000021,The haplotypes having the wild-type (R) allele at codon 620 and minor alleles at -1123 and/or +2740 were neutral as to the risk of autoimmune conditions in both populations,autoimmune conditions,(R) allele at codon 620,D001327,rs2476601
17000021,The haplotypes having the wild-type (R) allele at codon 620 and minor alleles at -1123 and/or +2740 were neutral as to the risk of autoimmune conditions in both populations,(R) allele at codon 620,autoimmune conditions,rs2476601,D001327
17033974,Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy,calcium,CACNA2D4,D002118,93589
17033974,Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy,calcium,cone dystrophy,D002118,D000077765
17033974,Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy,CACNA2D4,calcium,93589,D002118
17033974,Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy,CACNA2D4,cone dystrophy,93589,D000077765
17033974,Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy,cone dystrophy,calcium,D000077765,D002118
17033974,Mutation in the auxiliary calcium-channel subunit CACNA2D4 causes autosomal recessive cone dystrophy,cone dystrophy,CACNA2D4,D000077765,93589
17033974,The Cacna2d4 gene encodes an l-type calcium-channel auxiliary subunit of the alpha (2) delta type,calcium,l-type calcium-channel auxiliary subunit of the alpha (2) delta type,D002118,781
17033974,The Cacna2d4 gene encodes an l-type calcium-channel auxiliary subunit of the alpha (2) delta type,calcium,Cacna2d4,D002118,319734
17033974,The Cacna2d4 gene encodes an l-type calcium-channel auxiliary subunit of the alpha (2) delta type,l-type calcium-channel auxiliary subunit of the alpha (2) delta type,calcium,781,D002118
17033974,The Cacna2d4 gene encodes an l-type calcium-channel auxiliary subunit of the alpha (2) delta type,l-type calcium-channel auxiliary subunit of the alpha (2) delta type,Cacna2d4,781,319734
17033974,The Cacna2d4 gene encodes an l-type calcium-channel auxiliary subunit of the alpha (2) delta type,Cacna2d4,calcium,319734,D002118
17033974,The Cacna2d4 gene encodes an l-type calcium-channel auxiliary subunit of the alpha (2) delta type,Cacna2d4,l-type calcium-channel auxiliary subunit of the alpha (2) delta type,319734,781
17033974,"We performed mutation analyses of 34 patients who received an initial diagnosis of night blindness, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in CACNA2D4",CACNA2D4,c.2406C-->A,93589,rs71454844
17033974,"We performed mutation analyses of 34 patients who received an initial diagnosis of night blindness, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in CACNA2D4",CACNA2D4,night blindness,93589,D009755
17033974,"We performed mutation analyses of 34 patients who received an initial diagnosis of night blindness, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in CACNA2D4",c.2406C-->A,CACNA2D4,rs71454844,93589
17033974,"We performed mutation analyses of 34 patients who received an initial diagnosis of night blindness, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in CACNA2D4",c.2406C-->A,night blindness,rs71454844,D009755
17033974,"We performed mutation analyses of 34 patients who received an initial diagnosis of night blindness, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in CACNA2D4",night blindness,CACNA2D4,D009755,93589
17033974,"We performed mutation analyses of 34 patients who received an initial diagnosis of night blindness, and, in two affected siblings, we detected a homozygous nucleotide substitution (c.2406C-->A) in CACNA2D4",night blindness,c.2406C-->A,D009755,rs71454844
17033974,These findings represent the first report of a mutation in the human CACNA2D4 gene and define a novel gene defect that causes autosomal recessive cone dystrophy.,CACNA2D4,cone dystrophy,93589,D000077765
17033974,These findings represent the first report of a mutation in the human CACNA2D4 gene and define a novel gene defect that causes autosomal recessive cone dystrophy.,cone dystrophy,CACNA2D4,D000077765,93589
17273972,Human TBX1 missense mutations cause gain of function resulting in the same phenotype as 22q11.2 deletions,22q11.2 deletions,TBX1,D004062,6899
17273972,Human TBX1 missense mutations cause gain of function resulting in the same phenotype as 22q11.2 deletions,TBX1,22q11.2 deletions,6899,D004062
17273972,"Although haploinsufficiency of the T-box transcription factor gene TBX1 is thought to cause the phenotype, to date, only four different point mutations in TBX1 have been reported in association with six of the major features of 22q11.2 deletion syndrome",TBX1,22q11.2 deletion syndrome,6899,D004062
17273972,"Although haploinsufficiency of the T-box transcription factor gene TBX1 is thought to cause the phenotype, to date, only four different point mutations in TBX1 have been reported in association with six of the major features of 22q11.2 deletion syndrome",TBX1,T-box transcription factor,6899,6899
17273972,"Although haploinsufficiency of the T-box transcription factor gene TBX1 is thought to cause the phenotype, to date, only four different point mutations in TBX1 have been reported in association with six of the major features of 22q11.2 deletion syndrome",22q11.2 deletion syndrome,TBX1,D004062,6899
17273972,"Although haploinsufficiency of the T-box transcription factor gene TBX1 is thought to cause the phenotype, to date, only four different point mutations in TBX1 have been reported in association with six of the major features of 22q11.2 deletion syndrome",22q11.2 deletion syndrome,T-box transcription factor,D004062,6899
17273972,"Although haploinsufficiency of the T-box transcription factor gene TBX1 is thought to cause the phenotype, to date, only four different point mutations in TBX1 have been reported in association with six of the major features of 22q11.2 deletion syndrome",T-box transcription factor,TBX1,6899,6899
17273972,"Although haploinsufficiency of the T-box transcription factor gene TBX1 is thought to cause the phenotype, to date, only four different point mutations in TBX1 have been reported in association with six of the major features of 22q11.2 deletion syndrome",T-box transcription factor,22q11.2 deletion syndrome,6899,D004062
17273972,"We report a novel heterozygous missense mutation, H194Q, in a familial case of Shprintzen syndrome and show that this and the two previously reported missense mutations result in gain of function, possibly through stabilization of the protein dimer DNA complex",Shprintzen syndrome,H194Q,D004062,rs74315522
17273972,"We report a novel heterozygous missense mutation, H194Q, in a familial case of Shprintzen syndrome and show that this and the two previously reported missense mutations result in gain of function, possibly through stabilization of the protein dimer DNA complex",H194Q,Shprintzen syndrome,rs74315522,D004062
17286451,The first was to estimate the frequency of loss of heterozygosity (LOH) of the RB1 gene as a mechanism in disease causation in tumors of patients from India,RB,RB1,D012175,5925
17286451,The first was to estimate the frequency of loss of heterozygosity (LOH) of the RB1 gene as a mechanism in disease causation in tumors of patients from India,tumors,RB1,D009369,5925
17286451,The first was to estimate the frequency of loss of heterozygosity (LOH) of the RB1 gene as a mechanism in disease causation in tumors of patients from India,tumor,RB1,D009369,5925
17286451,The first was to estimate the frequency of loss of heterozygosity (LOH) of the RB1 gene as a mechanism in disease causation in tumors of patients from India,RB1,RB,5925,D012175
17286451,The first was to estimate the frequency of loss of heterozygosity (LOH) of the RB1 gene as a mechanism in disease causation in tumors of patients from India,RB1,tumors,5925,D009369
17286451,The first was to estimate the frequency of loss of heterozygosity (LOH) of the RB1 gene as a mechanism in disease causation in tumors of patients from India,RB1,tumor,5925,D009369
17286451,"The second objective was to employ RB1 molecular deletion and microsatellite-based linkage analysis as laboratory tools, while counseling families with a history of retinoblastoma (RB)",RB,RB1,D012175,5925
17286451,"The second objective was to employ RB1 molecular deletion and microsatellite-based linkage analysis as laboratory tools, while counseling families with a history of retinoblastoma (RB)",RB1,RB,5925,D012175
17286451,"The second objective was to employ RB1 molecular deletion and microsatellite-based linkage analysis as laboratory tools, while counseling families with a history of retinoblastoma (RB)",RB1,retinoblastoma,5925,D012175
17286451,"The second objective was to employ RB1 molecular deletion and microsatellite-based linkage analysis as laboratory tools, while counseling families with a history of retinoblastoma (RB)",retinoblastoma,RB1,D012175,5925
17286451,"Eight fluorescent microsatellite markers, both intragenic and flanking the RB1 gene, were used",RB,RB1,D012175,5925
17286451,"Eight fluorescent microsatellite markers, both intragenic and flanking the RB1 gene, were used",RB1,RB,5925,D012175
17286451,"RESULTS: LOH was found in conjunction with tumor formation in 72.9% of RB patients (39/54 patients; p=0.001; 95% CI 0.6028, 0.8417); however, we could not associate various other clinical parameters of RB patients with the presence or absence of RB1 LOH",RB,RB1,D012175,5925
17286451,"RESULTS: LOH was found in conjunction with tumor formation in 72.9% of RB patients (39/54 patients; p=0.001; 95% CI 0.6028, 0.8417); however, we could not associate various other clinical parameters of RB patients with the presence or absence of RB1 LOH",tumor,RB1,D009369,5925
17286451,"RESULTS: LOH was found in conjunction with tumor formation in 72.9% of RB patients (39/54 patients; p=0.001; 95% CI 0.6028, 0.8417); however, we could not associate various other clinical parameters of RB patients with the presence or absence of RB1 LOH",RB1,RB,5925,D012175
17286451,"RESULTS: LOH was found in conjunction with tumor formation in 72.9% of RB patients (39/54 patients; p=0.001; 95% CI 0.6028, 0.8417); however, we could not associate various other clinical parameters of RB patients with the presence or absence of RB1 LOH",RB1,tumor,5925,D009369
17286451,CONCLUSION: LOH of the RB1 gene could play an important role in tumor formation,RB,RB1,D012175,5925
17286451,CONCLUSION: LOH of the RB1 gene could play an important role in tumor formation,tumor,RB1,D009369,5925
17286451,CONCLUSION: LOH of the RB1 gene could play an important role in tumor formation,RB1,RB,5925,D012175
17286451,CONCLUSION: LOH of the RB1 gene could play an important role in tumor formation,RB1,tumor,5925,D009369
17286451,"Large deletions involving RB1 were observed, and a disease co-segregating haplotype was used for indirect genetic testing",RB,RB1,D012175,5925
17286451,"Large deletions involving RB1 were observed, and a disease co-segregating haplotype was used for indirect genetic testing",RB1,RB,5925,D012175
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,fibroblast growth factor receptor 1,IRF6,2260,3664
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,fibroblast growth factor receptor 1,FGFR1,2260,2260
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,fibroblast growth factor receptor 1,Interferon regulatory factor 6,2260,3664
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,fibroblast growth factor receptor 1,tooth agenesis,2260,D000848
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,IRF6,fibroblast growth factor receptor 1,3664,2260
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,IRF6,FGFR1,3664,2260
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,IRF6,Interferon regulatory factor 6,3664,3664
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,IRF6,tooth agenesis,3664,D000848
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,FGFR1,fibroblast growth factor receptor 1,2260,2260
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,FGFR1,IRF6,2260,3664
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,FGFR1,Interferon regulatory factor 6,2260,3664
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,FGFR1,tooth agenesis,2260,D000848
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,Interferon regulatory factor 6,fibroblast growth factor receptor 1,3664,2260
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,Interferon regulatory factor 6,IRF6,3664,3664
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,Interferon regulatory factor 6,FGFR1,3664,2260
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,Interferon regulatory factor 6,tooth agenesis,3664,D000848
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,tooth agenesis,fibroblast growth factor receptor 1,D000848,2260
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,tooth agenesis,IRF6,D000848,3664
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,tooth agenesis,FGFR1,D000848,2260
17318851,Interferon regulatory factor 6 (IRF6) and fibroblast growth factor receptor 1 (FGFR1) contribute to human tooth agenesis,tooth agenesis,Interferon regulatory factor 6,D000848,3664
17318851,"We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis",craniofacial syndromes,FGFR1,D019465,2260
17318851,"We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis",craniofacial syndromes,IRF6,D019465,3664
17318851,"We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis",FGFR1,craniofacial syndromes,2260,D019465
17318851,"We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis",FGFR1,tooth agenesis,2260,D000848
17318851,"We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis",FGFR1,IRF6,2260,3664
17318851,"We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis",tooth agenesis,FGFR1,D000848,2260
17318851,"We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis",tooth agenesis,IRF6,D000848,3664
17318851,"We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis",IRF6,craniofacial syndromes,3664,D019465
17318851,"We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis",IRF6,FGFR1,3664,2260
17318851,"We investigated two genes responsible for craniofacial syndromes, FGFR1 and IRF6, in a collection of families with isolated tooth agenesis",IRF6,tooth agenesis,3664,D000848
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",orofacial clefts,rs7802,C566121,rs7802
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",orofacial clefts,IRF6,C566121,3664
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",orofacial clefts,rs861019,C566121,rs861019
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",orofacial clefts,rs17015215,C566121,rs17015215
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",orofacial clefts,V274I,C566121,rs2235371
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs7802,orofacial clefts,rs7802,C566121
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs7802,IRF6,rs7802,3664
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs7802,rs861019,rs7802,rs861019
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs7802,rs17015215,rs7802,rs17015215
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs7802,V274I,rs7802,rs2235371
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs7802,tooth agenesis,rs7802,D000848
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",IRF6,orofacial clefts,3664,C566121
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",IRF6,rs7802,3664,rs7802
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",IRF6,rs861019,3664,rs861019
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",IRF6,rs17015215,3664,rs17015215
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",IRF6,V274I,3664,rs2235371
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",IRF6,tooth agenesis,3664,D000848
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs861019,orofacial clefts,rs861019,C566121
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs861019,rs7802,rs861019,rs7802
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs861019,IRF6,rs861019,3664
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs861019,rs17015215,rs861019,rs17015215
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs861019,V274I,rs861019,rs2235371
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs861019,tooth agenesis,rs861019,D000848
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs17015215,orofacial clefts,rs17015215,C566121
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs17015215,rs7802,rs17015215,rs7802
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs17015215,IRF6,rs17015215,3664
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs17015215,rs861019,rs17015215,rs861019
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs17015215,V274I,rs17015215,rs2235371
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",rs17015215,tooth agenesis,rs17015215,D000848
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",V274I,orofacial clefts,rs2235371,C566121
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",V274I,rs7802,rs2235371,rs7802
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",V274I,IRF6,rs2235371,3664
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",V274I,rs861019,rs2235371,rs861019
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",V274I,rs17015215,rs2235371,rs17015215
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",V274I,tooth agenesis,rs2235371,D000848
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",tooth agenesis,rs7802,D000848,rs7802
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",tooth agenesis,IRF6,D000848,3664
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",tooth agenesis,rs861019,D000848,rs861019
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",tooth agenesis,rs17015215,D000848,rs17015215
17318851,"The same variants in the IRF6 gene that are associated with isolated orofacial clefts are also associated with human tooth agenesis (rs861019, P = 0.058; rs17015215-V274I, P = 0.0006; rs7802, P = 0.004)",tooth agenesis,V274I,D000848,rs2235371
17318851,Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes,Van der Woude and popliteal pterygium syndromes,IRF6,"C536528,C562509",3664
17318851,Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes,IRF6,Van der Woude and popliteal pterygium syndromes,3664,"C536528,C562509"
17318851,Also it appears that preferential premolar agenesis is associated with FGFR1 (P = 0.014) and IRF6 (P = 0.002) markers,FGFR1,IRF6,2260,3664
17318851,Also it appears that preferential premolar agenesis is associated with FGFR1 (P = 0.014) and IRF6 (P = 0.002) markers,IRF6,FGFR1,3664,2260
17318851,"There were statistically significant data suggesting that IRF6 interacts not only with MSX1 (P = 0.001), but also with TGFA (P = 0.03).",MSX1,TGFA,4487,7039
17318851,"There were statistically significant data suggesting that IRF6 interacts not only with MSX1 (P = 0.001), but also with TGFA (P = 0.03).",MSX1,IRF6,4487,3664
17318851,"There were statistically significant data suggesting that IRF6 interacts not only with MSX1 (P = 0.001), but also with TGFA (P = 0.03).",TGFA,MSX1,7039,4487
17318851,"There were statistically significant data suggesting that IRF6 interacts not only with MSX1 (P = 0.001), but also with TGFA (P = 0.03).",TGFA,IRF6,7039,3664
17318851,"There were statistically significant data suggesting that IRF6 interacts not only with MSX1 (P = 0.001), but also with TGFA (P = 0.03).",IRF6,MSX1,3664,4487
17318851,"There were statistically significant data suggesting that IRF6 interacts not only with MSX1 (P = 0.001), but also with TGFA (P = 0.03).",IRF6,TGFA,3664,7039
17327131,The CYP2F1 is a human cytochrome P450 that is selectively expressed in lung tissue and involved in the metabolism of various pneumotoxicants with potential carcinogenic effects,carcinogenic,CYP2F1,D009369,1572
17327131,The CYP2F1 is a human cytochrome P450 that is selectively expressed in lung tissue and involved in the metabolism of various pneumotoxicants with potential carcinogenic effects,carcinogenic,cytochrome P450,D009369,1572
17327131,The CYP2F1 is a human cytochrome P450 that is selectively expressed in lung tissue and involved in the metabolism of various pneumotoxicants with potential carcinogenic effects,CYP2F1,carcinogenic,1572,D009369
17327131,The CYP2F1 is a human cytochrome P450 that is selectively expressed in lung tissue and involved in the metabolism of various pneumotoxicants with potential carcinogenic effects,CYP2F1,cytochrome P450,1572,1572
17327131,The CYP2F1 is a human cytochrome P450 that is selectively expressed in lung tissue and involved in the metabolism of various pneumotoxicants with potential carcinogenic effects,cytochrome P450,carcinogenic,1572,D009369
17327131,The CYP2F1 is a human cytochrome P450 that is selectively expressed in lung tissue and involved in the metabolism of various pneumotoxicants with potential carcinogenic effects,cytochrome P450,CYP2F1,1572,1572
17327131,"We analyzed the nucleotidic sequence of the CYP2F1 gene in DNA samples from 90 French Caucasians consisting in 44 patients with lung cancer and 46 control individuals, using single-strand conformation polymorphism analysis of PCR products (PCR-SSCP)",CYP2F1,lung cancer,1572,D008175
17327131,"We analyzed the nucleotidic sequence of the CYP2F1 gene in DNA samples from 90 French Caucasians consisting in 44 patients with lung cancer and 46 control individuals, using single-strand conformation polymorphism analysis of PCR products (PCR-SSCP)",lung cancer,CYP2F1,D008175,1572
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",Gln266His,Asp218Asn,rs75405062,rs305974
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",Gln266His,CYP2F1,rs75405062,1572
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",Gln266His,1-bp insertion,rs75405062,rs11399890
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",Gln266His,c.14_15insC,rs75405062,rs11399890
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",Asp218Asn,Gln266His,rs305974,rs75405062
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",Asp218Asn,CYP2F1,rs305974,1572
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",Asp218Asn,1-bp insertion,rs305974,rs11399890
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",Asp218Asn,c.14_15insC,rs305974,rs11399890
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",CYP2F1,Gln266His,1572,rs75405062
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",CYP2F1,Asp218Asn,1572,rs305974
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",CYP2F1,1-bp insertion,1572,rs11399890
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",CYP2F1,c.14_15insC,1572,rs11399890
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",1-bp insertion,Gln266His,rs11399890,rs75405062
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",1-bp insertion,Asp218Asn,rs11399890,rs305974
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",1-bp insertion,CYP2F1,rs11399890,1572
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",1-bp insertion,c.14_15insC,rs11399890,rs11399890
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",c.14_15insC,Gln266His,rs11399890,rs75405062
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",c.14_15insC,Asp218Asn,rs11399890,rs305974
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",c.14_15insC,CYP2F1,rs11399890,1572
17327131,"The most frequent allelic variant, CYP2F1*2A (25.6%), harbors a combination of 9 mutations, including 2 missense mutations (Asp218Asn and Gln266His) and a 1-bp insertion (c.14_15insC) that creates a premature stop codon in exon 2, probably leading to the synthesis of a severely truncated protein with no catalytic activity",c.14_15insC,1-bp insertion,rs11399890,rs11399890
17327131,"However, our preliminary results did not show any evidence that the CYP2F1 genetic polymorphism has implications in the pathogenesis of lung cancer.",CYP2F1,lung cancer,1572,D008175
17327131,"However, our preliminary results did not show any evidence that the CYP2F1 genetic polymorphism has implications in the pathogenesis of lung cancer.",lung cancer,CYP2F1,D008175,1572
17384765,"Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure",Succimer,lead,D004113,D007854
17384765,"Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure",Succimer,cognitive impairment,D004113,D003072
17384765,"Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure",lead,Succimer,D007854,D004113
17384765,"Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure",lead,cognitive impairment,D007854,D003072
17384765,"Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure",cognitive impairment,Succimer,D003072,D004113
17384765,"Succimer chelation improves learning, attention, and arousal regulation in lead-exposed rats but produces lasting cognitive impairment in the absence of lead exposure",cognitive impairment,lead,D003072,D007854
17384765,"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning",succimer,Pb,D004113,D007854
17384765,"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning",succimer,Pb poisoning,D004113,D007855
17384765,"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning",Pb,succimer,D007854,D004113
17384765,"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning",Pb,Pb poisoning,D007854,D007855
17384765,"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning",Pb poisoning,succimer,D007855,D004113
17384765,"OBJECTIVES: The present study was designed to answer these questions, using a rodent model of early childhood Pb exposure and treatment with succimer, a widely used chelating agent for the treatment of Pb poisoning",Pb poisoning,Pb,D007855,D007854
17384765,"RESULTS: Pb exposure produced lasting impairments in learning, attention, inhibitory control, and arousal regulation, paralleling the areas of dysfunction seen in Pb-exposed children","impairments in learning, attention, inhibitory control, and arousal regulation",Pb,"D007859,D019958",D007854
17384765,"RESULTS: Pb exposure produced lasting impairments in learning, attention, inhibitory control, and arousal regulation, paralleling the areas of dysfunction seen in Pb-exposed children",Pb,"impairments in learning, attention, inhibitory control, and arousal regulation",D007854,"D007859,D019958"
17384765,"Succimer treatment of the Pb-exposed rats significantly improved learning, attention, and arousal regulation, although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit",Succimer,Pb,D004113,D007854
17384765,"Succimer treatment of the Pb-exposed rats significantly improved learning, attention, and arousal regulation, although the efficacy of the treatment varied as a function of the Pb exposure level and the specific functional deficit",Pb,Succimer,D007854,D004113
17384765,"In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen",cognitive and affective dysfunction,Pb,"D003072,D019964",D007854
17384765,"In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen",cognitive and affective dysfunction,succimer,"D003072,D019964",D004113
17384765,"In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen",Pb,cognitive and affective dysfunction,D007854,"D003072,D019964"
17384765,"In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen",Pb,succimer,D007854,D004113
17384765,"In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen",succimer,cognitive and affective dysfunction,D004113,"D003072,D019964"
17384765,"In contrast, succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen",succimer,Pb,D004113,D007854
17384765,"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate cognitive deficits due to Pb exposure",Pb,cognitive deficits,D007854,D003072
17384765,"CONCLUSIONS: These are the first data, to our knowledge, to show that treatment with any chelating agent can alleviate cognitive deficits due to Pb exposure",cognitive deficits,Pb,D003072,D007854
17384765,These findings suggest that it may be possible to identify a succimer treatment protocol that improves cognitive outcomes in Pb-exposed children,succimer,Pb,D004113,D007854
17384765,These findings suggest that it may be possible to identify a succimer treatment protocol that improves cognitive outcomes in Pb-exposed children,Pb,succimer,D007854,D004113
17384765,"However, they also suggest that succimer treatment should be strongly discouraged for children who do not have elevated tissue levels of Pb or other heavy metals.",succimer,Pb,D004113,D007854
17384765,"However, they also suggest that succimer treatment should be strongly discouraged for children who do not have elevated tissue levels of Pb or other heavy metals.",Pb,succimer,D007854,D004113
17391797,The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population,phosphatidylethanolamine,NASH,D010714,D065626
17391797,The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population,phosphatidylethanolamine,V175M,D010714,rs7946
17391797,The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population,phosphatidylethanolamine,phosphatidylethanolamine N-methyltransferase,D010714,10400
17391797,The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population,NASH,phosphatidylethanolamine,D065626,D010714
17391797,The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population,NASH,V175M,D065626,rs7946
17391797,The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population,NASH,phosphatidylethanolamine N-methyltransferase,D065626,10400
17391797,The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population,V175M,phosphatidylethanolamine,rs7946,D010714
17391797,The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population,V175M,NASH,rs7946,D065626
17391797,The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population,V175M,phosphatidylethanolamine N-methyltransferase,rs7946,10400
17391797,The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population,phosphatidylethanolamine N-methyltransferase,phosphatidylethanolamine,10400,D010714
17391797,The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population,phosphatidylethanolamine N-methyltransferase,NASH,10400,D065626
17391797,The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population,phosphatidylethanolamine N-methyltransferase,V175M,10400,rs7946
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,phosphatidylethanolamine,phosphatidylcholine,D010714,D010713
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,phosphatidylethanolamine,Val175Met,D010714,rs7946
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,phosphatidylethanolamine,PEMT,D010714,10400
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,phosphatidylethanolamine,phosphatidylethanolamine N-methyltransferase,D010714,10400
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,phosphatidylcholine,phosphatidylethanolamine,D010713,D010714
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,phosphatidylcholine,Val175Met,D010713,rs7946
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,phosphatidylcholine,PEMT,D010713,10400
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,phosphatidylcholine,phosphatidylethanolamine N-methyltransferase,D010713,10400
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,Val175Met,phosphatidylethanolamine,rs7946,D010714
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,Val175Met,phosphatidylcholine,rs7946,D010713
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,Val175Met,PEMT,rs7946,10400
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,Val175Met,phosphatidylethanolamine N-methyltransferase,rs7946,10400
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,PEMT,phosphatidylethanolamine,10400,D010714
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,PEMT,phosphatidylcholine,10400,D010713
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,PEMT,Val175Met,10400,rs7946
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,PEMT,phosphatidylethanolamine N-methyltransferase,10400,10400
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,phosphatidylethanolamine N-methyltransferase,phosphatidylethanolamine,10400,D010714
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,phosphatidylethanolamine N-methyltransferase,phosphatidylcholine,10400,D010713
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,phosphatidylethanolamine N-methyltransferase,Val175Met,10400,rs7946
17391797,A functional polymorphism Val175Met was reported in phosphatidylethanolamine N-methyltransferase (PEMT) that catalyzes the conversion of phosphatidylethanolamine to phosphatidylcholine,phosphatidylethanolamine N-methyltransferase,PEMT,10400,10400
17391797,The aim of this study was to investigate whether the carriers of Val175Met variant impaired in PEMT activity are more susceptible to NASH,NASH,Val175Met,D065626,rs7946
17391797,The aim of this study was to investigate whether the carriers of Val175Met variant impaired in PEMT activity are more susceptible to NASH,NASH,PEMT,D065626,10400
17391797,The aim of this study was to investigate whether the carriers of Val175Met variant impaired in PEMT activity are more susceptible to NASH,Val175Met,NASH,rs7946,D065626
17391797,The aim of this study was to investigate whether the carriers of Val175Met variant impaired in PEMT activity are more susceptible to NASH,Val175Met,PEMT,rs7946,10400
17391797,The aim of this study was to investigate whether the carriers of Val175Met variant impaired in PEMT activity are more susceptible to NASH,PEMT,NASH,10400,D065626
17391797,The aim of this study was to investigate whether the carriers of Val175Met variant impaired in PEMT activity are more susceptible to NASH,PEMT,Val175Met,10400,rs7946
17391797,"RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01)",NASH,Val175Met,D065626,rs7946
17391797,"RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01)",NASH,PEMT,D065626,10400
17391797,"RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01)",Val175Met,NASH,rs7946,D065626
17391797,"RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01)",Val175Met,PEMT,rs7946,10400
17391797,"RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01)",PEMT,NASH,10400,D065626
17391797,"RESULTS: Val175Met variant allele of the PEMT gene was significantly more frequent in NASH patients than in healthy volunteers (p<0.001), and carriers of Val175Met variant were significantly more frequent in NASH patients than in healthy volunteers (p<0.01)",PEMT,Val175Met,10400,rs7946
17391797,"Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT",obese,Val175Met,D009765,rs7946
17391797,"Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT",obese,PEMT,D009765,10400
17391797,"Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT",Val175Met,obese,rs7946,D009765
17391797,"Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT",Val175Met,PEMT,rs7946,10400
17391797,"Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT",Val175Met,NASH,rs7946,D065626
17391797,"Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT",PEMT,obese,10400,D009765
17391797,"Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT",PEMT,Val175Met,10400,rs7946
17391797,"Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT",PEMT,NASH,10400,D065626
17391797,"Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT",NASH,Val175Met,D065626,rs7946
17391797,"Among NASH patients, body mass index was significantly lower (p<0.05), and non-obese patients were significantly more frequent (p<0.001) in carriers of Val175Met variant than in homozygotes of wild type PEMT",NASH,PEMT,D065626,10400
17391797,"CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.",obese,Val175Met,D009765,rs7946
17391797,"CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.",obese,PEMT,D009765,10400
17391797,"CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.",Val175Met,obese,rs7946,D009765
17391797,"CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.",Val175Met,PEMT,rs7946,10400
17391797,"CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.",Val175Met,NASH,rs7946,D065626
17391797,"CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.",PEMT,obese,10400,D009765
17391797,"CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.",PEMT,Val175Met,10400,rs7946
17391797,"CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.",PEMT,NASH,10400,D065626
17391797,"CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.",NASH,Val175Met,D065626,rs7946
17391797,"CONCLUSIONS: Val175Met variant of PEMT could be a candidate molecule that determines the susceptibility to NASH, because it is more frequently observed in NASH patients and non-obese persons with Val175Met variant of PEMT are facilitated to develop NASH.",NASH,PEMT,D065626,10400
17495183,Tenomodulin is associated with obesity and diabetes risk: the Finnish diabetes prevention study,Tenomodulin,diabetes,64102,D003920
17495183,Tenomodulin is associated with obesity and diabetes risk: the Finnish diabetes prevention study,Tenomodulin,obesity,64102,D009765
17495183,Tenomodulin is associated with obesity and diabetes risk: the Finnish diabetes prevention study,diabetes,Tenomodulin,D003920,64102
17495183,Tenomodulin is associated with obesity and diabetes risk: the Finnish diabetes prevention study,obesity,Tenomodulin,D009765,64102
17495183,We recently showed that long-term weight reduction changes the gene expression profile of adipose tissue in overweight individuals with impaired glucose tolerance (IGT),overweight,glucose,D050177,D005947
17495183,We recently showed that long-term weight reduction changes the gene expression profile of adipose tissue in overweight individuals with impaired glucose tolerance (IGT),glucose,overweight,D005947,D050177
17495183,We recently showed that long-term weight reduction changes the gene expression profile of adipose tissue in overweight individuals with impaired glucose tolerance (IGT),glucose,impaired glucose tolerance,D005947,D018149
17495183,We recently showed that long-term weight reduction changes the gene expression profile of adipose tissue in overweight individuals with impaired glucose tolerance (IGT),glucose,IGT,D005947,D018149
17495183,We recently showed that long-term weight reduction changes the gene expression profile of adipose tissue in overweight individuals with impaired glucose tolerance (IGT),impaired glucose tolerance,glucose,D018149,D005947
17495183,We recently showed that long-term weight reduction changes the gene expression profile of adipose tissue in overweight individuals with impaired glucose tolerance (IGT),IGT,glucose,D018149,D005947
17495183,"One of the responding genes was X-chromosomal tenomodulin (TNMD), a putative angiogenesis inhibitor",TNMD,tenomodulin,64102,64102
17495183,"One of the responding genes was X-chromosomal tenomodulin (TNMD), a putative angiogenesis inhibitor",tenomodulin,TNMD,64102,64102
17495183,"Our aim was to study the associations of individual single nucleotide polymorphisms and haplotypes with adiposity, glucose metabolism, and the risk of type 2 diabetes (T2D)",type 2 diabetes,glucose,D003924,D005947
17495183,"Our aim was to study the associations of individual single nucleotide polymorphisms and haplotypes with adiposity, glucose metabolism, and the risk of type 2 diabetes (T2D)",glucose,type 2 diabetes,D005947,D003924
17495183,"Our aim was to study the associations of individual single nucleotide polymorphisms and haplotypes with adiposity, glucose metabolism, and the risk of type 2 diabetes (T2D)",glucose,diabetes,D005947,D003920
17495183,"Our aim was to study the associations of individual single nucleotide polymorphisms and haplotypes with adiposity, glucose metabolism, and the risk of type 2 diabetes (T2D)",glucose,adiposity,D005947,D009765
17495183,"Our aim was to study the associations of individual single nucleotide polymorphisms and haplotypes with adiposity, glucose metabolism, and the risk of type 2 diabetes (T2D)",glucose,T2D,D005947,D003924
17495183,"Our aim was to study the associations of individual single nucleotide polymorphisms and haplotypes with adiposity, glucose metabolism, and the risk of type 2 diabetes (T2D)",diabetes,glucose,D003920,D005947
17495183,"Our aim was to study the associations of individual single nucleotide polymorphisms and haplotypes with adiposity, glucose metabolism, and the risk of type 2 diabetes (T2D)",adiposity,glucose,D009765,D005947
17495183,"Our aim was to study the associations of individual single nucleotide polymorphisms and haplotypes with adiposity, glucose metabolism, and the risk of type 2 diabetes (T2D)",T2D,glucose,D003924,D005947
17495183,"Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018)",rs4828037,rs11798018,rs4828037,rs11798018
17495183,"Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018)",rs4828037,adiposity,rs4828037,D009765
17495183,"Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018)",rs4828037,rs5966709,rs4828037,rs5966709
17495183,"Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018)",rs11798018,rs4828037,rs11798018,rs4828037
17495183,"Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018)",rs11798018,adiposity,rs11798018,D009765
17495183,"Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018)",rs11798018,rs5966709,rs11798018,rs5966709
17495183,"Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018)",adiposity,rs4828037,D009765,rs4828037
17495183,"Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018)",adiposity,rs11798018,D009765,rs11798018
17495183,"Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018)",adiposity,rs5966709,D009765,rs5966709
17495183,"Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018)",rs5966709,rs4828037,rs5966709,rs4828037
17495183,"Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018)",rs5966709,rs11798018,rs5966709,rs11798018
17495183,"Three markers of haploblock 1 were associated with features of adiposity in women (rs5966709, rs4828037) and men (rs11798018)",rs5966709,adiposity,rs5966709,D009765
17495183,Markers rs2073163 and rs1155794 from haploblock 2 were associated with 2-hour plasma glucose levels in men during the 3-year follow-up,rs1155794,rs2073163,rs1155794,rs2073163
17495183,Markers rs2073163 and rs1155794 from haploblock 2 were associated with 2-hour plasma glucose levels in men during the 3-year follow-up,rs1155794,glucose,rs1155794,D005947
17495183,Markers rs2073163 and rs1155794 from haploblock 2 were associated with 2-hour plasma glucose levels in men during the 3-year follow-up,rs2073163,rs1155794,rs2073163,rs1155794
17495183,Markers rs2073163 and rs1155794 from haploblock 2 were associated with 2-hour plasma glucose levels in men during the 3-year follow-up,rs2073163,glucose,rs2073163,D005947
17495183,Markers rs2073163 and rs1155794 from haploblock 2 were associated with 2-hour plasma glucose levels in men during the 3-year follow-up,glucose,rs1155794,D005947,rs1155794
17495183,Markers rs2073163 and rs1155794 from haploblock 2 were associated with 2-hour plasma glucose levels in men during the 3-year follow-up,glucose,rs2073163,D005947,rs2073163
17495183,The same two markers together with rs2073162 associated with the conversion of IGT to T2D in men,T2D,rs2073162,D003924,rs2073162
17495183,The same two markers together with rs2073162 associated with the conversion of IGT to T2D in men,rs2073162,T2D,rs2073162,D003924
17495183,The same two markers together with rs2073162 associated with the conversion of IGT to T2D in men,rs2073162,IGT,rs2073162,D018149
17495183,The same two markers together with rs2073162 associated with the conversion of IGT to T2D in men,IGT,rs2073162,D018149,rs2073162
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",rs1155974,glucose,rs1155974,D005947
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",rs1155974,rs2073163,rs1155974,rs2073163
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",rs1155974,rs2073162,rs1155974,rs2073162
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",rs1155974,T2D,rs1155974,D003924
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",glucose,rs1155974,D005947,rs1155974
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",glucose,rs2073163,D005947,rs2073163
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",glucose,rs2073162,D005947,rs2073162
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",glucose,T2D,D005947,D003924
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",rs2073163,rs1155974,rs2073163,rs1155974
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",rs2073163,glucose,rs2073163,D005947
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",rs2073163,rs2073162,rs2073163,rs2073162
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",rs2073163,T2D,rs2073163,D003924
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",rs2073162,rs1155974,rs2073162,rs1155974
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",rs2073162,glucose,rs2073162,D005947
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",rs2073162,rs2073163,rs2073162,rs2073163
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",rs2073162,T2D,rs2073162,D003924
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",T2D,rs1155974,D003924,rs1155974
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",T2D,glucose,D003924,D005947
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",T2D,rs2073163,D003924,rs2073163
17495183,"The risk of developing T2D was approximately 2-fold in individuals with genotypes associated with higher 2-hour plasma glucose levels; the hazard ratios were 2.192 (p = 0.025) for rs2073162-A, 2.191 (p = 0.027) for rs2073163-C, and 1.998 (p = 0.054) for rs1155974-T",T2D,rs2073162,D003924,rs2073162
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,glucose,IGT,D005947,D018149
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,glucose,adiposity,D005947,D009765
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,glucose,TNMD,D005947,64102
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,glucose,T2D,D005947,D003924
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,IGT,glucose,D018149,D005947
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,IGT,TNMD,D018149,64102
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,adiposity,glucose,D009765,D005947
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,adiposity,TNMD,D009765,64102
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,TNMD,glucose,64102,D005947
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,TNMD,IGT,64102,D018149
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,TNMD,adiposity,64102,D009765
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,TNMD,T2D,64102,D003924
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,T2D,glucose,D003924,D005947
17495183,These results suggest that TNMD polymorphisms are associated with adiposity and also with glucose metabolism and conversion from IGT to T2D in men.,T2D,TNMD,D003924,64102
17572393,Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia,cortical dysplasia,melatonin,D054220,D008550
17572393,Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia,cortical dysplasia,BCNU,D054220,D002330
17572393,Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia,melatonin,cortical dysplasia,D008550,D054220
17572393,Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia,melatonin,BCNU,D008550,D002330
17572393,Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia,BCNU,cortical dysplasia,D002330,D054220
17572393,Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU-induced cortical dysplasia,BCNU,melatonin,D002330,D008550
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses","1,3-bis (2-chloroethyl)-1-nitrosoure",carmustine,D002330,D002330
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses","1,3-bis (2-chloroethyl)-1-nitrosoure",BCNU,D002330,D002330
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses","1,3-bis (2-chloroethyl)-1-nitrosoure",melatonin,D002330,D008550
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses","1,3-bis (2-chloroethyl)-1-nitrosoure",cortical dysplasia,D002330,D054220
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",carmustine,"1,3-bis (2-chloroethyl)-1-nitrosoure",D002330,D002330
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",carmustine,BCNU,D002330,D002330
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",carmustine,melatonin,D002330,D008550
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",carmustine,cortical dysplasia,D002330,D054220
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",BCNU,"1,3-bis (2-chloroethyl)-1-nitrosoure",D002330,D002330
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",BCNU,carmustine,D002330,D002330
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",BCNU,melatonin,D002330,D008550
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",BCNU,cortical dysplasia,D002330,D054220
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",melatonin,"1,3-bis (2-chloroethyl)-1-nitrosoure",D008550,D002330
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",melatonin,carmustine,D008550,D002330
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",melatonin,BCNU,D008550,D002330
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",melatonin,cortical dysplasia,D008550,D054220
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",cortical dysplasia,"1,3-bis (2-chloroethyl)-1-nitrosoure",D054220,D002330
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",cortical dysplasia,carmustine,D054220,D002330
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",cortical dysplasia,BCNU,D054220,D002330
17572393,"This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine-[1,3-bis (2-chloroethyl)-1-nitrosoure] (BCNU) and to investigate the effects of exogenous melatonin upon cerebellar BCNU-induced cortical dysplasia, using histological and biochemical analyses",cortical dysplasia,melatonin,D054220,D008550
17572393,"Pregnant Wistar rats were assigned to five groups: intact-control, saline-control, melatonin-treated, BCNU-exposed and BCNU-exposed plus melatonin",melatonin,BCNU,D008550,D002330
17572393,"Pregnant Wistar rats were assigned to five groups: intact-control, saline-control, melatonin-treated, BCNU-exposed and BCNU-exposed plus melatonin",BCNU,melatonin,D002330,D008550
17572393,Rats were exposed to BCNU on embryonic day 15 and melatonin was given until delivery,melatonin,BCNU,D008550,D002330
17572393,Rats were exposed to BCNU on embryonic day 15 and melatonin was given until delivery,BCNU,melatonin,D002330,D008550
17572393,"Immuno/histochemistry and electron microscopy were carried out on the offspring cerebellum, and levels of malondialdehyde and superoxide dismutase were determined",superoxide dismutase,malondialdehyde,24786,D008315
17572393,"Immuno/histochemistry and electron microscopy were carried out on the offspring cerebellum, and levels of malondialdehyde and superoxide dismutase were determined",superoxide dismutase,superoxide,24786,D013481
17572393,"Immuno/histochemistry and electron microscopy were carried out on the offspring cerebellum, and levels of malondialdehyde and superoxide dismutase were determined",malondialdehyde,superoxide dismutase,D008315,24786
17572393,"Immuno/histochemistry and electron microscopy were carried out on the offspring cerebellum, and levels of malondialdehyde and superoxide dismutase were determined",malondialdehyde,superoxide,D008315,D013481
17572393,"Immuno/histochemistry and electron microscopy were carried out on the offspring cerebellum, and levels of malondialdehyde and superoxide dismutase were determined",superoxide,superoxide dismutase,D013481,24786
17572393,"Immuno/histochemistry and electron microscopy were carried out on the offspring cerebellum, and levels of malondialdehyde and superoxide dismutase were determined",superoxide,malondialdehyde,D013481,D008315
17572393,"Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed cortical dysplasia group",cortical dysplasia,BCNU,D054220,D002330
17572393,"Histopathologically, typical findings were observed in the cerebella from the control groups, but the findings consistent with early embryonic development were noted in BCNU-exposed cortical dysplasia group",BCNU,cortical dysplasia,D002330,D054220
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",BCNU,synaptophysin,D002330,24804
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",BCNU,transforming growth factor beta1,D002330,59086
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",BCNU,melatonin,D002330,D008550
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",BCNU,glial fibrillary acidic protein,D002330,24387
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",synaptophysin,BCNU,24804,D002330
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",synaptophysin,transforming growth factor beta1,24804,59086
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",synaptophysin,melatonin,24804,D008550
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",synaptophysin,glial fibrillary acidic protein,24804,24387
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",transforming growth factor beta1,BCNU,59086,D002330
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",transforming growth factor beta1,synaptophysin,59086,24804
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",transforming growth factor beta1,melatonin,59086,D008550
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",transforming growth factor beta1,glial fibrillary acidic protein,59086,24387
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",melatonin,BCNU,D008550,D002330
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",melatonin,synaptophysin,D008550,24804
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",melatonin,transforming growth factor beta1,D008550,59086
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",melatonin,glial fibrillary acidic protein,D008550,24387
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",glial fibrillary acidic protein,BCNU,24387,D002330
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",glial fibrillary acidic protein,synaptophysin,24387,24804
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",glial fibrillary acidic protein,transforming growth factor beta1,24387,59086
17572393,"There was a marked increase in the number of TUNEL positive cells and nestin positive cells in BCNU-exposed group, but a decreased immunoreactivity to glial fibrillary acidic protein, synaptophysin and transforming growth factor beta1 was observed, indicating a delayed maturation, and melatonin significantly reversed these changes",glial fibrillary acidic protein,melatonin,24387,D008550
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",BCNU,Malondialdehyde,D002330,D008315
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",BCNU,melatonin,D002330,D008550
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",BCNU,superoxide dismutase,D002330,24786
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",BCNU,malondialdehyde,D002330,D008315
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",BCNU,superoxide,D002330,D013481
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",Malondialdehyde,BCNU,D008315,D002330
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",Malondialdehyde,melatonin,D008315,D008550
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",Malondialdehyde,superoxide dismutase,D008315,24786
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",Malondialdehyde,malondialdehyde,D008315,D008315
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",Malondialdehyde,superoxide,D008315,D013481
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",melatonin,BCNU,D008550,D002330
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",melatonin,Malondialdehyde,D008550,D008315
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",melatonin,superoxide dismutase,D008550,24786
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",melatonin,malondialdehyde,D008550,D008315
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",melatonin,superoxide,D008550,D013481
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",superoxide dismutase,BCNU,24786,D002330
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",superoxide dismutase,Malondialdehyde,24786,D008315
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",superoxide dismutase,melatonin,24786,D008550
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",superoxide dismutase,malondialdehyde,24786,D008315
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",superoxide dismutase,superoxide,24786,D013481
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",malondialdehyde,BCNU,D008315,D002330
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",malondialdehyde,Malondialdehyde,D008315,D008315
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",malondialdehyde,melatonin,D008315,D008550
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",malondialdehyde,superoxide dismutase,D008315,24786
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",malondialdehyde,superoxide,D008315,D013481
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",superoxide,BCNU,D013481,D002330
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",superoxide,Malondialdehyde,D013481,D008315
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",superoxide,melatonin,D013481,D008550
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",superoxide,superoxide dismutase,D013481,24786
17572393,"Malondialdehyde level in BCNU-exposed group was higher than those in control groups and melatonin decreased malondialdehyde levels in BCNU group (P<0.01), while there were no significant differences in the superoxide dismutase levels between these groups",superoxide,malondialdehyde,D013481,D008315
17572393,These data suggest that exposure of animals to BCNU during pregnancy leads to delayed maturation of offspring cerebellum and melatonin protects the cerebellum against the effects of BCNU.,melatonin,BCNU,D008550,D002330
17572393,These data suggest that exposure of animals to BCNU during pregnancy leads to delayed maturation of offspring cerebellum and melatonin protects the cerebellum against the effects of BCNU.,BCNU,melatonin,D002330,D008550
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),RP,g.ORF15 + 652-653delAG,D012174,g|DEL|ORF15+652_653|AG
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),RP,RPGR,D012174,6103
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),XLRP,g.ORF15 + 652-653delAG,D012174,g|DEL|ORF15+652_653|AG
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),XLRP,RPGR,D012174,6103
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),g.ORF15 + 652-653delAG,RP,g|DEL|ORF15+652_653|AG,D012174
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),g.ORF15 + 652-653delAG,XLRP,g|DEL|ORF15+652_653|AG,D012174
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),g.ORF15 + 652-653delAG,RPGR,g|DEL|ORF15+652_653|AG,6103
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),g.ORF15 + 652-653delAG,X-linked retinitis pigmentosa,g|DEL|ORF15+652_653|AG,D012174
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),RPGR,RP,6103,D012174
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),RPGR,XLRP,6103,D012174
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),RPGR,g.ORF15 + 652-653delAG,6103,g|DEL|ORF15+652_653|AG
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),RPGR,X-linked retinitis pigmentosa,6103,D012174
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),X-linked retinitis pigmentosa,g.ORF15 + 652-653delAG,D012174,g|DEL|ORF15+652_653|AG
17935240,The g.ORF15 + 652-653delAG mutation in the RPGR gene is the most frequent mutation in X-linked retinitis pigmentosa (XLRP),X-linked retinitis pigmentosa,RPGR,D012174,6103
17935240,Haplotype analysis and mutational screening on the RPGR gene were performed,RP,RPGR,D012174,6103
17935240,Haplotype analysis and mutational screening on the RPGR gene were performed,RPGR,RP,6103,D012174
17935240,"In conclusion, we reported on a family in which an asymptomatic woman with somatic-gonadal mosaicism for a RPGR gene mutation transmitted the mutation to an asymptomatic daughter and to a son with XLRP",RP,RPGR,D012174,6103
17935240,"In conclusion, we reported on a family in which an asymptomatic woman with somatic-gonadal mosaicism for a RPGR gene mutation transmitted the mutation to an asymptomatic daughter and to a son with XLRP",XLRP,RPGR,D012174,6103
17935240,"In conclusion, we reported on a family in which an asymptomatic woman with somatic-gonadal mosaicism for a RPGR gene mutation transmitted the mutation to an asymptomatic daughter and to a son with XLRP",RPGR,RP,6103,D012174
17935240,"In conclusion, we reported on a family in which an asymptomatic woman with somatic-gonadal mosaicism for a RPGR gene mutation transmitted the mutation to an asymptomatic daughter and to a son with XLRP",RPGR,XLRP,6103,D012174
17962394,"Skewed X inactivation in an X linked nystagmus family resulted from a novel, p.R229G, missense mutation in the FRMD7 gene",X linked nystagmus,p.R229G,C580539,rs137852212
17962394,"Skewed X inactivation in an X linked nystagmus family resulted from a novel, p.R229G, missense mutation in the FRMD7 gene",X linked nystagmus,FRMD7,C580539,90167
17962394,"Skewed X inactivation in an X linked nystagmus family resulted from a novel, p.R229G, missense mutation in the FRMD7 gene",p.R229G,X linked nystagmus,rs137852212,C580539
17962394,"Skewed X inactivation in an X linked nystagmus family resulted from a novel, p.R229G, missense mutation in the FRMD7 gene",p.R229G,FRMD7,rs137852212,90167
17962394,"Skewed X inactivation in an X linked nystagmus family resulted from a novel, p.R229G, missense mutation in the FRMD7 gene",FRMD7,X linked nystagmus,90167,C580539
17962394,"Skewed X inactivation in an X linked nystagmus family resulted from a novel, p.R229G, missense mutation in the FRMD7 gene",FRMD7,p.R229G,90167,rs137852212
17962394,"X chromosome inactivation analysis was performed by enzymatic predigestion of DNA with a methylation-sensitive enzyme, followed by PCR of the polymorphic CAG repeat of the androgen receptor gene",androgen receptor,CAG repeat,367,c|DUP||CAG|
17962394,"X chromosome inactivation analysis was performed by enzymatic predigestion of DNA with a methylation-sensitive enzyme, followed by PCR of the polymorphic CAG repeat of the androgen receptor gene",CAG repeat,androgen receptor,c|DUP||CAG|,367
17962394,"A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed",p.R229G,FRMD7,rs137852212,90167
17962394,"A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed",p.R229G,arginine at amino acid position 229 by glycine,rs137852212,rs137852212
17962394,"A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed",p.R229G,c.686C>G,rs137852212,rs137852212
17962394,"A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed",FRMD7,p.R229G,90167,rs137852212
17962394,"A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed",FRMD7,arginine at amino acid position 229 by glycine,90167,rs137852212
17962394,"A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed",FRMD7,c.686C>G,90167,rs137852212
17962394,"A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed",arginine at amino acid position 229 by glycine,p.R229G,rs137852212,rs137852212
17962394,"A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed",arginine at amino acid position 229 by glycine,FRMD7,rs137852212,90167
17962394,"A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed",arginine at amino acid position 229 by glycine,c.686C>G,rs137852212,rs137852212
17962394,"A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed",c.686C>G,p.R229G,rs137852212,rs137852212
17962394,"A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed",c.686C>G,FRMD7,rs137852212,90167
17962394,"A novel missense c.686C>G mutation, which causes the substitution of a conserved arginine at amino acid position 229 by glycine (p.R229G) in exon 8 of the FRMD7 gene, was observed",c.686C>G,arginine at amino acid position 229 by glycine,rs137852212,rs137852212
17962394,"CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.",NYS,p.R229G,C580539,rs137852212
17962394,"CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.",NYS,FRMD7,C580539,90167
17962394,"CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.",p.R229G,NYS,rs137852212,C580539
17962394,"CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.",p.R229G,FRMD7,rs137852212,90167
17962394,"CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.",p.R229G,X linked NYS,rs137852212,C580539
17962394,"CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.",FRMD7,NYS,90167,C580539
17962394,"CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.",FRMD7,p.R229G,90167,rs137852212
17962394,"CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.",FRMD7,X linked NYS,90167,C580539
17962394,"CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.",X linked NYS,p.R229G,C580539,rs137852212
17962394,"CONCLUSIONS: A novel p.R229G mutation in the FRMD7 gene causes the NYS phenotype, and skewed X inactivation influences the manifestation of the disease in X linked NYS females.",X linked NYS,FRMD7,C580539,90167
18235024,Cone dystrophy with supernormal rod response is strictly associated with mutations in KCNV2,Cone dystrophy with supernormal rod response,KCNV2,C563678,169522
18235024,Cone dystrophy with supernormal rod response is strictly associated with mutations in KCNV2,KCNV2,Cone dystrophy with supernormal rod response,169522,C563678
18235024,Mutations in PDE6H and in KCNV2 have been described in CDSRR,KCNV2,CDSRR,169522,C563678
18235024,Mutations in PDE6H and in KCNV2 have been described in CDSRR,KCNV2,PDE6H,169522,5149
18235024,Mutations in PDE6H and in KCNV2 have been described in CDSRR,CDSRR,KCNV2,C563678,169522
18235024,Mutations in PDE6H and in KCNV2 have been described in CDSRR,CDSRR,PDE6H,C563678,5149
18235024,Mutations in PDE6H and in KCNV2 have been described in CDSRR,PDE6H,KCNV2,5149,169522
18235024,Mutations in PDE6H and in KCNV2 have been described in CDSRR,PDE6H,CDSRR,5149,C563678
18235024,The coding sequences and flanking intron/UTR sequences of PDE6C and KCNV2 were screened for mutations by means of DHPLC and direct DNA sequencing of PCR-amplified genomic DNA,KCNV2,PDE6C,169522,5146
18235024,The coding sequences and flanking intron/UTR sequences of PDE6C and KCNV2 were screened for mutations by means of DHPLC and direct DNA sequencing of PCR-amplified genomic DNA,PDE6C,KCNV2,5146,169522
18235024,"Whereas no mutations were detected in the PDE6H gene, mutations in KCNV2 were identified in all patients, in either the homozygous or compound heterozygous state",KCNV2,PDE6H,169522,5149
18235024,"Whereas no mutations were detected in the PDE6H gene, mutations in KCNV2 were identified in all patients, in either the homozygous or compound heterozygous state",PDE6H,KCNV2,5149,169522
18235024,CONCLUSIONS: The phenotype of cone dystrophy with supernormal rod response is tightly linked with mutations in KCNV2.,KCNV2,cone dystrophy with supernormal rod response,169522,C563678
18235024,CONCLUSIONS: The phenotype of cone dystrophy with supernormal rod response is tightly linked with mutations in KCNV2.,cone dystrophy with supernormal rod response,KCNV2,C563678,169522
18408250,A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population,IRF,IRF5,3663,3663
18408250,A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population,IRF,rheumatoid arthritis,3663,D001172
18408250,A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population,IRF5,IRF,3663,3663
18408250,A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population,IRF5,rheumatoid arthritis,3663,D001172
18408250,A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population,rheumatoid arthritis,IRF,D001172,3663
18408250,A single nucleotide polymorphism in the IRF5 promoter region is associated with susceptibility to rheumatoid arthritis in the Japanese population,rheumatoid arthritis,IRF5,D001172,3663
18408250,"OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines",IRF,Interferon regulatory factor 5,3663,3663
18408250,"OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines",IRF,IRF5,3663,3663
18408250,"OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines",IRF,proinflammatory cytokines,3663,3553
18408250,"OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines",Interferon regulatory factor 5,IRF,3663,3663
18408250,"OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines",Interferon regulatory factor 5,IRF5,3663,3663
18408250,"OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines",Interferon regulatory factor 5,proinflammatory cytokines,3663,3553
18408250,"OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines",IRF5,IRF,3663,3663
18408250,"OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines",IRF5,Interferon regulatory factor 5,3663,3663
18408250,"OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines",IRF5,proinflammatory cytokines,3663,3553
18408250,"OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines",proinflammatory cytokines,IRF,3553,3663
18408250,"OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines",proinflammatory cytokines,Interferon regulatory factor 5,3553,3663
18408250,"OBJECTIVES: Interferon regulatory factor 5 (IRF5) is a member of the IRF family of transcription factors, which regulate the production of proinflammatory cytokines",proinflammatory cytokines,IRF5,3553,3663
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",autoimmune diseases,IRF,D001327,3663
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",autoimmune diseases,IRF5,D001327,3663
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",systemic lupus erythaematosus,IRF,D008180,3663
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",systemic lupus erythaematosus,IRF5,D008180,3663
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",SLE,IRF,D008180,3663
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",SLE,IRF5,D008180,3663
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",IRF,autoimmune diseases,3663,D001327
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",IRF,systemic lupus erythaematosus,3663,D008180
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",IRF,SLE,3663,D008180
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",IRF,IRF5,3663,3663
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",IRF5,autoimmune diseases,3663,D001327
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",IRF5,systemic lupus erythaematosus,3663,D008180
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",IRF5,SLE,3663,D008180
18408250,"Polymorphisms in the IRF5 gene have been associated with susceptibility to systemic lupus erythaematosus (SLE) in Caucasian and Asian populations, but their involvement in other autoimmune diseases is still uncertain",IRF5,IRF,3663,3663
18408250,"Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects",IRF,RA,3663,D001172
18408250,"Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects",IRF,IRF5,3663,3663
18408250,"Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects",IRF,rheumatoid arthritis,3663,D001172
18408250,"Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects",RA,IRF,D001172,3663
18408250,"Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects",RA,IRF5,D001172,3663
18408250,"Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects",IRF5,IRF,3663,3663
18408250,"Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects",IRF5,RA,3663,D001172
18408250,"Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects",IRF5,rheumatoid arthritis,3663,D001172
18408250,"Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects",rheumatoid arthritis,IRF,D001172,3663
18408250,"Here, we assessed the genetic role of IRF5 in susceptibility to rheumatoid arthritis (RA) in Japanese subjects",rheumatoid arthritis,IRF5,D001172,3663
18408250,METHODS: We selected 13 single nucleotide polymorphisms (SNPs) and a CGGGG insertion-deletion polymorphism in the IRF5 gene,IRF,IRF5,3663,3663
18408250,METHODS: We selected 13 single nucleotide polymorphisms (SNPs) and a CGGGG insertion-deletion polymorphism in the IRF5 gene,IRF5,IRF,3663,3663
18408250,"We performed 2 sets of case-control comparisons using Japanese subjects (first set: 830 patients with RA and 658 controls; second set: 1112 patients with RA and 940 controls), and then performed a stratified analysis using human leukocyte antigen (HLA)-DRB1 shared epitope (SE) status",leukocyte antigen (HLA)-DRB1,RA,3123,D001172
18408250,"We performed 2 sets of case-control comparisons using Japanese subjects (first set: 830 patients with RA and 658 controls; second set: 1112 patients with RA and 940 controls), and then performed a stratified analysis using human leukocyte antigen (HLA)-DRB1 shared epitope (SE) status",RA,leukocyte antigen (HLA)-DRB1,D001172,3123
18408250,"RESULTS: A significant association of the rs729302 A allele with RA susceptibility was found in both sets (odds ratio (OR) 1.22, 95% CI 1.09 to 1.35, p<0.001 in the combined analysis)",rs729302,RA,rs729302,D001172
18408250,"RESULTS: A significant association of the rs729302 A allele with RA susceptibility was found in both sets (odds ratio (OR) 1.22, 95% CI 1.09 to 1.35, p<0.001 in the combined analysis)",RA,rs729302,D001172,rs729302
18408250,"When the patients were stratified by the SE, the rs729302 A allele was found to confer increased risk to RA in patients that were SE negative (OR 1.50, 95% CI 1.17 to 1.92, p = 0.001) as compared with patients carrying the SE (OR 1.11, 95% CI 0.93 to 1.33, p = 0.24)",rs729302,RA,rs729302,D001172
18408250,"When the patients were stratified by the SE, the rs729302 A allele was found to confer increased risk to RA in patients that were SE negative (OR 1.50, 95% CI 1.17 to 1.92, p = 0.001) as compared with patients carrying the SE (OR 1.11, 95% CI 0.93 to 1.33, p = 0.24)",RA,rs729302,D001172,rs729302
18408250,"In both sets, no genotyped polymorphisms were significantly associated with RA susceptibility, but rs729302 was significantly associated",rs729302,RA,rs729302,D001172
18408250,"In both sets, no genotyped polymorphisms were significantly associated with RA susceptibility, but rs729302 was significantly associated",RA,rs729302,D001172,rs729302
18408250,"CONCLUSIONS: These findings indicate that the promoter polymorphism of IRF5 is a genetic factor conferring predisposition to RA, and that it contributes considerably to disease pathogenesis in patients that were SE negative.",IRF,IRF5,3663,3663
18408250,"CONCLUSIONS: These findings indicate that the promoter polymorphism of IRF5 is a genetic factor conferring predisposition to RA, and that it contributes considerably to disease pathogenesis in patients that were SE negative.",IRF,RA,3663,D001172
18408250,"CONCLUSIONS: These findings indicate that the promoter polymorphism of IRF5 is a genetic factor conferring predisposition to RA, and that it contributes considerably to disease pathogenesis in patients that were SE negative.",IRF5,IRF,3663,3663
18408250,"CONCLUSIONS: These findings indicate that the promoter polymorphism of IRF5 is a genetic factor conferring predisposition to RA, and that it contributes considerably to disease pathogenesis in patients that were SE negative.",IRF5,RA,3663,D001172
18408250,"CONCLUSIONS: These findings indicate that the promoter polymorphism of IRF5 is a genetic factor conferring predisposition to RA, and that it contributes considerably to disease pathogenesis in patients that were SE negative.",RA,IRF,D001172,3663
18408250,"CONCLUSIONS: These findings indicate that the promoter polymorphism of IRF5 is a genetic factor conferring predisposition to RA, and that it contributes considerably to disease pathogenesis in patients that were SE negative.",RA,IRF5,D001172,3663
18487244,We investigated clinical and cellular phenotypes of 24 children with mutations in the catalytic (alpha) subunit of the mitochondrial DNA (mtDNA) gamma polymerase (POLG1),POLG1,mitochondrial DNA (mtDNA) gamma polymerase,5428,5428
18487244,We investigated clinical and cellular phenotypes of 24 children with mutations in the catalytic (alpha) subunit of the mitochondrial DNA (mtDNA) gamma polymerase (POLG1),mitochondrial DNA (mtDNA) gamma polymerase,POLG1,5428,5428
18487244,"Twenty-one had Alpers syndrome, the commonest severe POLG1 autosomal recessive phenotype, comprising hepatoencephalopathy and often mtDNA depletion",POLG1,Alpers syndrome,5428,D002549
18487244,"Twenty-one had Alpers syndrome, the commonest severe POLG1 autosomal recessive phenotype, comprising hepatoencephalopathy and often mtDNA depletion",POLG1,hepatoencephalopathy,5428,C563797
18487244,"Twenty-one had Alpers syndrome, the commonest severe POLG1 autosomal recessive phenotype, comprising hepatoencephalopathy and often mtDNA depletion",Alpers syndrome,POLG1,D002549,5428
18487244,"Twenty-one had Alpers syndrome, the commonest severe POLG1 autosomal recessive phenotype, comprising hepatoencephalopathy and often mtDNA depletion",hepatoencephalopathy,POLG1,C563797,5428
18631865,"mToR inhibitors-induced proteinuria: mechanisms, significance, and management",mToR inhibitors,proteinuria,-,D011507
18631865,"mToR inhibitors-induced proteinuria: mechanisms, significance, and management",mToR inhibitors,mToR,-,2475
18631865,"mToR inhibitors-induced proteinuria: mechanisms, significance, and management",proteinuria,mToR inhibitors,D011507,-
18631865,"mToR inhibitors-induced proteinuria: mechanisms, significance, and management",proteinuria,mToR,D011507,2475
18631865,"mToR inhibitors-induced proteinuria: mechanisms, significance, and management",mToR,mToR inhibitors,2475,-
18631865,"mToR inhibitors-induced proteinuria: mechanisms, significance, and management",mToR,proteinuria,2475,D011507
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",mToR,calcineurin inhibitors,2475,D065095
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",mToR,chronic allograft nephropathy,2475,D051436
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",mToR,mammalian target of rapamycin (mToR) inhibitors,2475,-
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",mToR,sirolimus,2475,D020123
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",calcineurin inhibitors,mToR,D065095,2475
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",calcineurin inhibitors,chronic allograft nephropathy,D065095,D051436
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",calcineurin inhibitors,mammalian target of rapamycin (mToR) inhibitors,D065095,-
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",calcineurin inhibitors,sirolimus,D065095,D020123
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",chronic allograft nephropathy,mToR,D051436,2475
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",chronic allograft nephropathy,calcineurin inhibitors,D051436,D065095
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",chronic allograft nephropathy,mammalian target of rapamycin (mToR) inhibitors,D051436,-
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",chronic allograft nephropathy,sirolimus,D051436,D020123
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",mammalian target of rapamycin (mToR) inhibitors,mToR,-,2475
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",mammalian target of rapamycin (mToR) inhibitors,calcineurin inhibitors,-,D065095
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",mammalian target of rapamycin (mToR) inhibitors,chronic allograft nephropathy,-,D051436
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",mammalian target of rapamycin (mToR) inhibitors,sirolimus,-,D020123
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",sirolimus,mToR,D020123,2475
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",sirolimus,calcineurin inhibitors,D020123,D065095
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",sirolimus,chronic allograft nephropathy,D020123,D051436
18631865,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy",sirolimus,mammalian target of rapamycin (mToR) inhibitors,D020123,-
18631865,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo,proteinuria,sirolimus,D011507,D020123
18631865,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo,proteinuria,calcineurin inhibitors,D011507,D065095
18631865,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo,sirolimus,proteinuria,D020123,D011507
18631865,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo,sirolimus,calcineurin inhibitors,D020123,D065095
18631865,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo,calcineurin inhibitors,proteinuria,D065095,D011507
18631865,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo,calcineurin inhibitors,sirolimus,D065095,D020123
18631865,"Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic",glomerulosclerosis,mToR,D005921,2475
18631865,"Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic",mToR,glomerulosclerosis,2475,D005921
18631865,We discuss herein the possible mechanisms and the significance of mToR blockade-induced proteinuria.,proteinuria,mToR,D011507,2475
18631865,We discuss herein the possible mechanisms and the significance of mToR blockade-induced proteinuria.,mToR,proteinuria,2475,D011507
18768591,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome,nephrotic,Serum- and glucocorticoid-inducible kinase 1,D009404,20393
18768591,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome,nephrotic,doxorubicin,D009404,D004317
18768591,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome,nephrotic syndrome,Serum- and glucocorticoid-inducible kinase 1,D009404,20393
18768591,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome,nephrotic syndrome,doxorubicin,D009404,D004317
18768591,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome,Serum- and glucocorticoid-inducible kinase 1,nephrotic,20393,D009404
18768591,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome,Serum- and glucocorticoid-inducible kinase 1,nephrotic syndrome,20393,D009404
18768591,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome,Serum- and glucocorticoid-inducible kinase 1,doxorubicin,20393,D004317
18768591,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome,doxorubicin,nephrotic,D004317,D009404
18768591,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome,doxorubicin,nephrotic syndrome,D004317,D009404
18768591,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome,doxorubicin,Serum- and glucocorticoid-inducible kinase 1,D004317,20393
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,volume retention,sodium,D016055,D012964
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,volume retention,Doxorubicin,D016055,D004317
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,sodium,volume retention,D012964,D016055
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,sodium,renal fibrosis,D012964,D007674
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,sodium,nephropathy,D012964,D007674
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,sodium,fibrosis,D012964,D005355
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,sodium,Doxorubicin,D012964,D004317
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,renal fibrosis,sodium,D007674,D012964
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,renal fibrosis,Doxorubicin,D007674,D004317
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,nephropathy,sodium,D007674,D012964
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,nephropathy,Doxorubicin,D007674,D004317
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,fibrosis,sodium,D005355,D012964
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,fibrosis,Doxorubicin,D005355,D004317
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,Doxorubicin,volume retention,D004317,D016055
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,Doxorubicin,sodium,D004317,D012964
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,Doxorubicin,renal fibrosis,D004317,D007674
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,Doxorubicin,nephropathy,D004317,D007674
18768591,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis,Doxorubicin,fibrosis,D004317,D005355
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,serum- and glucocorticoid-inducible kinase,mineralocorticoid,20393,D008901
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,serum- and glucocorticoid-inducible kinase,renal fibrosis,20393,D007674
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,serum- and glucocorticoid-inducible kinase,SGK1,20393,20393
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,serum- and glucocorticoid-inducible kinase,aldosterone,20393,D000450
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,serum- and glucocorticoid-inducible kinase,fibrosis,20393,D005355
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,serum- and glucocorticoid-inducible kinase,salt,20393,D012492
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,mineralocorticoid,serum- and glucocorticoid-inducible kinase,D008901,20393
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,mineralocorticoid,renal fibrosis,D008901,D007674
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,mineralocorticoid,SGK1,D008901,20393
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,mineralocorticoid,aldosterone,D008901,D000450
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,mineralocorticoid,fibrosis,D008901,D005355
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,mineralocorticoid,salt,D008901,D012492
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,renal fibrosis,serum- and glucocorticoid-inducible kinase,D007674,20393
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,renal fibrosis,mineralocorticoid,D007674,D008901
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,renal fibrosis,SGK1,D007674,20393
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,renal fibrosis,aldosterone,D007674,D000450
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,renal fibrosis,salt,D007674,D012492
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,SGK1,serum- and glucocorticoid-inducible kinase,20393,20393
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,SGK1,mineralocorticoid,20393,D008901
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,SGK1,renal fibrosis,20393,D007674
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,SGK1,aldosterone,20393,D000450
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,SGK1,fibrosis,20393,D005355
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,SGK1,salt,20393,D012492
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,aldosterone,serum- and glucocorticoid-inducible kinase,D000450,20393
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,aldosterone,mineralocorticoid,D000450,D008901
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,aldosterone,renal fibrosis,D000450,D007674
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,aldosterone,SGK1,D000450,20393
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,aldosterone,fibrosis,D000450,D005355
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,aldosterone,salt,D000450,D012492
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,fibrosis,serum- and glucocorticoid-inducible kinase,D005355,20393
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,fibrosis,mineralocorticoid,D005355,D008901
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,fibrosis,SGK1,D005355,20393
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,fibrosis,aldosterone,D005355,D000450
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,fibrosis,salt,D005355,D012492
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,salt,serum- and glucocorticoid-inducible kinase,D012492,20393
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,salt,mineralocorticoid,D012492,D008901
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,salt,renal fibrosis,D012492,D007674
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,salt,SGK1,D012492,20393
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,salt,aldosterone,D012492,D000450
18768591,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess,salt,fibrosis,D012492,D005355
18768591,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome,volume retention,SGK1,D016055,20393
18768591,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome,SGK1,volume retention,20393,D016055
18768591,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome,SGK1,nephrotic syndrome,20393,D009404
18768591,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome,SGK1,fibrosis,20393,D005355
18768591,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome,SGK1,nephrotic,20393,D009404
18768591,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome,nephrotic syndrome,SGK1,D009404,20393
18768591,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome,fibrosis,SGK1,D005355,20393
18768591,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome,nephrotic,SGK1,D009404,20393
18768591,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+))",sgk1,SGK1,20393,20393
18768591,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+))",sgk1,doxorubicin,20393,D004317
18768591,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+))",SGK1,sgk1,20393,20393
18768591,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+))",SGK1,doxorubicin,20393,D004317
18768591,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+))",doxorubicin,sgk1,D004317,20393
18768591,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+))",doxorubicin,SGK1,D004317,20393
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",proteinuria,crea,D011507,D003404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",proteinuria,Doxorubicin,D011507,D004317
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",proteinuria,sgk1,D011507,20393
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",lipidemia,crea,D006949,D003404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",lipidemia,Doxorubicin,D006949,D004317
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",lipidemia,sgk1,D006949,20393
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",nephrotic syndrome,crea,D009404,D003404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",nephrotic syndrome,Doxorubicin,D009404,D004317
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",nephrotic syndrome,sgk1,D009404,20393
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",crea,proteinuria,D003404,D011507
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",crea,lipidemia,D003404,D006949
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",crea,nephrotic syndrome,D003404,D009404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",crea,ascites,D003404,D001201
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",crea,Doxorubicin,D003404,D004317
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",crea,nephrotic,D003404,D009404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",crea,hypoalbuminemia,D003404,D034141
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",crea,sgk1,D003404,20393
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",ascites,crea,D001201,D003404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",ascites,Doxorubicin,D001201,D004317
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",ascites,sgk1,D001201,20393
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",Doxorubicin,proteinuria,D004317,D011507
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",Doxorubicin,lipidemia,D004317,D006949
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",Doxorubicin,nephrotic syndrome,D004317,D009404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",Doxorubicin,crea,D004317,D003404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",Doxorubicin,ascites,D004317,D001201
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",Doxorubicin,nephrotic,D004317,D009404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",Doxorubicin,hypoalbuminemia,D004317,D034141
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",Doxorubicin,sgk1,D004317,20393
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",nephrotic,crea,D009404,D003404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",nephrotic,Doxorubicin,D009404,D004317
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",nephrotic,sgk1,D009404,20393
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",hypoalbuminemia,crea,D034141,D003404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",hypoalbuminemia,Doxorubicin,D034141,D004317
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",hypoalbuminemia,sgk1,D034141,20393
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",sgk1,proteinuria,20393,D011507
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",sgk1,lipidemia,20393,D006949
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",sgk1,nephrotic syndrome,20393,D009404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",sgk1,crea,20393,D003404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",sgk1,ascites,20393,D001201
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",sgk1,Doxorubicin,20393,D004317
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",sgk1,nephrotic,20393,D009404
18768591,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes",sgk1,hypoalbuminemia,20393,D034141
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,SGK1,aldosterone,20393,D000450
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,SGK1,crea,20393,D003404
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,SGK1,nephrotic,20393,D009404
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,SGK1,sgk1,20393,20393
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,aldosterone,SGK1,D000450,20393
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,aldosterone,crea,D000450,D003404
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,aldosterone,nephrotic,D000450,D009404
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,aldosterone,sgk1,D000450,20393
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,crea,SGK1,D003404,20393
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,crea,aldosterone,D003404,D000450
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,crea,nephrotic,D003404,D009404
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,crea,sgk1,D003404,20393
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,nephrotic,SGK1,D009404,20393
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,nephrotic,aldosterone,D009404,D000450
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,nephrotic,crea,D009404,D003404
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,nephrotic,sgk1,D009404,20393
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,sgk1,SGK1,20393,20393
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,sgk1,aldosterone,20393,D000450
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,sgk1,crea,20393,D003404
18768591,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice,sgk1,nephrotic,20393,D009404
18768591,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs,sodium,weight gain,D012964,D015430
18768591,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs,sodium,crea,D012964,D003404
18768591,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs,sodium,sgk1,D012964,20393
18768591,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs,weight gain,sodium,D015430,D012964
18768591,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs,weight gain,crea,D015430,D003404
18768591,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs,weight gain,sgk1,D015430,20393
18768591,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs,crea,sodium,D003404,D012964
18768591,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs,crea,weight gain,D003404,D015430
18768591,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs,crea,sgk1,D003404,20393
18768591,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs,sgk1,sodium,20393,D012964
18768591,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs,sgk1,weight gain,20393,D015430
18768591,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs,sgk1,crea,20393,D003404
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",nephrotic syndrome,crea,D009404,D003404
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",nephrotic syndrome,urea,D009404,D014508
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",nephrotic syndrome,sgk1,D009404,20393
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",crea,nephrotic syndrome,D003404,D009404
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",crea,urea,D003404,D014508
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",crea,uremia,D003404,D014511
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",crea,nephrotic,D003404,D009404
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",crea,sgk1,D003404,20393
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",urea,nephrotic syndrome,D014508,D009404
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",urea,crea,D014508,D003404
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",urea,uremia,D014508,D014511
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",urea,nephrotic,D014508,D009404
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",urea,sgk1,D014508,20393
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",uremia,crea,D014511,D003404
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",uremia,urea,D014511,D014508
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",uremia,sgk1,D014511,20393
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",nephrotic,crea,D009404,D003404
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",nephrotic,urea,D009404,D014508
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",nephrotic,sgk1,D009404,20393
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",sgk1,nephrotic syndrome,20393,D009404
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",sgk1,crea,20393,D003404
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",sgk1,urea,20393,D014508
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",sgk1,uremia,20393,D014511
18768591,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs",sgk1,nephrotic,20393,D009404
18768591,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",volume retention,SGK1,D016055,20393
18768591,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",renal fibrosis,SGK1,D007674,20393
18768591,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",SGK1,volume retention,20393,D016055
18768591,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",SGK1,renal fibrosis,20393,D007674
18768591,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",SGK1,nephrotic syndrome,20393,D009404
18768591,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",SGK1,fibrosis,20393,D005355
18768591,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",SGK1,nephrotic,20393,D009404
18768591,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",nephrotic syndrome,SGK1,D009404,20393
18768591,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",fibrosis,SGK1,D005355,20393
18768591,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",nephrotic,SGK1,D009404,20393
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",HHEX,KCNQ1,3087,3784
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",HHEX,WFS1,3087,7466
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",HHEX,type 2 diabetes,3087,D003924
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",HHEX,CDKAL1,3087,54901
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",HHEX,IGF2BP2,3087,10644
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",HHEX,CDKN2A/B,3087,"1029,1030"
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",HHEX,SLC30A8,3087,169026
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",HHEX,FTO,3087,79068
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",KCNQ1,HHEX,3784,3087
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",KCNQ1,WFS1,3784,7466
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",KCNQ1,type 2 diabetes,3784,D003924
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",KCNQ1,CDKAL1,3784,54901
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",KCNQ1,IGF2BP2,3784,10644
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",KCNQ1,CDKN2A/B,3784,"1029,1030"
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",KCNQ1,SLC30A8,3784,169026
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",KCNQ1,FTO,3784,79068
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",WFS1,HHEX,7466,3087
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",WFS1,KCNQ1,7466,3784
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",WFS1,type 2 diabetes,7466,D003924
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",WFS1,CDKAL1,7466,54901
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",WFS1,IGF2BP2,7466,10644
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",WFS1,CDKN2A/B,7466,"1029,1030"
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",WFS1,SLC30A8,7466,169026
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",WFS1,FTO,7466,79068
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",type 2 diabetes,HHEX,D003924,3087
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",type 2 diabetes,KCNQ1,D003924,3784
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",type 2 diabetes,WFS1,D003924,7466
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",type 2 diabetes,CDKAL1,D003924,54901
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",type 2 diabetes,IGF2BP2,D003924,10644
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",type 2 diabetes,CDKN2A/B,D003924,"1029,1030"
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",type 2 diabetes,SLC30A8,D003924,169026
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",type 2 diabetes,FTO,D003924,79068
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKAL1,HHEX,54901,3087
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKAL1,KCNQ1,54901,3784
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKAL1,WFS1,54901,7466
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKAL1,type 2 diabetes,54901,D003924
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKAL1,IGF2BP2,54901,10644
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKAL1,CDKN2A/B,54901,"1029,1030"
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKAL1,SLC30A8,54901,169026
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKAL1,FTO,54901,79068
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",IGF2BP2,HHEX,10644,3087
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",IGF2BP2,KCNQ1,10644,3784
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",IGF2BP2,WFS1,10644,7466
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",IGF2BP2,type 2 diabetes,10644,D003924
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",IGF2BP2,CDKAL1,10644,54901
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",IGF2BP2,CDKN2A/B,10644,"1029,1030"
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",IGF2BP2,SLC30A8,10644,169026
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",IGF2BP2,FTO,10644,79068
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKN2A/B,HHEX,"1029,1030",3087
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKN2A/B,KCNQ1,"1029,1030",3784
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKN2A/B,WFS1,"1029,1030",7466
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKN2A/B,type 2 diabetes,"1029,1030",D003924
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKN2A/B,CDKAL1,"1029,1030",54901
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKN2A/B,IGF2BP2,"1029,1030",10644
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKN2A/B,SLC30A8,"1029,1030",169026
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",CDKN2A/B,FTO,"1029,1030",79068
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",SLC30A8,HHEX,169026,3087
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",SLC30A8,KCNQ1,169026,3784
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",SLC30A8,WFS1,169026,7466
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",SLC30A8,type 2 diabetes,169026,D003924
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",SLC30A8,CDKAL1,169026,54901
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",SLC30A8,IGF2BP2,169026,10644
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",SLC30A8,CDKN2A/B,169026,"1029,1030"
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",SLC30A8,FTO,169026,79068
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",FTO,HHEX,79068,3087
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",FTO,KCNQ1,79068,3784
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",FTO,WFS1,79068,7466
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",FTO,type 2 diabetes,79068,D003924
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",FTO,CDKAL1,79068,54901
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",FTO,IGF2BP2,79068,10644
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",FTO,CDKN2A/B,79068,"1029,1030"
18991055,"Association between polymorphisms in SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1, KCNQ1 and type 2 diabetes in the Korean population",FTO,SLC30A8,79068,169026
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",HHEX,KCNQ1,3087,3784
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",HHEX,WFS1,3087,7466
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",HHEX,T2DM,3087,D003924
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",HHEX,CDKAL1,3087,54901
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",HHEX,IGF2BP2,3087,10644
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",HHEX,CDKN2A/B,3087,"1029,1030"
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",HHEX,SLC30A8,3087,169026
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",HHEX,FTO,3087,79068
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",KCNQ1,HHEX,3784,3087
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",KCNQ1,WFS1,3784,7466
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",KCNQ1,T2DM,3784,D003924
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",KCNQ1,CDKAL1,3784,54901
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",KCNQ1,IGF2BP2,3784,10644
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",KCNQ1,CDKN2A/B,3784,"1029,1030"
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",KCNQ1,SLC30A8,3784,169026
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",KCNQ1,FTO,3784,79068
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",WFS1,HHEX,7466,3087
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",WFS1,KCNQ1,7466,3784
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",WFS1,T2DM,7466,D003924
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",WFS1,CDKAL1,7466,54901
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",WFS1,IGF2BP2,7466,10644
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",WFS1,CDKN2A/B,7466,"1029,1030"
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",WFS1,SLC30A8,7466,169026
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",WFS1,FTO,7466,79068
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",T2DM,HHEX,D003924,3087
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",T2DM,KCNQ1,D003924,3784
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",T2DM,WFS1,D003924,7466
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",T2DM,CDKAL1,D003924,54901
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",T2DM,IGF2BP2,D003924,10644
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",T2DM,CDKN2A/B,D003924,"1029,1030"
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",T2DM,SLC30A8,D003924,169026
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",T2DM,FTO,D003924,79068
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKAL1,HHEX,54901,3087
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKAL1,KCNQ1,54901,3784
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKAL1,WFS1,54901,7466
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKAL1,T2DM,54901,D003924
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKAL1,IGF2BP2,54901,10644
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKAL1,CDKN2A/B,54901,"1029,1030"
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKAL1,SLC30A8,54901,169026
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKAL1,FTO,54901,79068
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",IGF2BP2,HHEX,10644,3087
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",IGF2BP2,KCNQ1,10644,3784
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",IGF2BP2,WFS1,10644,7466
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",IGF2BP2,T2DM,10644,D003924
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",IGF2BP2,CDKAL1,10644,54901
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",IGF2BP2,CDKN2A/B,10644,"1029,1030"
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",IGF2BP2,SLC30A8,10644,169026
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",IGF2BP2,FTO,10644,79068
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKN2A/B,HHEX,"1029,1030",3087
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKN2A/B,KCNQ1,"1029,1030",3784
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKN2A/B,WFS1,"1029,1030",7466
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKN2A/B,T2DM,"1029,1030",D003924
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKN2A/B,CDKAL1,"1029,1030",54901
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKN2A/B,IGF2BP2,"1029,1030",10644
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKN2A/B,SLC30A8,"1029,1030",169026
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",CDKN2A/B,FTO,"1029,1030",79068
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",SLC30A8,HHEX,169026,3087
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",SLC30A8,KCNQ1,169026,3784
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",SLC30A8,WFS1,169026,7466
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",SLC30A8,T2DM,169026,D003924
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",SLC30A8,CDKAL1,169026,54901
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",SLC30A8,IGF2BP2,169026,10644
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",SLC30A8,CDKN2A/B,169026,"1029,1030"
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",SLC30A8,FTO,169026,79068
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",FTO,HHEX,79068,3087
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",FTO,KCNQ1,79068,3784
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",FTO,WFS1,79068,7466
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",FTO,T2DM,79068,D003924
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",FTO,CDKAL1,79068,54901
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",FTO,IGF2BP2,79068,10644
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",FTO,CDKN2A/B,79068,"1029,1030"
18991055,"The aim of the present study was to investigate the association among the polymorphisms of SLC30A8, HHEX, CDKN2A/B, IGF2BP2, FTO, WFS1, CDKAL1 and KCNQ1 and the risk of T2DM in the Korean population",FTO,SLC30A8,79068,169026
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs13266634,rs7754840,rs13266634,rs7754840
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs13266634,glucose,rs13266634,D005947
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs13266634,rs2237892,rs13266634,rs2237892
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs13266634,rs734312,rs13266634,rs734312
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs13266634,rs4402960,rs13266634,rs4402960
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs13266634,rs10811661,rs13266634,rs10811661
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs13266634,rs8050136,rs13266634,rs8050136
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs13266634,rs1111875,rs13266634,rs1111875
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs7754840,rs13266634,rs7754840,rs13266634
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs7754840,glucose,rs7754840,D005947
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs7754840,rs2237892,rs7754840,rs2237892
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs7754840,rs734312,rs7754840,rs734312
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs7754840,rs4402960,rs7754840,rs4402960
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs7754840,rs10811661,rs7754840,rs10811661
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs7754840,rs8050136,rs7754840,rs8050136
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs7754840,rs1111875,rs7754840,rs1111875
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",glucose,rs13266634,D005947,rs13266634
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",glucose,rs7754840,D005947,rs7754840
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",glucose,rs2237892,D005947,rs2237892
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",glucose,rs734312,D005947,rs734312
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",glucose,rs4402960,D005947,rs4402960
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",glucose,rs10811661,D005947,rs10811661
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",glucose,rs8050136,D005947,rs8050136
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",glucose,rs1111875,D005947,rs1111875
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs2237892,rs13266634,rs2237892,rs13266634
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs2237892,rs7754840,rs2237892,rs7754840
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs2237892,glucose,rs2237892,D005947
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs2237892,rs734312,rs2237892,rs734312
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs2237892,rs4402960,rs2237892,rs4402960
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs2237892,rs10811661,rs2237892,rs10811661
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs2237892,rs8050136,rs2237892,rs8050136
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs2237892,rs1111875,rs2237892,rs1111875
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs734312,rs13266634,rs734312,rs13266634
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs734312,rs7754840,rs734312,rs7754840
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs734312,glucose,rs734312,D005947
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs734312,rs2237892,rs734312,rs2237892
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs734312,rs4402960,rs734312,rs4402960
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs734312,rs10811661,rs734312,rs10811661
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs734312,rs8050136,rs734312,rs8050136
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs734312,rs1111875,rs734312,rs1111875
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs4402960,rs13266634,rs4402960,rs13266634
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs4402960,rs7754840,rs4402960,rs7754840
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs4402960,glucose,rs4402960,D005947
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs4402960,rs2237892,rs4402960,rs2237892
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs4402960,rs734312,rs4402960,rs734312
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs4402960,rs10811661,rs4402960,rs10811661
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs4402960,rs8050136,rs4402960,rs8050136
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs4402960,rs1111875,rs4402960,rs1111875
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs10811661,rs13266634,rs10811661,rs13266634
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs10811661,rs7754840,rs10811661,rs7754840
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs10811661,glucose,rs10811661,D005947
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs10811661,rs2237892,rs10811661,rs2237892
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs10811661,rs734312,rs10811661,rs734312
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs10811661,rs4402960,rs10811661,rs4402960
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs10811661,rs8050136,rs10811661,rs8050136
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs10811661,rs1111875,rs10811661,rs1111875
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs8050136,rs13266634,rs8050136,rs13266634
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs8050136,rs7754840,rs8050136,rs7754840
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs8050136,glucose,rs8050136,D005947
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs8050136,rs2237892,rs8050136,rs2237892
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs8050136,rs734312,rs8050136,rs734312
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs8050136,rs4402960,rs8050136,rs4402960
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs8050136,rs10811661,rs8050136,rs10811661
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs8050136,rs1111875,rs8050136,rs1111875
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs1111875,rs13266634,rs1111875,rs13266634
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs1111875,rs7754840,rs1111875,rs7754840
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs1111875,glucose,rs1111875,D005947
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs1111875,rs2237892,rs1111875,rs2237892
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs1111875,rs734312,rs1111875,rs734312
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs1111875,rs4402960,rs1111875,rs4402960
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs1111875,rs10811661,rs1111875,rs10811661
18991055,"We genotyped rs13266634, rs1111875, rs10811661, rs4402960, rs8050136, rs734312, rs7754840 and rs2237892 and measured the body weight, body mass index and fasting plasma glucose in all patients and controls",rs1111875,rs8050136,rs1111875,rs8050136
18991055,"The strongest association was found in a variant of CDKAL1 [rs7754840, odds ratio (OR) = 1.77, 95% CI = 1.50-2.10, p = 5.0 x 10(-11)]",CDKAL1,rs7754840,54901,rs7754840
18991055,"The strongest association was found in a variant of CDKAL1 [rs7754840, odds ratio (OR) = 1.77, 95% CI = 1.50-2.10, p = 5.0 x 10(-11)]",rs7754840,CDKAL1,rs7754840,54901
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",HHEX,KCNQ1,3087,3784
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",HHEX,T2DM,3087,D003924
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",HHEX,rs2237892,3087,rs2237892
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",HHEX,CDKN2A/B,3087,"1029,1030"
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",HHEX,rs10811661,3087,rs10811661
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",HHEX,rs1111875,3087,rs1111875
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",KCNQ1,HHEX,3784,3087
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",KCNQ1,T2DM,3784,D003924
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",KCNQ1,rs2237892,3784,rs2237892
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",KCNQ1,CDKN2A/B,3784,"1029,1030"
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",KCNQ1,rs10811661,3784,rs10811661
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",KCNQ1,rs1111875,3784,rs1111875
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",T2DM,HHEX,D003924,3087
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",T2DM,KCNQ1,D003924,3784
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",T2DM,rs2237892,D003924,rs2237892
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",T2DM,CDKN2A/B,D003924,"1029,1030"
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",T2DM,rs10811661,D003924,rs10811661
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",T2DM,rs1111875,D003924,rs1111875
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs2237892,HHEX,rs2237892,3087
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs2237892,KCNQ1,rs2237892,3784
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs2237892,T2DM,rs2237892,D003924
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs2237892,CDKN2A/B,rs2237892,"1029,1030"
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs2237892,rs10811661,rs2237892,rs10811661
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs2237892,rs1111875,rs2237892,rs1111875
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",CDKN2A/B,HHEX,"1029,1030",3087
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",CDKN2A/B,KCNQ1,"1029,1030",3784
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",CDKN2A/B,T2DM,"1029,1030",D003924
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",CDKN2A/B,rs2237892,"1029,1030",rs2237892
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",CDKN2A/B,rs10811661,"1029,1030",rs10811661
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",CDKN2A/B,rs1111875,"1029,1030",rs1111875
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs10811661,HHEX,rs10811661,3087
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs10811661,KCNQ1,rs10811661,3784
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs10811661,T2DM,rs10811661,D003924
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs10811661,rs2237892,rs10811661,rs2237892
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs10811661,CDKN2A/B,rs10811661,"1029,1030"
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs10811661,rs1111875,rs10811661,rs1111875
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs1111875,HHEX,rs1111875,3087
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs1111875,KCNQ1,rs1111875,3784
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs1111875,T2DM,rs1111875,D003924
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs1111875,rs2237892,rs1111875,rs2237892
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs1111875,CDKN2A/B,rs1111875,"1029,1030"
18991055,"The G allele of rs1111875 (OR = 1.43, 95% CI = 1.18-1.72, p = 1.8 x 10(-4)) in HHEX), the T allele of rs10811661 (OR = 1.47, 95% CI = 1.23-1.75, p = 2.1 x 10(-5)) in CDKN2A/B) and the C allele of rs2237892 (OR = 1.31, 95% CI = 1.10-1.56, p = 0.003) in KCNQ1 showed significant associations with T2DM",rs1111875,rs10811661,rs1111875,rs10811661
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",Rs13266634,WFS1,rs13266634,7466
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",Rs13266634,T2DM,rs13266634,D003924
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",Rs13266634,IGF2BP2,rs13266634,10644
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",Rs13266634,SLC30A8,rs13266634,169026
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",Rs13266634,FTO,rs13266634,79068
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",WFS1,Rs13266634,7466,rs13266634
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",WFS1,T2DM,7466,D003924
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",WFS1,IGF2BP2,7466,10644
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",WFS1,SLC30A8,7466,169026
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",WFS1,FTO,7466,79068
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",T2DM,Rs13266634,D003924,rs13266634
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",T2DM,WFS1,D003924,7466
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",T2DM,IGF2BP2,D003924,10644
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",T2DM,SLC30A8,D003924,169026
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",T2DM,FTO,D003924,79068
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",IGF2BP2,Rs13266634,10644,rs13266634
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",IGF2BP2,WFS1,10644,7466
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",IGF2BP2,T2DM,10644,D003924
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",IGF2BP2,SLC30A8,10644,169026
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",IGF2BP2,FTO,10644,79068
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",SLC30A8,Rs13266634,169026,rs13266634
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",SLC30A8,WFS1,169026,7466
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",SLC30A8,T2DM,169026,D003924
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",SLC30A8,IGF2BP2,169026,10644
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",SLC30A8,FTO,169026,79068
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",FTO,Rs13266634,79068,rs13266634
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",FTO,WFS1,79068,7466
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",FTO,T2DM,79068,D003924
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",FTO,IGF2BP2,79068,10644
18991055,"Rs13266634 (OR = 1.19, 95% CI = 1.00-1.42, p = 0.045) in SLC30A8 showed a nominal association with the risk of T2DM, whereas SNPs in IGF2BP2, FTO and WFS1 were not associated",FTO,SLC30A8,79068,169026
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",HHEX,KCNQ1,3087,3784
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",HHEX,T2DM,3087,D003924
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",HHEX,CDKAL1,3087,54901
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",HHEX,CDKN2A/B,3087,"1029,1030"
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",HHEX,SLC30A8,3087,169026
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",KCNQ1,HHEX,3784,3087
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",KCNQ1,T2DM,3784,D003924
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",KCNQ1,CDKAL1,3784,54901
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",KCNQ1,CDKN2A/B,3784,"1029,1030"
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",KCNQ1,SLC30A8,3784,169026
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",T2DM,HHEX,D003924,3087
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",T2DM,KCNQ1,D003924,3784
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",T2DM,CDKAL1,D003924,54901
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",T2DM,CDKN2A/B,D003924,"1029,1030"
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",T2DM,SLC30A8,D003924,169026
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",CDKAL1,HHEX,54901,3087
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",CDKAL1,KCNQ1,54901,3784
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",CDKAL1,T2DM,54901,D003924
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",CDKAL1,CDKN2A/B,54901,"1029,1030"
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",CDKAL1,SLC30A8,54901,169026
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",CDKN2A/B,HHEX,"1029,1030",3087
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",CDKN2A/B,KCNQ1,"1029,1030",3784
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",CDKN2A/B,T2DM,"1029,1030",D003924
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",CDKN2A/B,CDKAL1,"1029,1030",54901
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",CDKN2A/B,SLC30A8,"1029,1030",169026
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",SLC30A8,HHEX,169026,3087
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",SLC30A8,KCNQ1,169026,3784
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",SLC30A8,T2DM,169026,D003924
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",SLC30A8,CDKAL1,169026,54901
18991055,"In conclusion, we have shown that SNPs in HHEX, CDKN2A/B, CDKAL1, KCNQ1 and SLC30A8 confer a risk of T2DM in the Korean population.",SLC30A8,CDKN2A/B,169026,"1029,1030"
19058010,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats,isoproterenol,myocardial infarction,D007545,D009203
19058010,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats,isoproterenol,green tea,D007545,D010936
19058010,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats,isoproterenol,vitamin E,D007545,D014810
19058010,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats,myocardial infarction,isoproterenol,D009203,D007545
19058010,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats,myocardial infarction,green tea,D009203,D010936
19058010,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats,myocardial infarction,vitamin E,D009203,D014810
19058010,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats,green tea,isoproterenol,D010936,D007545
19058010,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats,green tea,myocardial infarction,D010936,D009203
19058010,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats,green tea,vitamin E,D010936,D014810
19058010,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats,vitamin E,isoproterenol,D014810,D007545
19058010,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats,vitamin E,myocardial infarction,D014810,D009203
19058010,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats,vitamin E,green tea,D014810,D010936
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",antioxidants,isoproterenol,D000975,D007545
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",antioxidants,myocardial infarction,D000975,D009203
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",antioxidants,green tea,D000975,D010936
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",antioxidants,lipid,D000975,D008055
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",antioxidants,vitamin E,D000975,D014810
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",antioxidants,ISO,D000975,D007545
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",isoproterenol,antioxidants,D007545,D000975
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",isoproterenol,myocardial infarction,D007545,D009203
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",isoproterenol,green tea,D007545,D010936
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",isoproterenol,lipid,D007545,D008055
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",isoproterenol,vitamin E,D007545,D014810
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",isoproterenol,ISO,D007545,D007545
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",myocardial infarction,antioxidants,D009203,D000975
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",myocardial infarction,isoproterenol,D009203,D007545
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",myocardial infarction,green tea,D009203,D010936
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",myocardial infarction,lipid,D009203,D008055
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",myocardial infarction,vitamin E,D009203,D014810
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",myocardial infarction,ISO,D009203,D007545
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",green tea,antioxidants,D010936,D000975
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",green tea,isoproterenol,D010936,D007545
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",green tea,myocardial infarction,D010936,D009203
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",green tea,lipid,D010936,D008055
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",green tea,vitamin E,D010936,D014810
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",green tea,ISO,D010936,D007545
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",lipid,antioxidants,D008055,D000975
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",lipid,isoproterenol,D008055,D007545
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",lipid,myocardial infarction,D008055,D009203
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",lipid,green tea,D008055,D010936
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",lipid,vitamin E,D008055,D014810
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",lipid,ISO,D008055,D007545
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",vitamin E,antioxidants,D014810,D000975
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",vitamin E,isoproterenol,D014810,D007545
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",vitamin E,myocardial infarction,D014810,D009203
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",vitamin E,green tea,D014810,D010936
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",vitamin E,lipid,D014810,D008055
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",vitamin E,ISO,D014810,D007545
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",ISO,antioxidants,D007545,D000975
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",ISO,isoproterenol,D007545,D007545
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",ISO,myocardial infarction,D007545,D009203
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",ISO,green tea,D007545,D010936
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",ISO,lipid,D007545,D008055
19058010,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats",ISO,vitamin E,D007545,D014810
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",antioxidants,Ca+2 ATPase,D000975,D000252
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",antioxidants,Mg+2 ATPase,D000975,D017301
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",antioxidants,Na+/ K+ ATPase,D000975,D000254
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",antioxidants,lipid,D000975,D008055
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",antioxidants,ISO,D000975,D007545
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Ca+2 ATPase,antioxidants,D000252,D000975
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Ca+2 ATPase,Mg+2 ATPase,D000252,D017301
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Ca+2 ATPase,Na+/ K+ ATPase,D000252,D000254
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Ca+2 ATPase,lipid,D000252,D008055
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Ca+2 ATPase,ISO,D000252,D007545
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Mg+2 ATPase,antioxidants,D017301,D000975
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Mg+2 ATPase,Ca+2 ATPase,D017301,D000252
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Mg+2 ATPase,Na+/ K+ ATPase,D017301,D000254
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Mg+2 ATPase,lipid,D017301,D008055
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Mg+2 ATPase,ISO,D017301,D007545
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Na+/ K+ ATPase,antioxidants,D000254,D000975
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Na+/ K+ ATPase,Ca+2 ATPase,D000254,D000252
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Na+/ K+ ATPase,Mg+2 ATPase,D000254,D017301
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Na+/ K+ ATPase,lipid,D000254,D008055
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",Na+/ K+ ATPase,ISO,D000254,D007545
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",lipid,antioxidants,D008055,D000975
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",lipid,Ca+2 ATPase,D008055,D000252
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",lipid,Mg+2 ATPase,D008055,D017301
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",lipid,Na+/ K+ ATPase,D008055,D000254
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",lipid,ISO,D008055,D007545
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",ISO,antioxidants,D007545,D000975
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",ISO,Ca+2 ATPase,D007545,D000252
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",ISO,Mg+2 ATPase,D007545,D017301
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",ISO,Na+/ K+ ATPase,D007545,D000254
19058010,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels",ISO,lipid,D007545,D008055
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",antioxidants,Ca+2 ATPase,D000975,D000252
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",antioxidants,Na+/K+ ATPase,D000975,D000254
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",antioxidants,Mg+2 ATPase,D000975,D017301
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",antioxidants,green tea,D000975,D010936
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",antioxidants,lipid,D000975,D008055
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",antioxidants,vitamin E,D000975,D014810
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",antioxidants,ISO,D000975,D007545
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Ca+2 ATPase,antioxidants,D000252,D000975
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Ca+2 ATPase,Na+/K+ ATPase,D000252,D000254
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Ca+2 ATPase,Mg+2 ATPase,D000252,D017301
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Ca+2 ATPase,green tea,D000252,D010936
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Ca+2 ATPase,lipid,D000252,D008055
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Ca+2 ATPase,vitamin E,D000252,D014810
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Ca+2 ATPase,ISO,D000252,D007545
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Na+/K+ ATPase,antioxidants,D000254,D000975
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Na+/K+ ATPase,Ca+2 ATPase,D000254,D000252
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Na+/K+ ATPase,Mg+2 ATPase,D000254,D017301
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Na+/K+ ATPase,green tea,D000254,D010936
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Na+/K+ ATPase,lipid,D000254,D008055
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Na+/K+ ATPase,vitamin E,D000254,D014810
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Na+/K+ ATPase,ISO,D000254,D007545
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Mg+2 ATPase,antioxidants,D017301,D000975
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Mg+2 ATPase,Ca+2 ATPase,D017301,D000252
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Mg+2 ATPase,Na+/K+ ATPase,D017301,D000254
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Mg+2 ATPase,green tea,D017301,D010936
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Mg+2 ATPase,lipid,D017301,D008055
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Mg+2 ATPase,vitamin E,D017301,D014810
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",Mg+2 ATPase,ISO,D017301,D007545
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",green tea,antioxidants,D010936,D000975
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",green tea,Ca+2 ATPase,D010936,D000252
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",green tea,Na+/K+ ATPase,D010936,D000254
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",green tea,Mg+2 ATPase,D010936,D017301
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",green tea,lipid,D010936,D008055
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",green tea,vitamin E,D010936,D014810
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",green tea,ISO,D010936,D007545
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",lipid,antioxidants,D008055,D000975
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",lipid,Ca+2 ATPase,D008055,D000252
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",lipid,Na+/K+ ATPase,D008055,D000254
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",lipid,Mg+2 ATPase,D008055,D017301
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",lipid,green tea,D008055,D010936
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",lipid,vitamin E,D008055,D014810
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",lipid,ISO,D008055,D007545
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",vitamin E,antioxidants,D014810,D000975
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",vitamin E,Ca+2 ATPase,D014810,D000252
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",vitamin E,Na+/K+ ATPase,D014810,D000254
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",vitamin E,Mg+2 ATPase,D014810,D017301
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",vitamin E,green tea,D014810,D010936
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",vitamin E,lipid,D014810,D008055
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",vitamin E,ISO,D014810,D007545
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",ISO,antioxidants,D007545,D000975
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",ISO,Ca+2 ATPase,D007545,D000252
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",ISO,Na+/K+ ATPase,D007545,D000254
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",ISO,Mg+2 ATPase,D007545,D017301
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",ISO,green tea,D007545,D010936
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",ISO,lipid,D007545,D008055
19058010,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups",ISO,vitamin E,D007545,D014810
19058010,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,myocardial infarction,green tea,D009203,D010936
19058010,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,myocardial infarction,vitamin E,D009203,D014810
19058010,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,myocardial infarction,ISO,D009203,D007545
19058010,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,green tea,myocardial infarction,D010936,D009203
19058010,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,green tea,vitamin E,D010936,D014810
19058010,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,green tea,ISO,D010936,D007545
19058010,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,vitamin E,myocardial infarction,D014810,D009203
19058010,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,vitamin E,green tea,D014810,D010936
19058010,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,vitamin E,ISO,D014810,D007545
19058010,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,ISO,myocardial infarction,D007545,D009203
19058010,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,ISO,green tea,D007545,D010936
19058010,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,ISO,vitamin E,D007545,D014810
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,p85alpha,Met326Ile,5295,rs3730089
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,p85alpha,polycystic ovary syndrome,5295,D011085
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,p85alpha,Phosphatidylinositol 3-kinase,5295,5295
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,p85alpha,326Ile,5295,rs3730089
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,Met326Ile,p85alpha,rs3730089,5295
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,Met326Ile,polycystic ovary syndrome,rs3730089,D011085
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,Met326Ile,Phosphatidylinositol 3-kinase,rs3730089,5295
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,Met326Ile,326Ile,rs3730089,rs3730089
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,polycystic ovary syndrome,p85alpha,D011085,5295
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,polycystic ovary syndrome,Met326Ile,D011085,rs3730089
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,polycystic ovary syndrome,Phosphatidylinositol 3-kinase,D011085,5295
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,polycystic ovary syndrome,326Ile,D011085,rs3730089
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,Phosphatidylinositol 3-kinase,p85alpha,5295,5295
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,Phosphatidylinositol 3-kinase,Met326Ile,5295,rs3730089
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,Phosphatidylinositol 3-kinase,polycystic ovary syndrome,5295,D011085
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,Phosphatidylinositol 3-kinase,326Ile,5295,rs3730089
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,326Ile,p85alpha,rs3730089,5295
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,326Ile,Met326Ile,rs3730089,rs3730089
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,326Ile,polycystic ovary syndrome,rs3730089,D011085
19218574,Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome,326Ile,Phosphatidylinositol 3-kinase,rs3730089,5295
19218574,Phosphatidylinositol (PI) 3-kinase is an important enzyme in the early insulin signaling cascade and plays a key role in insulin-mediated glucose transport,Phosphatidylinositol (PI) 3-kinase,glucose,5295,D005947
19218574,Phosphatidylinositol (PI) 3-kinase is an important enzyme in the early insulin signaling cascade and plays a key role in insulin-mediated glucose transport,Phosphatidylinositol (PI) 3-kinase,insulin,5295,3630
19218574,Phosphatidylinositol (PI) 3-kinase is an important enzyme in the early insulin signaling cascade and plays a key role in insulin-mediated glucose transport,glucose,Phosphatidylinositol (PI) 3-kinase,D005947,5295
19218574,Phosphatidylinositol (PI) 3-kinase is an important enzyme in the early insulin signaling cascade and plays a key role in insulin-mediated glucose transport,glucose,insulin,D005947,3630
19218574,Phosphatidylinositol (PI) 3-kinase is an important enzyme in the early insulin signaling cascade and plays a key role in insulin-mediated glucose transport,insulin,Phosphatidylinositol (PI) 3-kinase,3630,5295
19218574,Phosphatidylinositol (PI) 3-kinase is an important enzyme in the early insulin signaling cascade and plays a key role in insulin-mediated glucose transport,insulin,glucose,3630,D005947
19218574,"In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase",PI3-kinase,Met326Ile,5295,rs3730089
19218574,"In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase",PI3-kinase,p85alpha,5295,5295
19218574,"In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase",PI3-kinase,326Ile,5295,rs3730089
19218574,"In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase",Met326Ile,PI3-kinase,rs3730089,5295
19218574,"In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase",Met326Ile,p85alpha,rs3730089,5295
19218574,"In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase",Met326Ile,326Ile,rs3730089,rs3730089
19218574,"In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase",p85alpha,PI3-kinase,5295,5295
19218574,"In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase",p85alpha,Met326Ile,5295,rs3730089
19218574,"In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase",p85alpha,326Ile,5295,rs3730089
19218574,"In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase",326Ile,PI3-kinase,rs3730089,5295
19218574,"In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase",326Ile,Met326Ile,rs3730089,rs3730089
19218574,"In its regulatory subunit, p85alpha, there is a common amino acid substitution (the Met326Ile polymorphism), and this amino acid may be crucial for the function of the p85alpha regulatory subunit and PI3-kinase",326Ile,p85alpha,rs3730089,5295
19218574,METHODS: Analysis of the Met326Ile polymorphism was carried out on DNA samples from 256 PCOS patients and 283 controls,Met326Ile,326Ile,rs3730089,rs3730089
19218574,METHODS: Analysis of the Met326Ile polymorphism was carried out on DNA samples from 256 PCOS patients and 283 controls,Met326Ile,PCOS,rs3730089,D011085
19218574,METHODS: Analysis of the Met326Ile polymorphism was carried out on DNA samples from 256 PCOS patients and 283 controls,326Ile,Met326Ile,rs3730089,rs3730089
19218574,METHODS: Analysis of the Met326Ile polymorphism was carried out on DNA samples from 256 PCOS patients and 283 controls,326Ile,PCOS,rs3730089,D011085
19218574,METHODS: Analysis of the Met326Ile polymorphism was carried out on DNA samples from 256 PCOS patients and 283 controls,PCOS,Met326Ile,D011085,rs3730089
19218574,METHODS: Analysis of the Met326Ile polymorphism was carried out on DNA samples from 256 PCOS patients and 283 controls,PCOS,326Ile,D011085,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",Ile326Ile,Met326Ile,rs3730089,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",Ile326Ile,Met326Met,rs3730089,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",Ile326Ile,PCOS,rs3730089,D011085
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",Ile326Ile,326Ile,rs3730089,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",Met326Ile,Ile326Ile,rs3730089,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",Met326Ile,Met326Met,rs3730089,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",Met326Ile,PCOS,rs3730089,D011085
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",Met326Ile,326Ile,rs3730089,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",Met326Met,Ile326Ile,rs3730089,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",Met326Met,Met326Ile,rs3730089,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",Met326Met,PCOS,rs3730089,D011085
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",Met326Met,326Ile,rs3730089,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",PCOS,Ile326Ile,D011085,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",PCOS,Met326Ile,D011085,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",PCOS,Met326Met,D011085,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",PCOS,326Ile,D011085,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",326Ile,Ile326Ile,rs3730089,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",326Ile,Met326Ile,rs3730089,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",326Ile,Met326Met,rs3730089,rs3730089
19218574,"RESULTS: The genotype distribution of the Met326Ile polymorphism in the PCOS group was not different from that of the controls (Met326Met/Met326Ile/Ile326Ile rates were 73.4%/23.4%/3.2% and 70.3%/26.1%/3.6% for the PCOS and control groups, respectively, P = 0.72)",326Ile,PCOS,rs3730089,D011085
19218574,The PCOS group was divided into two subgroups according to the presence of the variant 326Ile allele,326Ile,PCOS,rs3730089,D011085
19218574,The PCOS group was divided into two subgroups according to the presence of the variant 326Ile allele,PCOS,326Ile,D011085,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Ile326Ile,Met326Ile,rs3730089,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Ile326Ile,testosterone,rs3730089,D013739
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Ile326Ile,Met326Met,rs3730089,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Ile326Ile,17-hydroxyprogesterone,rs3730089,D019326
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Ile326Ile,17-OHP,rs3730089,D019326
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Ile326Ile,326Ile,rs3730089,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Met326Ile,Ile326Ile,rs3730089,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Met326Ile,testosterone,rs3730089,D013739
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Met326Ile,Met326Met,rs3730089,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Met326Ile,17-hydroxyprogesterone,rs3730089,D019326
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Met326Ile,17-OHP,rs3730089,D019326
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Met326Ile,326Ile,rs3730089,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",testosterone,Ile326Ile,D013739,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",testosterone,Met326Ile,D013739,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",testosterone,Met326Met,D013739,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",testosterone,17-hydroxyprogesterone,D013739,D019326
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",testosterone,17-OHP,D013739,D019326
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",testosterone,326Ile,D013739,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Met326Met,Ile326Ile,rs3730089,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Met326Met,Met326Ile,rs3730089,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Met326Met,testosterone,rs3730089,D013739
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Met326Met,17-hydroxyprogesterone,rs3730089,D019326
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Met326Met,17-OHP,rs3730089,D019326
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",Met326Met,326Ile,rs3730089,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",17-hydroxyprogesterone,Ile326Ile,D019326,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",17-hydroxyprogesterone,Met326Ile,D019326,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",17-hydroxyprogesterone,testosterone,D019326,D013739
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",17-hydroxyprogesterone,Met326Met,D019326,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",17-hydroxyprogesterone,17-OHP,D019326,D019326
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",17-hydroxyprogesterone,326Ile,D019326,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",17-OHP,Ile326Ile,D019326,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",17-OHP,Met326Ile,D019326,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",17-OHP,testosterone,D019326,D013739
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",17-OHP,Met326Met,D019326,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",17-OHP,17-hydroxyprogesterone,D019326,D019326
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",17-OHP,326Ile,D019326,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",326Ile,Ile326Ile,rs3730089,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",326Ile,Met326Ile,rs3730089,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",326Ile,testosterone,rs3730089,D013739
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",326Ile,Met326Met,rs3730089,rs3730089
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",326Ile,17-hydroxyprogesterone,rs3730089,D019326
19218574,"Compared with those carrying at least one variant 326Ile allele, carriers with the Met326Met genotype had higher serum 17-hydroxyprogesterone (17-OHP) {1.1 [95% confidence interval (CI) 1.1-1.3] ng/ml in those with the Met326Met genotype versus 0.8 (95% CI 0.7-1.0) ng/ml in those with Ile326Ile and Met326Ile genotypes, P = 0.0073} and free testosterone levels [1.2 (95% CI 1.1-1.4) pg/ml for Met326Met genotype versus 0.9 (95% CI 0.6-1.3) pg/ml for Ile326Ile and Met326Ile genotypes, P = 0.038]",326Ile,17-OHP,rs3730089,D019326
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",Met326Ile,testosterone,rs3730089,D013739
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",Met326Ile,PI3-kinase,rs3730089,5295
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",Met326Ile,17-OHP,rs3730089,D019326
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",Met326Ile,PCOS,rs3730089,D011085
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",Met326Ile,326Ile,rs3730089,rs3730089
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",testosterone,Met326Ile,D013739,rs3730089
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",testosterone,PI3-kinase,D013739,5295
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",testosterone,17-OHP,D013739,D019326
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",testosterone,PCOS,D013739,D011085
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",testosterone,326Ile,D013739,rs3730089
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",PI3-kinase,Met326Ile,5295,rs3730089
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",PI3-kinase,testosterone,5295,D013739
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",PI3-kinase,17-OHP,5295,D019326
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",PI3-kinase,PCOS,5295,D011085
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",PI3-kinase,326Ile,5295,rs3730089
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",17-OHP,Met326Ile,D019326,rs3730089
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",17-OHP,testosterone,D019326,D013739
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",17-OHP,PI3-kinase,D019326,5295
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",17-OHP,PCOS,D019326,D011085
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",17-OHP,326Ile,D019326,rs3730089
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",PCOS,Met326Ile,D011085,rs3730089
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",PCOS,testosterone,D011085,D013739
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",PCOS,PI3-kinase,D011085,5295
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",PCOS,17-OHP,D011085,D019326
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",PCOS,326Ile,D011085,rs3730089
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",326Ile,Met326Ile,rs3730089,rs3730089
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",326Ile,testosterone,rs3730089,D013739
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",326Ile,PI3-kinase,rs3730089,5295
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",326Ile,17-OHP,rs3730089,D019326
19218574,"CONCLUSIONS: Our results suggest that the PI3-kinase gene Met326Ile polymorphism may not be a major determinant for the development of PCOS, but it may modulate the concentrations of serum 17-OHP or free testosterone in PCOS patients.",326Ile,PCOS,rs3730089,D011085
19353688,Pure monosomy and pure trisomy of 13q21.2-31.1 consequent to a familial insertional translocation: exclusion of PCDH9 as the responsible gene for autosomal dominant auditory neuropathy (AUNA1),autosomal dominant auditory neuropathy,PCDH9,C563790,5101
19353688,Pure monosomy and pure trisomy of 13q21.2-31.1 consequent to a familial insertional translocation: exclusion of PCDH9 as the responsible gene for autosomal dominant auditory neuropathy (AUNA1),PCDH9,autosomal dominant auditory neuropathy,5101,C563790
19353688,Pure monosomy and pure trisomy of 13q21.2-31.1 consequent to a familial insertional translocation: exclusion of PCDH9 as the responsible gene for autosomal dominant auditory neuropathy (AUNA1),PCDH9,AUNA1,5101,C563790
19353688,Pure monosomy and pure trisomy of 13q21.2-31.1 consequent to a familial insertional translocation: exclusion of PCDH9 as the responsible gene for autosomal dominant auditory neuropathy (AUNA1),AUNA1,PCDH9,C563790,5101
19353688,"As the AUNA1 deafness locus on 13q14-21 overlaps the IT in the PCDH9 (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families",protocadherin-9,deafness,5101,D003638
19353688,"As the AUNA1 deafness locus on 13q14-21 overlaps the IT in the PCDH9 (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families",protocadherin-9,PCDH9,5101,5101
19353688,"As the AUNA1 deafness locus on 13q14-21 overlaps the IT in the PCDH9 (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families",protocadherin-9,AUNA1,5101,C563790
19353688,"As the AUNA1 deafness locus on 13q14-21 overlaps the IT in the PCDH9 (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families",deafness,protocadherin-9,D003638,5101
19353688,"As the AUNA1 deafness locus on 13q14-21 overlaps the IT in the PCDH9 (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families",deafness,PCDH9,D003638,5101
19353688,"As the AUNA1 deafness locus on 13q14-21 overlaps the IT in the PCDH9 (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families",PCDH9,protocadherin-9,5101,5101
19353688,"As the AUNA1 deafness locus on 13q14-21 overlaps the IT in the PCDH9 (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families",PCDH9,deafness,5101,D003638
19353688,"As the AUNA1 deafness locus on 13q14-21 overlaps the IT in the PCDH9 (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families",PCDH9,AUNA1,5101,C563790
19353688,"As the AUNA1 deafness locus on 13q14-21 overlaps the IT in the PCDH9 (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families",AUNA1,protocadherin-9,C563790,5101
19353688,"As the AUNA1 deafness locus on 13q14-21 overlaps the IT in the PCDH9 (protocadherin-9) gene region, PCDH9 was investigated as a candidate gene for deafness in both families",AUNA1,PCDH9,C563790,5101
19353688,"Genotyping of STRs and single nucleotide polymorphisms defined the AUNA1 breakpoint as 35 kb 5' to PCDH9, with a 2.4 Mb area of overlap with the IT",PCDH9,AUNA1,5101,C563790
19353688,"Genotyping of STRs and single nucleotide polymorphisms defined the AUNA1 breakpoint as 35 kb 5' to PCDH9, with a 2.4 Mb area of overlap with the IT",AUNA1,PCDH9,C563790,5101
19353688,"We conclude that AUNA1 deafness does not share a common etiology with deafness associated with monosomy 13q21.2-q31.3; deafness may result from monosomy of PCHD9 or another gene in the IT, as has been demonstrated in contiguous gene deletion syndromes",deafness,PCHD9,D003638,5101
19353688,"We conclude that AUNA1 deafness does not share a common etiology with deafness associated with monosomy 13q21.2-q31.3; deafness may result from monosomy of PCHD9 or another gene in the IT, as has been demonstrated in contiguous gene deletion syndromes",PCHD9,deafness,5101,D003638
19353688,"We conclude that AUNA1 deafness does not share a common etiology with deafness associated with monosomy 13q21.2-q31.3; deafness may result from monosomy of PCHD9 or another gene in the IT, as has been demonstrated in contiguous gene deletion syndromes",PCHD9,AUNA1,5101,C563790
19353688,"We conclude that AUNA1 deafness does not share a common etiology with deafness associated with monosomy 13q21.2-q31.3; deafness may result from monosomy of PCHD9 or another gene in the IT, as has been demonstrated in contiguous gene deletion syndromes",AUNA1,PCHD9,C563790,5101
19521089,Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy,5-HTTLPR,Serotonin transporter,6532,6532
19521089,Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy,5-HTTLPR,Parkinson's disease,6532,D010300
19521089,Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy,Serotonin transporter,5-HTTLPR,6532,6532
19521089,Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy,Serotonin transporter,Parkinson's disease,6532,D010300
19521089,Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy,Parkinson's disease,5-HTTLPR,D010300,6532
19521089,Serotonin transporter gene polymorphic element 5-HTTLPR increases the risk of sporadic Parkinson's disease in Italy,Parkinson's disease,Serotonin transporter,D010300,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",5-HTTLPR,SLC6A4,6532,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",5-HTTLPR,serotonin transporter,6532,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",5-HTTLPR,insertion/deletion (long allele-L/short allele-S) of 43 bp,6532,c|INDEL||43
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",5-HTTLPR,PD,6532,D010300
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",SLC6A4,5-HTTLPR,6532,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",SLC6A4,serotonin transporter,6532,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",SLC6A4,insertion/deletion (long allele-L/short allele-S) of 43 bp,6532,c|INDEL||43
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",SLC6A4,PD,6532,D010300
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",serotonin transporter,5-HTTLPR,6532,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",serotonin transporter,SLC6A4,6532,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",serotonin transporter,insertion/deletion (long allele-L/short allele-S) of 43 bp,6532,c|INDEL||43
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",serotonin transporter,PD,6532,D010300
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",insertion/deletion (long allele-L/short allele-S) of 43 bp,5-HTTLPR,c|INDEL||43,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",insertion/deletion (long allele-L/short allele-S) of 43 bp,SLC6A4,c|INDEL||43,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",insertion/deletion (long allele-L/short allele-S) of 43 bp,serotonin transporter,c|INDEL||43,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",insertion/deletion (long allele-L/short allele-S) of 43 bp,PD,c|INDEL||43,D010300
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",PD,5-HTTLPR,D010300,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",PD,SLC6A4,D010300,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",PD,serotonin transporter,D010300,6532
19521089,"We conducted an association study assessing how PD risk in Italy was influenced by the serotonin transporter gene (SLC6A4) polymorphic region 5-HTTLPR, consisting of an insertion/deletion (long allele-L/short allele-S) of 43 bp in the SLC6A4 promoter region",PD,insertion/deletion (long allele-L/short allele-S) of 43 bp,D010300,c|INDEL||43
19521089,The SLC6A4 promoter single nucleotide polymorphism rs25531(A-->G) was evaluated too,A-->G,rs25531,rs25531,rs25531
19521089,The SLC6A4 promoter single nucleotide polymorphism rs25531(A-->G) was evaluated too,A-->G,SLC6A4,rs25531,6532
19521089,The SLC6A4 promoter single nucleotide polymorphism rs25531(A-->G) was evaluated too,rs25531,A-->G,rs25531,rs25531
19521089,The SLC6A4 promoter single nucleotide polymorphism rs25531(A-->G) was evaluated too,rs25531,SLC6A4,rs25531,6532
19521089,The SLC6A4 promoter single nucleotide polymorphism rs25531(A-->G) was evaluated too,SLC6A4,A-->G,6532,rs25531
19521089,The SLC6A4 promoter single nucleotide polymorphism rs25531(A-->G) was evaluated too,SLC6A4,rs25531,6532,rs25531
19521089,"An association between the 5-HTTLPR polymorphism and risk of PD (S/S genotype OR [95% CI]: 1.7[1.2-2.5], p = 0.002) was found",5-HTTLPR,PD,6532,D010300
19521089,"An association between the 5-HTTLPR polymorphism and risk of PD (S/S genotype OR [95% CI]: 1.7[1.2-2.5], p = 0.002) was found",PD,5-HTTLPR,D010300,6532
19521089,The rs25531 and the haplotype 5-HTTLPR/rs25531 did not associate with risk of PD,5-HTTLPR,rs25531,6532,rs25531
19521089,The rs25531 and the haplotype 5-HTTLPR/rs25531 did not associate with risk of PD,5-HTTLPR,PD,6532,D010300
19521089,The rs25531 and the haplotype 5-HTTLPR/rs25531 did not associate with risk of PD,rs25531,5-HTTLPR,rs25531,6532
19521089,The rs25531 and the haplotype 5-HTTLPR/rs25531 did not associate with risk of PD,rs25531,PD,rs25531,D010300
19521089,The rs25531 and the haplotype 5-HTTLPR/rs25531 did not associate with risk of PD,PD,5-HTTLPR,D010300,6532
19521089,The rs25531 and the haplotype 5-HTTLPR/rs25531 did not associate with risk of PD,PD,rs25531,D010300,rs25531
19521089,Our data indicate that the 5-HTTLPR polymorphic element within the SLC6A4 promoter may govern the genetic risk of PD in Italians.,5-HTTLPR,PD,6532,D010300
19521089,Our data indicate that the 5-HTTLPR polymorphic element within the SLC6A4 promoter may govern the genetic risk of PD in Italians.,5-HTTLPR,SLC6A4,6532,6532
19521089,Our data indicate that the 5-HTTLPR polymorphic element within the SLC6A4 promoter may govern the genetic risk of PD in Italians.,PD,5-HTTLPR,D010300,6532
19521089,Our data indicate that the 5-HTTLPR polymorphic element within the SLC6A4 promoter may govern the genetic risk of PD in Italians.,PD,SLC6A4,D010300,6532
19521089,Our data indicate that the 5-HTTLPR polymorphic element within the SLC6A4 promoter may govern the genetic risk of PD in Italians.,SLC6A4,5-HTTLPR,6532,6532
19521089,Our data indicate that the 5-HTTLPR polymorphic element within the SLC6A4 promoter may govern the genetic risk of PD in Italians.,SLC6A4,PD,6532,D010300
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,iron,iron deficiency anemia,D007501,D018798
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,iron,iron deficiency,D007501,D018798
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,iron,iron-refractory iron deficiency anemia,D007501,C562385
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,iron,Matriptase-2,D007501,164656
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,iron deficiency anemia,iron,D018798,D007501
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,iron deficiency anemia,Matriptase-2,D018798,164656
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,iron deficiency,iron,D018798,D007501
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,iron deficiency,Matriptase-2,D018798,164656
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,iron-refractory iron deficiency anemia,iron,C562385,D007501
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,iron-refractory iron deficiency anemia,Matriptase-2,C562385,164656
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,Matriptase-2,iron,164656,D007501
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,Matriptase-2,iron deficiency anemia,164656,D018798
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,Matriptase-2,iron deficiency,164656,D018798
19592582,Matriptase-2 mutations in iron-refractory iron deficiency anemia patients provide new insights into protease activation mechanisms,Matriptase-2,iron-refractory iron deficiency anemia,164656,C562385
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron,IRIDA,D007501,C562385
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron,iron deficiency anemia,D007501,D018798
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron,hepcidin,D007501,57817
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron,iron deficiency,D007501,D018798
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron,matriptase-2,D007501,164656
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron,iron-refractory iron deficiency anemia,D007501,C562385
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,IRIDA,iron,C562385,D007501
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,IRIDA,hepcidin,C562385,57817
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,IRIDA,matriptase-2,C562385,164656
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron deficiency anemia,iron,D018798,D007501
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron deficiency anemia,hepcidin,D018798,57817
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron deficiency anemia,matriptase-2,D018798,164656
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,hepcidin,iron,57817,D007501
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,hepcidin,IRIDA,57817,C562385
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,hepcidin,iron deficiency anemia,57817,D018798
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,hepcidin,iron deficiency,57817,D018798
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,hepcidin,matriptase-2,57817,164656
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,hepcidin,iron-refractory iron deficiency anemia,57817,C562385
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron deficiency,iron,D018798,D007501
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron deficiency,hepcidin,D018798,57817
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron deficiency,matriptase-2,D018798,164656
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,matriptase-2,iron,164656,D007501
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,matriptase-2,IRIDA,164656,C562385
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,matriptase-2,iron deficiency anemia,164656,D018798
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,matriptase-2,hepcidin,164656,57817
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,matriptase-2,iron deficiency,164656,D018798
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,matriptase-2,iron-refractory iron deficiency anemia,164656,C562385
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron-refractory iron deficiency anemia,iron,C562385,D007501
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron-refractory iron deficiency anemia,hepcidin,C562385,57817
19592582,Mutations leading to abrogation of matriptase-2 proteolytic activity in humans are associated with an iron-refractory iron deficiency anemia (IRIDA) due to elevated hepcidin levels,iron-refractory iron deficiency anemia,matriptase-2,C562385,164656
19592582,Here we describe two novel heterozygous mutations within the matriptase-2 (TMPRSS6) gene of monozygotic twin girls exhibiting an IRIDA phenotype,TMPRSS6,IRIDA,164656,C562385
19592582,Here we describe two novel heterozygous mutations within the matriptase-2 (TMPRSS6) gene of monozygotic twin girls exhibiting an IRIDA phenotype,TMPRSS6,matriptase-2,164656,164656
19592582,Here we describe two novel heterozygous mutations within the matriptase-2 (TMPRSS6) gene of monozygotic twin girls exhibiting an IRIDA phenotype,IRIDA,TMPRSS6,C562385,164656
19592582,Here we describe two novel heterozygous mutations within the matriptase-2 (TMPRSS6) gene of monozygotic twin girls exhibiting an IRIDA phenotype,IRIDA,matriptase-2,C562385,164656
19592582,Here we describe two novel heterozygous mutations within the matriptase-2 (TMPRSS6) gene of monozygotic twin girls exhibiting an IRIDA phenotype,matriptase-2,TMPRSS6,164656,164656
19592582,Here we describe two novel heterozygous mutations within the matriptase-2 (TMPRSS6) gene of monozygotic twin girls exhibiting an IRIDA phenotype,matriptase-2,IRIDA,164656,C562385
19592582,The first is the frameshift mutation (P686fs) caused by the insertion of the four nucleotides CCCC in exon 16 (2172_2173insCCCC) that is predicted to terminate translation before the catalytic serine,insertion of the four nucleotides CCCC,2172_2173insCCCC,c|INS||CCCC,c|INS|2172_2173|CCCC
19592582,The first is the frameshift mutation (P686fs) caused by the insertion of the four nucleotides CCCC in exon 16 (2172_2173insCCCC) that is predicted to terminate translation before the catalytic serine,insertion of the four nucleotides CCCC,P686fs,c|INS||CCCC,p|FS|P|686||
19592582,The first is the frameshift mutation (P686fs) caused by the insertion of the four nucleotides CCCC in exon 16 (2172_2173insCCCC) that is predicted to terminate translation before the catalytic serine,2172_2173insCCCC,insertion of the four nucleotides CCCC,c|INS|2172_2173|CCCC,c|INS||CCCC
19592582,The first is the frameshift mutation (P686fs) caused by the insertion of the four nucleotides CCCC in exon 16 (2172_2173insCCCC) that is predicted to terminate translation before the catalytic serine,2172_2173insCCCC,P686fs,c|INS|2172_2173|CCCC,p|FS|P|686||
19592582,The first is the frameshift mutation (P686fs) caused by the insertion of the four nucleotides CCCC in exon 16 (2172_2173insCCCC) that is predicted to terminate translation before the catalytic serine,P686fs,insertion of the four nucleotides CCCC,p|FS|P|686||,c|INS||CCCC
19592582,The first is the frameshift mutation (P686fs) caused by the insertion of the four nucleotides CCCC in exon 16 (2172_2173insCCCC) that is predicted to terminate translation before the catalytic serine,P686fs,2172_2173insCCCC,p|FS|P|686||,c|INS|2172_2173|CCCC
19592582,The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2,A118D,c.468C>T,p|SUB|A|118|D,c|SUB|C|468|T
19592582,The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2,A118D,matriptase-2,p|SUB|A|118|D,164656
19592582,The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2,A118D,c.467C>A,p|SUB|A|118|D,c|SUB|C|467|A
19592582,The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2,c.468C>T,A118D,c|SUB|C|468|T,p|SUB|A|118|D
19592582,The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2,c.468C>T,matriptase-2,c|SUB|C|468|T,164656
19592582,The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2,c.468C>T,c.467C>A,c|SUB|C|468|T,c|SUB|C|467|A
19592582,The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2,matriptase-2,A118D,164656,p|SUB|A|118|D
19592582,The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2,matriptase-2,c.468C>T,164656,c|SUB|C|468|T
19592582,The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2,matriptase-2,c.467C>A,164656,c|SUB|C|467|A
19592582,The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2,c.467C>A,A118D,c|SUB|C|467|A,p|SUB|A|118|D
19592582,The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2,c.467C>A,c.468C>T,c|SUB|C|467|A,c|SUB|C|468|T
19592582,The second mutation is the di-nucleotide substitution c.467C>A and c.468C>T in exon 3 that causes the missense mutation A118D in the SEA domain of the extracellular stem region of matriptase-2,c.467C>A,matriptase-2,c|SUB|C|467|A,164656
19592582,Functional analysis of both variant matriptase-2 proteases has revealed that they lead to ineffective suppression of hepcidin transcription,hepcidin,matriptase-2,57817,164656
19592582,Functional analysis of both variant matriptase-2 proteases has revealed that they lead to ineffective suppression of hepcidin transcription,matriptase-2,hepcidin,164656,57817
19592582,We also demonstrate that the A118D SEA domain mutation causes an intra-molecular structural imbalance that impairs matriptase-2 activation,A118D,matriptase-2,p|SUB|A|118|D,164656
19592582,We also demonstrate that the A118D SEA domain mutation causes an intra-molecular structural imbalance that impairs matriptase-2 activation,matriptase-2,A118D,164656,p|SUB|A|118|D
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",iron,TMPRSS6,D007501,164656
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",iron,iron deficiency,D007501,D018798
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",iron,matriptase-2,D007501,164656
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",iron,IRIDA,D007501,C562385
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",TMPRSS6,iron,164656,D007501
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",TMPRSS6,iron deficiency,164656,D018798
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",TMPRSS6,matriptase-2,164656,164656
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",TMPRSS6,IRIDA,164656,C562385
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",iron deficiency,iron,D018798,D007501
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",iron deficiency,TMPRSS6,D018798,164656
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",iron deficiency,matriptase-2,D018798,164656
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",matriptase-2,iron,164656,D007501
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",matriptase-2,TMPRSS6,164656,164656
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",matriptase-2,iron deficiency,164656,D018798
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",matriptase-2,IRIDA,164656,C562385
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",IRIDA,iron,C562385,D007501
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",IRIDA,TMPRSS6,C562385,164656
19592582,"Collectively, these results extend the pattern of TMPRSS6 mutations associated with IRIDA and functionally demonstrate that mutations affecting protease regions other than the catalytic domain may have a profound impact in the regulatory role of matriptase-2 during iron deficiency.",IRIDA,matriptase-2,C562385,164656
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,Acute renal failure,vancomycin,D058186,D014640
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,Acute renal failure,tenofovir,D058186,D000068698
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,AIDS,vancomycin,D000163,D014640
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,AIDS,tenofovir,D000163,D000068698
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,vancomycin,Acute renal failure,D014640,D058186
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,vancomycin,AIDS,D014640,D000163
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,vancomycin,renal failure,D014640,D051437
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,vancomycin,osteomyelitis,D014640,D010019
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,vancomycin,tenofovir,D014640,D000068698
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,renal failure,vancomycin,D051437,D014640
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,renal failure,tenofovir,D051437,D000068698
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,osteomyelitis,vancomycin,D010019,D014640
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,osteomyelitis,tenofovir,D010019,D000068698
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,tenofovir,Acute renal failure,D000068698,D058186
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,tenofovir,AIDS,D000068698,D000163
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,tenofovir,vancomycin,D000068698,D014640
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,tenofovir,renal failure,D000068698,D051437
19642243,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis,tenofovir,osteomyelitis,D000068698,D010019
19642243,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen,Renal failure,vancomycin,D051437,D014640
19642243,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen,Renal failure,tenofovir disoproxil fumarate,D051437,D000068698
19642243,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen,Renal failure,tenofovir,D051437,D000068698
19642243,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen,vancomycin,Renal failure,D014640,D051437
19642243,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen,vancomycin,tenofovir disoproxil fumarate,D014640,D000068698
19642243,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen,vancomycin,tenofovir,D014640,D000068698
19642243,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen,tenofovir disoproxil fumarate,Renal failure,D000068698,D051437
19642243,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen,tenofovir disoproxil fumarate,vancomycin,D000068698,D014640
19642243,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen,tenofovir disoproxil fumarate,tenofovir,D000068698,D000068698
19642243,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen,tenofovir,Renal failure,D000068698,D051437
19642243,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen,tenofovir,vancomycin,D000068698,D014640
19642243,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen,tenofovir,tenofovir disoproxil fumarate,D000068698,D000068698
19642243,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule,Tenofovir,Fanconi syndrome,D000068698,D005198
19642243,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule,Tenofovir,renal insufficiency,D000068698,D051437
19642243,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule,Fanconi syndrome,Tenofovir,D005198,D000068698
19642243,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule,renal insufficiency,Tenofovir,D051437,D000068698
19642243,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent,Vancomycin,nephrotoxic,D014640,D007674
19642243,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent,Vancomycin,nephrotoxicity,D014640,D007674
19642243,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent,nephrotoxic,Vancomycin,D007674,D014640
19642243,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent,nephrotoxicity,Vancomycin,D007674,D014640
19642243,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,tenofovir,vancomycin,D000068698,D014640
19642243,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,tenofovir,renal failure,D000068698,D051437
19642243,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,vancomycin,tenofovir,D014640,D000068698
19642243,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,vancomycin,renal failure,D014640,D051437
19642243,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,renal failure,tenofovir,D051437,D000068698
19642243,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,renal failure,vancomycin,D051437,D014640
19696792,Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression,irinotecan,ABCG2,D000077146,9429
19696792,Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression,irinotecan,myelosuppression,D000077146,D001855
19696792,Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression,ABCG2,irinotecan,9429,D000077146
19696792,Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression,ABCG2,myelosuppression,9429,D001855
19696792,Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression,myelosuppression,irinotecan,D001855,D000077146
19696792,Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression,myelosuppression,ABCG2,D001855,9429
19696792,"Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea",colorectal and lung cancers,Irinotecan,"D008175,D015179",D000077146
19696792,"Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea",Irinotecan,colorectal and lung cancers,D000077146,"D008175,D015179"
19696792,"Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea",Irinotecan,toxicities,D000077146,D064420
19696792,"Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea",Irinotecan,diarrhea,D000077146,D003967
19696792,"Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea",Irinotecan,myelosuppression,D000077146,D001855
19696792,"Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea",toxicities,Irinotecan,D064420,D000077146
19696792,"Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea",diarrhea,Irinotecan,D003967,D000077146
19696792,"Irinotecan is an anti-neoplastic agent that is widely used for treating colorectal and lung cancers, but often causes toxicities such as severe myelosuppression and diarrhea",myelosuppression,Irinotecan,D001855,D000077146
19696792,"In this study, we performed a two-stage case-control association study for irinotecan-induced severe myelosuppression (grades 3 and 4)",irinotecan,myelosuppression,D000077146,D001855
19696792,"In this study, we performed a two-stage case-control association study for irinotecan-induced severe myelosuppression (grades 3 and 4)",myelosuppression,irinotecan,D001855,D000077146
19696792,"In the first stage, 23 patients who developed severe myelosuppression and 58 patients who did not develop any toxicity were examined for 170 single nucleotide polymorphisms (SNPs) in 14 genes involved in the metabolism and transport of irinotecan",toxicity,irinotecan,D064420,D000077146
19696792,"In the first stage, 23 patients who developed severe myelosuppression and 58 patients who did not develop any toxicity were examined for 170 single nucleotide polymorphisms (SNPs) in 14 genes involved in the metabolism and transport of irinotecan",irinotecan,toxicity,D000077146,D064420
19696792,"In the first stage, 23 patients who developed severe myelosuppression and 58 patients who did not develop any toxicity were examined for 170 single nucleotide polymorphisms (SNPs) in 14 genes involved in the metabolism and transport of irinotecan",irinotecan,myelosuppression,D000077146,D001855
19696792,"In the first stage, 23 patients who developed severe myelosuppression and 58 patients who did not develop any toxicity were examined for 170 single nucleotide polymorphisms (SNPs) in 14 genes involved in the metabolism and transport of irinotecan",myelosuppression,irinotecan,D001855,D000077146
19696792,"An intronic SNP, rs2622604, in ABCG2 showed P(Fisher)=0.0419 in the second stage and indicated a significant association with severe myelosuppression in the combined study (P(Fisher)=0.000237; P(Corrected)=0.036)",rs2622604,ABCG2,rs2622604,9429
19696792,"An intronic SNP, rs2622604, in ABCG2 showed P(Fisher)=0.0419 in the second stage and indicated a significant association with severe myelosuppression in the combined study (P(Fisher)=0.000237; P(Corrected)=0.036)",rs2622604,myelosuppression,rs2622604,D001855
19696792,"An intronic SNP, rs2622604, in ABCG2 showed P(Fisher)=0.0419 in the second stage and indicated a significant association with severe myelosuppression in the combined study (P(Fisher)=0.000237; P(Corrected)=0.036)",ABCG2,rs2622604,9429,rs2622604
19696792,"An intronic SNP, rs2622604, in ABCG2 showed P(Fisher)=0.0419 in the second stage and indicated a significant association with severe myelosuppression in the combined study (P(Fisher)=0.000237; P(Corrected)=0.036)",ABCG2,myelosuppression,9429,D001855
19696792,"An intronic SNP, rs2622604, in ABCG2 showed P(Fisher)=0.0419 in the second stage and indicated a significant association with severe myelosuppression in the combined study (P(Fisher)=0.000237; P(Corrected)=0.036)",myelosuppression,rs2622604,D001855,rs2622604
19696792,"An intronic SNP, rs2622604, in ABCG2 showed P(Fisher)=0.0419 in the second stage and indicated a significant association with severe myelosuppression in the combined study (P(Fisher)=0.000237; P(Corrected)=0.036)",myelosuppression,ABCG2,D001855,9429
19696792,"Although only limited subjects were investigated, our results suggested that a genetic polymorphism in ABCG2 might alter the transport activity for the drug and elevate the systemic circulation level of irinotecan, leading to severe myelosuppression.",irinotecan,ABCG2,D000077146,9429
19696792,"Although only limited subjects were investigated, our results suggested that a genetic polymorphism in ABCG2 might alter the transport activity for the drug and elevate the systemic circulation level of irinotecan, leading to severe myelosuppression.",irinotecan,myelosuppression,D000077146,D001855
19696792,"Although only limited subjects were investigated, our results suggested that a genetic polymorphism in ABCG2 might alter the transport activity for the drug and elevate the systemic circulation level of irinotecan, leading to severe myelosuppression.",ABCG2,irinotecan,9429,D000077146
19696792,"Although only limited subjects were investigated, our results suggested that a genetic polymorphism in ABCG2 might alter the transport activity for the drug and elevate the systemic circulation level of irinotecan, leading to severe myelosuppression.",ABCG2,myelosuppression,9429,D001855
19696792,"Although only limited subjects were investigated, our results suggested that a genetic polymorphism in ABCG2 might alter the transport activity for the drug and elevate the systemic circulation level of irinotecan, leading to severe myelosuppression.",myelosuppression,irinotecan,D001855,D000077146
19696792,"Although only limited subjects were investigated, our results suggested that a genetic polymorphism in ABCG2 might alter the transport activity for the drug and elevate the systemic circulation level of irinotecan, leading to severe myelosuppression.",myelosuppression,ABCG2,D001855,9429
19728177,METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema,cerebral edema,acetaminophen,D001929,D000082
19728177,METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema,acetaminophen,cerebral edema,D000082,D001929
19728177,METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema,acetaminophen,FHF,D000082,D017114
19728177,METHOD: Case-based observations from a medical intensive care unit (MICU) in a tertiary care facility in a 27-year-old female with FHF from acetaminophen and resultant cerebral edema,FHF,acetaminophen,D017114,D000082
19728177,RESULTS: Our patient was admitted to the MICU after being found unresponsive with presumed toxicity from acetaminophen which was ingested over a 2-day period,toxicity,acetaminophen,D064420,D000082
19728177,RESULTS: Our patient was admitted to the MICU after being found unresponsive with presumed toxicity from acetaminophen which was ingested over a 2-day period,acetaminophen,toxicity,D000082,D064420
19728177,Initial evaluation confirmed FHF from acetaminophen and cerebral edema,cerebral edema,acetaminophen,D001929,D000082
19728177,Initial evaluation confirmed FHF from acetaminophen and cerebral edema,acetaminophen,cerebral edema,D000082,D001929
19728177,Initial evaluation confirmed FHF from acetaminophen and cerebral edema,acetaminophen,FHF,D000082,D017114
19728177,Initial evaluation confirmed FHF from acetaminophen and cerebral edema,FHF,acetaminophen,D017114,D000082
19728177,"CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery",cerebral edema,acetaminophen,D001929,D000082
19728177,"CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery",FHF,acetaminophen,D017114,D000082
19728177,"CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery",hypothermia,acetaminophen,D007036,D000082
19728177,"CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery",acetaminophen,cerebral edema,D000082,D001929
19728177,"CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery",acetaminophen,FHF,D000082,D017114
19728177,"CONCLUSION: In patients with FHF and cerebral edema from acetaminophen overdose, prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery",acetaminophen,hypothermia,D000082,D007036
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",tumor necrosis factor-alpha,metastasis,"21926,7124",D009362
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",tumor necrosis factor-alpha,nuclear factor-kappaB,"21926,7124","18033,4790"
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",tumor necrosis factor-alpha,bone morphogenetic protein-2,"21926,7124","12156,650"
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",tumor necrosis factor-alpha,prostate cancer,"21926,7124",D011471
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",metastasis,tumor necrosis factor-alpha,D009362,"21926,7124"
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",metastasis,nuclear factor-kappaB,D009362,"18033,4790"
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",metastasis,bone morphogenetic protein-2,D009362,"12156,650"
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",nuclear factor-kappaB,tumor necrosis factor-alpha,"18033,4790","21926,7124"
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",nuclear factor-kappaB,metastasis,"18033,4790",D009362
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",nuclear factor-kappaB,bone morphogenetic protein-2,"18033,4790","12156,650"
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",nuclear factor-kappaB,prostate cancer,"18033,4790",D011471
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",bone morphogenetic protein-2,tumor necrosis factor-alpha,"12156,650","21926,7124"
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",bone morphogenetic protein-2,metastasis,"12156,650",D009362
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",bone morphogenetic protein-2,nuclear factor-kappaB,"12156,650","18033,4790"
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",bone morphogenetic protein-2,prostate cancer,"12156,650",D011471
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",prostate cancer,tumor necrosis factor-alpha,D011471,"21926,7124"
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",prostate cancer,nuclear factor-kappaB,D011471,"18033,4790"
19811499,"Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells",prostate cancer,bone morphogenetic protein-2,D011471,"12156,650"
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,BMP,nuclear factor (NF)-kappaB,12156,4790
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,BMP,phosphoinositide 3-kinase (PI3K)/protein kinase B,12156,207
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,BMP,Akt,12156,207
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,BMP,prostate cancer,12156,D011471
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,BMP,bone morphogenetic protein (BMP)-2,12156,650
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,nuclear factor (NF)-kappaB,BMP,4790,12156
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,nuclear factor (NF)-kappaB,phosphoinositide 3-kinase (PI3K)/protein kinase B,4790,207
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,nuclear factor (NF)-kappaB,Akt,4790,207
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,nuclear factor (NF)-kappaB,prostate cancer,4790,D011471
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,nuclear factor (NF)-kappaB,bone morphogenetic protein (BMP)-2,4790,650
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,phosphoinositide 3-kinase (PI3K)/protein kinase B,BMP,207,12156
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,phosphoinositide 3-kinase (PI3K)/protein kinase B,nuclear factor (NF)-kappaB,207,4790
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,phosphoinositide 3-kinase (PI3K)/protein kinase B,Akt,207,207
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,phosphoinositide 3-kinase (PI3K)/protein kinase B,prostate cancer,207,D011471
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,phosphoinositide 3-kinase (PI3K)/protein kinase B,bone morphogenetic protein (BMP)-2,207,650
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,Akt,BMP,207,12156
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,Akt,nuclear factor (NF)-kappaB,207,4790
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,Akt,phosphoinositide 3-kinase (PI3K)/protein kinase B,207,207
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,Akt,prostate cancer,207,D011471
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,Akt,bone morphogenetic protein (BMP)-2,207,650
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,prostate cancer,BMP,D011471,12156
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,prostate cancer,nuclear factor (NF)-kappaB,D011471,4790
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,prostate cancer,phosphoinositide 3-kinase (PI3K)/protein kinase B,D011471,207
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,prostate cancer,Akt,D011471,207
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,prostate cancer,bone morphogenetic protein (BMP)-2,D011471,650
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,bone morphogenetic protein (BMP)-2,BMP,650,12156
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,bone morphogenetic protein (BMP)-2,nuclear factor (NF)-kappaB,650,4790
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,bone morphogenetic protein (BMP)-2,phosphoinositide 3-kinase (PI3K)/protein kinase B,650,207
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,bone morphogenetic protein (BMP)-2,Akt,650,207
19811499,We recently reported that phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) mediates transcriptional regulation and activation of bone morphogenetic protein (BMP)-2 signaling by nuclear factor (NF)-kappaB in bone metastatic prostate cancer cells,bone morphogenetic protein (BMP)-2,prostate cancer,650,D011471
19811499,"In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells",tumor necrosis factor (TNF)-alpha,p65,7124,5970
19811499,"In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells",tumor necrosis factor (TNF)-alpha,NF-kappaB,7124,4790
19811499,"In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells",tumor necrosis factor (TNF)-alpha,PC,7124,D011471
19811499,"In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells",p65,tumor necrosis factor (TNF)-alpha,5970,7124
19811499,"In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells",p65,NF-kappaB,5970,4790
19811499,"In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells",p65,PC,5970,D011471
19811499,"In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells",NF-kappaB,tumor necrosis factor (TNF)-alpha,4790,7124
19811499,"In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells",NF-kappaB,p65,4790,5970
19811499,"In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells",NF-kappaB,PC,4790,D011471
19811499,"In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells",PC,tumor necrosis factor (TNF)-alpha,D011471,7124
19811499,"In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells",PC,p65,D011471,5970
19811499,"In the present study, we demonstrate that NF-kappaB, whether activated by recombinant human tumor necrosis factor (TNF)-alpha or by ectopic expression of the p65 subunit, is involved in extracellular matrix adhesion and invasion of osteotropic PC-3 and C4-2B, but not LNCaP, cells",PC,NF-kappaB,D011471,4790
19811499,"The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells",osteocalcin,PC,632,D011471
19811499,"The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells",osteocalcin,osteopontin,632,6696
19811499,"The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells",osteocalcin,collagen IA1,632,1277
19811499,"The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells",PC,osteocalcin,D011471,632
19811499,"The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells",PC,osteopontin,D011471,6696
19811499,"The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells",PC,collagen IA1,D011471,1277
19811499,"The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells",osteopontin,osteocalcin,6696,632
19811499,"The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells",osteopontin,PC,6696,D011471
19811499,"The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells",osteopontin,collagen IA1,6696,1277
19811499,"The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells",collagen IA1,osteocalcin,1277,632
19811499,"The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells",collagen IA1,PC,1277,D011471
19811499,"The enhanced metastatic potential was associated with transcriptional upregulation of osteopontin, osteocalcin, and collagen IA1 in osteotropic PC cells, suggesting their role in osteomimicry of PC cells",collagen IA1,osteopontin,1277,6696
19811499,"Unlike BMP-4, BMP-2 protein enhanced the invasive properties of C4-2B cells, but not in LNCaP cells",BMP-2,BMP-4,12156,652
19811499,"Unlike BMP-4, BMP-2 protein enhanced the invasive properties of C4-2B cells, but not in LNCaP cells",BMP-2,BMP,12156,12156
19811499,"Unlike BMP-4, BMP-2 protein enhanced the invasive properties of C4-2B cells, but not in LNCaP cells",BMP-4,BMP-2,652,12156
19811499,"Unlike BMP-4, BMP-2 protein enhanced the invasive properties of C4-2B cells, but not in LNCaP cells",BMP-4,BMP,652,12156
19811499,"Unlike BMP-4, BMP-2 protein enhanced the invasive properties of C4-2B cells, but not in LNCaP cells",BMP,BMP-2,12156,12156
19811499,"Unlike BMP-4, BMP-2 protein enhanced the invasive properties of C4-2B cells, but not in LNCaP cells",BMP,BMP-4,12156,652
19811499,"In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion",NF-kappaB,BMP-2,4790,12156
19811499,"In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion",NF-kappaB,TNF-alpha,4790,7124
19811499,"In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion",NF-kappaB,BMP,4790,12156
19811499,"In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion",BMP-2,NF-kappaB,12156,4790
19811499,"In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion",BMP-2,TNF-alpha,12156,7124
19811499,"In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion",BMP-2,BMP,12156,12156
19811499,"In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion",TNF-alpha,NF-kappaB,7124,4790
19811499,"In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion",TNF-alpha,BMP-2,7124,12156
19811499,"In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion",TNF-alpha,BMP,7124,12156
19811499,"In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion",BMP,NF-kappaB,12156,4790
19811499,"In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion",BMP,BMP-2,12156,12156
19811499,"In addition, BMP-2 mediates TNF-alpha-induced invasion of C4-2B cells in a NF-kappaB-dependent fashion",BMP,TNF-alpha,12156,7124
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",receptor activator of NF-kappaB ligand,NF-kappaB,21943,4790
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",receptor activator of NF-kappaB ligand,BMP-2,21943,12156
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",receptor activator of NF-kappaB ligand,Smad,21943,17127
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",receptor activator of NF-kappaB ligand,TNF-alpha,21943,7124
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",receptor activator of NF-kappaB ligand,BMP,21943,12156
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",NF-kappaB,receptor activator of NF-kappaB ligand,4790,21943
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",NF-kappaB,BMP-2,4790,12156
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",NF-kappaB,Smad,4790,17127
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",NF-kappaB,TNF-alpha,4790,7124
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",NF-kappaB,BMP,4790,12156
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",BMP-2,receptor activator of NF-kappaB ligand,12156,21943
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",BMP-2,NF-kappaB,12156,4790
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",BMP-2,Smad,12156,17127
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",BMP-2,TNF-alpha,12156,7124
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",BMP-2,BMP,12156,12156
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",Smad,receptor activator of NF-kappaB ligand,17127,21943
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",Smad,NF-kappaB,17127,4790
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",Smad,BMP-2,17127,12156
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",Smad,TNF-alpha,17127,7124
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",Smad,BMP,17127,12156
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",TNF-alpha,receptor activator of NF-kappaB ligand,7124,21943
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",TNF-alpha,NF-kappaB,7124,4790
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",TNF-alpha,BMP-2,7124,12156
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",TNF-alpha,Smad,7124,17127
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",TNF-alpha,BMP,7124,12156
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",BMP,receptor activator of NF-kappaB ligand,12156,21943
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",BMP,NF-kappaB,12156,4790
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",BMP,BMP-2,12156,12156
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",BMP,Smad,12156,17127
19811499,"TNF-alpha or conditioned media (CM) of TNF-alpha-stimulated C4-2B cells upregulated BMP-2 and BMP-dependent Smad transcripts and inhibited receptor activator of NF-kappaB ligand transcripts in RAW 264.7 preosteoclast cells, respectively, implying that this factor may contribute to suppression of osteoclastogenesis via direct and paracrine mechanisms",BMP,TNF-alpha,12156,7124
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",NF-kappaB,BMP-2,4790,12156
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",NF-kappaB,BMP2,4790,650
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",NF-kappaB,TNF-alpha,4790,7124
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",NF-kappaB,BMP,4790,12156
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",BMP-2,NF-kappaB,12156,4790
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",BMP-2,BMP2,12156,650
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",BMP-2,TNF-alpha,12156,7124
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",BMP-2,BMP,12156,12156
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",BMP2,NF-kappaB,650,4790
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",BMP2,BMP-2,650,12156
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",BMP2,TNF-alpha,650,7124
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",BMP2,BMP,650,12156
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",TNF-alpha,NF-kappaB,7124,4790
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",TNF-alpha,BMP-2,7124,12156
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",TNF-alpha,BMP2,7124,650
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",TNF-alpha,BMP,7124,12156
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",BMP,NF-kappaB,12156,4790
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",BMP,BMP-2,12156,12156
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",BMP,BMP2,12156,650
19811499,"In contrast, CM of TNF-alpha-stimulate or BMP2-stimulated C4-2B cells induced in vitro mineralization of MC3T3-E1 osteoblast cells in a BMP-2-dependent and NF-kappaB-dependent manner, respectively",BMP,TNF-alpha,12156,7124
19918264,FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men,Gly388Arg,cancer,rs351855,D009369
19918264,FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men,Gly388Arg,FGFR4,rs351855,2264
19918264,FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men,Gly388Arg,prostate cancer,rs351855,D011471
19918264,FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men,cancer,Gly388Arg,D009369,rs351855
19918264,FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men,cancer,FGFR4,D009369,2264
19918264,FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men,FGFR4,Gly388Arg,2264,rs351855
19918264,FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men,FGFR4,cancer,2264,D009369
19918264,FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men,FGFR4,prostate cancer,2264,D011471
19918264,FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men,prostate cancer,Gly388Arg,D011471,rs351855
19918264,FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men,prostate cancer,FGFR4,D011471,2264
19918264,"Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth receptor family, was recently reported to be more abundantly expressed in malignant than benign prostate cells",Fibroblast growth factor receptor 4,FGFR4,2264,2264
19918264,"Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth receptor family, was recently reported to be more abundantly expressed in malignant than benign prostate cells",Fibroblast growth factor receptor 4,fibroblast growth receptor,2264,2264
19918264,"Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth receptor family, was recently reported to be more abundantly expressed in malignant than benign prostate cells",FGFR4,Fibroblast growth factor receptor 4,2264,2264
19918264,"Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth receptor family, was recently reported to be more abundantly expressed in malignant than benign prostate cells",FGFR4,fibroblast growth receptor,2264,2264
19918264,"Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth receptor family, was recently reported to be more abundantly expressed in malignant than benign prostate cells",fibroblast growth receptor,Fibroblast growth factor receptor 4,2264,2264
19918264,"Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth receptor family, was recently reported to be more abundantly expressed in malignant than benign prostate cells",fibroblast growth receptor,FGFR4,2264,2264
19918264,A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients,cancer,FGFR4,D009369,2264
19918264,A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients,cancer,glycine (Gly) with arginine (Arg),D009369,rs351855
19918264,A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients,FGFR4,cancer,2264,D009369
19918264,A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients,FGFR4,glycine (Gly) with arginine (Arg),2264,rs351855
19918264,A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients,FGFR4,prostate cancer,2264,D011471
19918264,A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients,glycine (Gly) with arginine (Arg),cancer,rs351855,D009369
19918264,A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients,glycine (Gly) with arginine (Arg),FGFR4,rs351855,2264
19918264,A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients,glycine (Gly) with arginine (Arg),prostate cancer,rs351855,D011471
19918264,A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients,prostate cancer,FGFR4,D011471,2264
19918264,A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients,prostate cancer,glycine (Gly) with arginine (Arg),D011471,rs351855
19918264,The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men,cancer,Gly(388)Arg,D009369,rs351855
19918264,The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men,cancer,FGFR4,D009369,2264
19918264,The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men,Gly(388)Arg,cancer,rs351855,D009369
19918264,The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men,Gly(388)Arg,FGFR4,rs351855,2264
19918264,The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men,Gly(388)Arg,prostate cancer,rs351855,D011471
19918264,The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men,FGFR4,cancer,2264,D009369
19918264,The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men,FGFR4,Gly(388)Arg,2264,rs351855
19918264,The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men,FGFR4,prostate cancer,2264,D011471
19918264,The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men,prostate cancer,Gly(388)Arg,D011471,rs351855
19918264,The single nucleotide polymorphism Gly(388)Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men,prostate cancer,FGFR4,D011471,2264
19923525,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice,Nimodipine,nitroglycerin,D009553,D005996
19923525,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice,Nimodipine,hypotension,D009553,D007022
19923525,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice,Nimodipine,memory impairment,D009553,D008569
19923525,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice,nitroglycerin,Nimodipine,D005996,D009553
19923525,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice,nitroglycerin,hypotension,D005996,D007022
19923525,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice,nitroglycerin,memory impairment,D005996,D008569
19923525,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice,hypotension,Nimodipine,D007022,D009553
19923525,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice,hypotension,nitroglycerin,D007022,D005996
19923525,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice,memory impairment,Nimodipine,D008569,D009553
19923525,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice,memory impairment,nitroglycerin,D008569,D005996
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,NIMO,nitroglycerin,D009553,D005996
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,NIMO,hypotension,D009553,D007022
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,NIMO,nimodipine,D009553,D009553
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,NIMO,NTG,D009553,D005996
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,nitroglycerin,NIMO,D005996,D009553
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,nitroglycerin,hypotension,D005996,D007022
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,nitroglycerin,nimodipine,D005996,D009553
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,nitroglycerin,NTG,D005996,D005996
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,hypotension,NIMO,D007022,D009553
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,hypotension,nitroglycerin,D007022,D005996
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,hypotension,nimodipine,D007022,D009553
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,hypotension,NTG,D007022,D005996
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,nimodipine,NIMO,D009553,D009553
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,nimodipine,nitroglycerin,D009553,D005996
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,nimodipine,hypotension,D009553,D007022
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,nimodipine,NTG,D009553,D005996
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,NTG,NIMO,D005996,D009553
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,NTG,nitroglycerin,D005996,D005996
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,NTG,hypotension,D005996,D007022
19923525,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory,NTG,nimodipine,D005996,D009553
19923525,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone",NTG,NIMO,D005996,D009553
19923525,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone",NIMO,NTG,D009553,D005996
19923525,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively)",hypotensive,NTG,D007022,D005996
19923525,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively)",hypotensive,NIMO,D007022,D009553
19923525,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively)",NTG,hypotensive,D005996,D007022
19923525,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively)",NTG,NIMO,D005996,D009553
19923525,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively)",NIMO,hypotensive,D009553,D007022
19923525,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively)",NIMO,NTG,D009553,D005996
19923525,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively",NTG,NIMO,D005996,D009553
19923525,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively",NIMO,NTG,D009553,D005996
19923525,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively",NTG,NIMO,D005996,D009553
19923525,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively",NIMO,NTG,D009553,D005996
19923525,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect",hypotension,NTG,D007022,D005996
19923525,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect",NTG,hypotension,D005996,D007022
19923525,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension,hypotension,NTG,D007022,D005996
19923525,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension,hypotension,NIMO,D007022,D009553
19923525,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension,NTG,hypotension,D005996,D007022
19923525,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension,NTG,NIMO,D005996,D009553
19923525,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension,NIMO,hypotension,D009553,D007022
19923525,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension,NIMO,NTG,D009553,D005996
19923525,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",hypotension,calcium,D007022,D002118
19923525,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",hypotension,NIMO,D007022,D009553
19923525,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",calcium,hypotension,D002118,D007022
19923525,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",calcium,NIMO,D002118,D009553
19923525,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",NIMO,hypotension,D009553,D007022
19923525,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",NIMO,calcium,D009553,D002118
20105280,BACKGROUND: Mammalian Ras genes regulate diverse cellular processes including proliferation and differentiation and are frequently mutated in human cancers,Ras,cancers,3265,D009369
20105280,BACKGROUND: Mammalian Ras genes regulate diverse cellular processes including proliferation and differentiation and are frequently mutated in human cancers,cancers,Ras,D009369,3265
20105280,Tumor development in response to Ras activation varies between different tissues and the molecular basis for these variations are poorly understood,Ras,Tumor,3265,D009369
20105280,Tumor development in response to Ras activation varies between different tissues and the molecular basis for these variations are poorly understood,Tumor,Ras,D009369,3265
20105280,Activation of the fibroblast growth factor (FGF) signaling pathway induces the corneal epithelial cells to proliferate and the lens epithelial cells to exit the cell cycle,fibroblast growth factor,FGF,64654,64654
20105280,Activation of the fibroblast growth factor (FGF) signaling pathway induces the corneal epithelial cells to proliferate and the lens epithelial cells to exit the cell cycle,FGF,fibroblast growth factor,64654,64654
20105280,We have generated transgenic mice that express a constitutively active version of human H-Ras in their lenses and corneas,Ras,H-Ras,3265,3265
20105280,We have generated transgenic mice that express a constitutively active version of human H-Ras in their lenses and corneas,H-Ras,Ras,3265,3265
20105280,RESULTS: Ras transgenic lenses and corneal epithelial cells showed increased proliferation with concomitant increases in cyclin D1 and D2 expression,cyclin D1 and D2,Ras,"12443,12444",3265
20105280,RESULTS: Ras transgenic lenses and corneal epithelial cells showed increased proliferation with concomitant increases in cyclin D1 and D2 expression,Ras,cyclin D1 and D2,3265,"12443,12444"
20105280,"Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas",cdk,Ras,12575,3265
20105280,"Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas",cdk,p57Kip2,12575,12577
20105280,"Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas",cdk,p27Kip1,12575,12576
20105280,"Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas",Ras,cdk,3265,12575
20105280,"Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas",Ras,p57Kip2,3265,12577
20105280,"Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas",Ras,p27Kip1,3265,12576
20105280,"Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas",p57Kip2,cdk,12577,12575
20105280,"Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas",p57Kip2,Ras,12577,3265
20105280,"Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas",p57Kip2,p27Kip1,12577,12576
20105280,"Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas",p27Kip1,cdk,12576,12575
20105280,"Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas",p27Kip1,Ras,12576,3265
20105280,"Coincidentally, cdk inhibitors p27Kip1 and p57Kip2 were upregulated in the Ras transgenic lenses but not in the corneas",p27Kip1,p57Kip2,12576,12577
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Raf,Erk2,109880,26413
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Raf,Spry 1,109880,24063
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Raf,Spry 2,109880,24064
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Raf,Erk,109880,"26413,26417"
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Raf,Ras,109880,3265
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Raf,Erk1,109880,26417
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk2,Raf,26413,109880
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk2,Spry 1,26413,24063
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk2,Spry 2,26413,24064
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk2,Erk,26413,"26413,26417"
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk2,Ras,26413,3265
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk2,Erk1,26413,26417
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Spry 1,Raf,24063,109880
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Spry 1,Erk2,24063,26413
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Spry 1,Spry 2,24063,24064
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Spry 1,Erk,24063,"26413,26417"
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Spry 1,Ras,24063,3265
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Spry 1,Erk1,24063,26417
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Spry 2,Raf,24064,109880
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Spry 2,Erk2,24064,26413
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Spry 2,Spry 1,24064,24063
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Spry 2,Erk,24064,"26413,26417"
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Spry 2,Ras,24064,3265
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Spry 2,Erk1,24064,26417
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk,Raf,"26413,26417",109880
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk,Erk2,"26413,26417",26413
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk,Spry 1,"26413,26417",24063
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk,Spry 2,"26413,26417",24064
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk,Ras,"26413,26417",3265
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk,Erk1,"26413,26417",26417
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Ras,Raf,3265,109880
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Ras,Erk2,3265,26413
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Ras,Spry 1,3265,24063
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Ras,Spry 2,3265,24064
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Ras,Erk,3265,"26413,26417"
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Ras,Erk1,3265,26417
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk1,Raf,26417,109880
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk1,Erk2,26417,26413
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk1,Spry 1,26417,24063
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk1,Spry 2,26417,24064
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk1,Erk,26417,"26413,26417"
20105280,"Phospho-Erk1 and Erk2 levels were elevated in the lens but not in the cornea and Spry 1 and Spry 2, negative regulators of Ras-Raf-Erk signaling, were upregulated more in the corneal than in the lens epithelial cells",Erk1,Ras,26417,3265
20105280,"Ras activation, though sufficient for upregulation of Prox1, a transcription factor critical for cell cycle exit and initiation of fiber differentiation, is not sufficient for induction of terminal fiber differentiation",Ras,Prox1,3265,19130
20105280,"Ras activation, though sufficient for upregulation of Prox1, a transcription factor critical for cell cycle exit and initiation of fiber differentiation, is not sufficient for induction of terminal fiber differentiation",Prox1,Ras,19130,3265
20105280,"Expression of Keratin 12, a marker of corneal epithelial differentiation, was reduced in the Ras transgenic corneas",Ras,Keratin 12,3265,268482
20105280,"Expression of Keratin 12, a marker of corneal epithelial differentiation, was reduced in the Ras transgenic corneas",Keratin 12,Ras,268482,3265
20195852,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study,contrast media,nephropathy,D003287,D007674
20195852,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study,nephropathy,contrast media,D007674,D003287
20195852,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography",contrast media,CIN,D003287,D007674
20195852,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography",contrast media,nephropathy,D003287,D007674
20195852,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography",CIN,contrast media,D007674,D003287
20195852,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography",nephropathy,contrast media,D007674,D003287
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",contrast media,iopromide,D003287,C038192
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",contrast media,CM,D003287,D003287
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",contrast media,cyanosis,D003287,D003490
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",contrast media,iohexol,D003287,D007472
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",contrast media,CIN,D003287,D007674
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",iopromide,contrast media,C038192,D003287
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",iopromide,CM,C038192,D003287
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",iopromide,cyanosis,C038192,D003490
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",iopromide,iohexol,C038192,D007472
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",iopromide,CIN,C038192,D007674
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",CM,contrast media,D003287,D003287
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",CM,iopromide,D003287,C038192
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",CM,cyanosis,D003287,D003490
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",CM,iohexol,D003287,D007472
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",CM,CIN,D003287,D007674
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",cyanosis,contrast media,D003490,D003287
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",cyanosis,iopromide,D003490,C038192
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",cyanosis,CM,D003490,D003287
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",cyanosis,iohexol,D003490,D007472
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",iohexol,contrast media,D007472,D003287
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",iohexol,iopromide,D007472,C038192
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",iohexol,CM,D007472,D003287
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",iohexol,cyanosis,D007472,D003490
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",iohexol,CIN,D007472,D007674
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",CIN,contrast media,D007674,D003287
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",CIN,iopromide,D007674,C038192
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",CIN,CM,D007674,D003287
20195852,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis",CIN,iohexol,D007674,D007472
20195852,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40)",iopromide,iohexol,C038192,D007472
20195852,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40)",iohexol,iopromide,D007472,C038192
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",sodium,Cr,D012964,D003404
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",sodium,CM,D012964,D003287
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",sodium,potassium,D012964,D011188
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",sodium,Na,D012964,D012964
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",sodium,K,D012964,D011188
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",sodium,creatinine,D012964,D003404
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",Cr,sodium,D003404,D012964
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",Cr,CM,D003404,D003287
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",Cr,potassium,D003404,D011188
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",Cr,Na,D003404,D012964
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",Cr,K,D003404,D011188
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",Cr,creatinine,D003404,D003404
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",CM,sodium,D003287,D012964
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",CM,Cr,D003287,D003404
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",CM,potassium,D003287,D011188
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",CM,Na,D003287,D012964
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",CM,K,D003287,D011188
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",CM,creatinine,D003287,D003404
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",potassium,sodium,D011188,D012964
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",potassium,Cr,D011188,D003404
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",potassium,CM,D011188,D003287
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",potassium,Na,D011188,D012964
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",potassium,K,D011188,D011188
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",potassium,creatinine,D011188,D003404
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",Na,sodium,D012964,D012964
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",Na,Cr,D012964,D003404
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",Na,CM,D012964,D003287
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",Na,potassium,D012964,D011188
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",Na,K,D012964,D011188
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",Na,creatinine,D012964,D003404
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",K,sodium,D011188,D012964
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",K,Cr,D011188,D003404
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",K,CM,D011188,D003287
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",K,potassium,D011188,D011188
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",K,Na,D011188,D012964
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",K,creatinine,D011188,D003404
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",creatinine,sodium,D003404,D012964
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",creatinine,Cr,D003404,D003404
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",creatinine,CM,D003404,D003287
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",creatinine,potassium,D003404,D011188
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",creatinine,Na,D003404,D012964
20195852,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use",creatinine,K,D003404,D011188
20195852,Urine samples for Na and Cr also were checked at the same intervals,Na,Cr,D012964,D003404
20195852,Urine samples for Na and Cr also were checked at the same intervals,Cr,Na,D003404,D012964
20195852,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014)",CM,CIN,D003287,D007674
20195852,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014)",CIN,CM,D007674,D003287
20195852,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",CM,cyanosis,D003287,D003490
20195852,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",CM,CIN,D003287,D007674
20195852,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",cyanosis,CM,D003490,D003287
20195852,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",CIN,CM,D007674,D003287
20520283,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia,asenapine,haloperidol,C522667,D006220
20520283,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia,asenapine,schizophrenia,C522667,D012559
20520283,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia,haloperidol,asenapine,D006220,C522667
20520283,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia,haloperidol,schizophrenia,D006220,D012559
20520283,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia,schizophrenia,asenapine,D012559,C522667
20520283,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia,schizophrenia,haloperidol,D012559,D006220
20520283,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features,bipolar I disorder,Asenapine,D001714,C522667
20520283,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features,psychotic,Asenapine,D011618,C522667
20520283,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features,schizophrenia,Asenapine,D012559,C522667
20520283,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features,Asenapine,bipolar I disorder,C522667,D001714
20520283,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features,Asenapine,psychotic,C522667,D011618
20520283,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features,Asenapine,schizophrenia,C522667,D012559
20520283,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features,Asenapine,manic,C522667,D001714
20520283,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features,manic,Asenapine,D001714,C522667
20520283,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity)",asenapine,haloperidol,C522667,D006220
20520283,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity)",asenapine,schizophrenia,C522667,D012559
20520283,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity)",haloperidol,asenapine,D006220,C522667
20520283,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity)",haloperidol,schizophrenia,D006220,D012559
20520283,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity)",schizophrenia,asenapine,D012559,C522667
20520283,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity)",schizophrenia,haloperidol,D012559,D006220
20520283,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05)",asenapine,haloperidol,C522667,D006220
20520283,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05)",haloperidol,asenapine,D006220,C522667
20520283,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively",asenapine,haloperidol,C522667,D006220
20520283,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively",haloperidol,asenapine,D006220,C522667
20520283,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively",asenapine,Extrapyramidal symptoms,C522667,D001480
20520283,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively",asenapine,haloperidol,C522667,D006220
20520283,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively",Extrapyramidal symptoms,asenapine,D001480,C522667
20520283,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively",Extrapyramidal symptoms,haloperidol,D001480,D006220
20520283,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively",haloperidol,asenapine,D006220,C522667
20520283,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively",haloperidol,Extrapyramidal symptoms,D006220,D001480
20520283,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",asenapine,haloperidol,C522667,D006220
20520283,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",asenapine,extrapyramidal symptoms,C522667,D001480
20520283,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",haloperidol,asenapine,D006220,C522667
20520283,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",haloperidol,extrapyramidal symptoms,D006220,D001480
20520283,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",extrapyramidal symptoms,asenapine,D001480,C522667
20520283,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",extrapyramidal symptoms,haloperidol,D001480,D006220
20528871,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma",nelarabine,cyclophosphamide,C104457,D003520
20528871,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma",nelarabine,etoposide,C104457,D005047
20528871,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma",nelarabine,T-cell lymphoblastic leukaemia and lymphoma,C104457,D015458|D016399
20528871,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma",cyclophosphamide,nelarabine,D003520,C104457
20528871,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma",cyclophosphamide,etoposide,D003520,D005047
20528871,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma",cyclophosphamide,T-cell lymphoblastic leukaemia and lymphoma,D003520,D015458|D016399
20528871,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma",etoposide,nelarabine,D005047,C104457
20528871,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma",etoposide,cyclophosphamide,D005047,D003520
20528871,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma",etoposide,T-cell lymphoblastic leukaemia and lymphoma,D005047,D015458|D016399
20528871,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma",T-cell lymphoblastic leukaemia and lymphoma,nelarabine,D015458|D016399,C104457
20528871,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma",T-cell lymphoblastic leukaemia and lymphoma,cyclophosphamide,D015458|D016399,D003520
20528871,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma",T-cell lymphoblastic leukaemia and lymphoma,etoposide,D015458|D016399,D005047
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,AraG,nelarabine,C104457,C104457
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,AraG,T-cell leukaemia or lymphoma,C104457,D015458|D016399
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,AraG,cyclophosphamide,C104457,D003520
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,AraG,CPM,C104457,D003520
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,AraG,etoposide,C104457,D005047
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,AraG,VP,C104457,D005047
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,nelarabine,AraG,C104457,C104457
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,nelarabine,T-cell leukaemia or lymphoma,C104457,D015458|D016399
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,nelarabine,cyclophosphamide,C104457,D003520
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,nelarabine,CPM,C104457,D003520
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,nelarabine,etoposide,C104457,D005047
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,nelarabine,VP,C104457,D005047
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,T-cell leukaemia or lymphoma,AraG,D015458|D016399,C104457
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,T-cell leukaemia or lymphoma,nelarabine,D015458|D016399,C104457
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,T-cell leukaemia or lymphoma,cyclophosphamide,D015458|D016399,D003520
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,T-cell leukaemia or lymphoma,CPM,D015458|D016399,D003520
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,T-cell leukaemia or lymphoma,etoposide,D015458|D016399,D005047
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,T-cell leukaemia or lymphoma,VP,D015458|D016399,D005047
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,cyclophosphamide,AraG,D003520,C104457
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,cyclophosphamide,nelarabine,D003520,C104457
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,cyclophosphamide,T-cell leukaemia or lymphoma,D003520,D015458|D016399
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,cyclophosphamide,CPM,D003520,D003520
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,cyclophosphamide,etoposide,D003520,D005047
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,cyclophosphamide,VP,D003520,D005047
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,CPM,AraG,D003520,C104457
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,CPM,nelarabine,D003520,C104457
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,CPM,T-cell leukaemia or lymphoma,D003520,D015458|D016399
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,CPM,cyclophosphamide,D003520,D003520
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,CPM,etoposide,D003520,D005047
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,CPM,VP,D003520,D005047
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,etoposide,AraG,D005047,C104457
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,etoposide,nelarabine,D005047,C104457
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,etoposide,T-cell leukaemia or lymphoma,D005047,D015458|D016399
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,etoposide,cyclophosphamide,D005047,D003520
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,etoposide,CPM,D005047,D003520
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,etoposide,VP,D005047,D005047
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,VP,AraG,D005047,C104457
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,VP,nelarabine,D005047,C104457
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,VP,T-cell leukaemia or lymphoma,D005047,D015458|D016399
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,VP,cyclophosphamide,D005047,D003520
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,VP,CPM,D005047,D003520
20528871,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma,VP,etoposide,D005047,D005047
20528871,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain,AraG,musculoskeletal pain,C104457,D059352
20528871,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain,AraG,neuropathy,C104457,D009422
20528871,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain,musculoskeletal pain,AraG,D059352,C104457
20528871,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain,neuropathy,AraG,D009422,C104457
20528871,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies",AraG,Haematological toxicity,C104457,D006402
20528871,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies",Haematological toxicity,AraG,D006402,C104457
20528871,All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/VP/CPM,AraG,VP,C104457,D005047
20528871,All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/VP/CPM,AraG,CPM,C104457,D003520
20528871,All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/VP/CPM,VP,AraG,D005047,C104457
20528871,All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/VP/CPM,VP,CPM,D005047,D003520
20528871,All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/VP/CPM,CPM,AraG,D003520,C104457
20528871,All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/VP/CPM,CPM,VP,D003520,D005047
20528871,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",neurological toxicity,AraG,D009422,C104457
20528871,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",neurological toxicity,cyclophosphamide,D009422,D003520
20528871,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",neurological toxicity,etoposide,D009422,D005047
20528871,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",AraG,neurological toxicity,C104457,D009422
20528871,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",AraG,cyclophosphamide,C104457,D003520
20528871,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",AraG,etoposide,C104457,D005047
20528871,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",cyclophosphamide,neurological toxicity,D003520,D009422
20528871,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",cyclophosphamide,AraG,D003520,C104457
20528871,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",cyclophosphamide,etoposide,D003520,D005047
20528871,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",etoposide,neurological toxicity,D005047,D009422
20528871,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",etoposide,AraG,D005047,C104457
20528871,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",etoposide,cyclophosphamide,D005047,D003520
20648600,High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B,co-infected with HIV and hepatitis B,lamivudine,"D006509,D015658",D019259
20648600,High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B,lamivudine,co-infected with HIV and hepatitis B,D019259,"D006509,D015658"
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),lamivudine,co-infected with HIV and hepatitis B,D019259,"D006509,D015658"
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),lamivudine,tenofovir,D019259,D000068698
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),lamivudine,TDF,D019259,D000068698
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),lamivudine,co-infected with HIV and hepatitis B virus,D019259,"D006509,D015658"
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),lamivudine,LAM,D019259,D019259
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),co-infected with HIV and hepatitis B,lamivudine,"D006509,D015658",D019259
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),co-infected with HIV and hepatitis B,tenofovir,"D006509,D015658",D000068698
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),co-infected with HIV and hepatitis B,TDF,"D006509,D015658",D000068698
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),co-infected with HIV and hepatitis B,LAM,"D006509,D015658",D019259
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),tenofovir,lamivudine,D000068698,D019259
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),tenofovir,co-infected with HIV and hepatitis B,D000068698,"D006509,D015658"
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),tenofovir,TDF,D000068698,D000068698
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),tenofovir,co-infected with HIV and hepatitis B virus,D000068698,"D006509,D015658"
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),tenofovir,LAM,D000068698,D019259
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),TDF,lamivudine,D000068698,D019259
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),TDF,co-infected with HIV and hepatitis B,D000068698,"D006509,D015658"
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),TDF,tenofovir,D000068698,D000068698
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),TDF,co-infected with HIV and hepatitis B virus,D000068698,"D006509,D015658"
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),TDF,LAM,D000068698,D019259
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),co-infected with HIV and hepatitis B virus,lamivudine,"D006509,D015658",D019259
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),co-infected with HIV and hepatitis B virus,tenofovir,"D006509,D015658",D000068698
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),co-infected with HIV and hepatitis B virus,TDF,"D006509,D015658",D000068698
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),co-infected with HIV and hepatitis B virus,LAM,"D006509,D015658",D019259
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),LAM,lamivudine,D019259,D019259
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),LAM,co-infected with HIV and hepatitis B,D019259,"D006509,D015658"
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),LAM,tenofovir,D019259,D000068698
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),LAM,TDF,D019259,D000068698
20648600,This study analyzed the genotype distribution and frequency of lamivudine (LAM) and tenofovir (TDF) resistance mutations in a group of patients co-infected with HIV and hepatitis B virus (HBV),LAM,co-infected with HIV and hepatitis B virus,D019259,"D006509,D015658"
20648600,Eighteen patients were treated with LAM and six patients were treated with LAM plus TDF,TDF,LAM,D000068698,D019259
20648600,Eighteen patients were treated with LAM and six patients were treated with LAM plus TDF,LAM,TDF,D019259,D000068698
20648600,The length of exposure to LAM and TDF varied from 4 to 216 months,TDF,LAM,D000068698,D019259
20648600,The length of exposure to LAM and TDF varied from 4 to 216 months,LAM,TDF,D019259,D000068698
20648600,LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia,viremia,L180M,D014766,p|SUB|L|180|M
20648600,LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia,viremia,LAM,D014766,D019259
20648600,LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia,viremia,M204V,D014766,p|SUB|M|204|V
20648600,LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia,L180M,viremia,p|SUB|L|180|M,D014766
20648600,LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia,L180M,LAM,p|SUB|L|180|M,D019259
20648600,LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia,L180M,M204V,p|SUB|L|180|M,p|SUB|M|204|V
20648600,LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia,LAM,viremia,D019259,D014766
20648600,LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia,LAM,L180M,D019259,p|SUB|L|180|M
20648600,LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia,LAM,M204V,D019259,p|SUB|M|204|V
20648600,LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia,M204V,viremia,p|SUB|M|204|V,D014766
20648600,LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia,M204V,L180M,p|SUB|M|204|V,p|SUB|L|180|M
20648600,LAM resistance substitutions (rtL180M + rtM204V) were detected in 10 (50%) of the 20 patients with viremia,M204V,LAM,p|SUB|M|204|V,D019259
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),envelope,I195M,944569,p|SUB|I|195|M
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),envelope,L180M,944569,p|SUB|L|180|M
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),envelope,polymerase,944569,944565
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),envelope,E164D,944569,p|SUB|E|164|D
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),envelope,V173L,944569,p|SUB|V|173|L
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),envelope,M204V,944569,p|SUB|M|204|V
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),I195M,envelope,p|SUB|I|195|M,944569
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),I195M,L180M,p|SUB|I|195|M,p|SUB|L|180|M
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),I195M,polymerase,p|SUB|I|195|M,944565
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),I195M,E164D,p|SUB|I|195|M,p|SUB|E|164|D
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),I195M,V173L,p|SUB|I|195|M,p|SUB|V|173|L
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),I195M,M204V,p|SUB|I|195|M,p|SUB|M|204|V
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),L180M,envelope,p|SUB|L|180|M,944569
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),L180M,I195M,p|SUB|L|180|M,p|SUB|I|195|M
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),L180M,polymerase,p|SUB|L|180|M,944565
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),L180M,E164D,p|SUB|L|180|M,p|SUB|E|164|D
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),L180M,V173L,p|SUB|L|180|M,p|SUB|V|173|L
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),L180M,M204V,p|SUB|L|180|M,p|SUB|M|204|V
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),polymerase,envelope,944565,944569
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),polymerase,I195M,944565,p|SUB|I|195|M
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),polymerase,L180M,944565,p|SUB|L|180|M
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),polymerase,E164D,944565,p|SUB|E|164|D
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),polymerase,V173L,944565,p|SUB|V|173|L
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),polymerase,M204V,944565,p|SUB|M|204|V
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),E164D,envelope,p|SUB|E|164|D,944569
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),E164D,I195M,p|SUB|E|164|D,p|SUB|I|195|M
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),E164D,L180M,p|SUB|E|164|D,p|SUB|L|180|M
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),E164D,polymerase,p|SUB|E|164|D,944565
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),E164D,V173L,p|SUB|E|164|D,p|SUB|V|173|L
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),E164D,M204V,p|SUB|E|164|D,p|SUB|M|204|V
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),V173L,envelope,p|SUB|V|173|L,944569
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),V173L,I195M,p|SUB|V|173|L,p|SUB|I|195|M
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),V173L,L180M,p|SUB|V|173|L,p|SUB|L|180|M
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),V173L,polymerase,p|SUB|V|173|L,944565
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),V173L,E164D,p|SUB|V|173|L,p|SUB|E|164|D
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),V173L,M204V,p|SUB|V|173|L,p|SUB|M|204|V
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),M204V,envelope,p|SUB|M|204|V,944569
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),M204V,I195M,p|SUB|M|204|V,p|SUB|I|195|M
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),M204V,L180M,p|SUB|M|204|V,p|SUB|L|180|M
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),M204V,polymerase,p|SUB|M|204|V,944565
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),M204V,E164D,p|SUB|M|204|V,p|SUB|E|164|D
20648600,Three patients with the triple polymerase substitution pattern (rtV173L + rtL180M + rtM204V) had associated changes in the envelope gene (sE164D + sI195M),M204V,V173L,p|SUB|M|204|V,p|SUB|V|173|L
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",G1764A,G1899A,g|SUB|G|1764|A,g|SUB|G|1899|A
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",G1764A,precore,g|SUB|G|1764|A,944568
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",G1764A,G1896A,g|SUB|G|1764|A,g|SUB|G|1896|A
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",G1764A,A1762T,g|SUB|G|1764|A,g|SUB|A|1762|T
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",G1899A,G1764A,g|SUB|G|1899|A,g|SUB|G|1764|A
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",G1899A,precore,g|SUB|G|1899|A,944568
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",G1899A,G1896A,g|SUB|G|1899|A,g|SUB|G|1896|A
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",G1899A,A1762T,g|SUB|G|1899|A,g|SUB|A|1762|T
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",precore,G1764A,944568,g|SUB|G|1764|A
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",precore,G1899A,944568,g|SUB|G|1899|A
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",precore,G1896A,944568,g|SUB|G|1896|A
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",precore,A1762T,944568,g|SUB|A|1762|T
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",G1896A,G1764A,g|SUB|G|1896|A,g|SUB|G|1764|A
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",G1896A,G1899A,g|SUB|G|1896|A,g|SUB|G|1899|A
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",G1896A,precore,g|SUB|G|1896|A,944568
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",G1896A,A1762T,g|SUB|G|1896|A,g|SUB|A|1762|T
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",A1762T,G1764A,g|SUB|A|1762|T,g|SUB|G|1764|A
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",A1762T,G1899A,g|SUB|A|1762|T,g|SUB|G|1899|A
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",A1762T,precore,g|SUB|A|1762|T,944568
20648600,"Mutations in the BCP region (A1762T, G1764A) and in the precore region (G1896A, G1899A) were also found",A1762T,G1896A,g|SUB|A|1762|T,g|SUB|G|1896|A
20683499,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats",streptozocin,Alzheimer's disease,D013311,D000544
20683499,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats",streptozocin,crocin,D013311,C029036
20683499,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats",streptozocin,constituents of Crocus sativus L.,D013311,D010936
20683499,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats",Alzheimer's disease,streptozocin,D000544,D013311
20683499,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats",Alzheimer's disease,crocin,D000544,C029036
20683499,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats",Alzheimer's disease,constituents of Crocus sativus L.,D000544,D010936
20683499,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats",crocin,streptozocin,C029036,D013311
20683499,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats",crocin,Alzheimer's disease,C029036,D000544
20683499,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats",crocin,constituents of Crocus sativus L.,C029036,D010936
20683499,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats",constituents of Crocus sativus L.,streptozocin,D010936,D013311
20683499,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats",constituents of Crocus sativus L.,Alzheimer's disease,D010936,D000544
20683499,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats",constituents of Crocus sativus L.,crocin,D010936,C029036
20683499,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L",crocin,carotenoids,C029036,D002338
20683499,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L",crocin,crocins,C029036,C029036
20683499,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L",carotenoids,crocin,D002338,C029036
20683499,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L",carotenoids,crocins,D002338,C029036
20683499,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L",crocins,crocin,C029036,C029036
20683499,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L",crocins,carotenoids,C029036,D002338
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",streptozocin,crocins,D013311,C029036
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",streptozocin,Alzheimer's disease,D013311,D000544
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",streptozocin,crocin,D013311,C029036
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",streptozocin,STZ,D013311,D013311
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",crocins,streptozocin,C029036,D013311
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",crocins,Alzheimer's disease,C029036,D000544
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",crocins,crocin,C029036,C029036
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",crocins,STZ,C029036,D013311
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",Alzheimer's disease,streptozocin,D000544,D013311
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",Alzheimer's disease,crocins,D000544,C029036
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",Alzheimer's disease,crocin,D000544,C029036
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",Alzheimer's disease,STZ,D000544,D013311
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",crocin,streptozocin,C029036,D013311
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",crocin,crocins,C029036,C029036
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",crocin,Alzheimer's disease,C029036,D000544
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",crocin,STZ,C029036,D013311
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",STZ,streptozocin,D013311,D013311
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",STZ,crocins,D013311,C029036
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",STZ,Alzheimer's disease,D013311,D000544
20683499,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated",STZ,crocin,D013311,C029036
20683499,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups",crocin,crocins,C029036,C029036
20683499,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups",crocin,STZ,C029036,D013311
20683499,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups",crocins,crocin,C029036,C029036
20683499,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups",crocins,STZ,C029036,D013311
20683499,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups",STZ,crocin,D013311,C029036
20683499,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups",STZ,crocins,D013311,C029036
20683499,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated",STZ,Alzheimer's disease,D013311,D000544
20683499,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated",Alzheimer's disease,STZ,D000544,D013311
20683499,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks",crocin,STZ,C029036,D013311
20683499,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks",STZ,crocin,D013311,C029036
20683499,RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats,crocin,STZ,C029036,D013311
20683499,RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats,STZ,crocin,D013311,C029036
20683499,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test",crocin,learning and memory impairment,C029036,"D007859,D008569"
20683499,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test",crocin,STZ,C029036,D013311
20683499,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test",learning and memory impairment,crocin,"D007859,D008569",C029036
20683499,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test",learning and memory impairment,STZ,"D007859,D008569",D013311
20683499,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test",STZ,crocin,D013311,C029036
20683499,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test",STZ,learning and memory impairment,D013311,"D007859,D008569"
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",Alzheimer's disease,crocin,D000544,C029036
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",Alzheimer's disease,STZ,D000544,D013311
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",cognitive deficits,crocin,D003072,C029036
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",cognitive deficits,STZ,D003072,D013311
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",crocin,Alzheimer's disease,C029036,D000544
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",crocin,cognitive deficits,C029036,D003072
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",crocin,neurodegenerative diseases,C029036,D019636
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",crocin,STZ,C029036,D013311
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",neurodegenerative diseases,crocin,D019636,C029036
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",neurodegenerative diseases,STZ,D019636,D013311
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",STZ,Alzheimer's disease,D013311,D000544
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",STZ,cognitive deficits,D013311,D003072
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",STZ,crocin,D013311,C029036
20683499,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",STZ,neurodegenerative diseases,D013311,D019636
20806042,A novel mutation in GJA8 causing congenital cataract-microcornea syndrome in a Chinese pedigree,microcornea,GJA8,D005124,2703
20806042,A novel mutation in GJA8 causing congenital cataract-microcornea syndrome in a Chinese pedigree,cataract,GJA8,D002386,2703
20806042,A novel mutation in GJA8 causing congenital cataract-microcornea syndrome in a Chinese pedigree,GJA8,microcornea,2703,D005124
20806042,A novel mutation in GJA8 causing congenital cataract-microcornea syndrome in a Chinese pedigree,GJA8,cataract,2703,D002386
20806042,A novel mutation in GJA8 causing congenital cataract-microcornea syndrome in a Chinese pedigree,GJA8,cataract-microcornea syndrome,2703,C538287
20806042,A novel mutation in GJA8 causing congenital cataract-microcornea syndrome in a Chinese pedigree,cataract-microcornea syndrome,GJA8,C538287,2703
20806042,"RESULTS: Direct sequencing of the encoding regions of the candidate genes revealed a heterozygous mutation c.592C-->T in exon 2 of the gap junction protein, alpha 8 (GJA8) gene","gap junction protein, alpha 8",c.592C-->T,2703,c|SUB|C|592|T
20806042,"RESULTS: Direct sequencing of the encoding regions of the candidate genes revealed a heterozygous mutation c.592C-->T in exon 2 of the gap junction protein, alpha 8 (GJA8) gene","gap junction protein, alpha 8",GJA8,2703,2703
20806042,"RESULTS: Direct sequencing of the encoding regions of the candidate genes revealed a heterozygous mutation c.592C-->T in exon 2 of the gap junction protein, alpha 8 (GJA8) gene",c.592C-->T,"gap junction protein, alpha 8",c|SUB|C|592|T,2703
20806042,"RESULTS: Direct sequencing of the encoding regions of the candidate genes revealed a heterozygous mutation c.592C-->T in exon 2 of the gap junction protein, alpha 8 (GJA8) gene",c.592C-->T,GJA8,c|SUB|C|592|T,2703
20806042,"RESULTS: Direct sequencing of the encoding regions of the candidate genes revealed a heterozygous mutation c.592C-->T in exon 2 of the gap junction protein, alpha 8 (GJA8) gene",GJA8,"gap junction protein, alpha 8",2703,2703
20806042,"RESULTS: Direct sequencing of the encoding regions of the candidate genes revealed a heterozygous mutation c.592C-->T in exon 2 of the gap junction protein, alpha 8 (GJA8) gene",GJA8,c.592C-->T,2703,c|SUB|C|592|T
20806042,This mutation was responsible for the familial disorder through the substitution of a highly conserved arginine to tryptophan at codon 198 (p.R198W),arginine to tryptophan at codon 198,p.R198W,p|SUB|R|198|W,p|SUB|R|198|W
20806042,This mutation was responsible for the familial disorder through the substitution of a highly conserved arginine to tryptophan at codon 198 (p.R198W),p.R198W,arginine to tryptophan at codon 198,p|SUB|R|198|W,p|SUB|R|198|W
20806042,CONCLUSIONS: This report is the first to relate p.R198W mutation in GJA8 with CCMC,CCMC,p.R198W,C538287,p|SUB|R|198|W
20806042,CONCLUSIONS: This report is the first to relate p.R198W mutation in GJA8 with CCMC,CCMC,GJA8,C538287,2703
20806042,CONCLUSIONS: This report is the first to relate p.R198W mutation in GJA8 with CCMC,p.R198W,CCMC,p|SUB|R|198|W,C538287
20806042,CONCLUSIONS: This report is the first to relate p.R198W mutation in GJA8 with CCMC,p.R198W,GJA8,p|SUB|R|198|W,2703
20806042,CONCLUSIONS: This report is the first to relate p.R198W mutation in GJA8 with CCMC,GJA8,CCMC,2703,C538287
20806042,CONCLUSIONS: This report is the first to relate p.R198W mutation in GJA8 with CCMC,GJA8,p.R198W,2703,p|SUB|R|198|W
20806042,"The result expands the mutation spectrum of GJA8 in associated with congenital cataract and microcornea, and implies that this gene has direct involvement with the development of the lens as well as the other anterior segment of the eye.",microcornea,GJA8,D005124,2703
20806042,"The result expands the mutation spectrum of GJA8 in associated with congenital cataract and microcornea, and implies that this gene has direct involvement with the development of the lens as well as the other anterior segment of the eye.",cataract,GJA8,D002386,2703
20806042,"The result expands the mutation spectrum of GJA8 in associated with congenital cataract and microcornea, and implies that this gene has direct involvement with the development of the lens as well as the other anterior segment of the eye.",GJA8,microcornea,2703,D005124
20806042,"The result expands the mutation spectrum of GJA8 in associated with congenital cataract and microcornea, and implies that this gene has direct involvement with the development of the lens as well as the other anterior segment of the eye.",GJA8,cataract,2703,D002386
21496008,Screening and cell-based assessment of mutations in the Aristaless-related homeobox (ARX) gene,ARX,Aristaless-related homeobox,170302,170302
21496008,Screening and cell-based assessment of mutations in the Aristaless-related homeobox (ARX) gene,Aristaless-related homeobox,ARX,170302,170302
21496008,"ARX mutations cause a diverse spectrum of human disorders, ranging from severe brain and genital malformations to non-syndromic intellectual disability (ID)",ID,ARX,D008607,170302
21496008,"ARX mutations cause a diverse spectrum of human disorders, ranging from severe brain and genital malformations to non-syndromic intellectual disability (ID)",ARX,ID,170302,D008607
21496008,"ARX mutations cause a diverse spectrum of human disorders, ranging from severe brain and genital malformations to non-syndromic intellectual disability (ID)",ARX,brain and genital malformations,170302,D000013
21496008,"ARX mutations cause a diverse spectrum of human disorders, ranging from severe brain and genital malformations to non-syndromic intellectual disability (ID)",ARX,intellectual disability,170302,D008607
21496008,"ARX mutations cause a diverse spectrum of human disorders, ranging from severe brain and genital malformations to non-syndromic intellectual disability (ID)",brain and genital malformations,ARX,D000013,170302
21496008,"ARX mutations cause a diverse spectrum of human disorders, ranging from severe brain and genital malformations to non-syndromic intellectual disability (ID)",intellectual disability,ARX,D008607,170302
21496008,"ARX is a transcription factor with multiple domains that include four polyalanine (pA) tracts, the first two of which are frequently expanded by mutations",polyalanine,ARX,C019529,170302
21496008,"ARX is a transcription factor with multiple domains that include four polyalanine (pA) tracts, the first two of which are frequently expanded by mutations",polyalanine,pA,C019529,C019529
21496008,"ARX is a transcription factor with multiple domains that include four polyalanine (pA) tracts, the first two of which are frequently expanded by mutations",ARX,polyalanine,170302,C019529
21496008,"ARX is a transcription factor with multiple domains that include four polyalanine (pA) tracts, the first two of which are frequently expanded by mutations",ARX,pA,170302,C019529
21496008,"ARX is a transcription factor with multiple domains that include four polyalanine (pA) tracts, the first two of which are frequently expanded by mutations",pA,polyalanine,C019529,C019529
21496008,"ARX is a transcription factor with multiple domains that include four polyalanine (pA) tracts, the first two of which are frequently expanded by mutations",pA,ARX,C019529,170302
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),pA,c.304ins(GCG)(7),C019529,c|INS|304|GCG(7)
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),pA,ID,C019529,D008607
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),pA,dup24bp,C019529,c|DUP||24|
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),pA,c.429_452dup,C019529,c|DUP|429_452||
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),pA,ARX,C019529,170302
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),c.304ins(GCG)(7),pA,c|INS|304|GCG(7),C019529
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),c.304ins(GCG)(7),ID,c|INS|304|GCG(7),D008607
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),c.304ins(GCG)(7),dup24bp,c|INS|304|GCG(7),c|DUP||24|
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),c.304ins(GCG)(7),c.429_452dup,c|INS|304|GCG(7),c|DUP|429_452||
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),c.304ins(GCG)(7),ARX,c|INS|304|GCG(7),170302
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),ID,pA,D008607,C019529
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),ID,c.304ins(GCG)(7),D008607,c|INS|304|GCG(7)
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),ID,dup24bp,D008607,c|DUP||24|
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),ID,c.429_452dup,D008607,c|DUP|429_452||
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),ID,ARX,D008607,170302
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),dup24bp,pA,c|DUP||24|,C019529
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),dup24bp,c.304ins(GCG)(7),c|DUP||24|,c|INS|304|GCG(7)
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),dup24bp,ID,c|DUP||24|,D008607
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),dup24bp,c.429_452dup,c|DUP||24|,c|DUP|429_452||
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),dup24bp,ARX,c|DUP||24|,170302
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),c.429_452dup,pA,c|DUP|429_452||,C019529
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),c.429_452dup,c.304ins(GCG)(7),c|DUP|429_452||,c|INS|304|GCG(7)
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),c.429_452dup,ID,c|DUP|429_452||,D008607
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),c.429_452dup,dup24bp,c|DUP|429_452||,c|DUP||24|
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),c.429_452dup,ARX,c|DUP|429_452||,170302
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),ARX,pA,170302,C019529
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),ARX,c.304ins(GCG)(7),170302,c|INS|304|GCG(7)
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),ARX,ID,170302,D008607
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),ARX,dup24bp,170302,c|DUP||24|
21496008,We progressively screened DNA samples from 613 individuals with ID initially for the most frequent ARX mutations (c.304ins(GCG)(7)'expansion' of pA1 and c.429_452dup 'dup24bp' of pA2),ARX,c.429_452dup,170302,c|DUP|429_452||
21496008,Five hundred samples without pA1 or pA2 mutations had the entire ARX ORF screened by single stranded polymorphism conformation (SSCP) and/or denaturing high pressure liquid chromatography (dHPLC) analysis,ARX,pA,170302,C019529
21496008,Five hundred samples without pA1 or pA2 mutations had the entire ARX ORF screened by single stranded polymorphism conformation (SSCP) and/or denaturing high pressure liquid chromatography (dHPLC) analysis,pA,ARX,C019529,170302
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",pA,dup33bp,C019529,c|DUP||33|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",pA,dup24bp,C019529,c|DUP||24|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",pA,dup27bp,C019529,c|DUP||27|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",pA,ARX,C019529,170302
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",pA,c.1074G>T,C019529,c|SUB|G|1074|T
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup33bp,pA,c|DUP||33|,C019529
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup33bp,dup24bp,c|DUP||33|,c|DUP||24|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup33bp,dup27bp,c|DUP||33|,c|DUP||27|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup33bp,ARX,c|DUP||33|,170302
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup33bp,c.1074G>T,c|DUP||33|,c|SUB|G|1074|T
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup24bp,pA,c|DUP||24|,C019529
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup24bp,dup33bp,c|DUP||24|,c|DUP||33|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup24bp,dup27bp,c|DUP||24|,c|DUP||27|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup24bp,ARX,c|DUP||24|,170302
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup24bp,c.1074G>T,c|DUP||24|,c|SUB|G|1074|T
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup27bp,pA,c|DUP||27|,C019529
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup27bp,dup33bp,c|DUP||27|,c|DUP||33|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup27bp,dup24bp,c|DUP||27|,c|DUP||24|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup27bp,ARX,c|DUP||27|,170302
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",dup27bp,c.1074G>T,c|DUP||27|,c|SUB|G|1074|T
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",ARX,pA,170302,C019529
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",ARX,dup33bp,170302,c|DUP||33|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",ARX,dup24bp,170302,c|DUP||24|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",ARX,dup27bp,170302,c|DUP||27|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",ARX,c.1074G>T,170302,c|SUB|G|1074|T
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",c.1074G>T,pA,c|SUB|G|1074|T,C019529
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",c.1074G>T,dup33bp,c|SUB|G|1074|T,c|DUP||33|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",c.1074G>T,dup24bp,c|SUB|G|1074|T,c|DUP||24|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",c.1074G>T,dup27bp,c|SUB|G|1074|T,c|DUP||27|
21496008,"Overall, eight families with six mutations in ARX were identified (1.31%): five duplication mutations in pA2 (0.82%) with three new clinical reports of families with the dup24bp and two duplications larger than the dup24bp mutation discovered (dup27bp, dup33bp); and three point mutations (0.6%), including one novel mutation in the homeodomain (c.1074G>T)",c.1074G>T,ARX,c|SUB|G|1074|T,170302
21699520,PTCH1 gene mutations in exon 17 and loss of heterozygosity on D9S180 microsatellite in sporadic and inherited human basal cell carcinomas,basal cell carcinomas,PTCH1,D002280,5727
21699520,PTCH1 gene mutations in exon 17 and loss of heterozygosity on D9S180 microsatellite in sporadic and inherited human basal cell carcinomas,PTCH1,basal cell carcinomas,5727,D002280
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",tumor,PTCH1,D009369,5727
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",tumor,PTCH2,D009369,8643
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",PTCH1,tumor,5727,D009369
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",PTCH1,PTCH2,5727,8643
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",PTCH1,BCC,5727,D002280
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",PTCH1,BCCs,5727,D002280
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",PTCH2,tumor,8643,D009369
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",PTCH2,PTCH1,8643,5727
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",PTCH2,BCC,8643,D002280
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",PTCH2,BCCs,8643,D002280
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",BCC,PTCH1,D002280,5727
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",BCC,PTCH2,D002280,8643
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",BCCs,PTCH1,D002280,5727
21699520,"Both sporadic and inherited BCCs are associated with mutations in the tumor suppressor gene PTCH1, but there is still uncertainty on the role of its homolog PTCH2",BCCs,PTCH2,D002280,8643
21699520,METHODS: DNA obtained from leukocytes and tumor cells was amplified by polymerase chain reaction regarding five exons of PTCH1 and PTCH2 and neighboring microsatellites,tumor,PTCH1,D009369,5727
21699520,METHODS: DNA obtained from leukocytes and tumor cells was amplified by polymerase chain reaction regarding five exons of PTCH1 and PTCH2 and neighboring microsatellites,tumor,PTCH2,D009369,8643
21699520,METHODS: DNA obtained from leukocytes and tumor cells was amplified by polymerase chain reaction regarding five exons of PTCH1 and PTCH2 and neighboring microsatellites,PTCH1,tumor,5727,D009369
21699520,METHODS: DNA obtained from leukocytes and tumor cells was amplified by polymerase chain reaction regarding five exons of PTCH1 and PTCH2 and neighboring microsatellites,PTCH1,PTCH2,5727,8643
21699520,METHODS: DNA obtained from leukocytes and tumor cells was amplified by polymerase chain reaction regarding five exons of PTCH1 and PTCH2 and neighboring microsatellites,PTCH2,tumor,8643,D009369
21699520,METHODS: DNA obtained from leukocytes and tumor cells was amplified by polymerase chain reaction regarding five exons of PTCH1 and PTCH2 and neighboring microsatellites,PTCH2,PTCH1,8643,5727
21699520,"One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein",PTCH1,p.R962T,5727,p|SUB|R|962|T
21699520,"One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein",PTCH1,g.2885G>C,5727,g|SUB|G|2885|C
21699520,"One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein",PTCH1,BCC,5727,D002280
21699520,"One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein",p.R962T,PTCH1,p|SUB|R|962|T,5727
21699520,"One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein",p.R962T,g.2885G>C,p|SUB|R|962|T,g|SUB|G|2885|C
21699520,"One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein",p.R962T,BCC,p|SUB|R|962|T,D002280
21699520,"One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein",g.2885G>C,PTCH1,g|SUB|G|2885|C,5727
21699520,"One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein",g.2885G>C,p.R962T,g|SUB|G|2885|C,p|SUB|R|962|T
21699520,"One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein",g.2885G>C,BCC,g|SUB|G|2885|C,D002280
21699520,"One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein",BCC,PTCH1,D002280,5727
21699520,"One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein",BCC,p.R962T,D002280,p|SUB|R|962|T
21699520,"One sporadic BCC presented the mutation g.2885G>C in exon 17 of PTCH1, which predicts the substitution p.R962T in an external domain of the protein",BCC,g.2885G>C,D002280,g|SUB|G|2885|C
21699520,"In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein",tumor,g.2839T>G,D009369,g|SUB|T|2839|G
21699520,"In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein",tumor,p.E947stop,D009369,p|SUB|E|947|X
21699520,"In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein",g.2839T>G,tumor,g|SUB|T|2839|G,D009369
21699520,"In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein",g.2839T>G,p.E947stop,g|SUB|T|2839|G,p|SUB|E|947|X
21699520,"In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein",g.2839T>G,Gorlin syndrome,g|SUB|T|2839|G,D001478
21699520,"In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein",p.E947stop,tumor,p|SUB|E|947|X,D009369
21699520,"In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein",p.E947stop,g.2839T>G,p|SUB|E|947|X,g|SUB|T|2839|G
21699520,"In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein",p.E947stop,Gorlin syndrome,p|SUB|E|947|X,D001478
21699520,"In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein",Gorlin syndrome,g.2839T>G,D001478,g|SUB|T|2839|G
21699520,"In addition, the leukocytes and tumor cells of one patient with Gorlin syndrome showed the mutation g.2839T>G in the same exon and gene, which predicts a p.E947stop and truncated protein",Gorlin syndrome,p.E947stop,D001478,p|SUB|E|947|X
21699520,All control and tumor samples presented IVS9 + 217T in intron 9 of PTCH1,tumor,PTCH1,D009369,5727
21699520,All control and tumor samples presented IVS9 + 217T in intron 9 of PTCH1,tumor,IVS9 + 217T,D009369,c|Allele|T|IVS9+217
21699520,All control and tumor samples presented IVS9 + 217T in intron 9 of PTCH1,PTCH1,tumor,5727,D009369
21699520,All control and tumor samples presented IVS9 + 217T in intron 9 of PTCH1,PTCH1,IVS9 + 217T,5727,c|Allele|T|IVS9+217
21699520,All control and tumor samples presented IVS9 + 217T in intron 9 of PTCH1,IVS9 + 217T,tumor,c|Allele|T|IVS9+217,D009369
21699520,All control and tumor samples presented IVS9 + 217T in intron 9 of PTCH1,IVS9 + 217T,PTCH1,c|Allele|T|IVS9+217,5727
21699520,CONCLUSION: Mutations found in the PTCH1 gene and neighboring repetitive sequences may have contributed to the development of the studied BCCs.,PTCH1,BCCs,5727,D002280
21699520,CONCLUSION: Mutations found in the PTCH1 gene and neighboring repetitive sequences may have contributed to the development of the studied BCCs.,PTCH1,BCC,5727,D002280
21699520,CONCLUSION: Mutations found in the PTCH1 gene and neighboring repetitive sequences may have contributed to the development of the studied BCCs.,BCCs,PTCH1,D002280,5727
21699520,CONCLUSION: Mutations found in the PTCH1 gene and neighboring repetitive sequences may have contributed to the development of the studied BCCs.,BCC,PTCH1,D002280,5727
21799811,Strong association of 677 C>T substitution in the MTHFR gene with male infertility--a study on an indian population and a meta-analysis,MTHFR,male infertility,4524,D007248
21799811,Strong association of 677 C>T substitution in the MTHFR gene with male infertility--a study on an indian population and a meta-analysis,MTHFR,677 C>T,4524,rs1801133
21799811,Strong association of 677 C>T substitution in the MTHFR gene with male infertility--a study on an indian population and a meta-analysis,male infertility,MTHFR,D007248,4524
21799811,Strong association of 677 C>T substitution in the MTHFR gene with male infertility--a study on an indian population and a meta-analysis,male infertility,677 C>T,D007248,rs1801133
21799811,Strong association of 677 C>T substitution in the MTHFR gene with male infertility--a study on an indian population and a meta-analysis,677 C>T,MTHFR,rs1801133,4524
21799811,Strong association of 677 C>T substitution in the MTHFR gene with male infertility--a study on an indian population and a meta-analysis,677 C>T,male infertility,rs1801133,D007248
21799811,"BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation",MTHFR,Methylenetetrahydrofolate reductase,4524,4524
21799811,"BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation",MTHFR,folate,4524,D005492
21799811,"BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation",MTHFR,methionine,4524,D008715
21799811,"BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation",Methylenetetrahydrofolate reductase,MTHFR,4524,4524
21799811,"BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation",Methylenetetrahydrofolate reductase,folate,4524,D005492
21799811,"BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation",Methylenetetrahydrofolate reductase,methionine,4524,D008715
21799811,"BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation",folate,MTHFR,D005492,4524
21799811,"BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation",folate,Methylenetetrahydrofolate reductase,D005492,4524
21799811,"BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation",folate,methionine,D005492,D008715
21799811,"BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation",methionine,MTHFR,D008715,4524
21799811,"BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation",methionine,Methylenetetrahydrofolate reductase,D008715,4524
21799811,"BACKGROUND: Methylenetetrahydrofolate reductase (MTHFR) is an important enzyme of folate and methionine metabolism, making it crucial for DNA synthesis and methylation",methionine,folate,D008715,D005492
21799811,"The objective of this study was to analyze MTHFR gene 677C>T polymorphism in infertile male individuals from North India, followed by a meta-analysis on our data and published studies",MTHFR,677C>T,4524,rs1801133
21799811,"The objective of this study was to analyze MTHFR gene 677C>T polymorphism in infertile male individuals from North India, followed by a meta-analysis on our data and published studies",677C>T,MTHFR,rs1801133,4524
21799811,Those studies analyzing 677C>T polymorphism in male infertility and presenting all relevant data were included in meta-analysis,677C>T,male infertility,rs1801133,D007248
21799811,Those studies analyzing 677C>T polymorphism in male infertility and presenting all relevant data were included in meta-analysis,male infertility,677C>T,D007248,rs1801133
21799811,"The overall summary estimate (OR) for allele and genotype meta-analysis were 1.304 (p=0.000), 1.310 (p=0.000), respectively, establishing significant association of 677C>T polymorphism with male infertility",677C>T,male infertility,rs1801133,D007248
21799811,"The overall summary estimate (OR) for allele and genotype meta-analysis were 1.304 (p=0.000), 1.310 (p=0.000), respectively, establishing significant association of 677C>T polymorphism with male infertility",male infertility,677C>T,D007248,rs1801133
21799811,CONCLUSIONS/SIGNIFICANCE: 677C>T substitution associated strongly with male infertility in Indian population,677C>T,male infertility,rs1801133,D007248
21799811,CONCLUSIONS/SIGNIFICANCE: 677C>T substitution associated strongly with male infertility in Indian population,male infertility,677C>T,D007248,rs1801133
21810259,"HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner",Tat,"indoleamine 2,3 dioxygenase",155871,15930
21810259,"HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner",Tat,p38 mitogen-activated protein kinase,155871,26416
21810259,"HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner","indoleamine 2,3 dioxygenase",Tat,15930,155871
21810259,"HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner","indoleamine 2,3 dioxygenase",p38 mitogen-activated protein kinase,15930,26416
21810259,"HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner",p38 mitogen-activated protein kinase,Tat,26416,155871
21810259,"HIV-1 Tat activates indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures in a p38 mitogen-activated protein kinase-dependent manner",p38 mitogen-activated protein kinase,"indoleamine 2,3 dioxygenase",26416,15930
21810259,"BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior",tryptophan,"indoleamine 2,3 dioxygenase",D014364,15930
21810259,"BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior",tryptophan,depressive,D014364,D000275
21810259,"BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior",tryptophan,IDO,D014364,3620
21810259,"BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior","indoleamine 2,3 dioxygenase",tryptophan,15930,D014364
21810259,"BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior","indoleamine 2,3 dioxygenase",depressive,15930,D000275
21810259,"BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior","indoleamine 2,3 dioxygenase",IDO,15930,3620
21810259,"BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior",depressive,tryptophan,D000275,D014364
21810259,"BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior",depressive,"indoleamine 2,3 dioxygenase",D000275,15930
21810259,"BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior",depressive,IDO,D000275,3620
21810259,"BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior",IDO,tryptophan,3620,D014364
21810259,"BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior",IDO,"indoleamine 2,3 dioxygenase",3620,15930
21810259,"BACKGROUND: We have established that activation of the tryptophan degrading enzyme indoleamine 2,3 dioxygenase (IDO) mediates the switch from cytokine-induced sickness behavior to depressive-like behavior",IDO,depressive,3620,D000275
21810259,"Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice",depressive,Tat,D000275,155871
21810259,"Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice",depressive,IDO,D000275,3620
21810259,"Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice",Tat,depressive,155871,D000275
21810259,"Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice",Tat,IDO,155871,3620
21810259,"Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice",IDO,depressive,3620,D000275
21810259,"Because human immunodeficiency virus type 1 (HIV-1) Tat protein causes depressive-like behavior in mice, we investigated its ability to activate IDO in organotypic hippocampal slice cultures (OHSCs) derived from neonatal C57BL/6 mice",IDO,Tat,3620,155871
21810259,p38 MAPK phosphorylation was analyzed by western blot,p38 MAPK,MAPK,26416,26416
21810259,p38 MAPK phosphorylation was analyzed by western blot,MAPK,p38 MAPK,26416,26416
21810259,RESULTS: Intracerebroventricular (i.c.v.) administration of Tat (40 ng) induced depressive-like behavior in the absence of sickness,Tat,depressive,155871,D000275
21810259,RESULTS: Intracerebroventricular (i.c.v.) administration of Tat (40 ng) induced depressive-like behavior in the absence of sickness,depressive,Tat,D000275,155871
21810259,Addition of Tat (40 ng/slice) to the medium of OHSCs induced IDO steady-state mRNA that peaked at 6 h,Tat,IDO,155871,3620
21810259,Addition of Tat (40 ng/slice) to the medium of OHSCs induced IDO steady-state mRNA that peaked at 6 h,IDO,Tat,3620,155871
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),IL-6,inducible isoform of nitric oxide synthase,16193,18126
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),IL-6,serotonin transporter,16193,15567
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),IL-6,Tat,16193,155871
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),IL-6,SERT,16193,15567
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),IL-6,TNFa,16193,21926
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),IL-6,iNOS,16193,18126
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),inducible isoform of nitric oxide synthase,IL-6,18126,16193
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),inducible isoform of nitric oxide synthase,serotonin transporter,18126,15567
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),inducible isoform of nitric oxide synthase,Tat,18126,155871
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),inducible isoform of nitric oxide synthase,SERT,18126,15567
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),inducible isoform of nitric oxide synthase,TNFa,18126,21926
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),inducible isoform of nitric oxide synthase,iNOS,18126,18126
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),serotonin transporter,IL-6,15567,16193
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),serotonin transporter,inducible isoform of nitric oxide synthase,15567,18126
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),serotonin transporter,Tat,15567,155871
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),serotonin transporter,SERT,15567,15567
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),serotonin transporter,TNFa,15567,21926
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),serotonin transporter,iNOS,15567,18126
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),Tat,IL-6,155871,16193
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),Tat,inducible isoform of nitric oxide synthase,155871,18126
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),Tat,serotonin transporter,155871,15567
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),Tat,SERT,155871,15567
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),Tat,TNFa,155871,21926
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),Tat,iNOS,155871,18126
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),SERT,IL-6,15567,16193
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),SERT,inducible isoform of nitric oxide synthase,15567,18126
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),SERT,serotonin transporter,15567,15567
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),SERT,Tat,15567,155871
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),SERT,TNFa,15567,21926
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),SERT,iNOS,15567,18126
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),TNFa,IL-6,21926,16193
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),TNFa,inducible isoform of nitric oxide synthase,21926,18126
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),TNFa,serotonin transporter,21926,15567
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),TNFa,Tat,21926,155871
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),TNFa,SERT,21926,15567
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),TNFa,iNOS,21926,18126
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),iNOS,IL-6,18126,16193
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),iNOS,inducible isoform of nitric oxide synthase,18126,18126
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),iNOS,serotonin transporter,18126,15567
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),iNOS,Tat,18126,155871
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),iNOS,SERT,18126,15567
21810259,Tat also induced the synthesis and release of TNFa and IL-6 protein in the supernatant of the slices and increased expression of the inducible isoform of nitric oxide synthase (iNOS) and the serotonin transporter (SERT),iNOS,TNFa,18126,21926
21810259,Tat had no effect on endogenous synthesis of IFNg,Tat,IFNg,155871,15978
21810259,Tat had no effect on endogenous synthesis of IFNg,IFNg,Tat,15978,155871
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",MAPK,Tat,26416,155871
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",MAPK,IDO,26416,3620
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",MAPK,SB 202190,26416,C090942
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",MAPK,p38 mitogen-activated protein kinase,26416,26416
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",Tat,MAPK,155871,26416
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",Tat,IDO,155871,3620
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",Tat,SB 202190,155871,C090942
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",Tat,p38 mitogen-activated protein kinase,155871,26416
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",IDO,MAPK,3620,26416
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",IDO,Tat,3620,155871
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",IDO,SB 202190,3620,C090942
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",IDO,p38 mitogen-activated protein kinase,3620,26416
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",SB 202190,MAPK,C090942,26416
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",SB 202190,Tat,C090942,155871
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",SB 202190,IDO,C090942,3620
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",SB 202190,p38 mitogen-activated protein kinase,C090942,26416
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",p38 mitogen-activated protein kinase,MAPK,26416,26416
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",p38 mitogen-activated protein kinase,Tat,26416,155871
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",p38 mitogen-activated protein kinase,IDO,26416,3620
21810259,"To explore the mechanisms of Tat-induced IDO expression, slices were pretreated with the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 for 30 min before Tat treatment",p38 mitogen-activated protein kinase,SB 202190,26416,C090942
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",IL-6,Tat,16193,155871
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",IL-6,SERT,16193,15567
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",IL-6,IDO,16193,3620
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",IL-6,SB 202190,16193,C090942
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",IL-6,TNFa,16193,21926
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",IL-6,iNOS,16193,18126
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",Tat,IL-6,155871,16193
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",Tat,SERT,155871,15567
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",Tat,IDO,155871,3620
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",Tat,SB 202190,155871,C090942
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",Tat,TNFa,155871,21926
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",Tat,iNOS,155871,18126
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",SERT,IL-6,15567,16193
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",SERT,Tat,15567,155871
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",SERT,IDO,15567,3620
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",SERT,SB 202190,15567,C090942
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",SERT,TNFa,15567,21926
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",SERT,iNOS,15567,18126
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",IDO,IL-6,3620,16193
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",IDO,Tat,3620,155871
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",IDO,SERT,3620,15567
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",IDO,SB 202190,3620,C090942
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",IDO,TNFa,3620,21926
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",IDO,iNOS,3620,18126
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",SB 202190,IL-6,C090942,16193
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",SB 202190,Tat,C090942,155871
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",SB 202190,SERT,C090942,15567
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",SB 202190,IDO,C090942,3620
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",SB 202190,TNFa,C090942,21926
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",SB 202190,iNOS,C090942,18126
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",TNFa,IL-6,21926,16193
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",TNFa,Tat,21926,155871
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",TNFa,SERT,21926,15567
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",TNFa,IDO,21926,3620
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",TNFa,SB 202190,21926,C090942
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",TNFa,iNOS,21926,18126
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",iNOS,IL-6,18126,16193
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",iNOS,Tat,18126,155871
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",iNOS,SERT,18126,15567
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",iNOS,IDO,18126,3620
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",iNOS,SB 202190,18126,C090942
21810259,"SB 202190 significantly decreased IDO expression induced by Tat, and this effect was accompanied by a reduction of Tat-induced expression of TNFa, IL-6, iNOS and SERT",iNOS,TNFa,18126,21926
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,MAPK,p38 MAPK,26416,26416
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,MAPK,Tat,26416,155871
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,MAPK,IFNg,26416,15978
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,MAPK,IDO,26416,3620
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,p38 MAPK,MAPK,26416,26416
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,p38 MAPK,Tat,26416,155871
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,p38 MAPK,IFNg,26416,15978
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,p38 MAPK,IDO,26416,3620
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,Tat,MAPK,155871,26416
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,Tat,p38 MAPK,155871,26416
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,Tat,IFNg,155871,15978
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,Tat,IDO,155871,3620
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,IFNg,MAPK,15978,26416
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,IFNg,p38 MAPK,15978,26416
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,IFNg,Tat,15978,155871
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,IFNg,IDO,15978,3620
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,IDO,MAPK,3620,26416
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,IDO,p38 MAPK,3620,26416
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,IDO,Tat,3620,155871
21810259,CONCLUSION: These data establish that Tat induces IDO expression via an IFNg-independent mechanism that depends upon activation of p38 MAPK,IDO,IFNg,3620,15978
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,HIV-1-infected,MAPK,D015658,26416
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,HIV-1-infected,p38 MAPK,D015658,26416
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,HIV-1-infected,IDO,D015658,3620
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,MAPK,HIV-1-infected,26416,D015658
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,MAPK,depressive,26416,D000275
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,MAPK,p38 MAPK,26416,26416
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,MAPK,depressive disorders,26416,D000275
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,MAPK,IDO,26416,3620
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,depressive,MAPK,D000275,26416
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,depressive,p38 MAPK,D000275,26416
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,depressive,IDO,D000275,3620
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,p38 MAPK,HIV-1-infected,26416,D015658
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,p38 MAPK,MAPK,26416,26416
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,p38 MAPK,depressive,26416,D000275
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,p38 MAPK,depressive disorders,26416,D000275
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,p38 MAPK,IDO,26416,3620
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,depressive disorders,MAPK,D000275,26416
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,depressive disorders,p38 MAPK,D000275,26416
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,depressive disorders,IDO,D000275,3620
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,IDO,HIV-1-infected,3620,D015658
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,IDO,MAPK,3620,26416
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,IDO,depressive,3620,D000275
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,IDO,p38 MAPK,3620,26416
21810259,Targeting IDO itself or the p38 MAPK signaling pathway could provide a novel therapy for comorbid depressive disorders in HIV-1-infected patients.,IDO,depressive disorders,3620,D000275
21911891,Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease,non-alcoholic fatty liver disease,Plasminogen activator inhibitor type 1,D065626,5054
21911891,Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease,obese,Plasminogen activator inhibitor type 1,D009765,5054
21911891,Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease,Plasminogen activator inhibitor type 1,non-alcoholic fatty liver disease,5054,D065626
21911891,Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease,Plasminogen activator inhibitor type 1,obese,5054,D009765
21911891,BACKGROUND: The plasminogen activator inhibitor type-1 (PAI-1) has been implicated in the regulation of fibrinolysis and extracellular matrix components,plasminogen activator inhibitor type-1,PAI-1,5054,5054
21911891,BACKGROUND: The plasminogen activator inhibitor type-1 (PAI-1) has been implicated in the regulation of fibrinolysis and extracellular matrix components,PAI-1,plasminogen activator inhibitor type-1,5054,5054
21911891,The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and may modulate hepatic fibrogenesis,PAI-1,hepatic fibrogenesis,5054,D008107
21911891,The single base pair guanine insertion/deletion polymorphism (4G/5G) within the promoter region of the PAI-1 gene influences PAI-1 synthesis and may modulate hepatic fibrogenesis,hepatic fibrogenesis,PAI-1,D008107,5054
21911891,AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients,obese,PAI-1,D009765,5054
21911891,AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients,NAFLD,PAI-1,D065626,5054
21911891,AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients,non-alcoholic fatty liver disease,PAI-1,D065626,5054
21911891,AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients,PAI-1,obese,5054,D009765
21911891,AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients,PAI-1,NAFLD,5054,D065626
21911891,AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients,PAI-1,non-alcoholic fatty liver disease,5054,D065626
21911891,AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients,PAI-1,liver fibrosis,5054,D008103
21911891,AIM: To evaluate the influence of PAI-1 serum levels and 4G/5G polymorphism on the risk of liver fibrosis associated to non-alcoholic fatty liver disease (NAFLD) in morbidly obese patients,liver fibrosis,PAI-1,D008103,5054
21911891,"RESULTS: BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects",obese,triglycerides,D009765,D014280
21911891,"RESULTS: BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects",triglycerides,obese,D014280,D009765
21911891,"RESULTS: BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects",triglycerides,hypertension,D014280,D006973
21911891,"RESULTS: BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects",triglycerides,diabetes,D014280,D003920
21911891,"RESULTS: BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects",hypertension,triglycerides,D006973,D014280
21911891,"RESULTS: BMI, insulinemia, triglycerides, HOMA-IR, hypertension and diabetes were significantly higher in obese patients compared to control subjects",diabetes,triglycerides,D003920,D014280
21911891,PAI-1 serum levels observed in obese patients were significantly lower (10.63 4.82) compared to controls (14.26 11.4; p < 0.05),obese,PAI-1,D009765,5054
21911891,PAI-1 serum levels observed in obese patients were significantly lower (10.63 4.82) compared to controls (14.26 11.4; p < 0.05),PAI-1,obese,5054,D009765
21911891,No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 4.35) compared to patients without liver fibrosis (10.61 5.2; p = 0.985),liver fibrosis,PAI-1,D008103,5054
21911891,No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 4.35) compared to patients without liver fibrosis (10.61 5.2; p = 0.985),obese,PAI-1,D009765,5054
21911891,No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 4.35) compared to patients without liver fibrosis (10.61 5.2; p = 0.985),PAI-1,liver fibrosis,5054,D008103
21911891,No differences were observed in PAI-1 plasma levels among obese patients with liver fibrosis (10.64 4.35) compared to patients without liver fibrosis (10.61 5.2; p = 0.985),PAI-1,obese,5054,D009765
21911891,PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6),liver fibrosis,PAI-1,D008103,5054
21911891,PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6),NASH,PAI-1,D065626,5054
21911891,PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6),PAI-1,liver fibrosis,5054,D008103
21911891,PAI-1 4G/5G promoter genotypes frequencies were similar in patients with or without liver fibrosis associated to NASH (p = 0.6),PAI-1,NASH,5054,D065626
21911891,CONCLUSIONS: Morbidly obese patients had significantly lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects,obese,PAI-1,D009765,5054
21911891,CONCLUSIONS: Morbidly obese patients had significantly lower PAI-1 serum levels with similar PAI-1 4G/5G genotypes frequencies compared to non-obese subjects,PAI-1,obese,5054,D009765
21911891,No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients.,liver fibrosis,PAI-1,D008103,5054
21911891,No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients.,obese,PAI-1,D009765,5054
21911891,No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients.,PAI-1,liver fibrosis,5054,D008103
21911891,No association was found between PAI-1 serum levels or 4G/5G genotype with liver fibrosis in obese patients.,PAI-1,obese,5054,D009765
22048266,Exploratory investigation on functional significance of ETS2 and SIM2 genes in Down syndrome,SIM2,ETS2,6493,2114
22048266,Exploratory investigation on functional significance of ETS2 and SIM2 genes in Down syndrome,SIM2,Down syndrome,6493,D004314
22048266,Exploratory investigation on functional significance of ETS2 and SIM2 genes in Down syndrome,ETS2,SIM2,2114,6493
22048266,Exploratory investigation on functional significance of ETS2 and SIM2 genes in Down syndrome,ETS2,Down syndrome,2114,D004314
22048266,Exploratory investigation on functional significance of ETS2 and SIM2 genes in Down syndrome,Down syndrome,SIM2,D004314,6493
22048266,Exploratory investigation on functional significance of ETS2 and SIM2 genes in Down syndrome,Down syndrome,ETS2,D004314,2114
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",Single minded 2,ETS2,6493,2114
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",Single minded 2,SIM2,6493,6493
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",Single minded 2,V-ets erythroblastosis virus E26 oncogene homolog2,6493,2114
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",Single minded 2,DS,6493,D004314
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",ETS2,Single minded 2,2114,6493
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",ETS2,SIM2,2114,6493
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",ETS2,V-ets erythroblastosis virus E26 oncogene homolog2,2114,2114
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",ETS2,DS,2114,D004314
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",SIM2,Single minded 2,6493,6493
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",SIM2,ETS2,6493,2114
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",SIM2,V-ets erythroblastosis virus E26 oncogene homolog2,6493,2114
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",SIM2,DS,6493,D004314
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",V-ets erythroblastosis virus E26 oncogene homolog2,Single minded 2,2114,6493
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",V-ets erythroblastosis virus E26 oncogene homolog2,ETS2,2114,2114
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",V-ets erythroblastosis virus E26 oncogene homolog2,SIM2,2114,6493
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",V-ets erythroblastosis virus E26 oncogene homolog2,DS,2114,D004314
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",DS,Single minded 2,D004314,6493
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",DS,ETS2,D004314,2114
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",DS,SIM2,D004314,6493
22048266,"In the present investigation four SNPs in two transcription factors, Single minded 2 (SIM2) and V-ets erythroblastosis virus E26 oncogene homolog2 (ETS2), located in the 21{st} chromosome were genotyped to understand their role in DS",DS,V-ets erythroblastosis virus E26 oncogene homolog2,D004314,2114
22048266,ETS2 rs461155 showed high heterozygosity in DS,rs461155,ETS2,rs461155,2114
22048266,ETS2 rs461155 showed high heterozygosity in DS,rs461155,DS,rs461155,D004314
22048266,ETS2 rs461155 showed high heterozygosity in DS,ETS2,rs461155,2114,rs461155
22048266,ETS2 rs461155 showed high heterozygosity in DS,ETS2,DS,2114,D004314
22048266,ETS2 rs461155 showed high heterozygosity in DS,DS,rs461155,D004314,rs461155
22048266,ETS2 rs461155 showed high heterozygosity in DS,DS,ETS2,D004314,2114
22048266,Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185),SIM2,rs2073601,6493,rs2073601
22048266,Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185),SIM2,rs2073416,6493,rs2073416
22048266,Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185),SIM2,DS,6493,D004314
22048266,Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185),rs2073601,SIM2,rs2073601,6493
22048266,Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185),rs2073601,rs2073416,rs2073601,rs2073416
22048266,Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185),rs2073601,DS,rs2073601,D004314
22048266,Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185),rs2073416,SIM2,rs2073416,6493
22048266,Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185),rs2073416,rs2073601,rs2073416,rs2073601
22048266,Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185),rs2073416,DS,rs2073416,D004314
22048266,Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185),DS,SIM2,D004314,6493
22048266,Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185),DS,rs2073601,D004314,rs2073601
22048266,Significantly lower frequency of SIM2 C-G haplotype (rs2073601-rs2073416) was noticed in individuals with DS (P value =0.01669) and their fathers (P value=0.01185),DS,rs2073416,D004314,rs2073416
22048266,"Data obtained indicate that the rs2073601 'A' allele, responsible for nonsynonymous substitution of leucine to methionine, may have some role in DS in this population.",rs2073601,leucine to methionine,rs2073601,rs2073601
22048266,"Data obtained indicate that the rs2073601 'A' allele, responsible for nonsynonymous substitution of leucine to methionine, may have some role in DS in this population.",rs2073601,DS,rs2073601,D004314
22048266,"Data obtained indicate that the rs2073601 'A' allele, responsible for nonsynonymous substitution of leucine to methionine, may have some role in DS in this population.",leucine to methionine,rs2073601,rs2073601,rs2073601
22048266,"Data obtained indicate that the rs2073601 'A' allele, responsible for nonsynonymous substitution of leucine to methionine, may have some role in DS in this population.",leucine to methionine,DS,rs2073601,D004314
22048266,"Data obtained indicate that the rs2073601 'A' allele, responsible for nonsynonymous substitution of leucine to methionine, may have some role in DS in this population.",DS,rs2073601,D004314,rs2073601
22048266,"Data obtained indicate that the rs2073601 'A' allele, responsible for nonsynonymous substitution of leucine to methionine, may have some role in DS in this population.",DS,leucine to methionine,D004314,rs2073601
22180037,Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population,prostate cancer,GSTP1,D011471,2950
22180037,Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population,prostate cancer,glutathione-S-transferase P1,D011471,2950
22180037,Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population,GSTP1,prostate cancer,2950,D011471
22180037,Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population,GSTP1,glutathione-S-transferase P1,2950,2950
22180037,Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population,glutathione-S-transferase P1,prostate cancer,2950,D011471
22180037,Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population,glutathione-S-transferase P1,GSTP1,2950,2950
22180037,Glutathione-S-transferase P1 (GSTP1) is a critical enzyme of the phase II detoxification pathway,GSTP1,Glutathione-S-transferase P1,2950,2950
22180037,Glutathione-S-transferase P1 (GSTP1) is a critical enzyme of the phase II detoxification pathway,Glutathione-S-transferase P1,GSTP1,2950,2950
22180037,"One of the common functional polymorphisms of GSTP1 is A > G at nucleotide 313, which results in an amino acid substitution (Ile105Val) at the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1",Ile105Val,A > G at nucleotide 313,rs1695,rs1695
22180037,"One of the common functional polymorphisms of GSTP1 is A > G at nucleotide 313, which results in an amino acid substitution (Ile105Val) at the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1",Ile105Val,GSTP1,rs1695,2950
22180037,"One of the common functional polymorphisms of GSTP1 is A > G at nucleotide 313, which results in an amino acid substitution (Ile105Val) at the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1",A > G at nucleotide 313,Ile105Val,rs1695,rs1695
22180037,"One of the common functional polymorphisms of GSTP1 is A > G at nucleotide 313, which results in an amino acid substitution (Ile105Val) at the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1",A > G at nucleotide 313,GSTP1,rs1695,2950
22180037,"One of the common functional polymorphisms of GSTP1 is A > G at nucleotide 313, which results in an amino acid substitution (Ile105Val) at the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1",GSTP1,Ile105Val,2950,rs1695
22180037,"One of the common functional polymorphisms of GSTP1 is A > G at nucleotide 313, which results in an amino acid substitution (Ile105Val) at the substrate binding site of GSTP1 and reduces catalytic activity of GSTP1",GSTP1,A > G at nucleotide 313,2950,rs1695
22180037,"To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique",Ile105Val,benign prostate hyperplasia,rs1695,D011470
22180037,"To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique",Ile105Val,GSTP1,rs1695,2950
22180037,"To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique",Ile105Val,prostate cancer,rs1695,D011471
22180037,"To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique",benign prostate hyperplasia,Ile105Val,D011470,rs1695
22180037,"To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique",benign prostate hyperplasia,GSTP1,D011470,2950
22180037,"To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique",GSTP1,Ile105Val,2950,rs1695
22180037,"To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique",GSTP1,benign prostate hyperplasia,2950,D011470
22180037,"To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique",GSTP1,prostate cancer,2950,D011471
22180037,"To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique",prostate cancer,Ile105Val,D011471,rs1695
22180037,"To investigate the GSTP1 Ile105Val genotype frequency in prostate cancer cases in the Kashmiri population, we designed a case-control study, in which 50 prostate cancer cases and 45 benign prostate hyperplasia cases were studied for GSTP1 Ile105Val polymorphism, compared to 80 controls taken from the general population, employing the PCR-RFLP technique",prostate cancer,GSTP1,D011471,2950
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",benign prostate hyperplasia,GSTP1,D011470,2950
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",benign prostate hyperplasia,Ile105Val,D011470,rs1695
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",benign prostate hyperplasia,Ile/Val,D011470,rs1695
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",GSTP1,benign prostate hyperplasia,2950,D011470
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",GSTP1,Ile105Val,2950,rs1695
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",GSTP1,Ile/Val,2950,rs1695
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",GSTP1,prostate cancer,2950,D011471
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",Ile105Val,benign prostate hyperplasia,rs1695,D011470
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",Ile105Val,GSTP1,rs1695,2950
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",Ile105Val,Ile/Val,rs1695,rs1695
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",Ile105Val,prostate cancer,rs1695,D011471
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",Ile/Val,benign prostate hyperplasia,rs1695,D011470
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",Ile/Val,GSTP1,rs1695,2950
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",Ile/Val,Ile105Val,rs1695,rs1695
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",Ile/Val,prostate cancer,rs1695,D011471
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",prostate cancer,GSTP1,D011471,2950
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",prostate cancer,Ile105Val,D011471,rs1695
22180037,"We found the frequency of the three different genotypes of GSTP1 Ile105Val in our ethnic Kashmir population, i.e., Ile/Ile, Ile/Val and Val/Val, to be 52.4, 33.3 and 14.3% among prostate cancer cases, 48.5, 37.5 and 14% among benign prostate hyperplasia cases and 73.8, 21.3 and 5% in the control population, respectively",prostate cancer,Ile/Val,D011471,rs1695
22180037,There was a significant association between the GSTP1 Ile/Val genotype and the advanced age group among the cases,GSTP1,Ile/Val,2950,rs1695
22180037,There was a significant association between the GSTP1 Ile/Val genotype and the advanced age group among the cases,Ile/Val,GSTP1,rs1695,2950
22180037,We conclude that GSTP1 Ile/Val polymorphism is involved in the risk of prostate cancer development in our population.,Ile/Val,GSTP1,rs1695,2950
22180037,We conclude that GSTP1 Ile/Val polymorphism is involved in the risk of prostate cancer development in our population.,Ile/Val,prostate cancer,rs1695,D011471
22180037,We conclude that GSTP1 Ile/Val polymorphism is involved in the risk of prostate cancer development in our population.,GSTP1,Ile/Val,2950,rs1695
22180037,We conclude that GSTP1 Ile/Val polymorphism is involved in the risk of prostate cancer development in our population.,GSTP1,prostate cancer,2950,D011471
22180037,We conclude that GSTP1 Ile/Val polymorphism is involved in the risk of prostate cancer development in our population.,prostate cancer,Ile/Val,D011471,rs1695
22180037,We conclude that GSTP1 Ile/Val polymorphism is involved in the risk of prostate cancer development in our population.,prostate cancer,GSTP1,D011471,2950
22369755,Reciprocal effects of NNK and SLURP-1 on oncogene expression in target epithelial cells,NNK,SLURP-1,C016583,57152
22369755,Reciprocal effects of NNK and SLURP-1 on oncogene expression in target epithelial cells,SLURP-1,NNK,57152,C016583
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,NNK,4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone,C016583,C016583
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,NNK,nitrosamine,C016583,D009602
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,NNK,nicotinic acetylcholine receptors,C016583,1136
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,NNK,carcinogenic,C016583,D009369
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone,NNK,C016583,C016583
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone,nitrosamine,C016583,D009602
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone,nicotinic acetylcholine receptors,C016583,1136
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone,carcinogenic,C016583,D009369
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,nitrosamine,NNK,D009602,C016583
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,nitrosamine,4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone,D009602,C016583
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,nitrosamine,nicotinic acetylcholine receptors,D009602,1136
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,nitrosamine,carcinogenic,D009602,D009369
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,nicotinic acetylcholine receptors,NNK,1136,C016583
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,nicotinic acetylcholine receptors,4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone,1136,C016583
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,nicotinic acetylcholine receptors,nitrosamine,1136,D009602
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,nicotinic acetylcholine receptors,carcinogenic,1136,D009369
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,carcinogenic,NNK,D009369,C016583
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,carcinogenic,4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone,D009369,C016583
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,carcinogenic,nitrosamine,D009369,D009602
22369755,AIMS: To elucidate how the nicotinic acetylcholine receptors expressed on bronchial and oral epithelial cells targeted by the tobacco nitrosamine (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) (NNK) facilitate carcinogenic transformation,carcinogenic,nicotinic acetylcholine receptors,D009369,1136
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",NNK,SLURP-1,C016583,57152
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",NNK,tumor,C016583,D009369
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",NNK,Ly-6/urokinase plasminogen activator receptor related protein-1,C016583,57152
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",NNK,tumorigenesis,C016583,D009369
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",SLURP-1,NNK,57152,C016583
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",SLURP-1,tumor,57152,D009369
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",SLURP-1,Ly-6/urokinase plasminogen activator receptor related protein-1,57152,57152
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",SLURP-1,tumorigenesis,57152,D009369
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",tumor,NNK,D009369,C016583
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",tumor,SLURP-1,D009369,57152
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",tumor,Ly-6/urokinase plasminogen activator receptor related protein-1,D009369,57152
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",Ly-6/urokinase plasminogen activator receptor related protein-1,NNK,57152,C016583
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",Ly-6/urokinase plasminogen activator receptor related protein-1,SLURP-1,57152,57152
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",Ly-6/urokinase plasminogen activator receptor related protein-1,tumor,57152,D009369
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",Ly-6/urokinase plasminogen activator receptor related protein-1,tumorigenesis,57152,D009369
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",tumorigenesis,NNK,D009369,C016583
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",tumorigenesis,SLURP-1,D009369,57152
22369755,"MAIN METHODS: Since NNK-dependent transformation can be abolished by the nicotinergic secreted mammalian Ly-6/urokinase plasminogen activator receptor related protein-1 (SLURP-1), we compared effects of NNK and recombinant (r)SLURP-1 on the expression of genes related to tumorigenesis in human immortalized bronchial and oral epithelial cell lines BEP2D and Het-1A, respectively",tumorigenesis,Ly-6/urokinase plasminogen activator receptor related protein-1,D009369,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NNK,SLURP-1,C016583,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NNK,MYB,C016583,4602
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NNK,SRC,C016583,6714
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NNK,PIK3CA,C016583,5290
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NNK,ETS1,C016583,2113
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NNK,rSLURP-1,C016583,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NNK,RB1,C016583,5925
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NNK,KIT,C016583,3815
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NNK,NRAS,C016583,4893
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NNK,AKT1,C016583,207
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SLURP-1,NNK,57152,C016583
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SLURP-1,MYB,57152,4602
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SLURP-1,SRC,57152,6714
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SLURP-1,PIK3CA,57152,5290
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SLURP-1,ETS1,57152,2113
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SLURP-1,rSLURP-1,57152,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SLURP-1,RB1,57152,5925
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SLURP-1,KIT,57152,3815
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SLURP-1,NRAS,57152,4893
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SLURP-1,AKT1,57152,207
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",MYB,NNK,4602,C016583
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",MYB,SLURP-1,4602,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",MYB,SRC,4602,6714
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",MYB,PIK3CA,4602,5290
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",MYB,ETS1,4602,2113
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",MYB,rSLURP-1,4602,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",MYB,RB1,4602,5925
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",MYB,KIT,4602,3815
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",MYB,NRAS,4602,4893
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",MYB,AKT1,4602,207
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SRC,NNK,6714,C016583
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SRC,SLURP-1,6714,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SRC,MYB,6714,4602
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SRC,PIK3CA,6714,5290
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SRC,ETS1,6714,2113
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SRC,rSLURP-1,6714,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SRC,RB1,6714,5925
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SRC,KIT,6714,3815
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SRC,NRAS,6714,4893
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",SRC,AKT1,6714,207
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",PIK3CA,NNK,5290,C016583
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",PIK3CA,SLURP-1,5290,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",PIK3CA,MYB,5290,4602
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",PIK3CA,SRC,5290,6714
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",PIK3CA,ETS1,5290,2113
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",PIK3CA,rSLURP-1,5290,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",PIK3CA,RB1,5290,5925
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",PIK3CA,KIT,5290,3815
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",PIK3CA,NRAS,5290,4893
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",PIK3CA,AKT1,5290,207
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",ETS1,NNK,2113,C016583
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",ETS1,SLURP-1,2113,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",ETS1,MYB,2113,4602
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",ETS1,SRC,2113,6714
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",ETS1,PIK3CA,2113,5290
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",ETS1,rSLURP-1,2113,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",ETS1,RB1,2113,5925
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",ETS1,KIT,2113,3815
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",ETS1,NRAS,2113,4893
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",ETS1,AKT1,2113,207
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",rSLURP-1,NNK,57152,C016583
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",rSLURP-1,SLURP-1,57152,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",rSLURP-1,MYB,57152,4602
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",rSLURP-1,SRC,57152,6714
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",rSLURP-1,PIK3CA,57152,5290
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",rSLURP-1,ETS1,57152,2113
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",rSLURP-1,RB1,57152,5925
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",rSLURP-1,KIT,57152,3815
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",rSLURP-1,NRAS,57152,4893
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",rSLURP-1,AKT1,57152,207
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",RB1,NNK,5925,C016583
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",RB1,SLURP-1,5925,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",RB1,MYB,5925,4602
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",RB1,SRC,5925,6714
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",RB1,PIK3CA,5925,5290
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",RB1,ETS1,5925,2113
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",RB1,rSLURP-1,5925,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",RB1,KIT,5925,3815
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",RB1,NRAS,5925,4893
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",RB1,AKT1,5925,207
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",KIT,NNK,3815,C016583
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",KIT,SLURP-1,3815,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",KIT,MYB,3815,4602
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",KIT,SRC,3815,6714
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",KIT,PIK3CA,3815,5290
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",KIT,ETS1,3815,2113
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",KIT,rSLURP-1,3815,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",KIT,RB1,3815,5925
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",KIT,NRAS,3815,4893
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",KIT,AKT1,3815,207
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NRAS,NNK,4893,C016583
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NRAS,SLURP-1,4893,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NRAS,MYB,4893,4602
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NRAS,SRC,4893,6714
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NRAS,PIK3CA,4893,5290
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NRAS,ETS1,4893,2113
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NRAS,rSLURP-1,4893,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NRAS,RB1,4893,5925
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NRAS,KIT,4893,3815
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",NRAS,AKT1,4893,207
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",AKT1,NNK,207,C016583
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",AKT1,SLURP-1,207,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",AKT1,MYB,207,4602
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",AKT1,SRC,207,6714
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",AKT1,PIK3CA,207,5290
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",AKT1,ETS1,207,2113
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",AKT1,rSLURP-1,207,57152
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",AKT1,RB1,207,5925
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",AKT1,KIT,207,3815
22369755,"KEY FINDINGS: NNK stimulated expression of oncogenic genes, including MYB and PIK3CA in BEP2D, ETS1, NRAS and SRC in Het-1A, and AKT1, KIT and RB1 in both cell types, which could be abolished in the presence of rSLURP-1",AKT1,NRAS,207,4893
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",NNK,SLURP-1,C016583,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",NNK,cancer,C016583,D009369
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",NNK,CDKN2A,C016583,1029
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",NNK,EGF,C016583,1950
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",NNK,rSLURP-1,C016583,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",NNK,STAT3,C016583,6774
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",NNK,HGF,C016583,3082
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",SLURP-1,NNK,57152,C016583
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",SLURP-1,cancer,57152,D009369
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",SLURP-1,CDKN2A,57152,1029
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",SLURP-1,EGF,57152,1950
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",SLURP-1,rSLURP-1,57152,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",SLURP-1,STAT3,57152,6774
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",SLURP-1,HGF,57152,3082
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",cancer,NNK,D009369,C016583
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",cancer,SLURP-1,D009369,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",cancer,CDKN2A,D009369,1029
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",cancer,EGF,D009369,1950
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",cancer,rSLURP-1,D009369,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",cancer,STAT3,D009369,6774
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",cancer,HGF,D009369,3082
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",CDKN2A,NNK,1029,C016583
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",CDKN2A,SLURP-1,1029,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",CDKN2A,cancer,1029,D009369
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",CDKN2A,EGF,1029,1950
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",CDKN2A,rSLURP-1,1029,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",CDKN2A,STAT3,1029,6774
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",CDKN2A,HGF,1029,3082
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",EGF,NNK,1950,C016583
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",EGF,SLURP-1,1950,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",EGF,cancer,1950,D009369
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",EGF,CDKN2A,1950,1029
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",EGF,rSLURP-1,1950,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",EGF,STAT3,1950,6774
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",EGF,HGF,1950,3082
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",rSLURP-1,NNK,57152,C016583
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",rSLURP-1,SLURP-1,57152,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",rSLURP-1,cancer,57152,D009369
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",rSLURP-1,CDKN2A,57152,1029
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",rSLURP-1,EGF,57152,1950
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",rSLURP-1,STAT3,57152,6774
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",rSLURP-1,HGF,57152,3082
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",STAT3,NNK,6774,C016583
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",STAT3,SLURP-1,6774,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",STAT3,cancer,6774,D009369
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",STAT3,CDKN2A,6774,1029
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",STAT3,EGF,6774,1950
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",STAT3,rSLURP-1,6774,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",STAT3,HGF,6774,3082
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",HGF,NNK,3082,C016583
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",HGF,SLURP-1,3082,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",HGF,cancer,3082,D009369
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",HGF,CDKN2A,3082,1029
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",HGF,EGF,3082,1950
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",HGF,rSLURP-1,3082,57152
22369755,"Other cancer-related genes whose upregulation by NNK was abolishable by rSLURP-1 were the growth factors EGF in BEP2D cells and HGF in Het-1A cells, and the transcription factors CDKN2A and STAT3 (Het-1A only)",HGF,STAT3,3082,6774
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",NNK,SLURP-1,C016583,57152
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",NNK,BAX,C016583,581
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",NNK,rSLURP-1,C016583,57152
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",NNK,CASP8,C016583,841
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",NNK,BCL2,C016583,596
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",NNK,TNF,C016583,7124
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",SLURP-1,NNK,57152,C016583
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",SLURP-1,BAX,57152,581
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",SLURP-1,rSLURP-1,57152,57152
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",SLURP-1,CASP8,57152,841
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",SLURP-1,BCL2,57152,596
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",SLURP-1,TNF,57152,7124
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",BAX,NNK,581,C016583
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",BAX,SLURP-1,581,57152
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",BAX,rSLURP-1,581,57152
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",BAX,CASP8,581,841
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",BAX,BCL2,581,596
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",BAX,TNF,581,7124
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",rSLURP-1,NNK,57152,C016583
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",rSLURP-1,SLURP-1,57152,57152
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",rSLURP-1,BAX,57152,581
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",rSLURP-1,CASP8,57152,841
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",rSLURP-1,BCL2,57152,596
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",rSLURP-1,TNF,57152,7124
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",CASP8,NNK,841,C016583
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",CASP8,SLURP-1,841,57152
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",CASP8,BAX,841,581
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",CASP8,rSLURP-1,841,57152
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",CASP8,BCL2,841,596
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",CASP8,TNF,841,7124
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",BCL2,NNK,596,C016583
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",BCL2,SLURP-1,596,57152
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",BCL2,BAX,596,581
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",BCL2,rSLURP-1,596,57152
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",BCL2,CASP8,596,841
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",BCL2,TNF,596,7124
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",TNF,NNK,7124,C016583
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",TNF,SLURP-1,7124,57152
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",TNF,BAX,7124,581
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",TNF,rSLURP-1,7124,57152
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",TNF,CASP8,7124,841
22369755,"NNK also upregulated the anti-apoptotic BCL2 (Het-1A) and downregulated the pro-apoptotic TNF (Het-1A), BAX and CASP8 (BEP2D), all of which could be abolished, in part, by rSLURP-1",TNF,BCL2,7124,596
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",NNK,tumor,C016583,D009369
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",NNK,beta-catenin,C016583,1499
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",NNK,CTNNB1,C016583,1499
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",NNK,SERPINB5,C016583,5268
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",NNK,CDKN3,C016583,1033
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",NNK,FOXD3,C016583,27022
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",tumor,NNK,D009369,C016583
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",tumor,beta-catenin,D009369,1499
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",tumor,CTNNB1,D009369,1499
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",tumor,SERPINB5,D009369,5268
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",tumor,CDKN3,D009369,1033
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",tumor,FOXD3,D009369,27022
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",beta-catenin,NNK,1499,C016583
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",beta-catenin,tumor,1499,D009369
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",beta-catenin,CTNNB1,1499,1499
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",beta-catenin,SERPINB5,1499,5268
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",beta-catenin,CDKN3,1499,1033
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",beta-catenin,FOXD3,1499,27022
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",CTNNB1,NNK,1499,C016583
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",CTNNB1,tumor,1499,D009369
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",CTNNB1,beta-catenin,1499,1499
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",CTNNB1,SERPINB5,1499,5268
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",CTNNB1,CDKN3,1499,1033
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",CTNNB1,FOXD3,1499,27022
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",SERPINB5,NNK,5268,C016583
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",SERPINB5,tumor,5268,D009369
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",SERPINB5,beta-catenin,5268,1499
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",SERPINB5,CTNNB1,5268,1499
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",SERPINB5,CDKN3,5268,1033
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",SERPINB5,FOXD3,5268,27022
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",CDKN3,NNK,1033,C016583
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",CDKN3,tumor,1033,D009369
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",CDKN3,beta-catenin,1033,1499
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",CDKN3,CTNNB1,1033,1499
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",CDKN3,SERPINB5,1033,5268
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",CDKN3,FOXD3,1033,27022
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",FOXD3,NNK,27022,C016583
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",FOXD3,tumor,27022,D009369
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",FOXD3,beta-catenin,27022,1499
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",FOXD3,CTNNB1,27022,1499
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",FOXD3,SERPINB5,27022,5268
22369755,"NNK decreased expression of the CTNNB1 gene encoding the intercellular adhesion molecule beta-catenin (BEP2D), as well as tumor suppressors CDKN3 and FOXD3 in BEP2D cells and SERPINB5 in Het-1A cells",FOXD3,CDKN3,27022,1033
22369755,These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3,NNK,RUNX3,C016583,864
22369755,These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3,NNK,SLURP-1,C016583,57152
22369755,These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3,NNK,rSLURP-1,C016583,57152
22369755,These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3,RUNX3,NNK,864,C016583
22369755,These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3,RUNX3,SLURP-1,864,57152
22369755,These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3,RUNX3,rSLURP-1,864,57152
22369755,These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3,SLURP-1,NNK,57152,C016583
22369755,These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3,SLURP-1,RUNX3,57152,864
22369755,These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3,SLURP-1,rSLURP-1,57152,57152
22369755,These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3,rSLURP-1,NNK,57152,C016583
22369755,These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3,rSLURP-1,RUNX3,57152,864
22369755,These pro-oncogenic effects of NNK were abolished by rSLURP-1 that also upregulated RUNX3,rSLURP-1,SLURP-1,57152,57152
22369755,SIGNIFICANCE: The obtained results identified target genes for both NNK and SLURP-1 and shed light on the molecular mechanism of their reciprocal effects on tumorigenic transformation of bronchial and oral epithelial cells.,NNK,SLURP-1,C016583,57152
22369755,SIGNIFICANCE: The obtained results identified target genes for both NNK and SLURP-1 and shed light on the molecular mechanism of their reciprocal effects on tumorigenic transformation of bronchial and oral epithelial cells.,NNK,tumor,C016583,D009369
22369755,SIGNIFICANCE: The obtained results identified target genes for both NNK and SLURP-1 and shed light on the molecular mechanism of their reciprocal effects on tumorigenic transformation of bronchial and oral epithelial cells.,NNK,tumorigenic,C016583,D009369
22369755,SIGNIFICANCE: The obtained results identified target genes for both NNK and SLURP-1 and shed light on the molecular mechanism of their reciprocal effects on tumorigenic transformation of bronchial and oral epithelial cells.,SLURP-1,NNK,57152,C016583
22369755,SIGNIFICANCE: The obtained results identified target genes for both NNK and SLURP-1 and shed light on the molecular mechanism of their reciprocal effects on tumorigenic transformation of bronchial and oral epithelial cells.,SLURP-1,tumor,57152,D009369
22369755,SIGNIFICANCE: The obtained results identified target genes for both NNK and SLURP-1 and shed light on the molecular mechanism of their reciprocal effects on tumorigenic transformation of bronchial and oral epithelial cells.,SLURP-1,tumorigenic,57152,D009369
22369755,SIGNIFICANCE: The obtained results identified target genes for both NNK and SLURP-1 and shed light on the molecular mechanism of their reciprocal effects on tumorigenic transformation of bronchial and oral epithelial cells.,tumor,NNK,D009369,C016583
22369755,SIGNIFICANCE: The obtained results identified target genes for both NNK and SLURP-1 and shed light on the molecular mechanism of their reciprocal effects on tumorigenic transformation of bronchial and oral epithelial cells.,tumor,SLURP-1,D009369,57152
22369755,SIGNIFICANCE: The obtained results identified target genes for both NNK and SLURP-1 and shed light on the molecular mechanism of their reciprocal effects on tumorigenic transformation of bronchial and oral epithelial cells.,tumorigenic,NNK,D009369,C016583
22369755,SIGNIFICANCE: The obtained results identified target genes for both NNK and SLURP-1 and shed light on the molecular mechanism of their reciprocal effects on tumorigenic transformation of bronchial and oral epithelial cells.,tumorigenic,SLURP-1,D009369,57152
22729903,Contribution of STAT4 gene single-nucleotide polymorphism to systemic lupus erythematosus in the Polish population,STAT4,systemic lupus erythematosus,6775,D008180
22729903,Contribution of STAT4 gene single-nucleotide polymorphism to systemic lupus erythematosus in the Polish population,systemic lupus erythematosus,STAT4,D008180,6775
22729903,The STAT4 has been found to be a susceptible gene in the development of systemic lupus erythematosus (SLE) in various populations,STAT4,systemic lupus erythematosus,6775,D008180
22729903,The STAT4 has been found to be a susceptible gene in the development of systemic lupus erythematosus (SLE) in various populations,STAT4,SLE,6775,D008180
22729903,The STAT4 has been found to be a susceptible gene in the development of systemic lupus erythematosus (SLE) in various populations,systemic lupus erythematosus,STAT4,D008180,6775
22729903,The STAT4 has been found to be a susceptible gene in the development of systemic lupus erythematosus (SLE) in various populations,SLE,STAT4,D008180,6775
22729903,"There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population",STAT4,SLE,6775,D008180
22729903,"There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population",STAT4,G > C,6775,rs7582694
22729903,"There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population",STAT4,rs7582694,6775,rs7582694
22729903,"There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population",SLE,STAT4,D008180,6775
22729903,"There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population",SLE,G > C,D008180,rs7582694
22729903,"There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population",SLE,rs7582694,D008180,rs7582694
22729903,"There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population",G > C,STAT4,rs7582694,6775
22729903,"There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population",G > C,SLE,rs7582694,D008180
22729903,"There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population",G > C,rs7582694,rs7582694,rs7582694
22729903,"There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population",rs7582694,STAT4,rs7582694,6775
22729903,"There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population",rs7582694,SLE,rs7582694,D008180
22729903,"There are evident population differences in the context of clinical manifestations of SLE, therefore we investigated the prevalence of the STAT4 G > C (rs7582694) polymorphism in patients with SLE (n = 253) and controls (n = 521) in a sample of the Polish population",rs7582694,G > C,rs7582694,rs7582694
22729903,"We found that patients with the STAT4 C/G and CC genotypes exhibited a 1.583-fold increased risk of SLE incidence (95 % CI = 1.168-2.145, p = 0.003), with OR for the C/C versus C/G and G/G genotypes was 1.967 (95 % CI = 1.152-3.358, p = 0.0119)",STAT4,SLE,6775,D008180
22729903,"We found that patients with the STAT4 C/G and CC genotypes exhibited a 1.583-fold increased risk of SLE incidence (95 % CI = 1.168-2.145, p = 0.003), with OR for the C/C versus C/G and G/G genotypes was 1.967 (95 % CI = 1.152-3.358, p = 0.0119)",SLE,STAT4,D008180,6775
22729903,"The OR for the STAT4 C allele frequency showed a 1.539-fold increased risk of SLE (95 % CI = 1.209-1.959, p = 0.0004)",STAT4,SLE,6775,D008180
22729903,"The OR for the STAT4 C allele frequency showed a 1.539-fold increased risk of SLE (95 % CI = 1.209-1.959, p = 0.0004)",SLE,STAT4,D008180,6775
22729903,"We also observed an increased frequency of STAT4 C/C and C/G genotypes in SLE patients with renal symptoms OR = 2.259 (1.365-3.738, p = 0.0014), (p (corr) = 0.0238) and in SLE patients with neurologic manifestations OR = 2.867 (1.467-5.604, p = 0.0016), (p (corr) = 0.0272)",STAT4,renal symptoms,6775,D007674
22729903,"We also observed an increased frequency of STAT4 C/C and C/G genotypes in SLE patients with renal symptoms OR = 2.259 (1.365-3.738, p = 0.0014), (p (corr) = 0.0238) and in SLE patients with neurologic manifestations OR = 2.867 (1.467-5.604, p = 0.0016), (p (corr) = 0.0272)",STAT4,SLE,6775,D008180
22729903,"We also observed an increased frequency of STAT4 C/C and C/G genotypes in SLE patients with renal symptoms OR = 2.259 (1.365-3.738, p = 0.0014), (p (corr) = 0.0238) and in SLE patients with neurologic manifestations OR = 2.867 (1.467-5.604, p = 0.0016), (p (corr) = 0.0272)",renal symptoms,STAT4,D007674,6775
22729903,"We also observed an increased frequency of STAT4 C/C and C/G genotypes in SLE patients with renal symptoms OR = 2.259 (1.365-3.738, p = 0.0014), (p (corr) = 0.0238) and in SLE patients with neurologic manifestations OR = 2.867 (1.467-5.604, p = 0.0016), (p (corr) = 0.0272)",SLE,STAT4,D008180,6775
22729903,"Moreover, we found a contribution of STAT4 C/C and C/G genotypes to the presence of the anti-snRNP Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476)",STAT4,snRNP,6775,57819
22729903,"Moreover, we found a contribution of STAT4 C/C and C/G genotypes to the presence of the anti-snRNP Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476)",STAT4,Scl-70,6775,7150
22729903,"Moreover, we found a contribution of STAT4 C/C and C/G genotypes to the presence of the anti-snRNP Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476)",snRNP,STAT4,57819,6775
22729903,"Moreover, we found a contribution of STAT4 C/C and C/G genotypes to the presence of the anti-snRNP Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476)",snRNP,Scl-70,57819,7150
22729903,"Moreover, we found a contribution of STAT4 C/C and C/G genotypes to the presence of the anti-snRNP Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476)",Scl-70,STAT4,7150,6775
22729903,"Moreover, we found a contribution of STAT4 C/C and C/G genotypes to the presence of the anti-snRNP Ab OR = 3.237 (1.667-6.288, p = 0.0003), (p (corr) = 0.0051) and the presence of the anti-Scl-70 Ab OR = 2.665 (1.380-5.147, p = 0.0028), (p (corr) = 0.0476)",Scl-70,snRNP,7150,57819
22729903,Our studies confirmed an association of the STAT4 C (rs7582694) variant with the development of SLE and occurrence of some clinical manifestations of the disease.,STAT4,SLE,6775,D008180
22729903,Our studies confirmed an association of the STAT4 C (rs7582694) variant with the development of SLE and occurrence of some clinical manifestations of the disease.,STAT4,rs7582694,6775,rs7582694
22729903,Our studies confirmed an association of the STAT4 C (rs7582694) variant with the development of SLE and occurrence of some clinical manifestations of the disease.,SLE,STAT4,D008180,6775
22729903,Our studies confirmed an association of the STAT4 C (rs7582694) variant with the development of SLE and occurrence of some clinical manifestations of the disease.,SLE,rs7582694,D008180,rs7582694
22729903,Our studies confirmed an association of the STAT4 C (rs7582694) variant with the development of SLE and occurrence of some clinical manifestations of the disease.,rs7582694,STAT4,rs7582694,6775
22729903,Our studies confirmed an association of the STAT4 C (rs7582694) variant with the development of SLE and occurrence of some clinical manifestations of the disease.,rs7582694,SLE,rs7582694,D008180
23872883,Biochemical effects of Solidago virgaurea extract on experimental cardiotoxicity,Solidago virgaurea extract,cardiotoxicity,D010936,D066126
23872883,Biochemical effects of Solidago virgaurea extract on experimental cardiotoxicity,cardiotoxicity,Solidago virgaurea extract,D066126,D010936
23872883,The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats,Solidago virgaurea extract,isoproterenol,D010936,D007545
23872883,The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats,Solidago virgaurea extract,cardiotoxicity,D010936,D066126
23872883,The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats,isoproterenol,Solidago virgaurea extract,D007545,D010936
23872883,The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats,isoproterenol,cardiotoxicity,D007545,D066126
23872883,The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats,cardiotoxicity,Solidago virgaurea extract,D066126,D010936
23872883,The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol-induced cardiotoxicity in rats,cardiotoxicity,isoproterenol,D066126,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,triglycerides,25721,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,creatine phosphokinase,25721,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,fatty acid,25721,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,cholesterol,25721,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,glutathione,25721,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,isoproterenol,25721,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,lactate dehydrogenase,25721,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,nitric oxide,25721,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,superoxide dismutase,25721,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,angiotensin-converting enzyme,25721,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,alanine transaminase,25721,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,MDA,25721,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",aspartate transaminase,malondialdehyde,25721,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,aspartate transaminase,D014280,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,creatine phosphokinase,D014280,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,fatty acid,D014280,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,cholesterol,D014280,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,glutathione,D014280,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,isoproterenol,D014280,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,lactate dehydrogenase,D014280,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,nitric oxide,D014280,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,superoxide dismutase,D014280,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,angiotensin-converting enzyme,D014280,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,alanine transaminase,D014280,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,MDA,D014280,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",triglycerides,malondialdehyde,D014280,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,aspartate transaminase,24264,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,triglycerides,24264,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,fatty acid,24264,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,cholesterol,24264,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,glutathione,24264,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,isoproterenol,24264,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,lactate dehydrogenase,24264,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,nitric oxide,24264,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,superoxide dismutase,24264,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,angiotensin-converting enzyme,24264,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,alanine transaminase,24264,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,MDA,24264,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",creatine phosphokinase,malondialdehyde,24264,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,aspartate transaminase,D005227,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,triglycerides,D005227,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,creatine phosphokinase,D005227,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,cholesterol,D005227,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,glutathione,D005227,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,isoproterenol,D005227,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,lactate dehydrogenase,D005227,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,nitric oxide,D005227,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,superoxide dismutase,D005227,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,angiotensin-converting enzyme,D005227,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,alanine transaminase,D005227,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,MDA,D005227,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",fatty acid,malondialdehyde,D005227,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,aspartate transaminase,D002784,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,triglycerides,D002784,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,creatine phosphokinase,D002784,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,fatty acid,D002784,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,glutathione,D002784,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,isoproterenol,D002784,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,lactate dehydrogenase,D002784,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,nitric oxide,D002784,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,superoxide dismutase,D002784,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,angiotensin-converting enzyme,D002784,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,alanine transaminase,D002784,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,MDA,D002784,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",cholesterol,malondialdehyde,D002784,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,aspartate transaminase,D005978,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,triglycerides,D005978,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,creatine phosphokinase,D005978,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,fatty acid,D005978,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,cholesterol,D005978,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,isoproterenol,D005978,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,lactate dehydrogenase,D005978,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,nitric oxide,D005978,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,superoxide dismutase,D005978,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,angiotensin-converting enzyme,D005978,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,alanine transaminase,D005978,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,MDA,D005978,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",glutathione,malondialdehyde,D005978,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,aspartate transaminase,D007545,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,triglycerides,D007545,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,creatine phosphokinase,D007545,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,fatty acid,D007545,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,cholesterol,D007545,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,glutathione,D007545,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,lactate dehydrogenase,D007545,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,nitric oxide,D007545,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,superoxide dismutase,D007545,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,angiotensin-converting enzyme,D007545,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,alanine transaminase,D007545,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,MDA,D007545,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",isoproterenol,malondialdehyde,D007545,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,aspartate transaminase,24533,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,triglycerides,24533,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,creatine phosphokinase,24533,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,fatty acid,24533,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,cholesterol,24533,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,glutathione,24533,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,isoproterenol,24533,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,nitric oxide,24533,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,superoxide dismutase,24533,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,angiotensin-converting enzyme,24533,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,alanine transaminase,24533,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,MDA,24533,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",lactate dehydrogenase,malondialdehyde,24533,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,aspartate transaminase,D009569,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,triglycerides,D009569,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,creatine phosphokinase,D009569,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,fatty acid,D009569,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,cholesterol,D009569,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,glutathione,D009569,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,isoproterenol,D009569,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,lactate dehydrogenase,D009569,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,superoxide dismutase,D009569,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,angiotensin-converting enzyme,D009569,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,alanine transaminase,D009569,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,MDA,D009569,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",nitric oxide,malondialdehyde,D009569,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,aspartate transaminase,24786,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,triglycerides,24786,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,creatine phosphokinase,24786,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,fatty acid,24786,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,cholesterol,24786,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,glutathione,24786,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,isoproterenol,24786,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,lactate dehydrogenase,24786,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,nitric oxide,24786,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,angiotensin-converting enzyme,24786,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,alanine transaminase,24786,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,MDA,24786,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",superoxide dismutase,malondialdehyde,24786,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,aspartate transaminase,24310,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,triglycerides,24310,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,creatine phosphokinase,24310,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,fatty acid,24310,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,cholesterol,24310,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,glutathione,24310,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,isoproterenol,24310,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,lactate dehydrogenase,24310,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,nitric oxide,24310,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,superoxide dismutase,24310,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,alanine transaminase,24310,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,MDA,24310,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",angiotensin-converting enzyme,malondialdehyde,24310,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,aspartate transaminase,81670,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,triglycerides,81670,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,creatine phosphokinase,81670,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,fatty acid,81670,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,cholesterol,81670,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,glutathione,81670,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,isoproterenol,81670,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,lactate dehydrogenase,81670,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,nitric oxide,81670,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,superoxide dismutase,81670,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,angiotensin-converting enzyme,81670,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,MDA,81670,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",alanine transaminase,malondialdehyde,81670,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,aspartate transaminase,D008315,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,triglycerides,D008315,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,creatine phosphokinase,D008315,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,fatty acid,D008315,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,cholesterol,D008315,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,glutathione,D008315,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,isoproterenol,D008315,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,lactate dehydrogenase,D008315,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,nitric oxide,D008315,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,superoxide dismutase,D008315,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,angiotensin-converting enzyme,D008315,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,alanine transaminase,D008315,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",MDA,malondialdehyde,D008315,D008315
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,aspartate transaminase,D008315,25721
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,triglycerides,D008315,D014280
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,creatine phosphokinase,D008315,24264
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,fatty acid,D008315,D005227
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,cholesterol,D008315,D002784
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,glutathione,D008315,D005978
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,isoproterenol,D008315,D007545
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,lactate dehydrogenase,D008315,24533
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,nitric oxide,D008315,D009569
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,superoxide dismutase,D008315,24786
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,angiotensin-converting enzyme,D008315,24310
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,alanine transaminase,D008315,81670
23872883,"The subcutaneous injection of isoproterenol (30 mg/kg) into rats twice at an interval of 24 h, for two consecutive days, led to a significant increase in serum lactate dehydrogenase, creatine phosphokinase, alanine transaminase, aspartate transaminase, and angiotensin-converting enzyme activities, total cholesterol, triglycerides, free serum fatty acid, cardiac tissue malondialdehyde (MDA), and nitric oxide levels and a significant decrease in levels of glutathione and superoxide dismutase in cardiac tissue as compared to the normal control group (P < 0.05)",malondialdehyde,MDA,D008315,D008315
23872883,"Captopril (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study",Captopril,cardioprotective drug,D002216,D002316
23872883,"Captopril (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study",Captopril,angiotensin-converting enzyme,D002216,24310
23872883,"Captopril (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study",cardioprotective drug,Captopril,D002316,D002216
23872883,"Captopril (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study",cardioprotective drug,angiotensin-converting enzyme,D002316,24310
23872883,"Captopril (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study",angiotensin-converting enzyme,Captopril,24310,D002216
23872883,"Captopril (50 mg/kg/day, given orally), an inhibitor of angiotensin-converting enzyme used as a standard cardioprotective drug, was used as a positive control in this study",angiotensin-converting enzyme,cardioprotective drug,24310,D002316
23872883,virgaurea extract exerts its protective effect by decreasing MDA level and increasing the antioxidant status in isoproterenol-treated rats,MDA,isoproterenol,D008315,D007545
23872883,virgaurea extract exerts its protective effect by decreasing MDA level and increasing the antioxidant status in isoproterenol-treated rats,isoproterenol,MDA,D007545,D008315
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)","3,4-methylenedioxymethamphetamine",impulsiveness,D018817,D010554
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)","3,4-methylenedioxymethamphetamine",ecstasy,D018817,D018817
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)","3,4-methylenedioxymethamphetamine",MDMA,D018817,D018817
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)","3,4-methylenedioxymethamphetamine",Depression,D018817,D003866
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",impulsiveness,"3,4-methylenedioxymethamphetamine",D010554,D018817
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",impulsiveness,ecstasy,D010554,D018817
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",impulsiveness,MDMA,D010554,D018817
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",ecstasy,"3,4-methylenedioxymethamphetamine",D018817,D018817
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",ecstasy,impulsiveness,D018817,D010554
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",ecstasy,MDMA,D018817,D018817
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",ecstasy,Depression,D018817,D003866
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",MDMA,"3,4-methylenedioxymethamphetamine",D018817,D018817
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",MDMA,impulsiveness,D018817,D010554
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",MDMA,ecstasy,D018817,D018817
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",MDMA,Depression,D018817,D003866
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",Depression,"3,4-methylenedioxymethamphetamine",D003866,D018817
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",Depression,ecstasy,D003866,D018817
24114426,"Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)",Depression,MDMA,D003866,D018817
24114426,"RATIONALE: Ecstasy (3,4-methylenedioxymethamphetamine, MDMA) is a worldwide recreational drug of abuse",MDMA,"3,4-methylenedioxymethamphetamine",D018817,D018817
24114426,"RATIONALE: Ecstasy (3,4-methylenedioxymethamphetamine, MDMA) is a worldwide recreational drug of abuse",MDMA,Ecstasy,D018817,D018817
24114426,"RATIONALE: Ecstasy (3,4-methylenedioxymethamphetamine, MDMA) is a worldwide recreational drug of abuse","3,4-methylenedioxymethamphetamine",MDMA,D018817,D018817
24114426,"RATIONALE: Ecstasy (3,4-methylenedioxymethamphetamine, MDMA) is a worldwide recreational drug of abuse","3,4-methylenedioxymethamphetamine",Ecstasy,D018817,D018817
24114426,"RATIONALE: Ecstasy (3,4-methylenedioxymethamphetamine, MDMA) is a worldwide recreational drug of abuse",Ecstasy,MDMA,D018817,D018817
24114426,"RATIONALE: Ecstasy (3,4-methylenedioxymethamphetamine, MDMA) is a worldwide recreational drug of abuse",Ecstasy,"3,4-methylenedioxymethamphetamine",D018817,D018817
24114426,"OBJECTIVES: The present study aimed to be the largest to date in sample size and 5HT-related behaviors; the first to compare present ecstasy users with past users after an abstinence of 4 or more years, and the first to include robust controls for other recreational substances",5HT,ecstasy,D012701,D018817
24114426,"OBJECTIVES: The present study aimed to be the largest to date in sample size and 5HT-related behaviors; the first to compare present ecstasy users with past users after an abstinence of 4 or more years, and the first to include robust controls for other recreational substances",ecstasy,5HT,D018817,D012701
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",AN,cannabis,"D000431,D009538",D002188
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",AN,nicotine,"D000431,D009538",D009538
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",AN,ecstasy,"D000431,D009538",D018817
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",AN,CAN,"D000431,D009538","D000431,D002188,D009538"
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",AN,MDMA,"D000431,D009538",D018817
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",AN,alcohol,"D000431,D009538",D000431
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",cannabis,AN,D002188,"D000431,D009538"
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",cannabis,nicotine,D002188,D009538
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",cannabis,ecstasy,D002188,D018817
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",cannabis,CAN,D002188,"D000431,D002188,D009538"
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",cannabis,MDMA,D002188,D018817
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",cannabis,alcohol,D002188,D000431
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",nicotine,AN,D009538,"D000431,D009538"
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",nicotine,cannabis,D009538,D002188
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",nicotine,ecstasy,D009538,D018817
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",nicotine,CAN,D009538,"D000431,D002188,D009538"
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",nicotine,MDMA,D009538,D018817
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",nicotine,alcohol,D009538,D000431
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",ecstasy,AN,D018817,"D000431,D009538"
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",ecstasy,cannabis,D018817,D002188
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",ecstasy,nicotine,D018817,D009538
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",ecstasy,CAN,D018817,"D000431,D002188,D009538"
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",ecstasy,MDMA,D018817,D018817
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",ecstasy,alcohol,D018817,D000431
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",CAN,AN,"D000431,D002188,D009538","D000431,D009538"
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",CAN,cannabis,"D000431,D002188,D009538",D002188
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",CAN,nicotine,"D000431,D002188,D009538",D009538
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",CAN,ecstasy,"D000431,D002188,D009538",D018817
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",CAN,MDMA,"D000431,D002188,D009538",D018817
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",CAN,alcohol,"D000431,D002188,D009538",D000431
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",MDMA,AN,D018817,"D000431,D009538"
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",MDMA,cannabis,D018817,D002188
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",MDMA,nicotine,D018817,D009538
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",MDMA,ecstasy,D018817,D018817
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",MDMA,CAN,D018817,"D000431,D002188,D009538"
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",MDMA,alcohol,D018817,D000431
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",alcohol,AN,D000431,"D000431,D009538"
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",alcohol,cannabis,D000431,D002188
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",alcohol,nicotine,D000431,D009538
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",alcohol,ecstasy,D000431,D018817
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",alcohol,CAN,D000431,"D000431,D002188,D009538"
24114426,"METHODS: A sample of 997 participants (52 % male) was recruited to four control groups (non-drug (ND), alcohol/nicotine (AN), cannabis/alcohol/nicotine (CAN), non-ecstasy polydrug (PD)), and two ecstasy polydrug groups (present (MDMA) and past users (EX-MDMA)",alcohol,MDMA,D000431,D018817
24114426,"RESULTS: While the CAN and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures",AN,MDMA,"D000431,D009538",D018817
24114426,"RESULTS: While the CAN and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures",AN,CAN,"D000431,D009538","D000431,D002188,D009538"
24114426,"RESULTS: While the CAN and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures",MDMA,AN,D018817,"D000431,D009538"
24114426,"RESULTS: While the CAN and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures",MDMA,CAN,D018817,"D000431,D002188,D009538"
24114426,"RESULTS: While the CAN and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures",CAN,AN,"D000431,D002188,D009538","D000431,D009538"
24114426,"RESULTS: While the CAN and PD groups tended to record greater deficits than the non-drug controls, the MDMA and EX-MDMA groups recorded greater deficits than all the control groups on ten of the 13 psychometric measures",CAN,MDMA,"D000431,D002188,D009538",D018817
24114426,"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.",depression,ecstasy,D003866,D018817
24114426,"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.",impulsiveness,ecstasy,D010554,D018817
24114426,"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.",impaired memory,ecstasy,D008569,D018817
24114426,"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.",sleep disturbance,ecstasy,D020920,D018817
24114426,"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.",ecstasy,depression,D018817,D003866
24114426,"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.",ecstasy,impulsiveness,D018817,D010554
24114426,"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.",ecstasy,impaired memory,D018817,D008569
24114426,"CONCLUSIONS: Given this record of impaired memory and clinically significant levels of depression, impulsiveness, and sleep disturbance, the prognosis for the current generation of ecstasy users is a major cause for concern.",ecstasy,sleep disturbance,D018817,D020920
24126708,Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients,HOMER1,Parkinson's disease,9456,D010300
24126708,Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients,HOMER1,levodopa,9456,D007980
24126708,Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients,Parkinson's disease,HOMER1,D010300,9456
24126708,Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients,Parkinson's disease,levodopa,D010300,D007980
24126708,Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients,levodopa,HOMER1,D007980,9456
24126708,Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson's disease patients,levodopa,Parkinson's disease,D007980,D010300
24126708,"Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations",visual hallucinations,Levodopa,D006212,D007980
24126708,"Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations",dyskinesia,Levodopa,D004409,D007980
24126708,"Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations",Levodopa,visual hallucinations,D007980,D006212
24126708,"Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations",Levodopa,dyskinesia,D007980,D004409
24126708,"Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations",Levodopa,Parkinson's disease,D007980,D010300
24126708,"Levodopa is the most effective symptomatic therapy for Parkinson's disease, but its chronic use could lead to chronic adverse outcomes, such as motor fluctuations, dyskinesia and visual hallucinations",Parkinson's disease,Levodopa,D010300,D007980
24126708,"HOMER1 is a protein with pivotal function in glutamate transmission, which has been related to the pathogenesis of these complications",HOMER1,glutamate,9456,D018698
24126708,"HOMER1 is a protein with pivotal function in glutamate transmission, which has been related to the pathogenesis of these complications",glutamate,HOMER1,D018698,9456
24126708,This study investigates whether polymorphisms in the HOMER1 gene promoter region are associated with the occurrence of the chronic complications of levodopa therapy,HOMER1,levodopa,9456,D007980
24126708,This study investigates whether polymorphisms in the HOMER1 gene promoter region are associated with the occurrence of the chronic complications of levodopa therapy,levodopa,HOMER1,D007980,9456
24126708,"Patients were genotyped for rs4704559, rs10942891 and rs4704560 by allelic discrimination with Taqman assays",rs4704559,rs10942891,rs4704559,rs10942891
24126708,"Patients were genotyped for rs4704559, rs10942891 and rs4704560 by allelic discrimination with Taqman assays",rs4704559,rs4704560,rs4704559,rs4704560
24126708,"Patients were genotyped for rs4704559, rs10942891 and rs4704560 by allelic discrimination with Taqman assays",rs10942891,rs4704559,rs10942891,rs4704559
24126708,"Patients were genotyped for rs4704559, rs10942891 and rs4704560 by allelic discrimination with Taqman assays",rs10942891,rs4704560,rs10942891,rs4704560
24126708,"Patients were genotyped for rs4704559, rs10942891 and rs4704560 by allelic discrimination with Taqman assays",rs4704560,rs4704559,rs4704560,rs4704559
24126708,"Patients were genotyped for rs4704559, rs10942891 and rs4704560 by allelic discrimination with Taqman assays",rs4704560,rs10942891,rs4704560,rs10942891
24126708,"The rs4704559 G allele was associated with a lower prevalence of dyskinesia (prevalence ratio (PR)=0.615, 95% confidence interval (CI) 0.426-0.887, P=0.009) and visual hallucinations (PR=0.515, 95% CI 0.295-0.899, P=0.020)",visual hallucinations,rs4704559,D006212,rs4704559
24126708,"The rs4704559 G allele was associated with a lower prevalence of dyskinesia (prevalence ratio (PR)=0.615, 95% confidence interval (CI) 0.426-0.887, P=0.009) and visual hallucinations (PR=0.515, 95% CI 0.295-0.899, P=0.020)",rs4704559,visual hallucinations,rs4704559,D006212
24126708,"The rs4704559 G allele was associated with a lower prevalence of dyskinesia (prevalence ratio (PR)=0.615, 95% confidence interval (CI) 0.426-0.887, P=0.009) and visual hallucinations (PR=0.515, 95% CI 0.295-0.899, P=0.020)",rs4704559,dyskinesia,rs4704559,D004409
24126708,"The rs4704559 G allele was associated with a lower prevalence of dyskinesia (prevalence ratio (PR)=0.615, 95% confidence interval (CI) 0.426-0.887, P=0.009) and visual hallucinations (PR=0.515, 95% CI 0.295-0.899, P=0.020)",dyskinesia,rs4704559,D004409,rs4704559
24126708,Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects.,rs4704559,HOMER1,rs4704559,9456
24126708,Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects.,rs4704559,levodopa,rs4704559,D007980
24126708,Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects.,HOMER1,rs4704559,9456,rs4704559
24126708,Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects.,HOMER1,levodopa,9456,D007980
24126708,Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects.,levodopa,rs4704559,D007980,rs4704559
24126708,Our data suggest that HOMER1 rs4704559 G allele has a protective role for the development of levodopa adverse effects.,levodopa,HOMER1,D007980,9456
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,Crocin,diazinon,C029036,D003976
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,Crocin,ERK1/2,C029036,"116590,50689"
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,Crocin,lipid,C029036,D008055
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,Crocin,ERK,C029036,"116590,50689"
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,diazinon,Crocin,D003976,C029036
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,diazinon,ERK1/2,D003976,"116590,50689"
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,diazinon,lipid,D003976,D008055
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,diazinon,ERK,D003976,"116590,50689"
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,ERK1/2,Crocin,"116590,50689",C029036
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,ERK1/2,diazinon,"116590,50689",D003976
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,ERK1/2,lipid,"116590,50689",D008055
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,ERK1/2,ERK,"116590,50689","116590,50689"
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,lipid,Crocin,D008055,C029036
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,lipid,diazinon,D008055,D003976
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,lipid,ERK1/2,D008055,"116590,50689"
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,lipid,ERK,D008055,"116590,50689"
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,ERK,Crocin,"116590,50689",C029036
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,ERK,diazinon,"116590,50689",D003976
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,ERK,ERK1/2,"116590,50689","116590,50689"
24132704,Crocin improves lipid dysregulation in subacute diazinon exposure through ERK1/2 pathway in rat liver,ERK,lipid,"116590,50689",D008055
24132704,INTRODUCTION: Diazinon Yis one of the most broadly used organophosphorus insecticides in agriculture,organophosphorus,Diazinon,D010755,D003976
24132704,INTRODUCTION: Diazinon Yis one of the most broadly used organophosphorus insecticides in agriculture,Diazinon,organophosphorus,D003976,D010755
24132704,It has been shown that exposure to diazinon may interfere with lipid metabolism,lipid,diazinon,D008055,D003976
24132704,It has been shown that exposure to diazinon may interfere with lipid metabolism,diazinon,lipid,D003976,D008055
24132704,"Moreover, the hypolipidemic effect of crocin has been established",crocin,lipid,C029036,D008055
24132704,"Moreover, the hypolipidemic effect of crocin has been established",lipid,crocin,D008055,C029036
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,LDLr,LDL,300438,D008077
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,LDLr,low-density lipoprotein receptor,300438,300438
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,LDLr,Extracellular signal-regulated kinase,300438,"116590,50689"
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,LDLr,ERK,300438,"116590,50689"
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,LDL,LDLr,D008077,300438
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,LDL,low-density lipoprotein receptor,D008077,300438
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,LDL,Extracellular signal-regulated kinase,D008077,"116590,50689"
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,LDL,ERK,D008077,"116590,50689"
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,low-density lipoprotein receptor,LDLr,300438,300438
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,low-density lipoprotein receptor,LDL,300438,D008077
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,low-density lipoprotein receptor,Extracellular signal-regulated kinase,300438,"116590,50689"
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,low-density lipoprotein receptor,ERK,300438,"116590,50689"
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,Extracellular signal-regulated kinase,LDLr,"116590,50689",300438
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,Extracellular signal-regulated kinase,LDL,"116590,50689",D008077
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,Extracellular signal-regulated kinase,low-density lipoprotein receptor,"116590,50689",300438
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,Extracellular signal-regulated kinase,ERK,"116590,50689","116590,50689"
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,ERK,LDLr,"116590,50689",300438
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,ERK,LDL,"116590,50689",D008077
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,ERK,low-density lipoprotein receptor,"116590,50689",300438
24132704,Earlier studies revealed the major role of Extracellular signal-regulated kinase (ERK) pathways in low-density lipoprotein receptor (LDLr) expression,ERK,Extracellular signal-regulated kinase,"116590,50689","116590,50689"
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",LDLr,LDL,300438,D008077
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",LDLr,diazinon,300438,D003976
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",LDLr,lipid,300438,D008055
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",LDLr,ERK,300438,"116590,50689"
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",LDL,LDLr,D008077,300438
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",LDL,diazinon,D008077,D003976
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",LDL,lipid,D008077,D008055
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",LDL,ERK,D008077,"116590,50689"
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",diazinon,LDLr,D003976,300438
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",diazinon,LDL,D003976,D008077
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",diazinon,lipid,D003976,D008055
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",diazinon,ERK,D003976,"116590,50689"
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",lipid,LDLr,D008055,300438
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",lipid,LDL,D008055,D008077
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",lipid,diazinon,D008055,D003976
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",lipid,ERK,D008055,"116590,50689"
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",ERK,LDLr,"116590,50689",300438
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",ERK,LDL,"116590,50689",D008077
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",ERK,diazinon,"116590,50689",D003976
24132704,"The aim of this study was to evaluate changes in the regulation of lipid metabolism, ERK and LDLr expression in the liver of rats exposed to subacute diazinon",ERK,lipid,"116590,50689",D008055
24132704,Furthermore ameliorating effect of crocin on diazinon induced disturbed cholesterol homeostasis was studied,crocin,cholesterol,C029036,D002784
24132704,Furthermore ameliorating effect of crocin on diazinon induced disturbed cholesterol homeostasis was studied,crocin,diazinon,C029036,D003976
24132704,Furthermore ameliorating effect of crocin on diazinon induced disturbed cholesterol homeostasis was studied,cholesterol,crocin,D002784,C029036
24132704,Furthermore ameliorating effect of crocin on diazinon induced disturbed cholesterol homeostasis was studied,cholesterol,diazinon,D002784,D003976
24132704,Furthermore ameliorating effect of crocin on diazinon induced disturbed cholesterol homeostasis was studied,diazinon,crocin,D003976,C029036
24132704,Furthermore ameliorating effect of crocin on diazinon induced disturbed cholesterol homeostasis was studied,diazinon,cholesterol,D003976,D002784
24132704,"METHODS: 24 Rats were divided into 4 groups and received following treatments for 4 weeks; Corn oil (control), diazinon (15mg/kg per day, orally) and crocin (12.5 and 25mg/kg per day, intraperitoneally) in combination with diazinon (15 mg/kg)",crocin,Corn oil,C029036,D003314
24132704,"METHODS: 24 Rats were divided into 4 groups and received following treatments for 4 weeks; Corn oil (control), diazinon (15mg/kg per day, orally) and crocin (12.5 and 25mg/kg per day, intraperitoneally) in combination with diazinon (15 mg/kg)",crocin,diazinon,C029036,D003976
24132704,"METHODS: 24 Rats were divided into 4 groups and received following treatments for 4 weeks; Corn oil (control), diazinon (15mg/kg per day, orally) and crocin (12.5 and 25mg/kg per day, intraperitoneally) in combination with diazinon (15 mg/kg)",Corn oil,crocin,D003314,C029036
24132704,"METHODS: 24 Rats were divided into 4 groups and received following treatments for 4 weeks; Corn oil (control), diazinon (15mg/kg per day, orally) and crocin (12.5 and 25mg/kg per day, intraperitoneally) in combination with diazinon (15 mg/kg)",Corn oil,diazinon,D003314,D003976
24132704,"METHODS: 24 Rats were divided into 4 groups and received following treatments for 4 weeks; Corn oil (control), diazinon (15mg/kg per day, orally) and crocin (12.5 and 25mg/kg per day, intraperitoneally) in combination with diazinon (15 mg/kg)",diazinon,crocin,D003976,C029036
24132704,"METHODS: 24 Rats were divided into 4 groups and received following treatments for 4 weeks; Corn oil (control), diazinon (15mg/kg per day, orally) and crocin (12.5 and 25mg/kg per day, intraperitoneally) in combination with diazinon (15 mg/kg)",diazinon,Corn oil,D003976,D003314
24132704,"The levels of cholesterol, triglyceride and LDL in blood of rats were analyzed",cholesterol,LDL,D002784,D008077
24132704,"The levels of cholesterol, triglyceride and LDL in blood of rats were analyzed",cholesterol,triglyceride,D002784,D014280
24132704,"The levels of cholesterol, triglyceride and LDL in blood of rats were analyzed",LDL,cholesterol,D008077,D002784
24132704,"The levels of cholesterol, triglyceride and LDL in blood of rats were analyzed",LDL,triglyceride,D008077,D014280
24132704,"The levels of cholesterol, triglyceride and LDL in blood of rats were analyzed",triglyceride,cholesterol,D014280,D002784
24132704,"The levels of cholesterol, triglyceride and LDL in blood of rats were analyzed",triglyceride,LDL,D014280,D008077
24132704,Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis,LDLr,LDL,300438,D008077
24132704,Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis,LDLr,ERK1/2,300438,"116590,50689"
24132704,Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis,LDLr,ERK,300438,"116590,50689"
24132704,Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis,LDL,LDLr,D008077,300438
24132704,Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis,LDL,ERK1/2,D008077,"116590,50689"
24132704,Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis,LDL,ERK,D008077,"116590,50689"
24132704,Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis,ERK1/2,LDLr,"116590,50689",300438
24132704,Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis,ERK1/2,LDL,"116590,50689",D008077
24132704,Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis,ERK1/2,ERK,"116590,50689","116590,50689"
24132704,Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis,ERK,LDLr,"116590,50689",300438
24132704,Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis,ERK,LDL,"116590,50689",D008077
24132704,Moreover mRNA levels of LDLr and ERK1/2 as well as protein levels of total and activated forms of ERK1/2 in rat liver were evaluated by Western blotting and quantitative real time polymerase chain reaction analysis,ERK,ERK1/2,"116590,50689","116590,50689"
24132704,"RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL",cholesterol,LDL,D002784,D008077
24132704,"RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL",cholesterol,diazinon,D002784,D003976
24132704,"RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL",cholesterol,triglyceride,D002784,D014280
24132704,"RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL",LDL,cholesterol,D008077,D002784
24132704,"RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL",LDL,diazinon,D008077,D003976
24132704,"RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL",LDL,triglyceride,D008077,D014280
24132704,"RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL",diazinon,cholesterol,D003976,D002784
24132704,"RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL",diazinon,LDL,D003976,D008077
24132704,"RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL",diazinon,triglyceride,D003976,D014280
24132704,"RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL",triglyceride,cholesterol,D014280,D002784
24132704,"RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL",triglyceride,LDL,D014280,D008077
24132704,"RESULTS: Our data showed that subacute exposure to diazinon significantly increased concentrations of cholesterol, triglyceride and LDL",triglyceride,diazinon,D014280,D003976
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,LDLr,LDL,300438,D008077
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,LDLr,diazinon,300438,D003976
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,LDLr,ERK1/2,300438,"116590,50689"
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,LDLr,ERK,300438,"116590,50689"
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,LDL,LDLr,D008077,300438
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,LDL,diazinon,D008077,D003976
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,LDL,ERK1/2,D008077,"116590,50689"
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,LDL,ERK,D008077,"116590,50689"
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,diazinon,LDLr,D003976,300438
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,diazinon,LDL,D003976,D008077
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,diazinon,ERK1/2,D003976,"116590,50689"
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,diazinon,ERK,D003976,"116590,50689"
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,ERK1/2,LDLr,"116590,50689",300438
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,ERK1/2,LDL,"116590,50689",D008077
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,ERK1/2,diazinon,"116590,50689",D003976
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,ERK1/2,ERK,"116590,50689","116590,50689"
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,ERK,LDLr,"116590,50689",300438
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,ERK,LDL,"116590,50689",D008077
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,ERK,diazinon,"116590,50689",D003976
24132704,Moreover diazinon decreased ERK1/2 protein phosphorylation and LDLr transcript,ERK,ERK1/2,"116590,50689","116590,50689"
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,LDLr,LDL,300438,D008077
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,LDLr,Crocin,300438,C029036
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,LDLr,hyperlipemia,300438,D006949
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,LDLr,diazinon,300438,D003976
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,LDLr,ERK,300438,"116590,50689"
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,LDL,LDLr,D008077,300438
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,LDL,Crocin,D008077,C029036
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,LDL,hyperlipemia,D008077,D006949
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,LDL,diazinon,D008077,D003976
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,LDL,ERK,D008077,"116590,50689"
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,Crocin,LDLr,C029036,300438
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,Crocin,LDL,C029036,D008077
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,Crocin,hyperlipemia,C029036,D006949
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,Crocin,diazinon,C029036,D003976
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,Crocin,ERK,C029036,"116590,50689"
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,hyperlipemia,LDLr,D006949,300438
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,hyperlipemia,LDL,D006949,D008077
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,hyperlipemia,Crocin,D006949,C029036
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,hyperlipemia,diazinon,D006949,D003976
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,hyperlipemia,ERK,D006949,"116590,50689"
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,diazinon,LDLr,D003976,300438
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,diazinon,LDL,D003976,D008077
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,diazinon,Crocin,D003976,C029036
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,diazinon,hyperlipemia,D003976,D006949
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,diazinon,ERK,D003976,"116590,50689"
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,ERK,LDLr,"116590,50689",300438
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,ERK,LDL,"116590,50689",D008077
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,ERK,Crocin,"116590,50689",C029036
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,ERK,hyperlipemia,"116590,50689",D006949
24132704,Crocin reduced inhibition of ERK activation and diazinon-induced hyperlipemia and increased levels of LDLr transcript,ERK,diazinon,"116590,50689",D003976
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,LDLr,LDL,300438,D008077
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,LDLr,Crocin,300438,C029036
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,LDLr,hyperlipemia,300438,D006949
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,LDLr,diazinon,300438,D003976
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,LDLr,ERK,300438,"116590,50689"
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,LDL,LDLr,D008077,300438
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,LDL,Crocin,D008077,C029036
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,LDL,hyperlipemia,D008077,D006949
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,LDL,diazinon,D008077,D003976
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,LDL,ERK,D008077,"116590,50689"
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,Crocin,LDLr,C029036,300438
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,Crocin,LDL,C029036,D008077
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,Crocin,hyperlipemia,C029036,D006949
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,Crocin,diazinon,C029036,D003976
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,Crocin,ERK,C029036,"116590,50689"
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,hyperlipemia,LDLr,D006949,300438
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,hyperlipemia,LDL,D006949,D008077
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,hyperlipemia,Crocin,D006949,C029036
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,hyperlipemia,diazinon,D006949,D003976
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,hyperlipemia,ERK,D006949,"116590,50689"
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,diazinon,LDLr,D003976,300438
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,diazinon,LDL,D003976,D008077
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,diazinon,Crocin,D003976,C029036
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,diazinon,hyperlipemia,D003976,D006949
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,diazinon,ERK,D003976,"116590,50689"
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,ERK,LDLr,"116590,50689",300438
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,ERK,LDL,"116590,50689",D008077
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,ERK,Crocin,"116590,50689",C029036
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,ERK,hyperlipemia,"116590,50689",D006949
24132704,CONCLUSIONS: Crocin may be considered as a novel protective agent in diazinon-induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression.,ERK,diazinon,"116590,50689",D003976
24535067,"Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study",etomidate,myoclonus,D005045,D009207
24535067,"Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study",etomidate,Fentanyl,D005045,D005283
24535067,"Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study",etomidate,midazolam,D005045,D008874
24535067,"Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study",myoclonus,etomidate,D009207,D005045
24535067,"Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study",myoclonus,Fentanyl,D009207,D005283
24535067,"Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study",myoclonus,midazolam,D009207,D008874
24535067,"Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study",Fentanyl,etomidate,D005283,D005045
24535067,"Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study",Fentanyl,myoclonus,D005283,D009207
24535067,"Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study",Fentanyl,midazolam,D005283,D008874
24535067,"Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study",midazolam,etomidate,D008874,D005045
24535067,"Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study",midazolam,myoclonus,D008874,D009207
24535067,"Prevention of etomidate-induced myoclonus: which is superior: Fentanyl, midazolam, or a combination? A Retrospective comparative study",midazolam,Fentanyl,D008874,D005283
24535067,"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus",etomidate,myoclonus,D005045,D009207
24535067,"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus",etomidate,midazolam,D005045,D008874
24535067,"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus",etomidate,fentanyl,D005045,D005283
24535067,"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus",myoclonus,etomidate,D009207,D005045
24535067,"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus",myoclonus,midazolam,D009207,D008874
24535067,"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus",myoclonus,fentanyl,D009207,D005283
24535067,"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus",midazolam,etomidate,D008874,D005045
24535067,"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus",midazolam,myoclonus,D008874,D009207
24535067,"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus",midazolam,fentanyl,D008874,D005283
24535067,"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus",fentanyl,etomidate,D005283,D005045
24535067,"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus",fentanyl,myoclonus,D005283,D009207
24535067,"BACKGROUND: In this retrospective comparative study, we aimed to compare the effectiveness of fentanyl, midazolam, and a combination of fentanyl and midazolam to prevent etomidate-induced myoclonus",fentanyl,midazolam,D005283,D008874
24535067,"Depending on the drugs that would be given before the induction of anesthesia with etomidate, the patients were separated into 4 groups: no pretreatment (Group NP), fentanyl 1 ug.kg-1 (Group F), midazolam 0.03 mg.kg-1 (Group M), and midazolam 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM)",etomidate,midazolam,D005045,D008874
24535067,"Depending on the drugs that would be given before the induction of anesthesia with etomidate, the patients were separated into 4 groups: no pretreatment (Group NP), fentanyl 1 ug.kg-1 (Group F), midazolam 0.03 mg.kg-1 (Group M), and midazolam 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM)",etomidate,fentanyl,D005045,D005283
24535067,"Depending on the drugs that would be given before the induction of anesthesia with etomidate, the patients were separated into 4 groups: no pretreatment (Group NP), fentanyl 1 ug.kg-1 (Group F), midazolam 0.03 mg.kg-1 (Group M), and midazolam 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM)",midazolam,etomidate,D008874,D005045
24535067,"Depending on the drugs that would be given before the induction of anesthesia with etomidate, the patients were separated into 4 groups: no pretreatment (Group NP), fentanyl 1 ug.kg-1 (Group F), midazolam 0.03 mg.kg-1 (Group M), and midazolam 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM)",midazolam,fentanyl,D008874,D005283
24535067,"Depending on the drugs that would be given before the induction of anesthesia with etomidate, the patients were separated into 4 groups: no pretreatment (Group NP), fentanyl 1 ug.kg-1 (Group F), midazolam 0.03 mg.kg-1 (Group M), and midazolam 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM)",fentanyl,etomidate,D005283,D005045
24535067,"Depending on the drugs that would be given before the induction of anesthesia with etomidate, the patients were separated into 4 groups: no pretreatment (Group NP), fentanyl 1 ug.kg-1 (Group F), midazolam 0.03 mg.kg-1 (Group M), and midazolam 0.015 mg.kg-1 + fentanyl 0.5 ug.kg-1 (Group FM)",fentanyl,midazolam,D005283,D008874
24535067,"Myoclonic movements are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection",etomidate,Myoclonic movements,D005045,D009069
24535067,"Myoclonic movements are evaluated, which were observed and graded according to clinical severity during the 2 minutes after etomidate injection",Myoclonic movements,etomidate,D009069,D005045
24535067,"The severity of pain due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated",pain,etomidate,D010146,D005045
24535067,"The severity of pain due to etomidate injection, mean arterial pressure, heart rate, and adverse effects were also evaluated",etomidate,pain,D005045,D010146
24535067,CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.,etomidate,myoclonus,D005045,D009207
24535067,CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.,etomidate,midazolam,D005045,D008874
24535067,CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.,etomidate,fentanyl,D005045,D005283
24535067,CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.,myoclonus,etomidate,D009207,D005045
24535067,CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.,myoclonus,midazolam,D009207,D008874
24535067,CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.,myoclonus,fentanyl,D009207,D005283
24535067,CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.,midazolam,etomidate,D008874,D005045
24535067,CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.,midazolam,myoclonus,D008874,D009207
24535067,CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.,midazolam,fentanyl,D008874,D005283
24535067,CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.,fentanyl,etomidate,D005283,D005045
24535067,CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.,fentanyl,myoclonus,D005283,D009207
24535067,CONCLUSIONS: We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate-induced myoclonus.,fentanyl,midazolam,D005283,D008874
24739405,Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice,amphetamine,dehydroepiandrosterone,D000661,D003687
24739405,Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice,amphetamine,schizophrenia,D000661,D012559
24739405,Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice,dehydroepiandrosterone,amphetamine,D003687,D000661
24739405,Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice,dehydroepiandrosterone,schizophrenia,D003687,D012559
24739405,Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice,schizophrenia,amphetamine,D012559,D000661
24739405,Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice,schizophrenia,dehydroepiandrosterone,D012559,D003687
24739405,OBJECTIVE: To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia,DHEA,dehydroepiandrosterone,D003687,D003687
24739405,OBJECTIVE: To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia,DHEA,schizophrenia,D003687,D012559
24739405,OBJECTIVE: To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia,dehydroepiandrosterone,DHEA,D003687,D003687
24739405,OBJECTIVE: To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia,dehydroepiandrosterone,schizophrenia,D003687,D012559
24739405,OBJECTIVE: To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia,schizophrenia,DHEA,D012559,D003687
24739405,OBJECTIVE: To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia,schizophrenia,dehydroepiandrosterone,D012559,D003687
24739405,"METHODS: Seventy Swiss albino female mice (25-35 g) were divided into 4 groups: amphetamine-free (control), amphetamine, 50, and 100 mg/kg DHEA",DHEA,amphetamine,D003687,D000661
24739405,"METHODS: Seventy Swiss albino female mice (25-35 g) were divided into 4 groups: amphetamine-free (control), amphetamine, 50, and 100 mg/kg DHEA",amphetamine,DHEA,D000661,D003687
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",hyper locomotion,Amphetamine,D006948,D000661
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",hyper locomotion,apomorphine,D006948,D001058
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",hyper locomotion,haloperidol,D006948,D006220
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",Amphetamine,hyper locomotion,D000661,D006948
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",Amphetamine,apomorphine,D000661,D001058
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",Amphetamine,schizophrenia,D000661,D012559
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",Amphetamine,catalepsy,D000661,D002375
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",Amphetamine,haloperidol,D000661,D006220
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",apomorphine,hyper locomotion,D001058,D006948
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",apomorphine,Amphetamine,D001058,D000661
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",apomorphine,schizophrenia,D001058,D012559
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",apomorphine,catalepsy,D001058,D002375
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",apomorphine,haloperidol,D001058,D006220
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",schizophrenia,Amphetamine,D012559,D000661
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",schizophrenia,apomorphine,D012559,D001058
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",schizophrenia,haloperidol,D012559,D006220
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",catalepsy,Amphetamine,D002375,D000661
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",catalepsy,apomorphine,D002375,D001058
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",catalepsy,haloperidol,D002375,D006220
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",haloperidol,hyper locomotion,D006220,D006948
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",haloperidol,Amphetamine,D006220,D000661
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",haloperidol,apomorphine,D006220,D001058
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",haloperidol,schizophrenia,D006220,D012559
24739405,"Amphetamine (3 mg/kg ip) induced hyper locomotion, apomorphine (1.5 mg/kg subcutaneously [sc]) induced climbing, and haloperidol (1.5 mg/kg sc) induced catalepsy tests were used as animal models of schizophrenia",haloperidol,catalepsy,D006220,D002375
24739405,"Both DHEA 50 mg/kg (p<0.05), and 100 mg/kg (p<0.01) significantly decreased all movements compared with the amphetamine-induced locomotion group",DHEA,amphetamine,D003687,D000661
24739405,"Both DHEA 50 mg/kg (p<0.05), and 100 mg/kg (p<0.01) significantly decreased all movements compared with the amphetamine-induced locomotion group",amphetamine,DHEA,D000661,D003687
24739405,There was a significant difference between groups in the haloperidol-induced catalepsy test (p<0.05),catalepsy,haloperidol,D002375,D006220
24739405,There was a significant difference between groups in the haloperidol-induced catalepsy test (p<0.05),haloperidol,catalepsy,D006220,D002375
24739405,"CONCLUSION: We observed that DHEA reduced locomotor activity and increased catalepsy at both doses, while it had no effect on climbing behavior",DHEA,catalepsy,D003687,D002375
24739405,"CONCLUSION: We observed that DHEA reduced locomotor activity and increased catalepsy at both doses, while it had no effect on climbing behavior",catalepsy,DHEA,D002375,D003687
24739405,"We suggest that DHEA displays typical neuroleptic-like effects, and may be used in the treatment of schizophrenia.",DHEA,schizophrenia,D003687,D012559
24739405,"We suggest that DHEA displays typical neuroleptic-like effects, and may be used in the treatment of schizophrenia.",schizophrenia,DHEA,D012559,D003687
24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors,collagen receptor,DDR,"4921,780","4921,780"
24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors,collagen receptor,collagen,"4921,780",1277
24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors,collagen receptor,DDR1,"4921,780",780
24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors,DDR,collagen receptor,"4921,780","4921,780"
24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors,DDR,collagen,"4921,780",1277
24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors,DDR,DDR1,"4921,780",780
24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors,collagen,collagen receptor,1277,"4921,780"
24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors,collagen,DDR,1277,"4921,780"
24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors,collagen,DDR1,1277,780
24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors,DDR1,collagen receptor,780,"4921,780"
24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors,DDR1,DDR,780,"4921,780"
24768818,Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors,DDR1,collagen,780,1277
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDRs,DDR2,"4921,780",4921
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDRs,DDR1,"4921,780",780
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDRs,receptor tyrosine kinases,"4921,780","4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDRs,collagen,"4921,780",1277
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDRs,DDR,"4921,780","4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDRs,discoidin domain receptors,"4921,780","4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR2,DDRs,4921,"4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR2,DDR1,4921,780
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR2,receptor tyrosine kinases,4921,"4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR2,collagen,4921,1277
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR2,DDR,4921,"4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR2,discoidin domain receptors,4921,"4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR1,DDRs,780,"4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR1,DDR2,780,4921
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR1,receptor tyrosine kinases,780,"4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR1,collagen,780,1277
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR1,DDR,780,"4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR1,discoidin domain receptors,780,"4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",receptor tyrosine kinases,DDRs,"4921,780","4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",receptor tyrosine kinases,DDR2,"4921,780",4921
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",receptor tyrosine kinases,DDR1,"4921,780",780
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",receptor tyrosine kinases,collagen,"4921,780",1277
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",receptor tyrosine kinases,DDR,"4921,780","4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",receptor tyrosine kinases,discoidin domain receptors,"4921,780","4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",collagen,DDRs,1277,"4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",collagen,DDR2,1277,4921
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",collagen,DDR1,1277,780
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",collagen,receptor tyrosine kinases,1277,"4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",collagen,DDR,1277,"4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",collagen,discoidin domain receptors,1277,"4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR,DDRs,"4921,780","4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR,DDR2,"4921,780",4921
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR,DDR1,"4921,780",780
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR,receptor tyrosine kinases,"4921,780","4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR,collagen,"4921,780",1277
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",DDR,discoidin domain receptors,"4921,780","4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",discoidin domain receptors,DDRs,"4921,780","4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",discoidin domain receptors,DDR2,"4921,780",4921
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",discoidin domain receptors,DDR1,"4921,780",780
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",discoidin domain receptors,receptor tyrosine kinases,"4921,780","4921,780"
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",discoidin domain receptors,collagen,"4921,780",1277
24768818,"The discoidin domain receptors (DDRs), DDR1 and DDR2, form a unique subfamily of receptor tyrosine kinases that are activated by the binding of triple-helical collagen",discoidin domain receptors,DDR,"4921,780","4921,780"
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR2,cancer,4921,D009369
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR2,fibrosis,4921,D005355
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR2,DDR1,4921,780
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR2,atherosclerosis,4921,D050197
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR2,DDR,4921,"4921,780"
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",cancer,DDR2,D009369,4921
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",cancer,DDR1,D009369,780
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",cancer,DDR,D009369,"4921,780"
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",fibrosis,DDR2,D005355,4921
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",fibrosis,DDR1,D005355,780
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",fibrosis,DDR,D005355,"4921,780"
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR1,DDR2,780,4921
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR1,cancer,780,D009369
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR1,fibrosis,780,D005355
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR1,atherosclerosis,780,D050197
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR1,DDR,780,"4921,780"
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",atherosclerosis,DDR2,D050197,4921
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",atherosclerosis,DDR1,D050197,780
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",atherosclerosis,DDR,D050197,"4921,780"
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR,DDR2,"4921,780",4921
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR,cancer,"4921,780",D009369
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR,fibrosis,"4921,780",D005355
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR,DDR1,"4921,780",780
24768818,"Excessive signaling by DDR1 and DDR2 has been linked to the progression of various human diseases, including fibrosis, atherosclerosis and cancer",DDR,atherosclerosis,"4921,780",D050197
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR1-IN-1,imatinib,-,D000068877
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR1-IN-1,ponatinib,-,C545373
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR1-IN-1,cancer,-,D009369
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR1-IN-1,DDR1,-,780
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR1-IN-1,receptor tyrosine kinases,-,"4921,780"
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR1-IN-1,DDR,-,"4921,780"
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",imatinib,DDR1-IN-1,D000068877,-
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",imatinib,ponatinib,D000068877,C545373
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",imatinib,cancer,D000068877,D009369
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",imatinib,DDR1,D000068877,780
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",imatinib,receptor tyrosine kinases,D000068877,"4921,780"
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",imatinib,DDR,D000068877,"4921,780"
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",ponatinib,DDR1-IN-1,C545373,-
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",ponatinib,imatinib,C545373,D000068877
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",ponatinib,cancer,C545373,D009369
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",ponatinib,DDR1,C545373,780
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",ponatinib,receptor tyrosine kinases,C545373,"4921,780"
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",ponatinib,DDR,C545373,"4921,780"
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",cancer,DDR1-IN-1,D009369,-
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",cancer,imatinib,D009369,D000068877
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",cancer,ponatinib,D009369,C545373
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",cancer,DDR1,D009369,780
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",cancer,receptor tyrosine kinases,D009369,"4921,780"
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",cancer,DDR,D009369,"4921,780"
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR1,DDR1-IN-1,780,-
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR1,imatinib,780,D000068877
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR1,ponatinib,780,C545373
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR1,cancer,780,D009369
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR1,receptor tyrosine kinases,780,"4921,780"
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR1,DDR,780,"4921,780"
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",receptor tyrosine kinases,DDR1-IN-1,"4921,780",-
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",receptor tyrosine kinases,imatinib,"4921,780",D000068877
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",receptor tyrosine kinases,ponatinib,"4921,780",C545373
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",receptor tyrosine kinases,cancer,"4921,780",D009369
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",receptor tyrosine kinases,DDR1,"4921,780",780
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",receptor tyrosine kinases,DDR,"4921,780","4921,780"
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR,DDR1-IN-1,"4921,780",-
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR,imatinib,"4921,780",D000068877
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR,ponatinib,"4921,780",C545373
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR,cancer,"4921,780",D009369
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR,DDR1,"4921,780",780
24768818,"We report the inhibition of these unusual receptor tyrosine kinases by the multi-targeted cancer drugs imatinib and ponatinib, as well as the selective type II inhibitor DDR1-IN-1",DDR,receptor tyrosine kinases,"4921,780","4921,780"
24768818,"Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM",Ponatinib,DDR,C545373,"4921,780"
24768818,"Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM",Ponatinib,DDR1,C545373,780
24768818,"Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM",Ponatinib,DDR2,C545373,4921
24768818,"Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM",DDR,Ponatinib,"4921,780",C545373
24768818,"Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM",DDR,DDR1,"4921,780",780
24768818,"Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM",DDR,DDR2,"4921,780",4921
24768818,"Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM",DDR1,Ponatinib,780,C545373
24768818,"Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM",DDR1,DDR,780,"4921,780"
24768818,"Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM",DDR1,DDR2,780,4921
24768818,"Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM",DDR2,Ponatinib,4921,C545373
24768818,"Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM",DDR2,DDR,4921,"4921,780"
24768818,"Ponatinib is identified as the more potent molecule, which inhibits DDR1 and DDR2 with an IC50 of 9nM",DDR2,DDR1,4921,780
24768818,"Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix",DFG,Asp-Phe-Gly,C553185,C553185
24768818,"Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix",DFG,DDR1,C553185,780
24768818,"Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix",DFG,DDR,C553185,"4921,780"
24768818,"Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix",Asp-Phe-Gly,DFG,C553185,C553185
24768818,"Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix",Asp-Phe-Gly,DDR1,C553185,780
24768818,"Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix",Asp-Phe-Gly,DDR,C553185,"4921,780"
24768818,"Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix",DDR1,DFG,780,C553185
24768818,"Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix",DDR1,Asp-Phe-Gly,780,C553185
24768818,"Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix",DDR1,DDR,780,"4921,780"
24768818,"Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix",DDR,DFG,"4921,780",C553185
24768818,"Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix",DDR,Asp-Phe-Gly,"4921,780",C553185
24768818,"Co-crystal structures of human DDR1 reveal a DFG-out conformation (DFG, Asp-Phe-Gly) of the kinase domain that is stabilized by an unusual salt bridge between the activation loop and aD helix",DDR,DDR1,"4921,780",780
24768818,"Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL",ABL,DDR,25,"4921,780"
24768818,"Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL",ABL,DDR1,25,780
24768818,"Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL",ABL,Abelson kinase,25,25
24768818,"Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL",DDR,ABL,"4921,780",25
24768818,"Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL",DDR,DDR1,"4921,780",780
24768818,"Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL",DDR,Abelson kinase,"4921,780",25
24768818,"Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL",DDR1,ABL,780,25
24768818,"Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL",DDR1,DDR,780,"4921,780"
24768818,"Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL",DDR1,Abelson kinase,780,25
24768818,"Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL",Abelson kinase,ABL,25,25
24768818,"Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL",Abelson kinase,DDR,25,"4921,780"
24768818,"Differences to Abelson kinase (ABL) are observed in the DDR1 P-loop, where a b-hairpin replaces the cage-like structure of ABL",Abelson kinase,DDR1,25,780
24768818,P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket,ABL,DDR,25,"4921,780"
24768818,P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket,ABL,DDR1,25,780
24768818,P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket,ABL,ATP,25,D000255
24768818,P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket,DDR,ABL,"4921,780",25
24768818,P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket,DDR,DDR1,"4921,780",780
24768818,P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket,DDR,ATP,"4921,780",D000255
24768818,P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket,DDR1,ABL,780,25
24768818,P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket,DDR1,DDR,780,"4921,780"
24768818,P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket,DDR1,ATP,780,D000255
24768818,P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket,ATP,ABL,D000255,25
24768818,P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket,ATP,DDR,D000255,"4921,780"
24768818,P-loop residues in DDR1 that confer drug resistance in ABL are therefore accommodated outside the ATP pocket,ATP,DDR1,D000255,780
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR1-IN-1,imatinib,-,D000068877
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR1-IN-1,ponatinib,-,C545373
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR1-IN-1,DDR1,-,780
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR1-IN-1,ABL,-,25
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR1-IN-1,DDR,-,"4921,780"
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",imatinib,DDR1-IN-1,D000068877,-
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",imatinib,ponatinib,D000068877,C545373
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",imatinib,DDR1,D000068877,780
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",imatinib,ABL,D000068877,25
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",imatinib,DDR,D000068877,"4921,780"
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",ponatinib,DDR1-IN-1,C545373,-
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",ponatinib,imatinib,C545373,D000068877
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",ponatinib,DDR1,C545373,780
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",ponatinib,ABL,C545373,25
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",ponatinib,DDR,C545373,"4921,780"
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR1,DDR1-IN-1,780,-
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR1,imatinib,780,D000068877
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR1,ponatinib,780,C545373
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR1,ABL,780,25
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR1,DDR,780,"4921,780"
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",ABL,DDR1-IN-1,25,-
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",ABL,imatinib,25,D000068877
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",ABL,ponatinib,25,C545373
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",ABL,DDR1,25,780
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",ABL,DDR,25,"4921,780"
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR,DDR1-IN-1,"4921,780",-
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR,imatinib,"4921,780",D000068877
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR,ponatinib,"4921,780",C545373
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR,DDR1,"4921,780",780
24768818,"Whereas imatinib and ponatinib bind potently to both the DDR and ABL kinases, the hydrophobic interactions of the ABL P-loop appear poorly satisfied by DDR1-IN-1 suggesting a structural basis for its DDR1 selectivity",DDR,ABL,"4921,780",25
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",DDR2,cancer,4921,D009369
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",DDR2,DDR1,4921,780
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",DDR2,DDR,4921,"4921,780"
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",DDR2,lung cancer,4921,D008175
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",cancer,DDR2,D009369,4921
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",cancer,DDR1,D009369,780
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",cancer,DDR,D009369,"4921,780"
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",DDR1,DDR2,780,4921
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",DDR1,cancer,780,D009369
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",DDR1,DDR,780,"4921,780"
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",DDR1,lung cancer,780,D008175
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",DDR,DDR2,"4921,780",4921
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",DDR,cancer,"4921,780",D009369
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",DDR,DDR1,"4921,780",780
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",DDR,lung cancer,"4921,780",D008175
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",lung cancer,DDR2,D008175,4921
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",lung cancer,DDR1,D008175,780
24768818,"Such inhibitors may have applications in clinical indications of DDR1 and DDR2 overexpression or mutation, including lung cancer.",lung cancer,DDR,D008175,"4921,780"
24853300,Crucial role of calbindin-D28k in the pathogenesis of Alzheimer's disease mouse model,calbindin-D28k,Alzheimer's disease,12307,D000544
24853300,Crucial role of calbindin-D28k in the pathogenesis of Alzheimer's disease mouse model,Alzheimer's disease,calbindin-D28k,D000544,12307
24853300,"Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis",Calbindin-D28k,CB,12307,12307
24853300,"Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis",Calbindin-D28k,calcium,12307,D002118
24853300,"Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis",Calbindin-D28k,neuronal death,12307,D009410
24853300,"Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis",CB,Calbindin-D28k,12307,12307
24853300,"Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis",CB,calcium,12307,D002118
24853300,"Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis",CB,neuronal death,12307,D009410
24853300,"Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis",calcium,Calbindin-D28k,D002118,12307
24853300,"Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis",calcium,CB,D002118,12307
24853300,"Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis",calcium,neuronal death,D002118,D009410
24853300,"Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis",neuronal death,Calbindin-D28k,D009410,12307
24853300,"Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis",neuronal death,CB,D009410,12307
24853300,"Calbindin-D28k (CB), one of the major calcium-binding and buffering proteins, has a critical role in preventing a neuronal death as well as maintaining calcium homeostasis",neuronal death,calcium,D009410,D002118
24853300,"Although marked reductions of CB expression have been observed in the brains of mice and humans with Alzheimer disease (AD), it is unknown whether these changes contribute to AD-related dysfunction",Alzheimer disease,CB,D000544,12307
24853300,"Although marked reductions of CB expression have been observed in the brains of mice and humans with Alzheimer disease (AD), it is unknown whether these changes contribute to AD-related dysfunction",CB,Alzheimer disease,12307,D000544
24853300,"Although marked reductions of CB expression have been observed in the brains of mice and humans with Alzheimer disease (AD), it is unknown whether these changes contribute to AD-related dysfunction",CB,AD,12307,D000544
24853300,"Although marked reductions of CB expression have been observed in the brains of mice and humans with Alzheimer disease (AD), it is unknown whether these changes contribute to AD-related dysfunction",AD,CB,D000544,12307
24853300,"To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice",CB,AD,12307,D000544
24853300,"To determine the pathogenic importance of CB depletions in AD models, we crossed 5 familial AD mutations (5XFAD; Tg) mice with CB knock-out (CBKO) mice and generated a novel line CBKO.5XFAD (CBKOTg) mice",AD,CB,D000544,12307
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,amyloid b-peptide,Ab,11820,11820
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,amyloid b-peptide,mitochondrial dysfunction,11820,D028361
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,amyloid b-peptide,neuronal loss,11820,D009410
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,amyloid b-peptide,CB,11820,12307
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,Ab,amyloid b-peptide,11820,11820
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,Ab,mitochondrial dysfunction,11820,D028361
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,Ab,neuronal loss,11820,D009410
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,Ab,CB,11820,12307
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,mitochondrial dysfunction,amyloid b-peptide,D028361,11820
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,mitochondrial dysfunction,Ab,D028361,11820
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,mitochondrial dysfunction,CB,D028361,12307
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,neuronal loss,amyloid b-peptide,D009410,11820
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,neuronal loss,Ab,D009410,11820
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,neuronal loss,CB,D009410,12307
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,CB,amyloid b-peptide,12307,11820
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,CB,Ab,12307,11820
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,CB,mitochondrial dysfunction,12307,D028361
24853300,Immunohistochemistry showed that CBKOTg mice had significant neuronal loss in the subiculum area without changing the magnitude (number) of amyloid b-peptide (Ab) plaques deposition and elicited significant apoptotic features and mitochondrial dysfunction compared with Tg mice,CB,neuronal loss,12307,D009410
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",extracellular signal-regulated kinase) 1/2,synaptophysin,"26413,26417",20977
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",extracellular signal-regulated kinase) 1/2,N-methyl-D-aspartate receptor 1,"26413,26417",14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",extracellular signal-regulated kinase) 1/2,NMDA receptor 1,"26413,26417",14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",extracellular signal-regulated kinase) 1/2,Ser-133,"26413,26417",p|Allele|S|133
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",extracellular signal-regulated kinase) 1/2,PSD-95,"26413,26417",13385
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",extracellular signal-regulated kinase) 1/2,mitogen-activated protein kinase,"26413,26417","26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",extracellular signal-regulated kinase) 1/2,cAMP response element-binding protein,"26413,26417",12912
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",extracellular signal-regulated kinase) 1/2,CB,"26413,26417",12307
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",extracellular signal-regulated kinase) 1/2,NMDA receptor 2A,"26413,26417",14811
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",synaptophysin,extracellular signal-regulated kinase) 1/2,20977,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",synaptophysin,N-methyl-D-aspartate receptor 1,20977,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",synaptophysin,NMDA receptor 1,20977,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",synaptophysin,Ser-133,20977,p|Allele|S|133
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",synaptophysin,PSD-95,20977,13385
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",synaptophysin,mitogen-activated protein kinase,20977,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",synaptophysin,cAMP response element-binding protein,20977,12912
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",synaptophysin,CB,20977,12307
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",synaptophysin,NMDA receptor 2A,20977,14811
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",N-methyl-D-aspartate receptor 1,extracellular signal-regulated kinase) 1/2,14810,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",N-methyl-D-aspartate receptor 1,synaptophysin,14810,20977
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",N-methyl-D-aspartate receptor 1,NMDA receptor 1,14810,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",N-methyl-D-aspartate receptor 1,Ser-133,14810,p|Allele|S|133
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",N-methyl-D-aspartate receptor 1,PSD-95,14810,13385
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",N-methyl-D-aspartate receptor 1,mitogen-activated protein kinase,14810,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",N-methyl-D-aspartate receptor 1,cAMP response element-binding protein,14810,12912
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",N-methyl-D-aspartate receptor 1,CB,14810,12307
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",N-methyl-D-aspartate receptor 1,NMDA receptor 2A,14810,14811
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 1,extracellular signal-regulated kinase) 1/2,14810,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 1,synaptophysin,14810,20977
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 1,N-methyl-D-aspartate receptor 1,14810,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 1,Ser-133,14810,p|Allele|S|133
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 1,PSD-95,14810,13385
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 1,mitogen-activated protein kinase,14810,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 1,cAMP response element-binding protein,14810,12912
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 1,CB,14810,12307
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 1,NMDA receptor 2A,14810,14811
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",Ser-133,extracellular signal-regulated kinase) 1/2,p|Allele|S|133,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",Ser-133,synaptophysin,p|Allele|S|133,20977
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",Ser-133,N-methyl-D-aspartate receptor 1,p|Allele|S|133,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",Ser-133,NMDA receptor 1,p|Allele|S|133,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",Ser-133,PSD-95,p|Allele|S|133,13385
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",Ser-133,mitogen-activated protein kinase,p|Allele|S|133,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",Ser-133,cAMP response element-binding protein,p|Allele|S|133,12912
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",Ser-133,CB,p|Allele|S|133,12307
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",Ser-133,NMDA receptor 2A,p|Allele|S|133,14811
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",PSD-95,extracellular signal-regulated kinase) 1/2,13385,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",PSD-95,synaptophysin,13385,20977
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",PSD-95,N-methyl-D-aspartate receptor 1,13385,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",PSD-95,NMDA receptor 1,13385,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",PSD-95,Ser-133,13385,p|Allele|S|133
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",PSD-95,mitogen-activated protein kinase,13385,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",PSD-95,cAMP response element-binding protein,13385,12912
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",PSD-95,CB,13385,12307
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",PSD-95,NMDA receptor 2A,13385,14811
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",mitogen-activated protein kinase,extracellular signal-regulated kinase) 1/2,"26413,26417","26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",mitogen-activated protein kinase,synaptophysin,"26413,26417",20977
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",mitogen-activated protein kinase,N-methyl-D-aspartate receptor 1,"26413,26417",14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",mitogen-activated protein kinase,NMDA receptor 1,"26413,26417",14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",mitogen-activated protein kinase,Ser-133,"26413,26417",p|Allele|S|133
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",mitogen-activated protein kinase,PSD-95,"26413,26417",13385
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",mitogen-activated protein kinase,cAMP response element-binding protein,"26413,26417",12912
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",mitogen-activated protein kinase,CB,"26413,26417",12307
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",mitogen-activated protein kinase,NMDA receptor 2A,"26413,26417",14811
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",cAMP response element-binding protein,extracellular signal-regulated kinase) 1/2,12912,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",cAMP response element-binding protein,synaptophysin,12912,20977
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",cAMP response element-binding protein,N-methyl-D-aspartate receptor 1,12912,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",cAMP response element-binding protein,NMDA receptor 1,12912,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",cAMP response element-binding protein,Ser-133,12912,p|Allele|S|133
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",cAMP response element-binding protein,PSD-95,12912,13385
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",cAMP response element-binding protein,mitogen-activated protein kinase,12912,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",cAMP response element-binding protein,CB,12912,12307
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",cAMP response element-binding protein,NMDA receptor 2A,12912,14811
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",CB,extracellular signal-regulated kinase) 1/2,12307,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",CB,synaptophysin,12307,20977
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",CB,N-methyl-D-aspartate receptor 1,12307,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",CB,NMDA receptor 1,12307,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",CB,Ser-133,12307,p|Allele|S|133
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",CB,PSD-95,12307,13385
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",CB,mitogen-activated protein kinase,12307,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",CB,cAMP response element-binding protein,12307,12912
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",CB,NMDA receptor 2A,12307,14811
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 2A,extracellular signal-regulated kinase) 1/2,14811,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 2A,synaptophysin,14811,20977
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 2A,N-methyl-D-aspartate receptor 1,14811,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 2A,NMDA receptor 1,14811,14810
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 2A,Ser-133,14811,p|Allele|S|133
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 2A,PSD-95,14811,13385
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 2A,mitogen-activated protein kinase,14811,"26413,26417"
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 2A,cAMP response element-binding protein,14811,12912
24853300,"Moreover, CBKOTg mice reduced levels of phosphorylated mitogen-activated protein kinase (extracellular signal-regulated kinase) 1/2 and cAMP response element-binding protein at Ser-133 and synaptic molecules such as N-methyl-D-aspartate receptor 1 (NMDA receptor 1), NMDA receptor 2A, PSD-95 and synaptophysin in the subiculum compared with Tg mice",NMDA receptor 2A,CB,14811,12307
24853300,"Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.",amyloid precursor protein,presenilin,11820,19164
24853300,"Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.",amyloid precursor protein,CB,11820,12307
24853300,"Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.",amyloid precursor protein,AD,11820,D000544
24853300,"Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.",presenilin,amyloid precursor protein,19164,11820
24853300,"Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.",presenilin,CB,19164,12307
24853300,"Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.",presenilin,AD,19164,D000544
24853300,"Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.",CB,amyloid precursor protein,12307,11820
24853300,"Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.",CB,presenilin,12307,19164
24853300,"Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.",CB,AD,12307,D000544
24853300,"Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.",AD,amyloid precursor protein,D000544,11820
24853300,"Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.",AD,presenilin,D000544,19164
24853300,"Importantly, this is the first experimental evidence that removal of CB from amyloid precursor protein/presenilin transgenic mice aggravates AD pathogenesis, suggesting that CB has a critical role in AD pathogenesis.",AD,CB,D000544,12307
25080425,Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats,betaine,isoproterenol,D001622,D007545
25080425,Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats,betaine,myocardial injury,D001622,D009202
25080425,Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats,betaine,signal transducer and activator of transcription 3,D001622,25125
25080425,Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats,isoproterenol,betaine,D007545,D001622
25080425,Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats,isoproterenol,myocardial injury,D007545,D009202
25080425,Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats,isoproterenol,signal transducer and activator of transcription 3,D007545,25125
25080425,Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats,myocardial injury,betaine,D009202,D001622
25080425,Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats,myocardial injury,isoproterenol,D009202,D007545
25080425,Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats,myocardial injury,signal transducer and activator of transcription 3,D009202,25125
25080425,Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats,signal transducer and activator of transcription 3,betaine,25125,D001622
25080425,Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats,signal transducer and activator of transcription 3,isoproterenol,25125,D007545
25080425,Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol-induced acute myocardial injury in rats,signal transducer and activator of transcription 3,myocardial injury,25125,D009202
25080425,The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect,betaine,signal transducer and activator of transcription 3,D001622,25125
25080425,The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect,betaine,STAT3,D001622,25125
25080425,The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect,betaine,myocardial ischemia,D001622,D017202
25080425,The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect,signal transducer and activator of transcription 3,betaine,25125,D001622
25080425,The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect,signal transducer and activator of transcription 3,STAT3,25125,25125
25080425,The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect,signal transducer and activator of transcription 3,myocardial ischemia,25125,D017202
25080425,The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect,STAT3,betaine,25125,D001622
25080425,The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect,STAT3,signal transducer and activator of transcription 3,25125,25125
25080425,The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect,STAT3,myocardial ischemia,25125,D017202
25080425,The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect,myocardial ischemia,betaine,D017202,D001622
25080425,The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect,myocardial ischemia,signal transducer and activator of transcription 3,D017202,25125
25080425,The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 (STAT3) and apoptotic pathways as the potential mechanism underlying the drug effect,myocardial ischemia,STAT3,D017202,25125
25080425,"Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol (85 mg/kg), for two consecutive days",isoproterenol,myocardial ischemic injury,D007545,D017202
25080425,"Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol (85 mg/kg), for two consecutive days",myocardial ischemic injury,isoproterenol,D017202,D007545
25080425,Oral administration of betaine (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ventricular remodeling,betaine,ventricular remodeling,D001622,D020257
25080425,Oral administration of betaine (200 and 400 mg/kg) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ventricular remodeling,ventricular remodeling,betaine,D020257,D001622
25080425,Western blot analysis showed that isoproterenol-induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium,betaine,isoproterenol,D001622,D007545
25080425,Western blot analysis showed that isoproterenol-induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium,betaine,STAT3,D001622,25125
25080425,Western blot analysis showed that isoproterenol-induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium,isoproterenol,betaine,D007545,D001622
25080425,Western blot analysis showed that isoproterenol-induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium,isoproterenol,STAT3,D007545,25125
25080425,Western blot analysis showed that isoproterenol-induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium,STAT3,betaine,25125,D001622
25080425,Western blot analysis showed that isoproterenol-induced phosphorylation of STAT3 was maintained or further enhanced by betaine treatment in myocardium,STAT3,isoproterenol,25125,D007545
25080425,"Furthermore, betaine (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax",betaine,Bcl-2,D001622,24224
25080425,"Furthermore, betaine (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax",betaine,Bax,D001622,24887
25080425,"Furthermore, betaine (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax",Bcl-2,betaine,24224,D001622
25080425,"Furthermore, betaine (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax",Bcl-2,Bax,24224,24887
25080425,"Furthermore, betaine (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax",Bax,betaine,24887,D001622
25080425,"Furthermore, betaine (200 and 400 mg/kg) treatment increased the ventricular expression of Bcl-2 and reduced the level of Bax, therefore causing a significant increase in the ratio of Bcl-2/Bax",Bax,Bcl-2,24887,24224
25080425,The protective role of betaine on myocardial damage was further confirmed by histopathological examination,betaine,myocardial damage,D001622,D009202
25080425,The protective role of betaine on myocardial damage was further confirmed by histopathological examination,myocardial damage,betaine,D009202,D001622
25080425,"In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.",betaine,STAT3,D001622,25125
25080425,"In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.",betaine,isoproterenol,D001622,D007545
25080425,"In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.",betaine,myocardial ischemia,D001622,D017202
25080425,"In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.",STAT3,betaine,25125,D001622
25080425,"In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.",STAT3,isoproterenol,25125,D007545
25080425,"In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.",STAT3,myocardial ischemia,25125,D017202
25080425,"In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.",isoproterenol,betaine,D007545,D001622
25080425,"In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.",isoproterenol,STAT3,D007545,25125
25080425,"In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.",isoproterenol,myocardial ischemia,D007545,D017202
25080425,"In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.",myocardial ischemia,betaine,D017202,D001622
25080425,"In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.",myocardial ischemia,STAT3,D017202,25125
25080425,"In summary, our results showed that betaine pretreatment attenuated isoproterenol-induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways.",myocardial ischemia,isoproterenol,D017202,D007545
25305591,VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses,vasoactive intestinal peptide receptor type 2,experimental autoimmune encephalomyelitis,22355,D004681
25305591,VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses,vasoactive intestinal peptide receptor type 2,VPAC2,22355,22355
25305591,VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses,experimental autoimmune encephalomyelitis,vasoactive intestinal peptide receptor type 2,D004681,22355
25305591,VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses,experimental autoimmune encephalomyelitis,VPAC2,D004681,22355
25305591,VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses,VPAC2,vasoactive intestinal peptide receptor type 2,22355,22355
25305591,VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses,VPAC2,experimental autoimmune encephalomyelitis,22355,D004681
25305591,Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems,PACAP,pituitary adenylyl cyclase-activating polypeptide,11516,11516
25305591,Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems,PACAP,Vasoactive intestinal peptide,11516,22353
25305591,Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems,PACAP,VIP,11516,22353
25305591,Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems,pituitary adenylyl cyclase-activating polypeptide,PACAP,11516,11516
25305591,Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems,pituitary adenylyl cyclase-activating polypeptide,Vasoactive intestinal peptide,11516,22353
25305591,Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems,pituitary adenylyl cyclase-activating polypeptide,VIP,11516,22353
25305591,Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems,Vasoactive intestinal peptide,PACAP,22353,11516
25305591,Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems,Vasoactive intestinal peptide,pituitary adenylyl cyclase-activating polypeptide,22353,11516
25305591,Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems,Vasoactive intestinal peptide,VIP,22353,22353
25305591,Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems,VIP,PACAP,22353,11516
25305591,Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems,VIP,pituitary adenylyl cyclase-activating polypeptide,22353,11516
25305591,Vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating polypeptide (PACAP) are two structurally-related neuropeptides with widespread expression in the central and peripheral nervous systems,VIP,Vasoactive intestinal peptide,22353,22353
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",PACAP,experimental autoimmune encephalomyelitis,11516,D004681
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",PACAP,inflammatory disease,11516,D007249
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",PACAP,EAE,11516,D004681
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",PACAP,inflammatory,11516,D007249
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",PACAP,VIP,11516,22353
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",experimental autoimmune encephalomyelitis,PACAP,D004681,11516
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",experimental autoimmune encephalomyelitis,VIP,D004681,22353
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",inflammatory disease,PACAP,D007249,11516
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",inflammatory disease,VIP,D007249,22353
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",EAE,PACAP,D004681,11516
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",EAE,VIP,D004681,22353
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",inflammatory,PACAP,D007249,11516
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",inflammatory,VIP,D007249,22353
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",VIP,PACAP,22353,11516
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",VIP,experimental autoimmune encephalomyelitis,22353,D004681
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",VIP,inflammatory disease,22353,D007249
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",VIP,EAE,22353,D004681
25305591,"Although these peptides have been repeatedly shown to exert potent anti-inflammatory actions when administered in animal models of inflammatory disease, mice deficient in VIP and PACAP were recently shown to exhibit different phenotypes (ameliorated and exacerbated, respectively) in response to experimental autoimmune encephalomyelitis (EAE)",VIP,inflammatory,22353,D007249
25305591,"Therefore, elucidating what are the specific immunoregulatory roles played by each of their receptor subtypes (VPAC1, VPAC2, and PAC1) is critical",VPAC1,PAC1,22354,11517
25305591,"Therefore, elucidating what are the specific immunoregulatory roles played by each of their receptor subtypes (VPAC1, VPAC2, and PAC1) is critical",VPAC1,VPAC2,22354,22355
25305591,"Therefore, elucidating what are the specific immunoregulatory roles played by each of their receptor subtypes (VPAC1, VPAC2, and PAC1) is critical",PAC1,VPAC1,11517,22354
25305591,"Therefore, elucidating what are the specific immunoregulatory roles played by each of their receptor subtypes (VPAC1, VPAC2, and PAC1) is critical",PAC1,VPAC2,11517,22355
25305591,"Therefore, elucidating what are the specific immunoregulatory roles played by each of their receptor subtypes (VPAC1, VPAC2, and PAC1) is critical",VPAC2,VPAC1,22355,22354
25305591,"Therefore, elucidating what are the specific immunoregulatory roles played by each of their receptor subtypes (VPAC1, VPAC2, and PAC1) is critical",VPAC2,PAC1,22355,11517
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,VPAC2,16193,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,anti-inflammatory cytokines,16193,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,IL-10,16193,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,TGFbeta,16193,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,EAE,16193,D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,inflammatory,16193,D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,proinflammatory cytokines,16193,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,IL-4,16193,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,VPAC2 receptor,16193,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,VIPR2,16193,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,IFN-gamma,16193,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,TNF-alpha,16193,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,VIP,16193,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,IL-17,16193,16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-6,MOG35-55,16193,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,IL-6,22355,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,anti-inflammatory cytokines,22355,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,IL-10,22355,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,TGFbeta,22355,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,EAE,22355,D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,inflammatory,22355,D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,proinflammatory cytokines,22355,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,IL-4,22355,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,VPAC2 receptor,22355,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,VIPR2,22355,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,IFN-gamma,22355,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,TNF-alpha,22355,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,VIP,22355,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,IL-17,22355,16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2,MOG35-55,22355,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,IL-6,"16153,16189,21803",16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,VPAC2,"16153,16189,21803",22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,IL-10,"16153,16189,21803",16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,TGFbeta,"16153,16189,21803",21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,EAE,"16153,16189,21803",D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,inflammatory,"16153,16189,21803",D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,proinflammatory cytokines,"16153,16189,21803","15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,IL-4,"16153,16189,21803",16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,VPAC2 receptor,"16153,16189,21803",22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,VIPR2,"16153,16189,21803",22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,IFN-gamma,"16153,16189,21803",15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,TNF-alpha,"16153,16189,21803",21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,VIP,"16153,16189,21803",22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,IL-17,"16153,16189,21803",16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",anti-inflammatory cytokines,MOG35-55,"16153,16189,21803",4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,IL-6,16153,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,VPAC2,16153,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,anti-inflammatory cytokines,16153,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,TGFbeta,16153,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,EAE,16153,D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,inflammatory,16153,D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,proinflammatory cytokines,16153,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,IL-4,16153,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,VPAC2 receptor,16153,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,VIPR2,16153,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,IFN-gamma,16153,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,TNF-alpha,16153,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,VIP,16153,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,IL-17,16153,16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-10,MOG35-55,16153,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,IL-6,21803,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,VPAC2,21803,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,anti-inflammatory cytokines,21803,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,IL-10,21803,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,EAE,21803,D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,inflammatory,21803,D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,proinflammatory cytokines,21803,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,IL-4,21803,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,VPAC2 receptor,21803,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,VIPR2,21803,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,IFN-gamma,21803,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,TNF-alpha,21803,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,VIP,21803,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,IL-17,21803,16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TGFbeta,MOG35-55,21803,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,IL-6,D004681,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,VPAC2,D004681,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,anti-inflammatory cytokines,D004681,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,IL-10,D004681,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,TGFbeta,D004681,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,proinflammatory cytokines,D004681,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,IL-4,D004681,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,VPAC2 receptor,D004681,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,VIPR2,D004681,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,IFN-gamma,D004681,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,TNF-alpha,D004681,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,VIP,D004681,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,IL-17,D004681,16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",EAE,MOG35-55,D004681,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,IL-6,D007249,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,VPAC2,D007249,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,anti-inflammatory cytokines,D007249,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,IL-10,D007249,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,TGFbeta,D007249,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,proinflammatory cytokines,D007249,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,IL-4,D007249,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,VPAC2 receptor,D007249,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,VIPR2,D007249,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,IFN-gamma,D007249,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,TNF-alpha,D007249,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,VIP,D007249,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,IL-17,D007249,16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",inflammatory,MOG35-55,D007249,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,IL-6,"15978,16171,16193,21926",16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,VPAC2,"15978,16171,16193,21926",22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,anti-inflammatory cytokines,"15978,16171,16193,21926","16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,IL-10,"15978,16171,16193,21926",16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,TGFbeta,"15978,16171,16193,21926",21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,EAE,"15978,16171,16193,21926",D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,inflammatory,"15978,16171,16193,21926",D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,IL-4,"15978,16171,16193,21926",16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,VPAC2 receptor,"15978,16171,16193,21926",22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,VIPR2,"15978,16171,16193,21926",22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,IFN-gamma,"15978,16171,16193,21926",15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,TNF-alpha,"15978,16171,16193,21926",21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,VIP,"15978,16171,16193,21926",22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,IL-17,"15978,16171,16193,21926",16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",proinflammatory cytokines,MOG35-55,"15978,16171,16193,21926",4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,IL-6,16189,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,VPAC2,16189,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,anti-inflammatory cytokines,16189,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,IL-10,16189,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,TGFbeta,16189,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,EAE,16189,D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,inflammatory,16189,D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,proinflammatory cytokines,16189,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,VPAC2 receptor,16189,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,VIPR2,16189,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,IFN-gamma,16189,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,TNF-alpha,16189,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,VIP,16189,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,IL-17,16189,16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-4,MOG35-55,16189,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,IL-6,22355,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,VPAC2,22355,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,anti-inflammatory cytokines,22355,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,IL-10,22355,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,TGFbeta,22355,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,EAE,22355,D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,inflammatory,22355,D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,proinflammatory cytokines,22355,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,IL-4,22355,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,VIPR2,22355,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,IFN-gamma,22355,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,TNF-alpha,22355,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,VIP,22355,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,IL-17,22355,16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VPAC2 receptor,MOG35-55,22355,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,IL-6,22355,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,VPAC2,22355,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,anti-inflammatory cytokines,22355,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,IL-10,22355,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,TGFbeta,22355,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,EAE,22355,D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,inflammatory,22355,D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,proinflammatory cytokines,22355,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,IL-4,22355,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,VPAC2 receptor,22355,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,IFN-gamma,22355,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,TNF-alpha,22355,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,VIP,22355,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,IL-17,22355,16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIPR2,MOG35-55,22355,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,IL-6,15978,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,VPAC2,15978,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,anti-inflammatory cytokines,15978,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,IL-10,15978,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,TGFbeta,15978,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,EAE,15978,D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,inflammatory,15978,D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,proinflammatory cytokines,15978,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,IL-4,15978,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,VPAC2 receptor,15978,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,VIPR2,15978,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,TNF-alpha,15978,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,VIP,15978,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,IL-17,15978,16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IFN-gamma,MOG35-55,15978,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,IL-6,21926,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,VPAC2,21926,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,anti-inflammatory cytokines,21926,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,IL-10,21926,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,TGFbeta,21926,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,EAE,21926,D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,inflammatory,21926,D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,proinflammatory cytokines,21926,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,IL-4,21926,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,VPAC2 receptor,21926,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,VIPR2,21926,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,IFN-gamma,21926,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,VIP,21926,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,IL-17,21926,16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",TNF-alpha,MOG35-55,21926,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,IL-6,22353,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,VPAC2,22353,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,anti-inflammatory cytokines,22353,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,IL-10,22353,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,TGFbeta,22353,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,EAE,22353,D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,inflammatory,22353,D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,proinflammatory cytokines,22353,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,IL-4,22353,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,VPAC2 receptor,22353,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,VIPR2,22353,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,IFN-gamma,22353,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,TNF-alpha,22353,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,IL-17,22353,16171
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",VIP,MOG35-55,22353,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,IL-6,16171,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,VPAC2,16171,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,anti-inflammatory cytokines,16171,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,IL-10,16171,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,TGFbeta,16171,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,EAE,16171,D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,inflammatory,16171,D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,proinflammatory cytokines,16171,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,IL-4,16171,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,VPAC2 receptor,16171,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,VIPR2,16171,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,IFN-gamma,16171,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,TNF-alpha,16171,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,VIP,16171,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",IL-17,MOG35-55,16171,4340
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,IL-6,4340,16193
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,VPAC2,4340,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,anti-inflammatory cytokines,4340,"16153,16189,21803"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,IL-10,4340,16153
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,TGFbeta,4340,21803
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,EAE,4340,D004681
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,inflammatory,4340,D007249
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,proinflammatory cytokines,4340,"15978,16171,16193,21926"
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,IL-4,4340,16189
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,VPAC2 receptor,4340,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,VIPR2,4340,22355
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,IFN-gamma,4340,15978
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,TNF-alpha,4340,21926
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,VIP,4340,22353
25305591,"In this study, we found that mice with a genetic deletion of VIPR2, encoding the VPAC2 receptor, exhibited exacerbated (MOG35-55)-induced EAE compared to wild type mice, characterized by enhanced clinical and histopathological features, increased proinflammatory cytokines (TNF-alpha, IL-6, IFN-gamma (Th1), and IL-17 (Th17)) and reduced anti-inflammatory cytokines (IL-10, TGFbeta, and IL-4 (Th2)) in the CNS and lymph nodes",MOG35-55,IL-17,4340,16171
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",FoxP3,VPAC2,20371,22355
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",FoxP3,EAE,20371,D004681
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",FoxP3,CD25,20371,16184
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",FoxP3,CD4,20371,12504
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",VPAC2,FoxP3,22355,20371
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",VPAC2,EAE,22355,D004681
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",VPAC2,CD25,22355,16184
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",VPAC2,CD4,22355,12504
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",EAE,FoxP3,D004681,20371
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",EAE,VPAC2,D004681,22355
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",EAE,CD25,D004681,16184
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",EAE,CD4,D004681,12504
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",CD25,FoxP3,16184,20371
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",CD25,VPAC2,16184,22355
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",CD25,EAE,16184,D004681
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",CD25,CD4,16184,12504
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",CD4,FoxP3,12504,20371
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",CD4,VPAC2,12504,22355
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",CD4,EAE,12504,D004681
25305591,"Moreover, the abundance and proliferative index of lymph node, thymus and CNS CD4(+)CD25(+)FoxP3(+) Tregs were strikingly reduced in VPAC2-deficient mice with EAE",CD4,CD25,12504,16184
25305591,"Overall, our results demonstrate critical protective roles for PACAP and the VPAC2 receptor against autoimmunity, promoting the expansion and maintenance of the Treg pool",PACAP,VPAC2 receptor,11516,22355
25305591,"Overall, our results demonstrate critical protective roles for PACAP and the VPAC2 receptor against autoimmunity, promoting the expansion and maintenance of the Treg pool",PACAP,VPAC2,11516,22355
25305591,"Overall, our results demonstrate critical protective roles for PACAP and the VPAC2 receptor against autoimmunity, promoting the expansion and maintenance of the Treg pool",VPAC2 receptor,PACAP,22355,11516
25305591,"Overall, our results demonstrate critical protective roles for PACAP and the VPAC2 receptor against autoimmunity, promoting the expansion and maintenance of the Treg pool",VPAC2 receptor,VPAC2,22355,22355
25305591,"Overall, our results demonstrate critical protective roles for PACAP and the VPAC2 receptor against autoimmunity, promoting the expansion and maintenance of the Treg pool",VPAC2,PACAP,22355,11516
25305591,"Overall, our results demonstrate critical protective roles for PACAP and the VPAC2 receptor against autoimmunity, promoting the expansion and maintenance of the Treg pool",VPAC2,VPAC2 receptor,22355,22355
25983002,Inhibition of LDHA suppresses tumor progression in prostate cancer,cancer,LDHA,D009369,3939
25983002,Inhibition of LDHA suppresses tumor progression in prostate cancer,tumor,LDHA,D009369,3939
25983002,Inhibition of LDHA suppresses tumor progression in prostate cancer,prostate cancer,LDHA,D011471,3939
25983002,Inhibition of LDHA suppresses tumor progression in prostate cancer,LDHA,cancer,3939,D009369
25983002,Inhibition of LDHA suppresses tumor progression in prostate cancer,LDHA,tumor,3939,D009369
25983002,Inhibition of LDHA suppresses tumor progression in prostate cancer,LDHA,prostate cancer,3939,D011471
25983002,Lactate dehydrogenase A (LDHA) executes the final step of aerobic glycolysis and has been reported to be involved in the tumor progression,tumor,Lactate dehydrogenase A,D009369,3939
25983002,Lactate dehydrogenase A (LDHA) executes the final step of aerobic glycolysis and has been reported to be involved in the tumor progression,tumor,LDHA,D009369,3939
25983002,Lactate dehydrogenase A (LDHA) executes the final step of aerobic glycolysis and has been reported to be involved in the tumor progression,Lactate dehydrogenase A,tumor,3939,D009369
25983002,Lactate dehydrogenase A (LDHA) executes the final step of aerobic glycolysis and has been reported to be involved in the tumor progression,Lactate dehydrogenase A,LDHA,3939,3939
25983002,Lactate dehydrogenase A (LDHA) executes the final step of aerobic glycolysis and has been reported to be involved in the tumor progression,LDHA,tumor,3939,D009369
25983002,Lactate dehydrogenase A (LDHA) executes the final step of aerobic glycolysis and has been reported to be involved in the tumor progression,LDHA,Lactate dehydrogenase A,3939,3939
25983002,"However, the function of LDHA in prostate cancer has not been studied",cancer,LDHA,D009369,3939
25983002,"However, the function of LDHA in prostate cancer has not been studied",prostate cancer,LDHA,D011471,3939
25983002,"However, the function of LDHA in prostate cancer has not been studied",LDHA,cancer,3939,D009369
25983002,"However, the function of LDHA in prostate cancer has not been studied",LDHA,prostate cancer,3939,D011471
25983002,"In current study, we observed overexpression of LDHA in the clinical prostate cancer samples compared with benign prostate hyperplasia tissues as demonstrated by immunohistochemistry and real-time qPCR",benign prostate hyperplasia,LDHA,D011470,3939
25983002,"In current study, we observed overexpression of LDHA in the clinical prostate cancer samples compared with benign prostate hyperplasia tissues as demonstrated by immunohistochemistry and real-time qPCR",cancer,LDHA,D009369,3939
25983002,"In current study, we observed overexpression of LDHA in the clinical prostate cancer samples compared with benign prostate hyperplasia tissues as demonstrated by immunohistochemistry and real-time qPCR",prostate cancer,LDHA,D011471,3939
25983002,"In current study, we observed overexpression of LDHA in the clinical prostate cancer samples compared with benign prostate hyperplasia tissues as demonstrated by immunohistochemistry and real-time qPCR",LDHA,benign prostate hyperplasia,3939,D011470
25983002,"In current study, we observed overexpression of LDHA in the clinical prostate cancer samples compared with benign prostate hyperplasia tissues as demonstrated by immunohistochemistry and real-time qPCR",LDHA,cancer,3939,D009369
25983002,"In current study, we observed overexpression of LDHA in the clinical prostate cancer samples compared with benign prostate hyperplasia tissues as demonstrated by immunohistochemistry and real-time qPCR",LDHA,prostate cancer,3939,D011471
25983002,"Attenuated expression of LDHA by siRNA or inhibition of LDHA activities by FX11 inhibited cell proliferation, migration, invasion, and promoted cell apoptosis of PC-3 and DU145 cells",FX11,LDHA,C547455,3939
25983002,"Attenuated expression of LDHA by siRNA or inhibition of LDHA activities by FX11 inhibited cell proliferation, migration, invasion, and promoted cell apoptosis of PC-3 and DU145 cells",LDHA,FX11,3939,C547455
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",LDHA,MMP-9,3939,4318
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",LDHA,glucose,3939,D005947
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",LDHA,FX11,3939,C547455
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",LDHA,lactate,3939,D019344
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",LDHA,PLAU,3939,5328
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",LDHA,cathepsin B,3939,1508
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",MMP-9,LDHA,4318,3939
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",MMP-9,glucose,4318,D005947
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",MMP-9,FX11,4318,C547455
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",MMP-9,lactate,4318,D019344
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",MMP-9,PLAU,4318,5328
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",MMP-9,cathepsin B,4318,1508
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",glucose,LDHA,D005947,3939
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",glucose,MMP-9,D005947,4318
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",glucose,FX11,D005947,C547455
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",glucose,lactate,D005947,D019344
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",glucose,PLAU,D005947,5328
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",glucose,cathepsin B,D005947,1508
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",FX11,LDHA,C547455,3939
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",FX11,MMP-9,C547455,4318
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",FX11,glucose,C547455,D005947
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",FX11,lactate,C547455,D019344
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",FX11,PLAU,C547455,5328
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",FX11,cathepsin B,C547455,1508
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",lactate,LDHA,D019344,3939
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",lactate,MMP-9,D019344,4318
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",lactate,glucose,D019344,D005947
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",lactate,FX11,D019344,C547455
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",lactate,PLAU,D019344,5328
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",lactate,cathepsin B,D019344,1508
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",PLAU,LDHA,5328,3939
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",PLAU,MMP-9,5328,4318
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",PLAU,glucose,5328,D005947
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",PLAU,FX11,5328,C547455
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",PLAU,lactate,5328,D019344
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",PLAU,cathepsin B,5328,1508
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",cathepsin B,LDHA,1508,3939
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",cathepsin B,MMP-9,1508,4318
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",cathepsin B,glucose,1508,D005947
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",cathepsin B,FX11,1508,C547455
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",cathepsin B,lactate,1508,D019344
25983002,"Mechanistically, decreased Warburg effect as demonstrated by reduced glucose consumption and lactate secretion and reduced expression of MMP-9, PLAU, and cathepsin B were found after LDHA knockdown or FX11 treatment in PC-3 and DU145 cells",cathepsin B,PLAU,1508,5328
25983002,"Taken together, our study revealed the oncogenic role of LDHA in prostate cancer and suggested that LDHA might be a potential therapeutic target.",cancer,LDHA,D009369,3939
25983002,"Taken together, our study revealed the oncogenic role of LDHA in prostate cancer and suggested that LDHA might be a potential therapeutic target.",prostate cancer,LDHA,D011471,3939
25983002,"Taken together, our study revealed the oncogenic role of LDHA in prostate cancer and suggested that LDHA might be a potential therapeutic target.",LDHA,cancer,3939,D009369
25983002,"Taken together, our study revealed the oncogenic role of LDHA in prostate cancer and suggested that LDHA might be a potential therapeutic target.",LDHA,prostate cancer,3939,D011471
25986755,Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure,AT2R,glomerulosclerosis,24182,D005921
25986755,Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure,AT2R,caffeine,24182,D002110
25986755,Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure,glomerulosclerosis,AT2R,D005921,24182
25986755,Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure,glomerulosclerosis,caffeine,D005921,D002110
25986755,Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure,caffeine,AT2R,D002110,24182
25986755,Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure,caffeine,glomerulosclerosis,D002110,D005921
25986755,UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring,caffeine,intrauterine growth retardation,D002110,D005317
25986755,UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring,caffeine,IUGR,D002110,D005317
25986755,UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring,intrauterine growth retardation,caffeine,D005317,D002110
25986755,UNASSIGNED: Our previous study has indicated that prenatal caffeine exposure (PCE) could induce intrauterine growth retardation (IUGR) of offspring,IUGR,caffeine,D005317,D002110
25986755,"The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein",glomerulosclerosis,creatinine,D005921,D003404
25986755,"The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein",interstitial fibrosis,creatinine,D005355,D003404
25986755,"The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein",creatinine,glomerulosclerosis,D003404,D005921
25986755,"The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis, accompanied by elevated levels of serum creatinine and urine protein",creatinine,interstitial fibrosis,D003404,D005355
25986755,"Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased",AT2R,AT1aR,24182,24180
25986755,"Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased",AT2R,angiotensin II receptor type 2,24182,24182
25986755,"Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased",AT2R,angiotensin II receptor type 1a,24182,24180
25986755,"Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased",AT1aR,AT2R,24180,24182
25986755,"Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased",AT1aR,angiotensin II receptor type 2,24180,24182
25986755,"Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased",AT1aR,angiotensin II receptor type 1a,24180,24180
25986755,"Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased",angiotensin II receptor type 2,AT2R,24182,24182
25986755,"Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased",angiotensin II receptor type 2,AT1aR,24182,24180
25986755,"Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased",angiotensin II receptor type 2,angiotensin II receptor type 1a,24182,24180
25986755,"Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased",angiotensin II receptor type 1a,AT2R,24180,24182
25986755,"Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased",angiotensin II receptor type 1a,AT1aR,24180,24180
25986755,"Renal angiotensin II receptor type 2 (AT2R) gene expression in adult offspring was reduced by PCE, whereas the renal angiotensin II receptor type 1a (AT1aR)/AT2R expression ratio was increased",angiotensin II receptor type 1a,angiotensin II receptor type 2,24180,24182
25986755,"Observation by electronic microscope revealed structural damage of podocytes; the reduced expression level of podocyte marker genes, nephrin and podocin, was also detected by q-PCR",nephrin,podocin,64563,170672
25986755,"Observation by electronic microscope revealed structural damage of podocytes; the reduced expression level of podocyte marker genes, nephrin and podocin, was also detected by q-PCR",podocin,nephrin,170672,64563
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",AT2R,glial-cell-line-derived neurotrophic factor,24182,25453
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",AT2R,c-Ret,24182,24716
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",AT2R,tyrosine kinase receptor,24182,24716
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",AT2R,GDNF,24182,25453
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",glial-cell-line-derived neurotrophic factor,AT2R,25453,24182
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",glial-cell-line-derived neurotrophic factor,c-Ret,25453,24716
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",glial-cell-line-derived neurotrophic factor,tyrosine kinase receptor,25453,24716
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",glial-cell-line-derived neurotrophic factor,GDNF,25453,25453
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",c-Ret,AT2R,24716,24182
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",c-Ret,glial-cell-line-derived neurotrophic factor,24716,25453
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",c-Ret,tyrosine kinase receptor,24716,24716
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",c-Ret,GDNF,24716,25453
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",tyrosine kinase receptor,AT2R,24716,24182
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",tyrosine kinase receptor,glial-cell-line-derived neurotrophic factor,24716,25453
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",tyrosine kinase receptor,c-Ret,24716,24716
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",tyrosine kinase receptor,GDNF,24716,25453
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",GDNF,AT2R,25453,24182
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",GDNF,glial-cell-line-derived neurotrophic factor,25453,25453
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",GDNF,c-Ret,25453,24716
25986755,"Moreover, AT2R gene and protein expressions in fetal kidneys were inhibited by PCE, associated with the repression of the gene expression of glial-cell-line-derived neurotrophic factor (GDNF)/tyrosine kinase receptor (c-Ret) signaling pathway",GDNF,tyrosine kinase receptor,25453,24716
25986755,"These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.",AT2R,dysplasia of fetal kidneys,24182,D007674
25986755,"These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.",AT2R,glomerulosclerosis,24182,D005921
25986755,"These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.",dysplasia of fetal kidneys,AT2R,D007674,24182
25986755,"These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring, and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis.",glomerulosclerosis,AT2R,D005921,24182
26027517,The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair,LPA,GPCR,53978,295589
26027517,The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair,LPA,LPA2,53978,"498609,53978"
26027517,The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair,LPA,autotaxin,53978,84050
26027517,The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair,GPCR,LPA,295589,53978
26027517,The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair,GPCR,LPA2,295589,"498609,53978"
26027517,The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair,GPCR,autotaxin,295589,84050
26027517,The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair,LPA2,LPA,"498609,53978",53978
26027517,The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair,LPA2,GPCR,"498609,53978",295589
26027517,The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair,LPA2,autotaxin,"498609,53978",84050
26027517,The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair,autotaxin,LPA,84050,53978
26027517,The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair,autotaxin,GPCR,84050,295589
26027517,The autotaxin-LPA2 GPCR axis is modulated by gamma-irradiation and facilitates DNA damage repair,autotaxin,LPA2,84050,"498609,53978"
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,ATX,LPA,"18606,84050",53978
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,ATX,GPCR,"18606,84050",295589
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,ATX,LPA2,"18606,84050","498609,53978"
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,ATX,autotaxin,"18606,84050",84050
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,ATX,radiation injury,"18606,84050",D011832
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,LPA,ATX,53978,"18606,84050"
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,LPA,GPCR,53978,295589
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,LPA,LPA2,53978,"498609,53978"
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,LPA,autotaxin,53978,84050
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,LPA,radiation injury,53978,D011832
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,GPCR,ATX,295589,"18606,84050"
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,GPCR,LPA,295589,53978
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,GPCR,LPA2,295589,"498609,53978"
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,GPCR,autotaxin,295589,84050
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,GPCR,radiation injury,295589,D011832
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,LPA2,ATX,"498609,53978","18606,84050"
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,LPA2,LPA,"498609,53978",53978
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,LPA2,GPCR,"498609,53978",295589
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,LPA2,autotaxin,"498609,53978",84050
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,LPA2,radiation injury,"498609,53978",D011832
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,autotaxin,ATX,84050,"18606,84050"
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,autotaxin,LPA,84050,53978
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,autotaxin,GPCR,84050,295589
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,autotaxin,LPA2,84050,"498609,53978"
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,autotaxin,radiation injury,84050,D011832
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,radiation injury,ATX,D011832,"18606,84050"
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,radiation injury,LPA,D011832,53978
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,radiation injury,GPCR,D011832,295589
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,radiation injury,LPA2,D011832,"498609,53978"
26027517,In this study we characterized the effects of radiation injury on the expression and function of the autotaxin (ATX)-LPA2 GPCR axis,radiation injury,autotaxin,D011832,84050
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",ATM/ATR kinases,NF-kappaB,"300711,685055",81736
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",ATM/ATR kinases,lpa2,"300711,685055",498609
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",ATM/ATR kinases,ATM,"300711,685055",300711
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",ATM/ATR kinases,CGK-733,"300711,685055",C512273
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",NF-kappaB,ATM/ATR kinases,81736,"300711,685055"
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",NF-kappaB,lpa2,81736,498609
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",NF-kappaB,ATM,81736,300711
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",NF-kappaB,CGK-733,81736,C512273
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",lpa2,ATM/ATR kinases,498609,"300711,685055"
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",lpa2,NF-kappaB,498609,81736
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",lpa2,ATM,498609,300711
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",lpa2,CGK-733,498609,C512273
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",ATM,ATM/ATR kinases,300711,"300711,685055"
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",ATM,NF-kappaB,300711,81736
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",ATM,lpa2,300711,498609
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",ATM,CGK-733,300711,C512273
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",CGK-733,ATM/ATR kinases,C512273,"300711,685055"
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",CGK-733,NF-kappaB,C512273,81736
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",CGK-733,lpa2,C512273,498609
26027517,"In IEC-6 crypt cells and jejunum enteroids quantitative RT-PCR showed a time- and dose-dependent upregulation of lpa2 in response to gamma-irradiation that was abolished by mutation of the NF-kappaB site in the lpa2 promoter or by inhibition of ATM/ATR kinases with CGK-733, suggesting that lpa2 is a DNA damage response gene upregulated by ATM via NF-kappaB",CGK-733,ATM,C512273,300711
26027517,"The resolution kinetics of the DNA damage marker gamma-H2AX in LPA-treated IEC-6 cells exposed to gamma-irradiation was accelerated compared to vehicle, whereas pharmacological inhibition of LPA2 delayed the resolution of gamma-H2AX",LPA,gamma-H2AX,53978,15270
26027517,"The resolution kinetics of the DNA damage marker gamma-H2AX in LPA-treated IEC-6 cells exposed to gamma-irradiation was accelerated compared to vehicle, whereas pharmacological inhibition of LPA2 delayed the resolution of gamma-H2AX",LPA,LPA2,53978,"498609,53978"
26027517,"The resolution kinetics of the DNA damage marker gamma-H2AX in LPA-treated IEC-6 cells exposed to gamma-irradiation was accelerated compared to vehicle, whereas pharmacological inhibition of LPA2 delayed the resolution of gamma-H2AX",gamma-H2AX,LPA,15270,53978
26027517,"The resolution kinetics of the DNA damage marker gamma-H2AX in LPA-treated IEC-6 cells exposed to gamma-irradiation was accelerated compared to vehicle, whereas pharmacological inhibition of LPA2 delayed the resolution of gamma-H2AX",gamma-H2AX,LPA2,15270,"498609,53978"
26027517,"The resolution kinetics of the DNA damage marker gamma-H2AX in LPA-treated IEC-6 cells exposed to gamma-irradiation was accelerated compared to vehicle, whereas pharmacological inhibition of LPA2 delayed the resolution of gamma-H2AX",LPA2,LPA,"498609,53978",53978
26027517,"The resolution kinetics of the DNA damage marker gamma-H2AX in LPA-treated IEC-6 cells exposed to gamma-irradiation was accelerated compared to vehicle, whereas pharmacological inhibition of LPA2 delayed the resolution of gamma-H2AX",LPA2,gamma-H2AX,"498609,53978",15270
26027517,"In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained",LPA1    '3,LPA,"14745,65086",53978
26027517,"In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained",LPA1    '3,LPA2,"14745,65086","498609,53978"
26027517,"In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained",LPA1    '3,gamma-H2AX,"14745,65086",15270
26027517,"In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained",LPA,LPA1    '3,53978,"14745,65086"
26027517,"In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained",LPA,LPA2,53978,"498609,53978"
26027517,"In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained",LPA,gamma-H2AX,53978,15270
26027517,"In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained",LPA2,LPA1    '3,"498609,53978","14745,65086"
26027517,"In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained",LPA2,LPA,"498609,53978",53978
26027517,"In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained",LPA2,gamma-H2AX,"498609,53978",15270
26027517,"In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained",gamma-H2AX,LPA1    '3,15270,"14745,65086"
26027517,"In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained",gamma-H2AX,LPA,15270,53978
26027517,"In LPA2-reconstituted MEF cells lacking LPA1    '3 the levels of gamma-H2AX decreased rapidly, whereas in Vector MEF were high and remained sustained",gamma-H2AX,LPA2,15270,"498609,53978"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,AKT,ERK1    '2,11651,"26413,26417"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,AKT,LPA,11651,53978
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,AKT,C311A,11651,p|SUB|C|311|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,AKT,LPA2,11651,"498609,53978"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,AKT,L351A,11651,p|SUB|L|351|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,AKT,C314A,11651,p|SUB|C|314|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,AKT,PI3K,11651,18708
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,ERK1    '2,AKT,"26413,26417",11651
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,ERK1    '2,LPA,"26413,26417",53978
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,ERK1    '2,C311A,"26413,26417",p|SUB|C|311|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,ERK1    '2,LPA2,"26413,26417","498609,53978"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,ERK1    '2,L351A,"26413,26417",p|SUB|L|351|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,ERK1    '2,C314A,"26413,26417",p|SUB|C|314|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,ERK1    '2,PI3K,"26413,26417",18708
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA,AKT,53978,11651
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA,ERK1    '2,53978,"26413,26417"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA,C311A,53978,p|SUB|C|311|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA,LPA2,53978,"498609,53978"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA,L351A,53978,p|SUB|L|351|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA,C314A,53978,p|SUB|C|314|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA,PI3K,53978,18708
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C311A,AKT,p|SUB|C|311|A,11651
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C311A,ERK1    '2,p|SUB|C|311|A,"26413,26417"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C311A,LPA,p|SUB|C|311|A,53978
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C311A,LPA2,p|SUB|C|311|A,"498609,53978"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C311A,L351A,p|SUB|C|311|A,p|SUB|L|351|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C311A,C314A,p|SUB|C|311|A,p|SUB|C|314|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C311A,PI3K,p|SUB|C|311|A,18708
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA2,AKT,"498609,53978",11651
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA2,ERK1    '2,"498609,53978","26413,26417"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA2,LPA,"498609,53978",53978
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA2,C311A,"498609,53978",p|SUB|C|311|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA2,L351A,"498609,53978",p|SUB|L|351|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA2,C314A,"498609,53978",p|SUB|C|314|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,LPA2,PI3K,"498609,53978",18708
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,L351A,AKT,p|SUB|L|351|A,11651
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,L351A,ERK1    '2,p|SUB|L|351|A,"26413,26417"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,L351A,LPA,p|SUB|L|351|A,53978
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,L351A,C311A,p|SUB|L|351|A,p|SUB|C|311|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,L351A,LPA2,p|SUB|L|351|A,"498609,53978"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,L351A,C314A,p|SUB|L|351|A,p|SUB|C|314|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,L351A,PI3K,p|SUB|L|351|A,18708
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C314A,AKT,p|SUB|C|314|A,11651
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C314A,ERK1    '2,p|SUB|C|314|A,"26413,26417"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C314A,LPA,p|SUB|C|314|A,53978
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C314A,C311A,p|SUB|C|314|A,p|SUB|C|311|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C314A,LPA2,p|SUB|C|314|A,"498609,53978"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C314A,L351A,p|SUB|C|314|A,p|SUB|L|351|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,C314A,PI3K,p|SUB|C|314|A,18708
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,PI3K,AKT,18708,11651
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,PI3K,ERK1    '2,18708,"26413,26417"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,PI3K,LPA,18708,53978
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,PI3K,C311A,18708,p|SUB|C|311|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,PI3K,LPA2,18708,"498609,53978"
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,PI3K,L351A,18708,p|SUB|L|351|A
26027517,Inhibition of ERK1    '2 or PI3K/AKT signaling axis by pertussis toxin or the C311A/C314A/L351A mutation in the C-terminus of LPA2 abrogated the effect of LPA on DNA repair,PI3K,C314A,18708,p|SUB|C|314|A
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",Sca-1,Lin,110454,83557
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",Sca-1,LPA,110454,53978
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",Sca-1,LPA2,110454,"498609,53978"
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",Sca-1,c-Kit,110454,16590
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",Lin,Sca-1,83557,110454
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",Lin,LPA,83557,53978
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",Lin,LPA2,83557,"498609,53978"
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",Lin,c-Kit,83557,16590
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",LPA,Sca-1,53978,110454
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",LPA,Lin,53978,83557
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",LPA,LPA2,53978,"498609,53978"
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",LPA,c-Kit,53978,16590
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",LPA2,Sca-1,"498609,53978",110454
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",LPA2,Lin,"498609,53978",83557
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",LPA2,LPA,"498609,53978",53978
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",LPA2,c-Kit,"498609,53978",16590
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",c-Kit,Sca-1,16590,110454
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",c-Kit,Lin,16590,83557
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",c-Kit,LPA,16590,53978
26027517,"LPA2 transcripts in Lin(-)Sca-1(+)c-Kit(+) enriched for bone marrow stem cells were 27- and 5-fold higher than in common myeloid or lymphoid progenitors, respectively",c-Kit,LPA2,16590,"498609,53978"
26027517,"Furthermore, after irradiation higher residual gamma-H2AX levels were detected in the bone marrow or jejunum of irradiated LPA2-KO mice compared to WT mice",LPA,gamma-H2AX,53978,15270
26027517,"Furthermore, after irradiation higher residual gamma-H2AX levels were detected in the bone marrow or jejunum of irradiated LPA2-KO mice compared to WT mice",LPA,LPA2,53978,"498609,53978"
26027517,"Furthermore, after irradiation higher residual gamma-H2AX levels were detected in the bone marrow or jejunum of irradiated LPA2-KO mice compared to WT mice",gamma-H2AX,LPA,15270,53978
26027517,"Furthermore, after irradiation higher residual gamma-H2AX levels were detected in the bone marrow or jejunum of irradiated LPA2-KO mice compared to WT mice",gamma-H2AX,LPA2,15270,"498609,53978"
26027517,"Furthermore, after irradiation higher residual gamma-H2AX levels were detected in the bone marrow or jejunum of irradiated LPA2-KO mice compared to WT mice",LPA2,LPA,"498609,53978",53978
26027517,"Furthermore, after irradiation higher residual gamma-H2AX levels were detected in the bone marrow or jejunum of irradiated LPA2-KO mice compared to WT mice",LPA2,gamma-H2AX,"498609,53978",15270
26027517,We found that gamma-irradiation increases plasma ATX activity and LPA level that is in part due to the previously established radiation-induced upregulation of TNFalpha,LPA,TNFalpha,53978,21926
26027517,We found that gamma-irradiation increases plasma ATX activity and LPA level that is in part due to the previously established radiation-induced upregulation of TNFalpha,LPA,ATX,53978,"18606,84050"
26027517,We found that gamma-irradiation increases plasma ATX activity and LPA level that is in part due to the previously established radiation-induced upregulation of TNFalpha,TNFalpha,LPA,21926,53978
26027517,We found that gamma-irradiation increases plasma ATX activity and LPA level that is in part due to the previously established radiation-induced upregulation of TNFalpha,TNFalpha,ATX,21926,"18606,84050"
26027517,We found that gamma-irradiation increases plasma ATX activity and LPA level that is in part due to the previously established radiation-induced upregulation of TNFalpha,ATX,LPA,"18606,84050",53978
26027517,We found that gamma-irradiation increases plasma ATX activity and LPA level that is in part due to the previously established radiation-induced upregulation of TNFalpha,ATX,TNFalpha,"18606,84050",21926
26027517,These findings identify ATX and LPA2 as radiation-regulated genes that appear to play a physiological role in DNA repair,LPA,LPA2,53978,"498609,53978"
26027517,These findings identify ATX and LPA2 as radiation-regulated genes that appear to play a physiological role in DNA repair,LPA,ATX,53978,"18606,84050"
26027517,These findings identify ATX and LPA2 as radiation-regulated genes that appear to play a physiological role in DNA repair,LPA2,LPA,"498609,53978",53978
26027517,These findings identify ATX and LPA2 as radiation-regulated genes that appear to play a physiological role in DNA repair,LPA2,ATX,"498609,53978","18606,84050"
26027517,These findings identify ATX and LPA2 as radiation-regulated genes that appear to play a physiological role in DNA repair,ATX,LPA,"18606,84050",53978
26027517,These findings identify ATX and LPA2 as radiation-regulated genes that appear to play a physiological role in DNA repair,ATX,LPA2,"18606,84050","498609,53978"
26110643,"Protein-Trap Insertional Mutagenesis Uncovers New Genes Involved in Zebrafish Skin Development, Including a Neuregulin 2a-Based ErbB Signaling Pathway Required during Median Fin Fold Morphogenesis",Trap,Neuregulin 2a,436725,100006951
26110643,"Protein-Trap Insertional Mutagenesis Uncovers New Genes Involved in Zebrafish Skin Development, Including a Neuregulin 2a-Based ErbB Signaling Pathway Required during Median Fin Fold Morphogenesis",Trap,ErbB,436725,"386635,386966"
26110643,"Protein-Trap Insertional Mutagenesis Uncovers New Genes Involved in Zebrafish Skin Development, Including a Neuregulin 2a-Based ErbB Signaling Pathway Required during Median Fin Fold Morphogenesis",Neuregulin 2a,Trap,100006951,436725
26110643,"Protein-Trap Insertional Mutagenesis Uncovers New Genes Involved in Zebrafish Skin Development, Including a Neuregulin 2a-Based ErbB Signaling Pathway Required during Median Fin Fold Morphogenesis",Neuregulin 2a,ErbB,100006951,"386635,386966"
26110643,"Protein-Trap Insertional Mutagenesis Uncovers New Genes Involved in Zebrafish Skin Development, Including a Neuregulin 2a-Based ErbB Signaling Pathway Required during Median Fin Fold Morphogenesis",ErbB,Trap,"386635,386966",436725
26110643,"Protein-Trap Insertional Mutagenesis Uncovers New Genes Involved in Zebrafish Skin Development, Including a Neuregulin 2a-Based ErbB Signaling Pathway Required during Median Fin Fold Morphogenesis",ErbB,Neuregulin 2a,"386635,386966",100006951
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fkbp10b,ahnak,324381,559276
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fkbp10b,megf6a,324381,565108
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fkbp10b,grip1,324381,558006
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fkbp10b,col4a4,324381,554270
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fkbp10b,nrg2a,324381,100006951
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fkbp10b,arhgef25b,324381,569561
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fkbp10b,capn12,324381,799247
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fkbp10b,msxc,324381,30526
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fkbp10b,fras1,324381,563428
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fkbp10b,hmcn1,324381,559150
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",ahnak,fkbp10b,559276,324381
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",ahnak,megf6a,559276,565108
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",ahnak,grip1,559276,558006
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",ahnak,col4a4,559276,554270
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",ahnak,nrg2a,559276,100006951
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",ahnak,arhgef25b,559276,569561
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",ahnak,capn12,559276,799247
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",ahnak,msxc,559276,30526
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",ahnak,fras1,559276,563428
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",ahnak,hmcn1,559276,559150
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",megf6a,fkbp10b,565108,324381
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",megf6a,ahnak,565108,559276
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",megf6a,grip1,565108,558006
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",megf6a,col4a4,565108,554270
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",megf6a,nrg2a,565108,100006951
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",megf6a,arhgef25b,565108,569561
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",megf6a,capn12,565108,799247
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",megf6a,msxc,565108,30526
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",megf6a,fras1,565108,563428
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",megf6a,hmcn1,565108,559150
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",grip1,fkbp10b,558006,324381
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",grip1,ahnak,558006,559276
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",grip1,megf6a,558006,565108
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",grip1,col4a4,558006,554270
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",grip1,nrg2a,558006,100006951
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",grip1,arhgef25b,558006,569561
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",grip1,capn12,558006,799247
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",grip1,msxc,558006,30526
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",grip1,fras1,558006,563428
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",grip1,hmcn1,558006,559150
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",col4a4,fkbp10b,554270,324381
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",col4a4,ahnak,554270,559276
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",col4a4,megf6a,554270,565108
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",col4a4,grip1,554270,558006
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",col4a4,nrg2a,554270,100006951
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",col4a4,arhgef25b,554270,569561
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",col4a4,capn12,554270,799247
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",col4a4,msxc,554270,30526
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",col4a4,fras1,554270,563428
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",col4a4,hmcn1,554270,559150
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",nrg2a,fkbp10b,100006951,324381
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",nrg2a,ahnak,100006951,559276
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",nrg2a,megf6a,100006951,565108
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",nrg2a,grip1,100006951,558006
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",nrg2a,col4a4,100006951,554270
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",nrg2a,arhgef25b,100006951,569561
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",nrg2a,capn12,100006951,799247
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",nrg2a,msxc,100006951,30526
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",nrg2a,fras1,100006951,563428
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",nrg2a,hmcn1,100006951,559150
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",arhgef25b,fkbp10b,569561,324381
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",arhgef25b,ahnak,569561,559276
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",arhgef25b,megf6a,569561,565108
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",arhgef25b,grip1,569561,558006
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",arhgef25b,col4a4,569561,554270
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",arhgef25b,nrg2a,569561,100006951
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",arhgef25b,capn12,569561,799247
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",arhgef25b,msxc,569561,30526
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",arhgef25b,fras1,569561,563428
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",arhgef25b,hmcn1,569561,559150
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",capn12,fkbp10b,799247,324381
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",capn12,ahnak,799247,559276
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",capn12,megf6a,799247,565108
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",capn12,grip1,799247,558006
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",capn12,col4a4,799247,554270
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",capn12,nrg2a,799247,100006951
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",capn12,arhgef25b,799247,569561
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",capn12,msxc,799247,30526
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",capn12,fras1,799247,563428
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",capn12,hmcn1,799247,559150
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",msxc,fkbp10b,30526,324381
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",msxc,ahnak,30526,559276
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",msxc,megf6a,30526,565108
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",msxc,grip1,30526,558006
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",msxc,col4a4,30526,554270
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",msxc,nrg2a,30526,100006951
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",msxc,arhgef25b,30526,569561
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",msxc,capn12,30526,799247
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",msxc,fras1,30526,563428
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",msxc,hmcn1,30526,559150
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fras1,fkbp10b,563428,324381
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fras1,ahnak,563428,559276
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fras1,megf6a,563428,565108
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fras1,grip1,563428,558006
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fras1,col4a4,563428,554270
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fras1,nrg2a,563428,100006951
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fras1,arhgef25b,563428,569561
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fras1,capn12,563428,799247
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fras1,msxc,563428,30526
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",fras1,hmcn1,563428,559150
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",hmcn1,fkbp10b,559150,324381
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",hmcn1,ahnak,559150,559276
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",hmcn1,megf6a,559150,565108
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",hmcn1,grip1,559150,558006
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",hmcn1,col4a4,559150,554270
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",hmcn1,nrg2a,559150,100006951
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",hmcn1,arhgef25b,559150,569561
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",hmcn1,capn12,559150,799247
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",hmcn1,msxc,559150,30526
26110643,"Eight genes--fras1, grip1, hmcn1, msxc, col4a4, ahnak, capn12, and nrg2a--had been described in an integumentary context to varying degrees, while arhgef25b, fkbp10b, and megf6a emerged as novel skin genes",hmcn1,fras1,559150,563428
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,neuregulin 2a,AKT,100006951,101910198
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,neuregulin 2a,Nrg2a,100006951,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,neuregulin 2a,ErbB2/3,100006951,"386635,386966"
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,neuregulin 2a,Neuregulin 2a,100006951,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,neuregulin 2a,nrg2a,100006951,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,neuregulin 2a,ErbB,100006951,"386635,386966"
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,AKT,neuregulin 2a,101910198,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,AKT,Nrg2a,101910198,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,AKT,ErbB2/3,101910198,"386635,386966"
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,AKT,Neuregulin 2a,101910198,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,AKT,nrg2a,101910198,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,AKT,ErbB,101910198,"386635,386966"
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,Nrg2a,neuregulin 2a,100006951,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,Nrg2a,AKT,100006951,101910198
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,Nrg2a,ErbB2/3,100006951,"386635,386966"
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,Nrg2a,Neuregulin 2a,100006951,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,Nrg2a,nrg2a,100006951,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,Nrg2a,ErbB,100006951,"386635,386966"
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,ErbB2/3,neuregulin 2a,"386635,386966",100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,ErbB2/3,AKT,"386635,386966",101910198
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,ErbB2/3,Nrg2a,"386635,386966",100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,ErbB2/3,Neuregulin 2a,"386635,386966",100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,ErbB2/3,nrg2a,"386635,386966",100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,ErbB2/3,ErbB,"386635,386966","386635,386966"
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,Neuregulin 2a,neuregulin 2a,100006951,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,Neuregulin 2a,AKT,100006951,101910198
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,Neuregulin 2a,Nrg2a,100006951,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,Neuregulin 2a,ErbB2/3,100006951,"386635,386966"
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,Neuregulin 2a,nrg2a,100006951,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,Neuregulin 2a,ErbB,100006951,"386635,386966"
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,nrg2a,neuregulin 2a,100006951,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,nrg2a,AKT,100006951,101910198
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,nrg2a,Nrg2a,100006951,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,nrg2a,ErbB2/3,100006951,"386635,386966"
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,nrg2a,Neuregulin 2a,100006951,100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,nrg2a,ErbB,100006951,"386635,386966"
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,ErbB,neuregulin 2a,"386635,386966",100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,ErbB,AKT,"386635,386966",101910198
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,ErbB,Nrg2a,"386635,386966",100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,ErbB,ErbB2/3,"386635,386966","386635,386966"
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,ErbB,Neuregulin 2a,"386635,386966",100006951
26110643,Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the apicobasal organization of a subset of epidermal cells during median fin fold (MFF) morphogenesis,ErbB,nrg2a,"386635,386966",100006951
26110643,"In nrg2a mutant larvae, the basal keratinocytes within the apical MFF, known as ridge cells, displayed reduced pAKT levels as well as reduced apical domains and exaggerated basolateral domains",nrg2a,AKT,100006951,101910198
26110643,"In nrg2a mutant larvae, the basal keratinocytes within the apical MFF, known as ridge cells, displayed reduced pAKT levels as well as reduced apical domains and exaggerated basolateral domains",AKT,nrg2a,101910198,100006951
26110643,Pharmacological inhibition verified that Nrg2a signals through the ErbB receptor tyrosine kinase network,Nrg2a,ErbB receptor tyrosine kinase,100006951,"386635,386966"
26110643,Pharmacological inhibition verified that Nrg2a signals through the ErbB receptor tyrosine kinase network,Nrg2a,ErbB,100006951,"386635,386966"
26110643,Pharmacological inhibition verified that Nrg2a signals through the ErbB receptor tyrosine kinase network,ErbB receptor tyrosine kinase,Nrg2a,"386635,386966",100006951
26110643,Pharmacological inhibition verified that Nrg2a signals through the ErbB receptor tyrosine kinase network,ErbB receptor tyrosine kinase,ErbB,"386635,386966","386635,386966"
26110643,Pharmacological inhibition verified that Nrg2a signals through the ErbB receptor tyrosine kinase network,ErbB,Nrg2a,"386635,386966",100006951
26110643,Pharmacological inhibition verified that Nrg2a signals through the ErbB receptor tyrosine kinase network,ErbB,ErbB receptor tyrosine kinase,"386635,386966","386635,386966"
26110643,"Moreover, knockdown of the epithelial polarity regulator and tumor suppressor lgl2 ameliorated the nrg2a mutant phenotype",nrg2a,tumor,100006951,D009369
26110643,"Moreover, knockdown of the epithelial polarity regulator and tumor suppressor lgl2 ameliorated the nrg2a mutant phenotype",nrg2a,lgl2,100006951,795670
26110643,"Moreover, knockdown of the epithelial polarity regulator and tumor suppressor lgl2 ameliorated the nrg2a mutant phenotype",tumor,nrg2a,D009369,100006951
26110643,"Moreover, knockdown of the epithelial polarity regulator and tumor suppressor lgl2 ameliorated the nrg2a mutant phenotype",tumor,lgl2,D009369,795670
26110643,"Moreover, knockdown of the epithelial polarity regulator and tumor suppressor lgl2 ameliorated the nrg2a mutant phenotype",lgl2,nrg2a,795670,100006951
26110643,"Moreover, knockdown of the epithelial polarity regulator and tumor suppressor lgl2 ameliorated the nrg2a mutant phenotype",lgl2,tumor,795670,D009369
26110643,Identifying Lgl2 as an antagonist of Nrg2a-ErbB signaling revealed a significantly earlier role for Lgl2 during epidermal morphogenesis than has been described to date,Nrg2a,Lgl2,100006951,795670
26110643,Identifying Lgl2 as an antagonist of Nrg2a-ErbB signaling revealed a significantly earlier role for Lgl2 during epidermal morphogenesis than has been described to date,Nrg2a,ErbB,100006951,"386635,386966"
26110643,Identifying Lgl2 as an antagonist of Nrg2a-ErbB signaling revealed a significantly earlier role for Lgl2 during epidermal morphogenesis than has been described to date,Lgl2,Nrg2a,795670,100006951
26110643,Identifying Lgl2 as an antagonist of Nrg2a-ErbB signaling revealed a significantly earlier role for Lgl2 during epidermal morphogenesis than has been described to date,Lgl2,ErbB,795670,"386635,386966"
26110643,Identifying Lgl2 as an antagonist of Nrg2a-ErbB signaling revealed a significantly earlier role for Lgl2 during epidermal morphogenesis than has been described to date,ErbB,Nrg2a,"386635,386966",100006951
26110643,Identifying Lgl2 as an antagonist of Nrg2a-ErbB signaling revealed a significantly earlier role for Lgl2 during epidermal morphogenesis than has been described to date,ErbB,Lgl2,"386635,386966",795670
26516699,Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model,Kras,G12D,3845,p|SUB|G|12|D
26516699,Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model,Kras,pancreatic cancer,3845,D010190
26516699,Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model,Kras,Pdx1,3845,18609
26516699,Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model,G12D,Kras,p|SUB|G|12|D,3845
26516699,Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model,G12D,pancreatic cancer,p|SUB|G|12|D,D010190
26516699,Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model,G12D,Pdx1,p|SUB|G|12|D,18609
26516699,Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model,pancreatic cancer,Kras,D010190,3845
26516699,Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model,pancreatic cancer,G12D,D010190,p|SUB|G|12|D
26516699,Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model,pancreatic cancer,Pdx1,D010190,18609
26516699,Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model,Pdx1,Kras,18609,3845
26516699,Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model,Pdx1,G12D,18609,p|SUB|G|12|D
26516699,Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model,Pdx1,pancreatic cancer,18609,D010190
26516699,"In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model",Kras,G12D,3845,p|SUB|G|12|D
26516699,"In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model",Kras,Pdx1,3845,18609
26516699,"In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model",Kras,PC,3845,D010190
26516699,"In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model",G12D,Kras,p|SUB|G|12|D,3845
26516699,"In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model",G12D,Pdx1,p|SUB|G|12|D,18609
26516699,"In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model",G12D,PC,p|SUB|G|12|D,D010190
26516699,"In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model",Pdx1,Kras,18609,3845
26516699,"In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model",Pdx1,G12D,18609,p|SUB|G|12|D
26516699,"In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model",Pdx1,PC,18609,D010190
26516699,"In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model",PC,Kras,D010190,3845
26516699,"In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model",PC,G12D,D010190,p|SUB|G|12|D
26516699,"In this study, we investigated the global miRNA expression profile and their processing machinery during PC progression using the KrasG12D;Pdx1-Cre (KC) mouse model",PC,Pdx1,D010190,18609
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-150,miR-217,387168,387213
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-150,miR-148a,387168,387166
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-150,miR-146b,387168,751550
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-150,miR-31,387168,723895
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-150,miR-216,387168,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-150,miR-138,387168,"387156,723956"
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-150,miR-494,387168,723878
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-150,miR-21,387168,387140
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-150,miR-216a,387168,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-150,miR-205,387168,387201
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-150,miR-192,387168,387187
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-217,miR-150,387213,387168
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-217,miR-148a,387213,387166
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-217,miR-146b,387213,751550
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-217,miR-31,387213,723895
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-217,miR-216,387213,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-217,miR-138,387213,"387156,723956"
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-217,miR-494,387213,723878
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-217,miR-21,387213,387140
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-217,miR-216a,387213,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-217,miR-205,387213,387201
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-217,miR-192,387213,387187
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-148a,miR-150,387166,387168
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-148a,miR-217,387166,387213
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-148a,miR-146b,387166,751550
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-148a,miR-31,387166,723895
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-148a,miR-216,387166,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-148a,miR-138,387166,"387156,723956"
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-148a,miR-494,387166,723878
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-148a,miR-21,387166,387140
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-148a,miR-216a,387166,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-148a,miR-205,387166,387201
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-148a,miR-192,387166,387187
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-146b,miR-150,751550,387168
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-146b,miR-217,751550,387213
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-146b,miR-148a,751550,387166
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-146b,miR-31,751550,723895
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-146b,miR-216,751550,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-146b,miR-138,751550,"387156,723956"
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-146b,miR-494,751550,723878
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-146b,miR-21,751550,387140
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-146b,miR-216a,751550,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-146b,miR-205,751550,387201
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-146b,miR-192,751550,387187
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-31,miR-150,723895,387168
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-31,miR-217,723895,387213
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-31,miR-148a,723895,387166
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-31,miR-146b,723895,751550
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-31,miR-216,723895,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-31,miR-138,723895,"387156,723956"
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-31,miR-494,723895,723878
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-31,miR-21,723895,387140
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-31,miR-216a,723895,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-31,miR-205,723895,387201
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-31,miR-192,723895,387187
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216,miR-150,387212,387168
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216,miR-217,387212,387213
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216,miR-148a,387212,387166
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216,miR-146b,387212,751550
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216,miR-31,387212,723895
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216,miR-138,387212,"387156,723956"
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216,miR-494,387212,723878
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216,miR-21,387212,387140
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216,miR-216a,387212,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216,miR-205,387212,387201
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216,miR-192,387212,387187
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-138,miR-150,"387156,723956",387168
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-138,miR-217,"387156,723956",387213
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-138,miR-148a,"387156,723956",387166
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-138,miR-146b,"387156,723956",751550
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-138,miR-31,"387156,723956",723895
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-138,miR-216,"387156,723956",387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-138,miR-494,"387156,723956",723878
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-138,miR-21,"387156,723956",387140
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-138,miR-216a,"387156,723956",387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-138,miR-205,"387156,723956",387201
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-138,miR-192,"387156,723956",387187
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-494,miR-150,723878,387168
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-494,miR-217,723878,387213
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-494,miR-148a,723878,387166
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-494,miR-146b,723878,751550
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-494,miR-31,723878,723895
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-494,miR-216,723878,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-494,miR-138,723878,"387156,723956"
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-494,miR-21,723878,387140
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-494,miR-216a,723878,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-494,miR-205,723878,387201
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-494,miR-192,723878,387187
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-21,miR-150,387140,387168
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-21,miR-217,387140,387213
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-21,miR-148a,387140,387166
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-21,miR-146b,387140,751550
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-21,miR-31,387140,723895
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-21,miR-216,387140,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-21,miR-138,387140,"387156,723956"
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-21,miR-494,387140,723878
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-21,miR-216a,387140,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-21,miR-205,387140,387201
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-21,miR-192,387140,387187
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216a,miR-150,387212,387168
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216a,miR-217,387212,387213
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216a,miR-148a,387212,387166
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216a,miR-146b,387212,751550
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216a,miR-31,387212,723895
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216a,miR-216,387212,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216a,miR-138,387212,"387156,723956"
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216a,miR-494,387212,723878
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216a,miR-21,387212,387140
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216a,miR-205,387212,387201
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-216a,miR-192,387212,387187
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-205,miR-150,387201,387168
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-205,miR-217,387201,387213
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-205,miR-148a,387201,387166
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-205,miR-146b,387201,751550
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-205,miR-31,387201,723895
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-205,miR-216,387201,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-205,miR-138,387201,"387156,723956"
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-205,miR-494,387201,723878
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-205,miR-21,387201,387140
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-205,miR-216a,387201,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-205,miR-192,387201,387187
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-192,miR-150,387187,387168
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-192,miR-217,387187,387213
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-192,miR-148a,387187,387166
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-192,miR-146b,387187,751550
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-192,miR-31,387187,723895
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-192,miR-216,387187,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-192,miR-138,387187,"387156,723956"
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-192,miR-494,387187,723878
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-192,miR-21,387187,387140
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-192,miR-216a,387187,387212
26516699,"At 25 weeks, the miRNA microarray analysis revealed significant downregulation of miR-150, miR-494, miR-138, miR-148a, miR-216a, and miR-217 and upregulation of miR-146b, miR-205, miR-31, miR-192, and miR-21 in KC mice compared to controls",miR-192,miR-205,387187,387201
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Dicer,TARBP2,192119,21357
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Dicer,Ago2,192119,239528
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Dicer,TRKRA,192119,18211
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Dicer,DGCR8,192119,94223
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Dicer,Exportin-5,192119,72322
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",TARBP2,Dicer,21357,192119
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",TARBP2,Ago2,21357,239528
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",TARBP2,TRKRA,21357,18211
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",TARBP2,DGCR8,21357,94223
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",TARBP2,Exportin-5,21357,72322
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Ago2,Dicer,239528,192119
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Ago2,TARBP2,239528,21357
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Ago2,TRKRA,239528,18211
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Ago2,DGCR8,239528,94223
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Ago2,Exportin-5,239528,72322
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",TRKRA,Dicer,18211,192119
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",TRKRA,TARBP2,18211,21357
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",TRKRA,Ago2,18211,239528
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",TRKRA,DGCR8,18211,94223
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",TRKRA,Exportin-5,18211,72322
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",DGCR8,Dicer,94223,192119
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",DGCR8,TARBP2,94223,21357
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",DGCR8,Ago2,94223,239528
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",DGCR8,TRKRA,94223,18211
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",DGCR8,Exportin-5,94223,72322
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Exportin-5,Dicer,72322,192119
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Exportin-5,TARBP2,72322,21357
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Exportin-5,Ago2,72322,239528
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Exportin-5,TRKRA,72322,18211
26516699,"Further, expression of miRNA biosynthetic machinery including Dicer, Exportin-5, TRKRA, and TARBP2 were downregulated, while DGCR8 and Ago2 were upregulated in KC mice",Exportin-5,DGCR8,72322,94223
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-217,387168,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-345,387168,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-146b,387168,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-195,387168,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,Let-96,387168,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-216,387168,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-483-3p,387168,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-1273,387168,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-141,387168,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-34c,387168,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-223,387168,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-26b,387168,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-21,387168,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-205,387168,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,Let-7b,387168,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-150,miR-100,387168,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-150,387213,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-345,387213,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-146b,387213,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-195,387213,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,Let-96,387213,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-216,387213,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-483-3p,387213,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-1273,387213,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-141,387213,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-34c,387213,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-223,387213,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-26b,387213,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-21,387213,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-205,387213,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,Let-7b,387213,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-217,miR-100,387213,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-150,723946,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-217,723946,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-146b,723946,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-195,723946,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,Let-96,723946,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-216,723946,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-483-3p,723946,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-1273,723946,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-141,723946,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-34c,723946,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-223,723946,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-26b,723946,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-21,723946,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-205,723946,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,Let-7b,723946,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-345,miR-100,723946,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-150,751550,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-217,751550,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-345,751550,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-195,751550,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,Let-96,751550,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-216,751550,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-483-3p,751550,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-1273,751550,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-141,751550,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-34c,751550,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-223,751550,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-26b,751550,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-21,751550,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-205,751550,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,Let-7b,751550,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-146b,miR-100,751550,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-150,387190,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-217,387190,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-345,387190,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-146b,387190,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,Let-96,387190,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-216,387190,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-483-3p,387190,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-1273,387190,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-141,387190,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-34c,387190,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-223,387190,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-26b,387190,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-21,387190,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-205,387190,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,Let-7b,387190,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-195,miR-100,387190,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-150,-,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-217,-,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-345,-,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-146b,-,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-195,-,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-216,-,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-483-3p,-,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-1273,-,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-141,-,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-34c,-,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-223,-,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-26b,-,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-21,-,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-205,-,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,Let-7b,-,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-96,miR-100,-,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-150,387212,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-217,387212,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-345,387212,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-146b,387212,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-195,387212,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,Let-96,387212,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-483-3p,387212,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-1273,387212,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-141,387212,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-34c,387212,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-223,387212,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-26b,387212,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-21,387212,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-205,387212,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,Let-7b,387212,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-216,miR-100,387212,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-150,723874,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-217,723874,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-345,723874,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-146b,723874,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-195,723874,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,Let-96,723874,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-216,723874,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-1273,723874,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-141,723874,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-34c,723874,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-223,723874,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-26b,723874,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-21,723874,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-205,723874,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,Let-7b,723874,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-483-3p,miR-100,723874,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-150,100422821,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-217,100422821,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-345,100422821,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-146b,100422821,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-195,100422821,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,Let-96,100422821,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-216,100422821,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-483-3p,100422821,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-141,100422821,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-34c,100422821,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-223,100422821,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-26b,100422821,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-21,100422821,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-205,100422821,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,Let-7b,100422821,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-1273,miR-100,100422821,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-150,387159,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-217,387159,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-345,387159,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-146b,387159,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-195,387159,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,Let-96,387159,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-216,387159,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-483-3p,387159,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-1273,387159,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-34c,387159,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-223,387159,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-26b,387159,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-21,387159,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-205,387159,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,Let-7b,387159,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-141,miR-100,387159,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-150,723932,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-217,723932,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-345,723932,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-146b,723932,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-195,723932,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,Let-96,723932,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-216,723932,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-483-3p,723932,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-1273,723932,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-141,723932,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-223,723932,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-26b,723932,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-21,723932,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-205,723932,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,Let-7b,723932,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-34c,miR-100,723932,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-150,723814,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-217,723814,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-345,723814,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-146b,723814,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-195,723814,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,Let-96,723814,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-216,723814,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-483-3p,723814,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-1273,723814,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-141,723814,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-34c,723814,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-26b,723814,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-21,723814,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-205,723814,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,Let-7b,723814,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-223,miR-100,723814,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-150,387219,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-217,387219,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-345,387219,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-146b,387219,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-195,387219,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,Let-96,387219,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-216,387219,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-483-3p,387219,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-1273,387219,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-141,387219,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-34c,387219,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-223,387219,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-21,387219,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-205,387219,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,Let-7b,387219,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-26b,miR-100,387219,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-150,387140,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-217,387140,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-345,387140,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-146b,387140,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-195,387140,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,Let-96,387140,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-216,387140,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-483-3p,387140,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-1273,387140,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-141,387140,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-34c,387140,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-223,387140,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-26b,387140,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-205,387140,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,Let-7b,387140,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-21,miR-100,387140,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-150,387201,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-217,387201,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-345,387201,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-146b,387201,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-195,387201,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,Let-96,387201,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-216,387201,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-483-3p,387201,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-1273,387201,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-141,387201,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-34c,387201,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-223,387201,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-26b,387201,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-21,387201,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,Let-7b,387201,406884
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-205,miR-100,387201,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-150,406884,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-217,406884,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-345,406884,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-146b,406884,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-195,406884,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,Let-96,406884,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-216,406884,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-483-3p,406884,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-1273,406884,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-141,406884,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-34c,406884,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-223,406884,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-26b,406884,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-21,406884,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-205,406884,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",Let-7b,miR-100,406884,723892
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-150,723892,387168
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-217,723892,387213
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-345,723892,723946
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-146b,723892,751550
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-195,723892,387190
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,Let-96,723892,-
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-216,723892,387212
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-483-3p,723892,723874
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-1273,723892,100422821
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-141,723892,387159
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-34c,723892,723932
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-223,723892,723814
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-26b,723892,387219
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-21,723892,387140
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,miR-205,723892,387201
26516699,"In addition, from 10 to 50 weeks of age, stage-specific expression profiling of miRNA in KC mice revealed downregulation of miR-216, miR-217, miR-100, miR-345, miR-141, miR-483-3p, miR-26b, miR-150, miR-195, Let-7b and Let-96 and upregulation of miR-21, miR-205, miR-146b, miR-34c, miR-1273, miR-223 and miR-195 compared to control mice",miR-100,Let-7b,723892,406884
26516699,"Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression",PC,MSST1,D010190,-
26516699,"Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression",PC,KRAS,D010190,3845
26516699,"Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression",PC,Let-7b,D010190,406884
26516699,"Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression",MSST1,PC,-,D010190
26516699,"Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression",MSST1,KRAS,-,3845
26516699,"Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression",MSST1,Let-7b,-,406884
26516699,"Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression",KRAS,PC,3845,D010190
26516699,"Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression",KRAS,MSST1,3845,-
26516699,"Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression",KRAS,Let-7b,3845,406884
26516699,"Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression",Let-7b,PC,406884,D010190
26516699,"Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression",Let-7b,MSST1,406884,-
26516699,"Interestingly, the differential expression of miRNA in mice also corroborated with the miRNA expression in human PC cell lines and tissue samples; ectopic expression of Let-7b in CD18/HPAF and Capan1 cells resulted in the downregulation of KRAS and MSST1 expression",Let-7b,KRAS,406884,3845
26731607,Growth arrest and DNA-damage-inducible 45 alpha (GADD45A) is induced by genotoxic stress in HSCs,GADD45A,Growth arrest and DNA-damage-inducible 45 alpha,13197,13197
26731607,Growth arrest and DNA-damage-inducible 45 alpha (GADD45A) is induced by genotoxic stress in HSCs,Growth arrest and DNA-damage-inducible 45 alpha,GADD45A,13197,13197
26731607,"The differentiation induction by GADD45A was transmitted by activating p38 Mitogen-activated protein kinase (MAPK) signaling and allowed the generation of megakaryocytic-erythroid, myeloid, and lymphoid lineages",p38 Mitogen-activated protein kinase,MAPK,26416,26416
26731607,"The differentiation induction by GADD45A was transmitted by activating p38 Mitogen-activated protein kinase (MAPK) signaling and allowed the generation of megakaryocytic-erythroid, myeloid, and lymphoid lineages",p38 Mitogen-activated protein kinase,GADD45A,26416,13197
26731607,"The differentiation induction by GADD45A was transmitted by activating p38 Mitogen-activated protein kinase (MAPK) signaling and allowed the generation of megakaryocytic-erythroid, myeloid, and lymphoid lineages",MAPK,p38 Mitogen-activated protein kinase,26416,26416
26731607,"The differentiation induction by GADD45A was transmitted by activating p38 Mitogen-activated protein kinase (MAPK) signaling and allowed the generation of megakaryocytic-erythroid, myeloid, and lymphoid lineages",MAPK,GADD45A,26416,13197
26731607,"The differentiation induction by GADD45A was transmitted by activating p38 Mitogen-activated protein kinase (MAPK) signaling and allowed the generation of megakaryocytic-erythroid, myeloid, and lymphoid lineages",GADD45A,p38 Mitogen-activated protein kinase,13197,26416
26731607,"The differentiation induction by GADD45A was transmitted by activating p38 Mitogen-activated protein kinase (MAPK) signaling and allowed the generation of megakaryocytic-erythroid, myeloid, and lymphoid lineages",GADD45A,MAPK,13197,26416
27134166,"Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance",tumors,VEGF,D009369,"22339,7422"
27134166,"Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance",tumor,VEGF,D009369,"22339,7422"
27134166,"Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance",cancer,VEGF,D009369,"22339,7422"
27134166,"Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance",VEGF,tumors,"22339,7422",D009369
27134166,"Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance",VEGF,tumor,"22339,7422",D009369
27134166,"Therapeutic targeting of tumor angiogenesis with VEGF inhibitors results in demonstrable, but transitory efficacy in certain human tumors and mouse models of cancer, limited by unconventional forms of adaptive/evasive resistance",VEGF,cancer,"22339,7422",D009369
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",glucose,hypoxic,D005947,D000860
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",glucose,lactate,D005947,D019344
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",glucose,GLUT1,D005947,20525
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",glucose,MCT4,D005947,80879
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",glucose,HIF1a,D005947,15251
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",hypoxic,glucose,D000860,D005947
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",hypoxic,lactate,D000860,D019344
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",hypoxic,GLUT1,D000860,20525
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",hypoxic,MCT4,D000860,80879
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",hypoxic,HIF1a,D000860,15251
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",lactate,glucose,D019344,D005947
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",lactate,hypoxic,D019344,D000860
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",lactate,GLUT1,D019344,20525
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",lactate,MCT4,D019344,80879
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",lactate,HIF1a,D019344,15251
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",GLUT1,glucose,20525,D005947
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",GLUT1,hypoxic,20525,D000860
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",GLUT1,lactate,20525,D019344
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",GLUT1,MCT4,20525,80879
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",GLUT1,HIF1a,20525,15251
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",MCT4,glucose,80879,D005947
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",MCT4,hypoxic,80879,D000860
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",MCT4,lactate,80879,D019344
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",MCT4,GLUT1,80879,20525
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",MCT4,HIF1a,80879,15251
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",HIF1a,glucose,15251,D005947
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",HIF1a,hypoxic,15251,D000860
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",HIF1a,lactate,15251,D019344
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",HIF1a,GLUT1,15251,20525
27134166,"The glucose and lactate transporters GLUT1 and MCT4 are induced in distal hypoxic cells in a HIF1a-dependent fashion, indicative of glycolysis",HIF1a,MCT4,15251,80879
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",MCT1,Tumor,20501,D009369
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",MCT1,mTOR,20501,56717
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",MCT1,lactate,20501,D019344
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",MCT1,p-S6,20501,72508
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",Tumor,MCT1,D009369,20501
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",Tumor,mTOR,D009369,56717
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",Tumor,lactate,D009369,D019344
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",Tumor,p-S6,D009369,72508
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",mTOR,MCT1,56717,20501
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",mTOR,Tumor,56717,D009369
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",mTOR,lactate,56717,D019344
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",mTOR,p-S6,56717,72508
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",lactate,MCT1,D019344,20501
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",lactate,Tumor,D019344,D009369
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",lactate,mTOR,D019344,56717
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",lactate,p-S6,D019344,72508
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",p-S6,MCT1,72508,20501
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",p-S6,Tumor,72508,D009369
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",p-S6,mTOR,72508,56717
27134166,"Tumor cells proximal to blood vessels instead express the lactate transporter MCT1, and p-S6, the latter reflecting mTOR signaling",p-S6,lactate,72508,D019344
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",cancer,mTOR,D009369,56717
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",cancer,glutamine,D009369,D005973
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",cancer,lactate,D009369,D019344
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",mTOR,cancer,56717,D009369
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",mTOR,glutamine,56717,D005973
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",mTOR,Normoxic cancer,56717,D009369
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",mTOR,lactate,56717,D019344
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",glutamine,cancer,D005973,D009369
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",glutamine,mTOR,D005973,56717
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",glutamine,Normoxic cancer,D005973,D009369
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",glutamine,lactate,D005973,D019344
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",Normoxic cancer,mTOR,D009369,56717
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",Normoxic cancer,glutamine,D009369,D005973
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",Normoxic cancer,lactate,D009369,D019344
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",lactate,cancer,D019344,D009369
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",lactate,mTOR,D019344,56717
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",lactate,glutamine,D019344,D005973
27134166,"Normoxic cancer cells import and metabolize lactate, resulting in upregulation of mTOR signaling via glutamine metabolism enhanced by lactate catabolism",lactate,Normoxic cancer,D019344,D009369
27134166,"Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate",lactate,cancer,D019344,D009369
27134166,"Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate",lactate,glucose,D019344,D005947
27134166,"Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate",lactate,hypoxic,D019344,D000860
27134166,"Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate",cancer,lactate,D009369,D019344
27134166,"Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate",cancer,glucose,D009369,D005947
27134166,"Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate",glucose,lactate,D005947,D019344
27134166,"Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate",glucose,cancer,D005947,D009369
27134166,"Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate",glucose,hypoxic,D005947,D000860
27134166,"Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate",hypoxic,lactate,D000860,D019344
27134166,"Thus, metabolic symbiosis is established in the face of angiogenesis inhibition, whereby hypoxic cancer cells import glucose and export lactate, while normoxic cells import and catabolize lactate",hypoxic,glucose,D000860,D005947
27134166,"mTOR signaling inhibition disrupts this metabolic symbiosis, associated with upregulation of the glucose transporter GLUT2.",glucose,mTOR,D005947,56717
27134166,"mTOR signaling inhibition disrupts this metabolic symbiosis, associated with upregulation of the glucose transporter GLUT2.",glucose,GLUT2,D005947,20526
27134166,"mTOR signaling inhibition disrupts this metabolic symbiosis, associated with upregulation of the glucose transporter GLUT2.",mTOR,glucose,56717,D005947
27134166,"mTOR signaling inhibition disrupts this metabolic symbiosis, associated with upregulation of the glucose transporter GLUT2.",mTOR,GLUT2,56717,20526
27134166,"mTOR signaling inhibition disrupts this metabolic symbiosis, associated with upregulation of the glucose transporter GLUT2.",GLUT2,glucose,20526,D005947
27134166,"mTOR signaling inhibition disrupts this metabolic symbiosis, associated with upregulation of the glucose transporter GLUT2.",GLUT2,mTOR,20526,56717
27248656,Hsp90beta is involved in the development of high salt-diet-induced nephropathy via interaction with various signalling proteins,nephropathy,salt,D007674,D012492
27248656,Hsp90beta is involved in the development of high salt-diet-induced nephropathy via interaction with various signalling proteins,nephropathy,Hsp90beta,D007674,301252
27248656,Hsp90beta is involved in the development of high salt-diet-induced nephropathy via interaction with various signalling proteins,salt,nephropathy,D012492,D007674
27248656,Hsp90beta is involved in the development of high salt-diet-induced nephropathy via interaction with various signalling proteins,salt,Hsp90beta,D012492,301252
27248656,Hsp90beta is involved in the development of high salt-diet-induced nephropathy via interaction with various signalling proteins,Hsp90beta,nephropathy,301252,D007674
27248656,Hsp90beta is involved in the development of high salt-diet-induced nephropathy via interaction with various signalling proteins,Hsp90beta,salt,301252,D012492
27248656,"A high-salt diet often leads to a local intrarenal increase in renal hypoxia and oxidative stress, which are responsible for an excess production of pathogenic substances",renal hypoxia,salt,D007674,D012492
27248656,"A high-salt diet often leads to a local intrarenal increase in renal hypoxia and oxidative stress, which are responsible for an excess production of pathogenic substances",salt,renal hypoxia,D012492,D007674
27248656,"Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis",renal inflammation,salt,D007674,D012492
27248656,"Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis",proteinuria,salt,D011507,D012492
27248656,"Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis",fibrosis,salt,D005355,D012492
27248656,"Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis",hypertensive,salt,D006973,D012492
27248656,"Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis",salt,renal inflammation,D012492,D007674
27248656,"Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis",salt,proteinuria,D012492,D011507
27248656,"Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis",salt,fibrosis,D012492,D005355
27248656,"Here, Wistar Kyoto/spontaneous hypertensive (WKY/SHR) rats fed a high-salt diet developed severe proteinuria, resulting from pronounced renal inflammation, fibrosis and tubular epithelial cell apoptosis",salt,hypertensive,D012492,D006973
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",IL-6,HIF-1alpha,24498,29560
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",IL-6,MCP-1,24498,24770
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",IL-6,TNF-alpha,24498,24835
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",IL-6,salt,24498,D012492
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",IL-6,Hsp90beta,24498,301252
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",IL-6,"TGF-beta,",24498,59086
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",HIF-1alpha,IL-6,29560,24498
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",HIF-1alpha,MCP-1,29560,24770
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",HIF-1alpha,TNF-alpha,29560,24835
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",HIF-1alpha,salt,29560,D012492
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",HIF-1alpha,Hsp90beta,29560,301252
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",HIF-1alpha,"TGF-beta,",29560,59086
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",MCP-1,IL-6,24770,24498
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",MCP-1,HIF-1alpha,24770,29560
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",MCP-1,TNF-alpha,24770,24835
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",MCP-1,salt,24770,D012492
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",MCP-1,Hsp90beta,24770,301252
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",MCP-1,"TGF-beta,",24770,59086
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",TNF-alpha,IL-6,24835,24498
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",TNF-alpha,HIF-1alpha,24835,29560
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",TNF-alpha,MCP-1,24835,24770
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",TNF-alpha,salt,24835,D012492
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",TNF-alpha,Hsp90beta,24835,301252
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",TNF-alpha,"TGF-beta,",24835,59086
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",salt,IL-6,D012492,24498
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",salt,HIF-1alpha,D012492,29560
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",salt,MCP-1,D012492,24770
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",salt,TNF-alpha,D012492,24835
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",salt,Hsp90beta,D012492,301252
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",salt,"TGF-beta,",D012492,59086
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",Hsp90beta,IL-6,301252,24498
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",Hsp90beta,HIF-1alpha,301252,29560
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",Hsp90beta,MCP-1,301252,24770
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",Hsp90beta,TNF-alpha,301252,24835
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",Hsp90beta,salt,301252,D012492
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading",Hsp90beta,"TGF-beta,",301252,59086
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading","TGF-beta,",IL-6,59086,24498
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading","TGF-beta,",HIF-1alpha,59086,29560
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading","TGF-beta,",MCP-1,59086,24770
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading","TGF-beta,",TNF-alpha,59086,24835
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading","TGF-beta,",salt,59086,D012492
27248656,"Hsp90beta, TGF-beta, HIF-1alpha, TNF-alpha, IL-6 and MCP-1 were shown to be highly expressed in response to salt loading","TGF-beta,",Hsp90beta,59086,301252
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",NF-kappaB,salt,81736,D012492
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",NF-kappaB,Hsp90beta,81736,301252
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",NF-kappaB,Bcl-2,81736,24224
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",NF-kappaB,p38,81736,81649
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",salt,NF-kappaB,D012492,81736
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",salt,Hsp90beta,D012492,301252
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",salt,Bcl-2,D012492,24224
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",salt,p38,D012492,81649
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",Hsp90beta,NF-kappaB,301252,81736
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",Hsp90beta,salt,301252,D012492
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",Hsp90beta,Bcl-2,301252,24224
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",Hsp90beta,p38,301252,81649
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",Bcl-2,NF-kappaB,24224,81736
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",Bcl-2,salt,24224,D012492
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",Bcl-2,Hsp90beta,24224,301252
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",Bcl-2,p38,24224,81649
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",p38,NF-kappaB,81649,81736
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",p38,salt,81649,D012492
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",p38,Hsp90beta,81649,301252
27248656,"Next, we found that Hsp90beta might play the key role in non-pressure-related effects of salt loading through a series of cellular signalling events, including the NF-kappaB, p38 activation and Bcl-2 inactivation",p38,Bcl-2,81649,24224
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",proteinuria,NF-kappaB,D011507,81736
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",proteinuria,mTOR,D011507,56718
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",proteinuria,17-DMAG,D011507,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",proteinuria,salt,D011507,D012492
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",proteinuria,Hsp90beta,D011507,301252
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",proteinuria,17-dimethylaminoethylamino-17-demethoxygeldanamycin,D011507,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",proteinuria,p38,D011507,81649
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",NF-kappaB,proteinuria,81736,D011507
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",NF-kappaB,mTOR,81736,56718
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",NF-kappaB,renal damage,81736,D007674
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",NF-kappaB,17-DMAG,81736,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",NF-kappaB,salt,81736,D012492
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",NF-kappaB,Hsp90beta,81736,301252
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",NF-kappaB,17-dimethylaminoethylamino-17-demethoxygeldanamycin,81736,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",NF-kappaB,p38,81736,81649
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",mTOR,proteinuria,56718,D011507
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",mTOR,NF-kappaB,56718,81736
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",mTOR,renal damage,56718,D007674
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",mTOR,17-DMAG,56718,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",mTOR,salt,56718,D012492
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",mTOR,Hsp90beta,56718,301252
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",mTOR,17-dimethylaminoethylamino-17-demethoxygeldanamycin,56718,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",mTOR,p38,56718,81649
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",renal damage,NF-kappaB,D007674,81736
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",renal damage,mTOR,D007674,56718
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",renal damage,17-DMAG,D007674,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",renal damage,salt,D007674,D012492
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",renal damage,Hsp90beta,D007674,301252
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",renal damage,17-dimethylaminoethylamino-17-demethoxygeldanamycin,D007674,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",renal damage,p38,D007674,81649
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-DMAG,proteinuria,C448659,D011507
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-DMAG,NF-kappaB,C448659,81736
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-DMAG,mTOR,C448659,56718
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-DMAG,renal damage,C448659,D007674
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-DMAG,salt,C448659,D012492
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-DMAG,Hsp90beta,C448659,301252
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-DMAG,17-dimethylaminoethylamino-17-demethoxygeldanamycin,C448659,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-DMAG,p38,C448659,81649
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",salt,proteinuria,D012492,D011507
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",salt,NF-kappaB,D012492,81736
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",salt,mTOR,D012492,56718
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",salt,renal damage,D012492,D007674
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",salt,17-DMAG,D012492,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",salt,Hsp90beta,D012492,301252
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",salt,17-dimethylaminoethylamino-17-demethoxygeldanamycin,D012492,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",salt,p38,D012492,81649
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",Hsp90beta,proteinuria,301252,D011507
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",Hsp90beta,NF-kappaB,301252,81736
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",Hsp90beta,mTOR,301252,56718
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",Hsp90beta,renal damage,301252,D007674
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",Hsp90beta,17-DMAG,301252,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",Hsp90beta,salt,301252,D012492
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",Hsp90beta,17-dimethylaminoethylamino-17-demethoxygeldanamycin,301252,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",Hsp90beta,p38,301252,81649
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-dimethylaminoethylamino-17-demethoxygeldanamycin,proteinuria,C448659,D011507
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-dimethylaminoethylamino-17-demethoxygeldanamycin,NF-kappaB,C448659,81736
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-dimethylaminoethylamino-17-demethoxygeldanamycin,mTOR,C448659,56718
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-dimethylaminoethylamino-17-demethoxygeldanamycin,renal damage,C448659,D007674
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-dimethylaminoethylamino-17-demethoxygeldanamycin,17-DMAG,C448659,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-dimethylaminoethylamino-17-demethoxygeldanamycin,salt,C448659,D012492
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-dimethylaminoethylamino-17-demethoxygeldanamycin,Hsp90beta,C448659,301252
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",17-dimethylaminoethylamino-17-demethoxygeldanamycin,p38,C448659,81649
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",p38,proteinuria,81649,D011507
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",p38,NF-kappaB,81649,81736
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",p38,mTOR,81649,56718
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",p38,renal damage,81649,D007674
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",p38,17-DMAG,81649,C448659
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",p38,salt,81649,D012492
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",p38,Hsp90beta,81649,301252
27248656,"In our study, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) or Hsp90beta knockdown dramatically alleviated the high-salt-diet-induced proteinuria and renal damage without altering blood pressure significantly, when it reversed activations of NF-kappaB, mTOR and p38 signalling cascades",p38,17-dimethylaminoethylamino-17-demethoxygeldanamycin,81649,C448659
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",AMPKalpha,TAK1,65248,313121
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",AMPKalpha,HIF-1alpha,65248,29560
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",AMPKalpha,IKKalpha/beta,65248,"309361,84351"
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",AMPKalpha,Hsp90beta,65248,301252
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",AMPKalpha,Raptor,65248,287871
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",TAK1,AMPKalpha,313121,65248
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",TAK1,HIF-1alpha,313121,29560
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",TAK1,IKKalpha/beta,313121,"309361,84351"
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",TAK1,Hsp90beta,313121,301252
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",TAK1,Raptor,313121,287871
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",HIF-1alpha,AMPKalpha,29560,65248
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",HIF-1alpha,TAK1,29560,313121
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",HIF-1alpha,IKKalpha/beta,29560,"309361,84351"
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",HIF-1alpha,Hsp90beta,29560,301252
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",HIF-1alpha,Raptor,29560,287871
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",IKKalpha/beta,AMPKalpha,"309361,84351",65248
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",IKKalpha/beta,TAK1,"309361,84351",313121
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",IKKalpha/beta,HIF-1alpha,"309361,84351",29560
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",IKKalpha/beta,Hsp90beta,"309361,84351",301252
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",IKKalpha/beta,Raptor,"309361,84351",287871
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",Hsp90beta,AMPKalpha,301252,65248
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",Hsp90beta,TAK1,301252,313121
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",Hsp90beta,HIF-1alpha,301252,29560
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",Hsp90beta,IKKalpha/beta,301252,"309361,84351"
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",Hsp90beta,Raptor,301252,287871
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",Raptor,AMPKalpha,287871,65248
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",Raptor,TAK1,287871,313121
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",Raptor,HIF-1alpha,287871,29560
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",Raptor,IKKalpha/beta,287871,"309361,84351"
27248656,"Meanwhile, Co-IP results demonstrated that Hsp90beta could interact with and stabilize TAK1, AMPKalpha, IKKalpha/beta, HIF-1alpha and Raptor, whereas Hsp90beta inhibition disrupted this process",Raptor,Hsp90beta,287871,301252
27248656,"In conclusion, salt loading indeed exhibited non-pressure-related impacts on proteinuria and renal dysfunction in WKY/SHR rats",proteinuria,salt,D011507,D012492
27248656,"In conclusion, salt loading indeed exhibited non-pressure-related impacts on proteinuria and renal dysfunction in WKY/SHR rats",renal dysfunction,salt,D051437,D012492
27248656,"In conclusion, salt loading indeed exhibited non-pressure-related impacts on proteinuria and renal dysfunction in WKY/SHR rats",salt,proteinuria,D012492,D011507
27248656,"In conclusion, salt loading indeed exhibited non-pressure-related impacts on proteinuria and renal dysfunction in WKY/SHR rats",salt,renal dysfunction,D012492,D051437
27248656,"Hsp90beta inhibition caused the destabilization of upstream mediators in various pathogenic signalling events, thereby effectively ameliorating this nephropathy owing to renal hypoxia and oxidative stress",nephropathy,Hsp90beta,D007674,301252
27248656,"Hsp90beta inhibition caused the destabilization of upstream mediators in various pathogenic signalling events, thereby effectively ameliorating this nephropathy owing to renal hypoxia and oxidative stress",renal hypoxia,Hsp90beta,D007674,301252
27248656,"Hsp90beta inhibition caused the destabilization of upstream mediators in various pathogenic signalling events, thereby effectively ameliorating this nephropathy owing to renal hypoxia and oxidative stress",Hsp90beta,nephropathy,301252,D007674
27248656,"Hsp90beta inhibition caused the destabilization of upstream mediators in various pathogenic signalling events, thereby effectively ameliorating this nephropathy owing to renal hypoxia and oxidative stress",Hsp90beta,renal hypoxia,301252,D007674
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Trans-Fats,Metabolic Syndrome,D044242,D008659
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Trans-Fats,Fructose,D044242,D005632
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Trans-Fats,Nonalcoholic Fatty Liver Disease,D044242,D065626
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Trans-Fats,11b-HSD1,D044242,15483
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Metabolic Syndrome,Trans-Fats,D008659,D044242
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Metabolic Syndrome,Fructose,D008659,D005632
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Metabolic Syndrome,11b-HSD1,D008659,15483
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Fructose,Trans-Fats,D005632,D044242
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Fructose,Metabolic Syndrome,D005632,D008659
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Fructose,Nonalcoholic Fatty Liver Disease,D005632,D065626
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Fructose,11b-HSD1,D005632,15483
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Nonalcoholic Fatty Liver Disease,Trans-Fats,D065626,D044242
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Nonalcoholic Fatty Liver Disease,Fructose,D065626,D005632
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,Nonalcoholic Fatty Liver Disease,11b-HSD1,D065626,15483
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,11b-HSD1,Trans-Fats,15483,D044242
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,11b-HSD1,Metabolic Syndrome,15483,D008659
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,11b-HSD1,Fructose,15483,D005632
27384305,Male 11b-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease,11b-HSD1,Nonalcoholic Fatty Liver Disease,15483,D065626
27384305,"Glucocorticoids can promote steatosis by stimulating lipolysis within adipose tissue, free fatty acid delivery to liver and hepatic de novo lipogenesis",Glucocorticoids,steatosis,D005938,D005234
27384305,"Glucocorticoids can promote steatosis by stimulating lipolysis within adipose tissue, free fatty acid delivery to liver and hepatic de novo lipogenesis",Glucocorticoids,free fatty acid,D005938,D005230
27384305,"Glucocorticoids can promote steatosis by stimulating lipolysis within adipose tissue, free fatty acid delivery to liver and hepatic de novo lipogenesis",steatosis,Glucocorticoids,D005234,D005938
27384305,"Glucocorticoids can promote steatosis by stimulating lipolysis within adipose tissue, free fatty acid delivery to liver and hepatic de novo lipogenesis",steatosis,free fatty acid,D005234,D005230
27384305,"Glucocorticoids can promote steatosis by stimulating lipolysis within adipose tissue, free fatty acid delivery to liver and hepatic de novo lipogenesis",free fatty acid,Glucocorticoids,D005230,D005938
27384305,"Glucocorticoids can promote steatosis by stimulating lipolysis within adipose tissue, free fatty acid delivery to liver and hepatic de novo lipogenesis",free fatty acid,steatosis,D005230,D005234
27384305,Glucocorticoids can be reactivated in liver through 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) enzyme activity,Glucocorticoids,11b-hydroxysteroid dehydrogenase type 1,D005938,15483
27384305,Glucocorticoids can be reactivated in liver through 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) enzyme activity,Glucocorticoids,11b-HSD1,D005938,15483
27384305,Glucocorticoids can be reactivated in liver through 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) enzyme activity,11b-hydroxysteroid dehydrogenase type 1,Glucocorticoids,15483,D005938
27384305,Glucocorticoids can be reactivated in liver through 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) enzyme activity,11b-hydroxysteroid dehydrogenase type 1,11b-HSD1,15483,15483
27384305,Glucocorticoids can be reactivated in liver through 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) enzyme activity,11b-HSD1,Glucocorticoids,15483,D005938
27384305,Glucocorticoids can be reactivated in liver through 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1) enzyme activity,11b-HSD1,11b-hydroxysteroid dehydrogenase type 1,15483,15483
27384305,Inhibition of 11b-HSD1 has been suggested as a potential treatment for NAFLD,NAFLD,11b-HSD1,D065626,15483
27384305,Inhibition of 11b-HSD1 has been suggested as a potential treatment for NAFLD,11b-HSD1,NAFLD,15483,D065626
27384305,"To test this, male mice with global (11b-HSD1 knockout [KO]) and liver-specific (LKO) 11b-HSD1 loss of function were fed the American Lifestyle Induced Obesity Syndrome (ALIOS) diet, known to recapitulate the spectrum of NAFLD, and metabolic and liver phenotypes assessed",NAFLD,11b-HSD1,D065626,15483
27384305,"To test this, male mice with global (11b-HSD1 knockout [KO]) and liver-specific (LKO) 11b-HSD1 loss of function were fed the American Lifestyle Induced Obesity Syndrome (ALIOS) diet, known to recapitulate the spectrum of NAFLD, and metabolic and liver phenotypes assessed",11b-HSD1,NAFLD,15483,D065626
27384305,"Body weight, muscle and adipose tissue masses, and parameters of glucose homeostasis showed that 11b-HSD1KO and LKO mice were not protected from systemic metabolic disease",glucose,metabolic disease,D005947,D008659
27384305,"Body weight, muscle and adipose tissue masses, and parameters of glucose homeostasis showed that 11b-HSD1KO and LKO mice were not protected from systemic metabolic disease",glucose,11b-HSD1,D005947,15483
27384305,"Body weight, muscle and adipose tissue masses, and parameters of glucose homeostasis showed that 11b-HSD1KO and LKO mice were not protected from systemic metabolic disease",metabolic disease,glucose,D008659,D005947
27384305,"Body weight, muscle and adipose tissue masses, and parameters of glucose homeostasis showed that 11b-HSD1KO and LKO mice were not protected from systemic metabolic disease",metabolic disease,11b-HSD1,D008659,15483
27384305,"Body weight, muscle and adipose tissue masses, and parameters of glucose homeostasis showed that 11b-HSD1KO and LKO mice were not protected from systemic metabolic disease",11b-HSD1,glucose,15483,D005947
27384305,"Body weight, muscle and adipose tissue masses, and parameters of glucose homeostasis showed that 11b-HSD1KO and LKO mice were not protected from systemic metabolic disease",11b-HSD1,metabolic disease,15483,D008659
27384305,"Evaluation of hepatic histology, triglyceride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11b-HSD1KO, LKO, and control mice",NAFLD,triglyceride,D065626,D014280
27384305,"Evaluation of hepatic histology, triglyceride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11b-HSD1KO, LKO, and control mice",NAFLD,11b-HSD1,D065626,15483
27384305,"Evaluation of hepatic histology, triglyceride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11b-HSD1KO, LKO, and control mice",triglyceride,NAFLD,D014280,D065626
27384305,"Evaluation of hepatic histology, triglyceride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11b-HSD1KO, LKO, and control mice",triglyceride,11b-HSD1,D014280,15483
27384305,"Evaluation of hepatic histology, triglyceride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11b-HSD1KO, LKO, and control mice",triglyceride,steatosis,D014280,D005234
27384305,"Evaluation of hepatic histology, triglyceride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11b-HSD1KO, LKO, and control mice",11b-HSD1,NAFLD,15483,D065626
27384305,"Evaluation of hepatic histology, triglyceride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11b-HSD1KO, LKO, and control mice",11b-HSD1,triglyceride,15483,D014280
27384305,"Evaluation of hepatic histology, triglyceride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11b-HSD1KO, LKO, and control mice",11b-HSD1,steatosis,15483,D005234
27384305,"Evaluation of hepatic histology, triglyceride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11b-HSD1KO, LKO, and control mice",steatosis,triglyceride,D005234,D014280
27384305,"Evaluation of hepatic histology, triglyceride content, and blinded NAFLD activity score assessment indicated that levels of steatosis were similar between 11b-HSD1KO, LKO, and control mice",steatosis,11b-HSD1,D005234,15483
27384305,"Unexpectedly, histological analysis revealed significantly increased levels of immune foci present in livers of 11b-HSD1KO but not LKO or control mice, suggestive of a transition to NASH",NASH,11b-HSD1,D065626,15483
27384305,"Unexpectedly, histological analysis revealed significantly increased levels of immune foci present in livers of 11b-HSD1KO but not LKO or control mice, suggestive of a transition to NASH",11b-HSD1,NASH,15483,D065626
27384305,These data indicate that 11b-HSD1-deficient mice are not protected from metabolic disease or hepatosteatosis in the face of a NAFLD-inducing diet,NAFLD,11b-HSD1,D065626,15483
27384305,These data indicate that 11b-HSD1-deficient mice are not protected from metabolic disease or hepatosteatosis in the face of a NAFLD-inducing diet,11b-HSD1,NAFLD,15483,D065626
27384305,These data indicate that 11b-HSD1-deficient mice are not protected from metabolic disease or hepatosteatosis in the face of a NAFLD-inducing diet,11b-HSD1,metabolic disease,15483,D008659
27384305,These data indicate that 11b-HSD1-deficient mice are not protected from metabolic disease or hepatosteatosis in the face of a NAFLD-inducing diet,11b-HSD1,hepatosteatosis,15483,D005234
27384305,These data indicate that 11b-HSD1-deficient mice are not protected from metabolic disease or hepatosteatosis in the face of a NAFLD-inducing diet,11b-HSD1,steatosis,15483,D005234
27384305,These data indicate that 11b-HSD1-deficient mice are not protected from metabolic disease or hepatosteatosis in the face of a NAFLD-inducing diet,metabolic disease,11b-HSD1,D008659,15483
27384305,These data indicate that 11b-HSD1-deficient mice are not protected from metabolic disease or hepatosteatosis in the face of a NAFLD-inducing diet,hepatosteatosis,11b-HSD1,D005234,15483
27384305,These data indicate that 11b-HSD1-deficient mice are not protected from metabolic disease or hepatosteatosis in the face of a NAFLD-inducing diet,steatosis,11b-HSD1,D005234,15483
27384305,"However, global deficiency of 11b-HSD1 did increase markers of hepatic inflammation and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.",NASH,11b-HSD1,D065626,15483
27384305,"However, global deficiency of 11b-HSD1 did increase markers of hepatic inflammation and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.",hepatic inflammation,11b-HSD1,D008107,15483
27384305,"However, global deficiency of 11b-HSD1 did increase markers of hepatic inflammation and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.",11b-HSD1,NASH,15483,D065626
27384305,"However, global deficiency of 11b-HSD1 did increase markers of hepatic inflammation and suggests a critical role for 11b-HSD1 in restraining the transition to NASH.",11b-HSD1,hepatic inflammation,15483,D008107
27640183,Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo,Erythropoietin,erythropoietin receptor,13856,2057
27640183,Erythropoietin does not activate erythropoietin receptor signaling or lipolytic pathways in human subcutaneous white adipose tissue in vivo,erythropoietin receptor,Erythropoietin,2057,13856
27640183,"BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented",Epo,Erythropoietin,2056,13856
27640183,"BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented",Epo,lipid,2056,D008055
27640183,"BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented",Erythropoietin,Epo,13856,2056
27640183,"BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented",Erythropoietin,lipid,13856,D008055
27640183,"BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented",lipid,Epo,D008055,2056
27640183,"BACKGROUND: Erythropoietin (Epo) exerts direct effects on white adipose tissue (WAT) in mice in addition to its erythropoietic effects, and in humans Epo increases resting energy expenditure and affect serum lipid levels, but direct effects of Epo in human WAT have not been documented",lipid,Erythropoietin,D008055,13856
27640183,"METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha",ESA,Darbepoietin-alpha,D006397,-
27640183,"METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha",ESA,Epo,D006397,2056
27640183,"METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha",ESA,erythropoiesis-stimulating agent,D006397,D006397
27640183,"METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha",Darbepoietin-alpha,ESA,-,D006397
27640183,"METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha",Darbepoietin-alpha,Epo,-,2056
27640183,"METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha",Darbepoietin-alpha,erythropoiesis-stimulating agent,-,D006397
27640183,"METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha",Epo,ESA,2056,D006397
27640183,"METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha",Epo,Darbepoietin-alpha,2056,-
27640183,"METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha",Epo,erythropoiesis-stimulating agent,2056,D006397
27640183,"METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha",erythropoiesis-stimulating agent,ESA,D006397,D006397
27640183,"METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha",erythropoiesis-stimulating agent,Darbepoietin-alpha,D006397,-
27640183,"METHOD: Data were obtained from two clinical trials: 1) acute Epo exposure (rHuEpo, 400 IU/kg) followed by WAT biopsies after 1 h and 2) 10 weeks treatment with the erythropoiesis-stimulating agent (ESA) Darbepoietin-alpha",erythropoiesis-stimulating agent,Epo,D006397,2056
27640183,Biopsies were analyzed by PCR for Epo receptor (Epo-R) mRNA,Epo-R,Epo receptor,2057,2057
27640183,Biopsies were analyzed by PCR for Epo receptor (Epo-R) mRNA,Epo-R,Epo,2057,2056
27640183,Biopsies were analyzed by PCR for Epo receptor (Epo-R) mRNA,Epo receptor,Epo-R,2057,2057
27640183,Biopsies were analyzed by PCR for Epo receptor (Epo-R) mRNA,Epo receptor,Epo,2057,2056
27640183,Biopsies were analyzed by PCR for Epo receptor (Epo-R) mRNA,Epo,Epo-R,2056,2057
27640183,Biopsies were analyzed by PCR for Epo receptor (Epo-R) mRNA,Epo,Epo receptor,2056,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,Cidea,63924,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,SDHA,63924,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,LYN,63924,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,ACC,63924,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,CGI-58,63924,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,Perilipin,63924,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,ATGL,63924,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,p38MAPK,63924,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,AMPK,63924,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,Epo-R,63924,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,VDAC,63924,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,p70s6k,63924,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,Akt,63924,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,STAT5,63924,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,G0S2,63924,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,Epo,63924,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,HSP90,63924,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,HSL,63924,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidec,PDH,63924,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,Cidec,1149,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,SDHA,1149,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,LYN,1149,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,ACC,1149,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,CGI-58,1149,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,Perilipin,1149,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,ATGL,1149,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,p38MAPK,1149,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,AMPK,1149,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,Epo-R,1149,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,VDAC,1149,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,p70s6k,1149,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,Akt,1149,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,STAT5,1149,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,G0S2,1149,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,Epo,1149,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,HSP90,1149,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,HSL,1149,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Cidea,PDH,1149,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,Cidec,6389,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,Cidea,6389,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,LYN,6389,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,ACC,6389,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,CGI-58,6389,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,Perilipin,6389,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,ATGL,6389,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,p38MAPK,6389,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,AMPK,6389,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,Epo-R,6389,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,VDAC,6389,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,p70s6k,6389,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,Akt,6389,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,STAT5,6389,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,G0S2,6389,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,Epo,6389,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,HSP90,6389,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,HSL,6389,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",SDHA,PDH,6389,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,Cidec,4067,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,Cidea,4067,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,SDHA,4067,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,ACC,4067,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,CGI-58,4067,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,Perilipin,4067,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,ATGL,4067,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,p38MAPK,4067,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,AMPK,4067,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,Epo-R,4067,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,VDAC,4067,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,p70s6k,4067,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,Akt,4067,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,STAT5,4067,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,G0S2,4067,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,Epo,4067,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,HSP90,4067,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,HSL,4067,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",LYN,PDH,4067,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,Cidec,31,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,Cidea,31,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,SDHA,31,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,LYN,31,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,CGI-58,31,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,Perilipin,31,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,ATGL,31,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,p38MAPK,31,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,AMPK,31,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,Epo-R,31,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,VDAC,31,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,p70s6k,31,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,Akt,31,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,STAT5,31,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,G0S2,31,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,Epo,31,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,HSP90,31,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,HSL,31,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ACC,PDH,31,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,Cidec,51099,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,Cidea,51099,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,SDHA,51099,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,LYN,51099,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,ACC,51099,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,Perilipin,51099,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,ATGL,51099,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,p38MAPK,51099,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,AMPK,51099,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,Epo-R,51099,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,VDAC,51099,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,p70s6k,51099,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,Akt,51099,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,STAT5,51099,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,G0S2,51099,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,Epo,51099,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,HSP90,51099,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,HSL,51099,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",CGI-58,PDH,51099,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,Cidec,5346,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,Cidea,5346,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,SDHA,5346,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,LYN,5346,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,ACC,5346,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,CGI-58,5346,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,ATGL,5346,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,p38MAPK,5346,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,AMPK,5346,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,Epo-R,5346,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,VDAC,5346,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,p70s6k,5346,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,Akt,5346,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,STAT5,5346,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,G0S2,5346,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,Epo,5346,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,HSP90,5346,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,HSL,5346,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Perilipin,PDH,5346,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,Cidec,57104,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,Cidea,57104,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,SDHA,57104,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,LYN,57104,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,ACC,57104,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,CGI-58,57104,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,Perilipin,57104,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,p38MAPK,57104,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,AMPK,57104,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,Epo-R,57104,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,VDAC,57104,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,p70s6k,57104,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,Akt,57104,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,STAT5,57104,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,G0S2,57104,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,Epo,57104,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,HSP90,57104,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,HSL,57104,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",ATGL,PDH,57104,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,Cidec,1432,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,Cidea,1432,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,SDHA,1432,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,LYN,1432,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,ACC,1432,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,CGI-58,1432,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,Perilipin,1432,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,ATGL,1432,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,AMPK,1432,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,Epo-R,1432,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,VDAC,1432,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,p70s6k,1432,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,Akt,1432,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,STAT5,1432,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,G0S2,1432,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,Epo,1432,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,HSP90,1432,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,HSL,1432,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p38MAPK,PDH,1432,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,Cidec,5562,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,Cidea,5562,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,SDHA,5562,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,LYN,5562,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,ACC,5562,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,CGI-58,5562,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,Perilipin,5562,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,ATGL,5562,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,p38MAPK,5562,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,Epo-R,5562,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,VDAC,5562,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,p70s6k,5562,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,Akt,5562,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,STAT5,5562,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,G0S2,5562,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,Epo,5562,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,HSP90,5562,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,HSL,5562,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",AMPK,PDH,5562,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,Cidec,2057,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,Cidea,2057,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,SDHA,2057,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,LYN,2057,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,ACC,2057,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,CGI-58,2057,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,Perilipin,2057,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,ATGL,2057,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,p38MAPK,2057,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,AMPK,2057,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,VDAC,2057,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,p70s6k,2057,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,Akt,2057,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,STAT5,2057,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,G0S2,2057,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,Epo,2057,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,HSP90,2057,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,HSL,2057,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo-R,PDH,2057,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,Cidec,7416,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,Cidea,7416,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,SDHA,7416,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,LYN,7416,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,ACC,7416,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,CGI-58,7416,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,Perilipin,7416,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,ATGL,7416,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,p38MAPK,7416,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,AMPK,7416,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,Epo-R,7416,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,p70s6k,7416,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,Akt,7416,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,STAT5,7416,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,G0S2,7416,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,Epo,7416,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,HSP90,7416,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,HSL,7416,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",VDAC,PDH,7416,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,Cidec,6198,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,Cidea,6198,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,SDHA,6198,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,LYN,6198,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,ACC,6198,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,CGI-58,6198,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,Perilipin,6198,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,ATGL,6198,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,p38MAPK,6198,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,AMPK,6198,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,Epo-R,6198,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,VDAC,6198,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,Akt,6198,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,STAT5,6198,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,G0S2,6198,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,Epo,6198,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,HSP90,6198,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,HSL,6198,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",p70s6k,PDH,6198,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,Cidec,207,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,Cidea,207,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,SDHA,207,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,LYN,207,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,ACC,207,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,CGI-58,207,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,Perilipin,207,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,ATGL,207,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,p38MAPK,207,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,AMPK,207,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,Epo-R,207,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,VDAC,207,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,p70s6k,207,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,STAT5,207,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,G0S2,207,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,Epo,207,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,HSP90,207,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,HSL,207,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Akt,PDH,207,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,Cidec,6776,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,Cidea,6776,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,SDHA,6776,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,LYN,6776,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,ACC,6776,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,CGI-58,6776,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,Perilipin,6776,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,ATGL,6776,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,p38MAPK,6776,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,AMPK,6776,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,Epo-R,6776,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,VDAC,6776,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,p70s6k,6776,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,Akt,6776,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,G0S2,6776,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,Epo,6776,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,HSP90,6776,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,HSL,6776,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",STAT5,PDH,6776,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,Cidec,50486,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,Cidea,50486,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,SDHA,50486,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,LYN,50486,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,ACC,50486,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,CGI-58,50486,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,Perilipin,50486,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,ATGL,50486,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,p38MAPK,50486,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,AMPK,50486,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,Epo-R,50486,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,VDAC,50486,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,p70s6k,50486,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,Akt,50486,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,STAT5,50486,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,Epo,50486,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,HSP90,50486,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,HSL,50486,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",G0S2,PDH,50486,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,Cidec,2056,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,Cidea,2056,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,SDHA,2056,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,LYN,2056,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,ACC,2056,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,CGI-58,2056,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,Perilipin,2056,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,ATGL,2056,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,p38MAPK,2056,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,AMPK,2056,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,Epo-R,2056,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,VDAC,2056,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,p70s6k,2056,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,Akt,2056,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,STAT5,2056,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,G0S2,2056,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,HSP90,2056,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,HSL,2056,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",Epo,PDH,2056,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,Cidec,3320,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,Cidea,3320,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,SDHA,3320,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,LYN,3320,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,ACC,3320,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,CGI-58,3320,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,Perilipin,3320,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,ATGL,3320,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,p38MAPK,3320,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,AMPK,3320,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,Epo-R,3320,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,VDAC,3320,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,p70s6k,3320,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,Akt,3320,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,STAT5,3320,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,G0S2,3320,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,Epo,3320,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,HSL,3320,3991
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSP90,PDH,3320,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,Cidec,3991,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,Cidea,3991,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,SDHA,3991,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,LYN,3991,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,ACC,3991,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,CGI-58,3991,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,Perilipin,3991,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,ATGL,3991,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,p38MAPK,3991,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,AMPK,3991,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,Epo-R,3991,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,VDAC,3991,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,p70s6k,3991,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,Akt,3991,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,STAT5,3991,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,G0S2,3991,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,Epo,3991,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,HSP90,3991,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",HSL,PDH,3991,54704
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,Cidec,54704,63924
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,Cidea,54704,1149
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,SDHA,54704,6389
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,LYN,54704,4067
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,ACC,54704,31
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,CGI-58,54704,51099
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,Perilipin,54704,5346
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,ATGL,54704,57104
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,p38MAPK,54704,1432
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,AMPK,54704,5562
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,Epo-R,54704,2057
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,VDAC,54704,7416
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,p70s6k,54704,6198
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,Akt,54704,207
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,STAT5,54704,6776
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,G0S2,54704,50486
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,Epo,54704,2056
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,HSP90,54704,3320
27640183,"A new and highly specific antibody (A82, Amgen) was used to evaluate the presence of Epo-R by western blot analysis in addition to Epo-R signaling proteins (Akt, STAT5, p70s6k, LYN, and p38MAPK), activation of lipolytic pathways (ATGL, HSL, CGI-58, G0S2, Perilipin, Cidea, Cidec, AMPK, and ACC), and mitochondrial biogenesis (VDAC, HSP90, PDH, and SDHA)",PDH,HSL,54704,3991
27640183,RESULTS: No evidence of in vivo activation of the Epo-R in WAT could be documented despite detectable levels of Epo-R mRNA,Epo-R,Epo,2057,2056
27640183,RESULTS: No evidence of in vivo activation of the Epo-R in WAT could be documented despite detectable levels of Epo-R mRNA,Epo,Epo-R,2056,2057
27825100,High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy,glucose,diabetic nephropathy,D005947,D003928
27825100,High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy,diabetic nephropathy,glucose,D003928,D005947
27825100,"In 5 mM glucose medium, we observed a stepwise activation of oxidative metabolism during cell differentiation that was characterized by peroxisome proliferator-activated receptor-g coactivator 1a (PGC-1a)-dependent stimulation of mitochondrial biogenesis and function, with concomitant reduction of the glycolytic enzyme content",peroxisome proliferator-activated receptor-g coactivator 1a,glucose,10891,D005947
27825100,"In 5 mM glucose medium, we observed a stepwise activation of oxidative metabolism during cell differentiation that was characterized by peroxisome proliferator-activated receptor-g coactivator 1a (PGC-1a)-dependent stimulation of mitochondrial biogenesis and function, with concomitant reduction of the glycolytic enzyme content",peroxisome proliferator-activated receptor-g coactivator 1a,PGC-1a,10891,10891
27825100,"In 5 mM glucose medium, we observed a stepwise activation of oxidative metabolism during cell differentiation that was characterized by peroxisome proliferator-activated receptor-g coactivator 1a (PGC-1a)-dependent stimulation of mitochondrial biogenesis and function, with concomitant reduction of the glycolytic enzyme content",glucose,peroxisome proliferator-activated receptor-g coactivator 1a,D005947,10891
27825100,"In 5 mM glucose medium, we observed a stepwise activation of oxidative metabolism during cell differentiation that was characterized by peroxisome proliferator-activated receptor-g coactivator 1a (PGC-1a)-dependent stimulation of mitochondrial biogenesis and function, with concomitant reduction of the glycolytic enzyme content",glucose,PGC-1a,D005947,10891
27825100,"In 5 mM glucose medium, we observed a stepwise activation of oxidative metabolism during cell differentiation that was characterized by peroxisome proliferator-activated receptor-g coactivator 1a (PGC-1a)-dependent stimulation of mitochondrial biogenesis and function, with concomitant reduction of the glycolytic enzyme content",PGC-1a,peroxisome proliferator-activated receptor-g coactivator 1a,10891,10891
27825100,"In 5 mM glucose medium, we observed a stepwise activation of oxidative metabolism during cell differentiation that was characterized by peroxisome proliferator-activated receptor-g coactivator 1a (PGC-1a)-dependent stimulation of mitochondrial biogenesis and function, with concomitant reduction of the glycolytic enzyme content",PGC-1a,glucose,10891,D005947
27825100,"Conversely, when podocytes were cultured in high glucose (20 mM), stepwise oxidative phosphorylation biogenesis was aborted, and a glycolytic switch occurred, with consecutive lactic acidosis",lactic acidosis,glucose,D000140,D005947
27825100,"Conversely, when podocytes were cultured in high glucose (20 mM), stepwise oxidative phosphorylation biogenesis was aborted, and a glycolytic switch occurred, with consecutive lactic acidosis",glucose,lactic acidosis,D005947,D000140
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",PGC-1a,glucose,10891,D005947
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",PGC-1a,AMPK,10891,5562
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",PGC-1a,serine-threonine liver kinase B1,10891,6794
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",PGC-1a,master regulators of oxidative metabolism transcription factor A mitochondrial,10891,10891
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",glucose,PGC-1a,D005947,10891
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",glucose,AMPK,D005947,5562
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",glucose,serine-threonine liver kinase B1,D005947,6794
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",glucose,master regulators of oxidative metabolism transcription factor A mitochondrial,D005947,10891
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",AMPK,PGC-1a,5562,10891
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",AMPK,glucose,5562,D005947
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",AMPK,serine-threonine liver kinase B1,5562,6794
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",AMPK,master regulators of oxidative metabolism transcription factor A mitochondrial,5562,10891
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",serine-threonine liver kinase B1,PGC-1a,6794,10891
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",serine-threonine liver kinase B1,glucose,6794,D005947
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",serine-threonine liver kinase B1,AMPK,6794,5562
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",serine-threonine liver kinase B1,master regulators of oxidative metabolism transcription factor A mitochondrial,6794,10891
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",master regulators of oxidative metabolism transcription factor A mitochondrial,PGC-1a,10891,10891
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",master regulators of oxidative metabolism transcription factor A mitochondrial,glucose,10891,D005947
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",master regulators of oxidative metabolism transcription factor A mitochondrial,AMPK,10891,5562
27825100,"Expression of the master regulators of oxidative metabolism transcription factor A mitochondrial, PGC-1a, AMPK, and serine-threonine liver kinase B1 was altered by high glucose, as well as their downstream signaling networks",master regulators of oxidative metabolism transcription factor A mitochondrial,serine-threonine liver kinase B1,10891,6794
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",myocyte-specific enhancer factor 2C,myogenic factor 5,4208,4617
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",myocyte-specific enhancer factor 2C,glucose,4208,D005947
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",myocyte-specific enhancer factor 2C,MEF2C,4208,4208
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",myocyte-specific enhancer factor 2C,MYF5,4208,4617
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",myogenic factor 5,myocyte-specific enhancer factor 2C,4617,4208
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",myogenic factor 5,glucose,4617,D005947
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",myogenic factor 5,MEF2C,4617,4208
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",myogenic factor 5,MYF5,4617,4617
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",glucose,myocyte-specific enhancer factor 2C,D005947,4208
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",glucose,myogenic factor 5,D005947,4617
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",glucose,MEF2C,D005947,4208
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",glucose,MYF5,D005947,4617
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",MEF2C,myocyte-specific enhancer factor 2C,4208,4208
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",MEF2C,myogenic factor 5,4208,4617
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",MEF2C,glucose,4208,D005947
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",MEF2C,MYF5,4208,4617
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",MYF5,myocyte-specific enhancer factor 2C,4617,4208
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",MYF5,myogenic factor 5,4617,4617
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",MYF5,glucose,4617,D005947
27825100,"Focused transcriptomics revealed that myocyte-specific enhancer factor 2C (MEF2C) and myogenic factor 5 (MYF5) expression was inhibited by high glucose levels, and endoribonuclease-prepared small interfering RNA-mediated combined inhibition of those transcription factors phenocopied the glycolytic shift that was observed in high glucose conditions",MYF5,MEF2C,4617,4208
27825100,"Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy",PGC-1a,diabetic nephropathy,10891,D003928
27825100,"Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy",PGC-1a,MEF2C,10891,4208
27825100,"Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy",PGC-1a,MYF5,10891,4617
27825100,"Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy",diabetic nephropathy,PGC-1a,D003928,10891
27825100,"Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy",diabetic nephropathy,MEF2C,D003928,4208
27825100,"Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy",diabetic nephropathy,MYF5,D003928,4617
27825100,"Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy",MEF2C,PGC-1a,4208,10891
27825100,"Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy",MEF2C,diabetic nephropathy,4208,D003928
27825100,"Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy",MEF2C,MYF5,4208,4617
27825100,"Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy",MYF5,PGC-1a,4617,10891
27825100,"Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy",MYF5,diabetic nephropathy,4617,D003928
27825100,"Accordingly, a reduced expression of MEF2C, MYF5, and PGC-1a was found in kidney tissue sections that were obtained from patients with diabetic nephropathy",MYF5,MEF2C,4617,4208
27825100,"These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R",glucose,MYF5,D005947,4617
27825100,"These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R",glucose,MEF2C,D005947,4208
27825100,"These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R",MYF5,glucose,4617,D005947
27825100,"These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R",MYF5,MEF2C,4617,4208
27825100,"These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R",MEF2C,glucose,4208,D005947
27825100,"These findings obtained in human samples demonstrate that MEF2C-MYF5-dependent bioenergetic dedifferentiation occurs in podocytes that are confronted with a high-glucose milieu.-Imasawa, T., Obre, E., Bellance, N., Lavie, J., Imasawa, T., Rigothier, C., Delmas, Y., Combe, C., Lacombe, D., Benard, G., Claverol, S., Bonneu, M., Rossignol, R",MEF2C,MYF5,4208,4617
27825100,High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.,glucose,diabetic nephropathy,D005947,D003928
27825100,High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy.,diabetic nephropathy,glucose,D003928,D005947
28098423,Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats,cardiac dysfunction,doxorubicin,D006331,D004317
28098423,Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats,cardiac dysfunction,Brain-derived neurotrophic factor,D006331,24225
28098423,Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats,cardiac dysfunction,Akt,D006331,24185
28098423,Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats,doxorubicin,cardiac dysfunction,D004317,D006331
28098423,Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats,doxorubicin,Brain-derived neurotrophic factor,D004317,24225
28098423,Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats,doxorubicin,Akt,D004317,24185
28098423,Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats,Brain-derived neurotrophic factor,cardiac dysfunction,24225,D006331
28098423,Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats,Brain-derived neurotrophic factor,doxorubicin,24225,D004317
28098423,Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats,Brain-derived neurotrophic factor,Akt,24225,24185
28098423,Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats,Akt,cardiac dysfunction,24185,D006331
28098423,Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats,Akt,doxorubicin,24185,D004317
28098423,Brain-derived neurotrophic factor attenuates doxorubicin-induced cardiac dysfunction through activating Akt signalling in rats,Akt,Brain-derived neurotrophic factor,24185,24225
28098423,The clinical application of doxorubicin (Dox) is limited by its adverse effect of cardiotoxicity,cardiotoxicity,doxorubicin,D066126,D004317
28098423,The clinical application of doxorubicin (Dox) is limited by its adverse effect of cardiotoxicity,cardiotoxicity,Dox,D066126,D004317
28098423,The clinical application of doxorubicin (Dox) is limited by its adverse effect of cardiotoxicity,doxorubicin,cardiotoxicity,D004317,D066126
28098423,The clinical application of doxorubicin (Dox) is limited by its adverse effect of cardiotoxicity,doxorubicin,Dox,D004317,D004317
28098423,The clinical application of doxorubicin (Dox) is limited by its adverse effect of cardiotoxicity,Dox,cardiotoxicity,D004317,D066126
28098423,The clinical application of doxorubicin (Dox) is limited by its adverse effect of cardiotoxicity,Dox,doxorubicin,D004317,D004317
28098423,Previous studies have suggested the cardioprotective effect of brain-derived neurotrophic factor (BDNF),brain-derived neurotrophic factor,BDNF,24225,24225
28098423,Previous studies have suggested the cardioprotective effect of brain-derived neurotrophic factor (BDNF),BDNF,brain-derived neurotrophic factor,24225,24225
28098423,We hypothesize that BDNF could protect against Dox-induced cardiotoxicity,BDNF,cardiotoxicity,24225,D066126
28098423,We hypothesize that BDNF could protect against Dox-induced cardiotoxicity,BDNF,Dox,24225,D004317
28098423,We hypothesize that BDNF could protect against Dox-induced cardiotoxicity,cardiotoxicity,BDNF,D066126,24225
28098423,We hypothesize that BDNF could protect against Dox-induced cardiotoxicity,cardiotoxicity,Dox,D066126,D004317
28098423,We hypothesize that BDNF could protect against Dox-induced cardiotoxicity,Dox,BDNF,D004317,24225
28098423,We hypothesize that BDNF could protect against Dox-induced cardiotoxicity,Dox,cardiotoxicity,D004317,D066126
28098423,"Sprague Dawley rats were injected with Dox (2.5 mg/kg, 3 times/week, i.p.), in the presence or absence of recombinant BDNF (0.4 ug/kg, i.v.) for 2 weeks",BDNF,Dox,24225,D004317
28098423,"Sprague Dawley rats were injected with Dox (2.5 mg/kg, 3 times/week, i.p.), in the presence or absence of recombinant BDNF (0.4 ug/kg, i.v.) for 2 weeks",Dox,BDNF,D004317,24225
28098423,H9c2 cells were treated with Dox (1 uM) and/or BDNF (400 ng/ml) for 24 hrs,BDNF,Dox,24225,D004317
28098423,H9c2 cells were treated with Dox (1 uM) and/or BDNF (400 ng/ml) for 24 hrs,Dox,BDNF,D004317,24225
28098423,Functional roles of BDNF against Dox-induced cardiac injury were examined both in vivo and in vitro,BDNF,cardiac injury,24225,D006331
28098423,Functional roles of BDNF against Dox-induced cardiac injury were examined both in vivo and in vitro,BDNF,Dox,24225,D004317
28098423,Functional roles of BDNF against Dox-induced cardiac injury were examined both in vivo and in vitro,cardiac injury,BDNF,D006331,24225
28098423,Functional roles of BDNF against Dox-induced cardiac injury were examined both in vivo and in vitro,cardiac injury,Dox,D006331,D004317
28098423,Functional roles of BDNF against Dox-induced cardiac injury were examined both in vivo and in vitro,Dox,BDNF,D004317,24225
28098423,Functional roles of BDNF against Dox-induced cardiac injury were examined both in vivo and in vitro,Dox,cardiac injury,D004317,D006331
28098423,"Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration",TrkB,tropomyosin-related kinase B,25054,25054
28098423,"Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration",TrkB,BDNF,25054,24225
28098423,"Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration",TrkB,Dox,25054,D004317
28098423,"Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration",tropomyosin-related kinase B,TrkB,25054,25054
28098423,"Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration",tropomyosin-related kinase B,BDNF,25054,24225
28098423,"Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration",tropomyosin-related kinase B,Dox,25054,D004317
28098423,"Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration",BDNF,TrkB,24225,25054
28098423,"Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration",BDNF,tropomyosin-related kinase B,24225,25054
28098423,"Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration",BDNF,Dox,24225,D004317
28098423,"Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration",Dox,TrkB,D004317,25054
28098423,"Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration",Dox,tropomyosin-related kinase B,D004317,25054
28098423,"Protein level of BDNF was reduced in Dox-treated rat ventricles, whereas BDNF and its receptor tropomyosin-related kinase B (TrkB) were markedly up-regulated after BDNF administration",Dox,BDNF,D004317,24225
28098423,"Brain-derived neurotrophic factor significantly inhibited Dox-induced cardiomyocyte apoptosis, oxidative stress and cardiac dysfunction in rats",cardiac dysfunction,Brain-derived neurotrophic factor,D006331,24225
28098423,"Brain-derived neurotrophic factor significantly inhibited Dox-induced cardiomyocyte apoptosis, oxidative stress and cardiac dysfunction in rats",cardiac dysfunction,Dox,D006331,D004317
28098423,"Brain-derived neurotrophic factor significantly inhibited Dox-induced cardiomyocyte apoptosis, oxidative stress and cardiac dysfunction in rats",Brain-derived neurotrophic factor,cardiac dysfunction,24225,D006331
28098423,"Brain-derived neurotrophic factor significantly inhibited Dox-induced cardiomyocyte apoptosis, oxidative stress and cardiac dysfunction in rats",Brain-derived neurotrophic factor,Dox,24225,D004317
28098423,"Brain-derived neurotrophic factor significantly inhibited Dox-induced cardiomyocyte apoptosis, oxidative stress and cardiac dysfunction in rats",Dox,cardiac dysfunction,D004317,D006331
28098423,"Brain-derived neurotrophic factor significantly inhibited Dox-induced cardiomyocyte apoptosis, oxidative stress and cardiac dysfunction in rats",Dox,Brain-derived neurotrophic factor,D004317,24225
28098423,"Meanwhile, BDNF increased cell viability, inhibited apoptosis and DNA damage of Dox-treated H9c2 cells",BDNF,Dox,24225,D004317
28098423,"Meanwhile, BDNF increased cell viability, inhibited apoptosis and DNA damage of Dox-treated H9c2 cells",Dox,BDNF,D004317,24225
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,mammalian target of rapamycin,extracellular regulated protein kinase,56718,116590
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,mammalian target of rapamycin,BDNF,56718,24225
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,mammalian target of rapamycin,Akt,56718,24185
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,mammalian target of rapamycin,p38 mitogen-activated protein kinase,56718,81649
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,mammalian target of rapamycin,Bad,56718,64639
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,extracellular regulated protein kinase,mammalian target of rapamycin,116590,56718
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,extracellular regulated protein kinase,BDNF,116590,24225
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,extracellular regulated protein kinase,Akt,116590,24185
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,extracellular regulated protein kinase,p38 mitogen-activated protein kinase,116590,81649
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,extracellular regulated protein kinase,Bad,116590,64639
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,BDNF,mammalian target of rapamycin,24225,56718
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,BDNF,extracellular regulated protein kinase,24225,116590
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,BDNF,Akt,24225,24185
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,BDNF,p38 mitogen-activated protein kinase,24225,81649
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,BDNF,Bad,24225,64639
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,Akt,mammalian target of rapamycin,24185,56718
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,Akt,extracellular regulated protein kinase,24185,116590
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,Akt,BDNF,24185,24225
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,Akt,p38 mitogen-activated protein kinase,24185,81649
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,Akt,Bad,24185,64639
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,p38 mitogen-activated protein kinase,mammalian target of rapamycin,81649,56718
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,p38 mitogen-activated protein kinase,extracellular regulated protein kinase,81649,116590
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,p38 mitogen-activated protein kinase,BDNF,81649,24225
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,p38 mitogen-activated protein kinase,Akt,81649,24185
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,p38 mitogen-activated protein kinase,Bad,81649,64639
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,Bad,mammalian target of rapamycin,64639,56718
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,Bad,extracellular regulated protein kinase,64639,116590
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,Bad,BDNF,64639,24225
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,Bad,Akt,64639,24185
28098423,Investigations of the underlying mechanisms revealed that BDNF activated Akt and preserved phosphorylation of mammalian target of rapamycin and Bad without affecting p38 mitogen-activated protein kinase and extracellular regulated protein kinase pathways,Bad,p38 mitogen-activated protein kinase,64639,81649
28098423,"Furthermore, the beneficial effect of BDNF was abolished by BDNF scavenger TrkB-Fc or Akt inhibitor",Akt,BDNF,24185,24225
28098423,"Furthermore, the beneficial effect of BDNF was abolished by BDNF scavenger TrkB-Fc or Akt inhibitor",Akt,TrkB,24185,25054
28098423,"Furthermore, the beneficial effect of BDNF was abolished by BDNF scavenger TrkB-Fc or Akt inhibitor",BDNF,Akt,24225,24185
28098423,"Furthermore, the beneficial effect of BDNF was abolished by BDNF scavenger TrkB-Fc or Akt inhibitor",BDNF,TrkB,24225,25054
28098423,"Furthermore, the beneficial effect of BDNF was abolished by BDNF scavenger TrkB-Fc or Akt inhibitor",TrkB,Akt,25054,24185
28098423,"Furthermore, the beneficial effect of BDNF was abolished by BDNF scavenger TrkB-Fc or Akt inhibitor",TrkB,BDNF,25054,24225
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",cardiotoxicity,BDNF,D066126,24225
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",cardiotoxicity,Dox,D066126,D004317
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",cardiotoxicity,Akt,D066126,24185
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",cancer,BDNF,D009369,24225
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",cancer,Dox,D009369,D004317
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",cancer,Akt,D009369,24185
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",BDNF,cardiotoxicity,24225,D066126
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",BDNF,cancer,24225,D009369
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",BDNF,Dox,24225,D004317
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",BDNF,Akt,24225,24185
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",Dox,cardiotoxicity,D004317,D066126
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",Dox,cancer,D004317,D009369
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",Dox,BDNF,D004317,24225
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",Dox,Akt,D004317,24185
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",Akt,cardiotoxicity,24185,D066126
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",Akt,cancer,24185,D009369
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",Akt,BDNF,24185,24225
28098423,"In conclusion, our findings reveal a potent protective role of BDNF against Dox-induced cardiotoxicity by activating Akt signalling, which may facilitate the safe use of Dox in cancer treatment.",Akt,Dox,24185,D004317
28279980,GLUT4 Is Not Necessary for Overload-Induced Glucose Uptake or Hypertrophic Growth in Mouse Skeletal Muscle,Glucose,GLUT,D005947,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,GLUT4 Is Not Necessary for Overload-Induced Glucose Uptake or Hypertrophic Growth in Mouse Skeletal Muscle,Glucose,GLUT4,D005947,20528
28279980,GLUT4 Is Not Necessary for Overload-Induced Glucose Uptake or Hypertrophic Growth in Mouse Skeletal Muscle,GLUT,Glucose,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D005947
28279980,GLUT4 Is Not Necessary for Overload-Induced Glucose Uptake or Hypertrophic Growth in Mouse Skeletal Muscle,GLUT,GLUT4,"170441,20525,20526,20527,20528,227659,353169,56017,56485",20528
28279980,GLUT4 Is Not Necessary for Overload-Induced Glucose Uptake or Hypertrophic Growth in Mouse Skeletal Muscle,GLUT4,Glucose,20528,D005947
28279980,GLUT4 Is Not Necessary for Overload-Induced Glucose Uptake or Hypertrophic Growth in Mouse Skeletal Muscle,GLUT4,GLUT,20528,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown",GLUT,glucose,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D005947
28279980,"GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown",GLUT,insulin,"170441,20525,20526,20527,20528,227659,353169,56017,56485",3630
28279980,"GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown",GLUT,GLUT4,"170441,20525,20526,20527,20528,227659,353169,56017,56485",20528
28279980,"GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown",glucose,GLUT,D005947,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown",glucose,insulin,D005947,3630
28279980,"GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown",glucose,GLUT4,D005947,20528
28279980,"GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown",insulin,GLUT,3630,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown",insulin,glucose,3630,D005947
28279980,"GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown",insulin,GLUT4,3630,20528
28279980,"GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown",GLUT4,GLUT,20528,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown",GLUT4,glucose,20528,D005947
28279980,"GLUT4 is necessary for acute insulin- and contraction-induced skeletal muscle glucose uptake, but its role in chronic muscle loading (overload)-induced glucose uptake is unknown",GLUT4,insulin,20528,3630
28279980,Our goal was to determine whether GLUT4 is required for overload-induced glucose uptake,GLUT,glucose,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D005947
28279980,Our goal was to determine whether GLUT4 is required for overload-induced glucose uptake,GLUT,GLUT4,"170441,20525,20526,20527,20528,227659,353169,56017,56485",20528
28279980,Our goal was to determine whether GLUT4 is required for overload-induced glucose uptake,glucose,GLUT,D005947,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,Our goal was to determine whether GLUT4 is required for overload-induced glucose uptake,glucose,GLUT4,D005947,20528
28279980,Our goal was to determine whether GLUT4 is required for overload-induced glucose uptake,GLUT4,GLUT,20528,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,Our goal was to determine whether GLUT4 is required for overload-induced glucose uptake,GLUT4,glucose,20528,D005947
28279980,"After 5 days, muscle weights and ex vivo [(3)H]-2-deoxy-d-glucose uptake were assessed",glucose,[(3)H]-2-deoxy-d-glucose,D005947,D003847
28279980,"After 5 days, muscle weights and ex vivo [(3)H]-2-deoxy-d-glucose uptake were assessed",[(3)H]-2-deoxy-d-glucose,glucose,D003847,D005947
28279980,"Overload-induced muscle glucose uptake and hypertrophic growth were not impaired in muscle-specific GLUT4 knockout mice, demonstrating that GLUT4 is not necessary for these processes",GLUT,glucose,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D005947
28279980,"Overload-induced muscle glucose uptake and hypertrophic growth were not impaired in muscle-specific GLUT4 knockout mice, demonstrating that GLUT4 is not necessary for these processes",GLUT,GLUT4,"170441,20525,20526,20527,20528,227659,353169,56017,56485",20528
28279980,"Overload-induced muscle glucose uptake and hypertrophic growth were not impaired in muscle-specific GLUT4 knockout mice, demonstrating that GLUT4 is not necessary for these processes",glucose,GLUT,D005947,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload-induced muscle glucose uptake and hypertrophic growth were not impaired in muscle-specific GLUT4 knockout mice, demonstrating that GLUT4 is not necessary for these processes",glucose,GLUT4,D005947,20528
28279980,"Overload-induced muscle glucose uptake and hypertrophic growth were not impaired in muscle-specific GLUT4 knockout mice, demonstrating that GLUT4 is not necessary for these processes",GLUT4,GLUT,20528,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload-induced muscle glucose uptake and hypertrophic growth were not impaired in muscle-specific GLUT4 knockout mice, demonstrating that GLUT4 is not necessary for these processes",GLUT4,glucose,20528,D005947
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",cytochalasin B,sodium,D003571,D012964
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",cytochalasin B,GLUT,D003571,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",cytochalasin B,glucose,D003571,D005947
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",cytochalasin B,GLUTs,D003571,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",cytochalasin B,phloridzin,D003571,D010695
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",sodium,cytochalasin B,D012964,D003571
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",sodium,GLUT,D012964,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",sodium,glucose,D012964,D005947
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",sodium,GLUTs,D012964,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",sodium,phloridzin,D012964,D010695
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",GLUT,cytochalasin B,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D003571
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",GLUT,sodium,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D012964
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",GLUT,glucose,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D005947
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",GLUT,GLUTs,"170441,20525,20526,20527,20528,227659,353169,56017,56485","170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",GLUT,phloridzin,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D010695
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",glucose,cytochalasin B,D005947,D003571
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",glucose,sodium,D005947,D012964
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",glucose,GLUT,D005947,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",glucose,GLUTs,D005947,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",glucose,phloridzin,D005947,D010695
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",GLUTs,cytochalasin B,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D003571
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",GLUTs,sodium,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D012964
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",GLUTs,GLUT,"170441,20525,20526,20527,20528,227659,353169,56017,56485","170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",GLUTs,glucose,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D005947
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",GLUTs,phloridzin,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D010695
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",phloridzin,cytochalasin B,D010695,D003571
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",phloridzin,sodium,D010695,D012964
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",phloridzin,GLUT,D010695,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",phloridzin,glucose,D010695,D005947
28279980,"The facilitative GLUT inhibitor cytochalasin B, but not the sodium-dependent glucose cotransport inhibitor phloridzin, prevented overload-induced uptake demonstrating that GLUTs mediate this effect",phloridzin,GLUTs,D010695,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"To assess which GLUT, hexose competition experiments were performed",hexose,GLUT,D006601,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"To assess which GLUT, hexose competition experiments were performed",GLUT,hexose,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D006601
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT12,GLUT,353169,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT12,glucose,353169,D005947
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT12,GLUT8,353169,56017
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT12,d-fructose,353169,D005632
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT12,GLUT5,353169,56485
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT12,GLUT1,353169,20525
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT12,[(3)H]-2-deoxy-d-glucose,353169,D003847
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT12,GLUT2,353169,20526
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT,GLUT12,"170441,20525,20526,20527,20528,227659,353169,56017,56485",353169
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT,glucose,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D005947
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT,GLUT8,"170441,20525,20526,20527,20528,227659,353169,56017,56485",56017
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT,d-fructose,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D005632
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT,GLUT5,"170441,20525,20526,20527,20528,227659,353169,56017,56485",56485
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT,GLUT1,"170441,20525,20526,20527,20528,227659,353169,56017,56485",20525
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT,[(3)H]-2-deoxy-d-glucose,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D003847
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT,GLUT2,"170441,20525,20526,20527,20528,227659,353169,56017,56485",20526
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",glucose,GLUT12,D005947,353169
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",glucose,GLUT,D005947,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",glucose,GLUT8,D005947,56017
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",glucose,d-fructose,D005947,D005632
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",glucose,GLUT5,D005947,56485
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",glucose,GLUT1,D005947,20525
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",glucose,[(3)H]-2-deoxy-d-glucose,D005947,D003847
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",glucose,GLUT2,D005947,20526
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT8,GLUT12,56017,353169
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT8,GLUT,56017,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT8,glucose,56017,D005947
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT8,d-fructose,56017,D005632
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT8,GLUT5,56017,56485
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT8,GLUT1,56017,20525
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT8,[(3)H]-2-deoxy-d-glucose,56017,D003847
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT8,GLUT2,56017,20526
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",d-fructose,GLUT12,D005632,353169
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",d-fructose,GLUT,D005632,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",d-fructose,glucose,D005632,D005947
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",d-fructose,GLUT8,D005632,56017
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",d-fructose,GLUT5,D005632,56485
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",d-fructose,GLUT1,D005632,20525
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",d-fructose,[(3)H]-2-deoxy-d-glucose,D005632,D003847
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",d-fructose,GLUT2,D005632,20526
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT5,GLUT12,56485,353169
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT5,GLUT,56485,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT5,glucose,56485,D005947
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT5,GLUT8,56485,56017
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT5,d-fructose,56485,D005632
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT5,GLUT1,56485,20525
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT5,[(3)H]-2-deoxy-d-glucose,56485,D003847
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT5,GLUT2,56485,20526
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT1,GLUT12,20525,353169
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT1,GLUT,20525,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT1,glucose,20525,D005947
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT1,GLUT8,20525,56017
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT1,d-fructose,20525,D005632
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT1,GLUT5,20525,56485
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT1,[(3)H]-2-deoxy-d-glucose,20525,D003847
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT1,GLUT2,20525,20526
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",[(3)H]-2-deoxy-d-glucose,GLUT12,D003847,353169
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",[(3)H]-2-deoxy-d-glucose,GLUT,D003847,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",[(3)H]-2-deoxy-d-glucose,glucose,D003847,D005947
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",[(3)H]-2-deoxy-d-glucose,GLUT8,D003847,56017
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",[(3)H]-2-deoxy-d-glucose,d-fructose,D003847,D005632
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",[(3)H]-2-deoxy-d-glucose,GLUT5,D003847,56485
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",[(3)H]-2-deoxy-d-glucose,GLUT1,D003847,20525
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",[(3)H]-2-deoxy-d-glucose,GLUT2,D003847,20526
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT2,GLUT12,20526,353169
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT2,GLUT,20526,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT2,glucose,20526,D005947
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT2,GLUT8,20526,56017
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT2,d-fructose,20526,D005632
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT2,GLUT5,20526,56485
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT2,GLUT1,20526,20525
28279980,"Overload-induced [(3)H]-2-deoxy-d-glucose uptake was not inhibited by d-fructose, demonstrating that the fructose-transporting GLUT2, GLUT5, GLUT8, and GLUT12 do not mediate this effect",GLUT2,[(3)H]-2-deoxy-d-glucose,20526,D003847
28279980,"To assess additional GLUTs, immunoblots were performed",GLUT,GLUTs,"170441,20525,20526,20527,20528,227659,353169,56017,56485","170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"To assess additional GLUTs, immunoblots were performed",GLUTs,GLUT,"170441,20525,20526,20527,20528,227659,353169,56017,56485","170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT,GLUT1,"170441,20525,20526,20527,20528,227659,353169,56017,56485",20525
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT,GLUT10,"170441,20525,20526,20527,20528,227659,353169,56017,56485",170441
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT,GLUT6,"170441,20525,20526,20527,20528,227659,353169,56017,56485",227659
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT,GLUT3,"170441,20525,20526,20527,20528,227659,353169,56017,56485",20527
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT1,GLUT,20525,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT1,GLUT10,20525,170441
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT1,GLUT6,20525,227659
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT1,GLUT3,20525,20527
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT10,GLUT,170441,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT10,GLUT1,170441,20525
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT10,GLUT6,170441,227659
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT10,GLUT3,170441,20527
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT6,GLUT,227659,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT6,GLUT1,227659,20525
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT6,GLUT10,227659,170441
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT6,GLUT3,227659,20527
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT3,GLUT,20527,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT3,GLUT1,20527,20525
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT3,GLUT10,20527,170441
28279980,"Overload increased GLUT1, GLUT3, GLUT6, and GLUT10 protein levels twofold to fivefold",GLUT3,GLUT6,20527,227659
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT,glucose,"170441,20525,20526,20527,20528,227659,353169,56017,56485",D005947
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT,GLUT1,"170441,20525,20526,20527,20528,227659,353169,56017,56485",20525
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT,GLUT10,"170441,20525,20526,20527,20528,227659,353169,56017,56485",170441
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT,GLUT4,"170441,20525,20526,20527,20528,227659,353169,56017,56485",20528
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT,GLUT6,"170441,20525,20526,20527,20528,227659,353169,56017,56485",227659
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT,GLUT3,"170441,20525,20526,20527,20528,227659,353169,56017,56485",20527
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",glucose,GLUT,D005947,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",glucose,GLUT1,D005947,20525
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",glucose,GLUT10,D005947,170441
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",glucose,GLUT4,D005947,20528
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",glucose,GLUT6,D005947,227659
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",glucose,GLUT3,D005947,20527
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT1,GLUT,20525,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT1,glucose,20525,D005947
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT1,GLUT10,20525,170441
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT1,GLUT4,20525,20528
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT1,GLUT6,20525,227659
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT1,GLUT3,20525,20527
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT10,GLUT,170441,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT10,glucose,170441,D005947
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT10,GLUT1,170441,20525
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT10,GLUT4,170441,20528
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT10,GLUT6,170441,227659
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT10,GLUT3,170441,20527
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT4,GLUT,20528,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT4,glucose,20528,D005947
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT4,GLUT1,20528,20525
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT4,GLUT10,20528,170441
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT4,GLUT6,20528,227659
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT4,GLUT3,20528,20527
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT6,GLUT,227659,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT6,glucose,227659,D005947
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT6,GLUT1,227659,20525
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT6,GLUT10,227659,170441
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT6,GLUT4,227659,20528
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT6,GLUT3,227659,20527
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT3,GLUT,20527,"170441,20525,20526,20527,20528,227659,353169,56017,56485"
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT3,glucose,20527,D005947
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT3,GLUT1,20527,20525
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT3,GLUT10,20527,170441
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT3,GLUT4,20527,20528
28279980,"Collectively, these results demonstrate that GLUT4 is not necessary for overload-induced muscle glucose uptake or hypertrophic growth and suggest that GLUT1, GLUT3, GLUT6, and/or GLUT10 mediate overload-induced glucose uptake.",GLUT3,GLUT6,20527,227659
28348168,Conditionally deleting one copy of FGF receptor 2 (FGFR2) in adult mouse airway basal cells results in self-renewal and differentiation phenotypes,FGF receptor 2,FGFR2,14183,14183
28348168,Conditionally deleting one copy of FGF receptor 2 (FGFR2) in adult mouse airway basal cells results in self-renewal and differentiation phenotypes,FGFR2,FGF receptor 2,14183,14183
28348168,We show that FGFR2 signalling correlates with maintenance of expression of a key transcription factor for basal cell self-renewal and differentiation: SOX2,SOX2,FGFR2,20674,14183
28348168,We show that FGFR2 signalling correlates with maintenance of expression of a key transcription factor for basal cell self-renewal and differentiation: SOX2,FGFR2,SOX2,14183,20674
28348168,"This heterozygous phenotype illustrates that subtle changes in receptor tyrosine kinase signalling can have significant effects, perhaps providing an explanation for the numerous changes seen in cancer.",cancer,receptor tyrosine kinase,D009369,14183
28348168,"This heterozygous phenotype illustrates that subtle changes in receptor tyrosine kinase signalling can have significant effects, perhaps providing an explanation for the numerous changes seen in cancer.",receptor tyrosine kinase,cancer,14183,D009369
28481876,Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies,malignancies,miniature chromosome maintenance 8,D009369,84515
28481876,Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies,miniature chromosome maintenance 8,malignancies,84515,D009369
28481876,"Miniature chromosome maintenance (MCM) proteins play critical roles in DNA replication licensing, initiation and elongation",Miniature chromosome maintenance,MCM,84515,84515
28481876,"Miniature chromosome maintenance (MCM) proteins play critical roles in DNA replication licensing, initiation and elongation",MCM,Miniature chromosome maintenance,84515,84515
28481876,"MCM8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human malignancies",malignancies,MCM8,D009369,84515
28481876,"MCM8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human malignancies",malignancies,MCM,D009369,84515
28481876,"MCM8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human malignancies",MCM8,malignancies,84515,D009369
28481876,"MCM8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human malignancies",MCM8,MCM,84515,84515
28481876,"MCM8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human malignancies",MCM,malignancies,84515,D009369
28481876,"MCM8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human malignancies",MCM,MCM8,84515,84515
28481876,The gain of MCM8 is associated with aggressive clinical features of several human cancers,cancer,MCM8,D009369,84515
28481876,The gain of MCM8 is associated with aggressive clinical features of several human cancers,cancer,MCM,D009369,84515
28481876,The gain of MCM8 is associated with aggressive clinical features of several human cancers,MCM8,cancer,84515,D009369
28481876,The gain of MCM8 is associated with aggressive clinical features of several human cancers,MCM8,cancers,84515,D009369
28481876,The gain of MCM8 is associated with aggressive clinical features of several human cancers,MCM8,MCM,84515,84515
28481876,The gain of MCM8 is associated with aggressive clinical features of several human cancers,cancers,MCM8,D009369,84515
28481876,The gain of MCM8 is associated with aggressive clinical features of several human cancers,cancers,MCM,D009369,84515
28481876,The gain of MCM8 is associated with aggressive clinical features of several human cancers,MCM,cancer,84515,D009369
28481876,The gain of MCM8 is associated with aggressive clinical features of several human cancers,MCM,MCM8,84515,84515
28481876,The gain of MCM8 is associated with aggressive clinical features of several human cancers,MCM,cancers,84515,D009369
28481876,Increased expression of MCM8 in prostate cancer is associated with cancer recurrence,cancer,MCM8,D009369,84515
28481876,Increased expression of MCM8 in prostate cancer is associated with cancer recurrence,cancer,MCM,D009369,84515
28481876,Increased expression of MCM8 in prostate cancer is associated with cancer recurrence,MCM8,cancer,84515,D009369
28481876,Increased expression of MCM8 in prostate cancer is associated with cancer recurrence,MCM8,prostate cancer,84515,D011471
28481876,Increased expression of MCM8 in prostate cancer is associated with cancer recurrence,MCM8,MCM,84515,84515
28481876,Increased expression of MCM8 in prostate cancer is associated with cancer recurrence,prostate cancer,MCM8,D011471,84515
28481876,Increased expression of MCM8 in prostate cancer is associated with cancer recurrence,prostate cancer,MCM,D011471,84515
28481876,Increased expression of MCM8 in prostate cancer is associated with cancer recurrence,MCM,cancer,84515,D009369
28481876,Increased expression of MCM8 in prostate cancer is associated with cancer recurrence,MCM,MCM8,84515,84515
28481876,Increased expression of MCM8 in prostate cancer is associated with cancer recurrence,MCM,prostate cancer,84515,D011471
28481876,"Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells",MCM8,tumour,84515,D009369
28481876,"Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells",MCM8,immunodeficiency,84515,D007153
28481876,"Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells",MCM8,MCM,84515,84515
28481876,"Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells",tumour,MCM8,D009369,84515
28481876,"Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells",tumour,MCM,D009369,84515
28481876,"Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells",immunodeficiency,MCM8,D007153,84515
28481876,"Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells",immunodeficiency,MCM,D007153,84515
28481876,"Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells",MCM,MCM8,84515,84515
28481876,"Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells",MCM,tumour,84515,D009369
28481876,"Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells",MCM,immunodeficiency,84515,D007153
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,cyclin D1,MCM8,595,84515
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,cyclin D1,cyclin-dependent kinase 4,595,1019
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,cyclin D1,Rb,595,5925
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,cyclin D1,MCM,595,84515
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,MCM8,cyclin D1,84515,595
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,MCM8,cyclin-dependent kinase 4,84515,1019
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,MCM8,Rb,84515,5925
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,MCM8,MCM,84515,84515
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,cyclin-dependent kinase 4,cyclin D1,1019,595
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,cyclin-dependent kinase 4,MCM8,1019,84515
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,cyclin-dependent kinase 4,Rb,1019,5925
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,cyclin-dependent kinase 4,MCM,1019,84515
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,Rb,cyclin D1,5925,595
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,Rb,MCM8,5925,84515
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,Rb,cyclin-dependent kinase 4,5925,1019
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,Rb,MCM,5925,84515
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,MCM,cyclin D1,84515,595
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,MCM,MCM8,84515,84515
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,MCM,cyclin-dependent kinase 4,84515,1019
28481876,MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo,MCM,Rb,84515,5925
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,cancer,cyclin D1,D009369,595
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,cancer,MCM8,D009369,84515
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,cancer,Rb,D009369,5925
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,cancer,MCM,D009369,84515
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,cyclin D1,cancer,595,D009369
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,cyclin D1,MCM8,595,84515
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,cyclin D1,Rb,595,5925
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,cyclin D1,MCM,595,84515
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,MCM8,cancer,84515,D009369
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,MCM8,cyclin D1,84515,595
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,MCM8,Rb,84515,5925
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,MCM8,MCM,84515,84515
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,Rb,cancer,5925,D009369
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,Rb,cyclin D1,5925,595
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,Rb,MCM8,5925,84515
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,Rb,MCM,5925,84515
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,MCM,cancer,84515,D009369
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,MCM,cyclin D1,84515,595
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,MCM,MCM8,84515,84515
28481876,The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells,MCM,Rb,84515,5925
28481876,"As a result, our study showed that copy number increase and overexpression of MCM8 may play critical roles in human cancer development.",cancer,MCM8,D009369,84515
28481876,"As a result, our study showed that copy number increase and overexpression of MCM8 may play critical roles in human cancer development.",cancer,MCM,D009369,84515
28481876,"As a result, our study showed that copy number increase and overexpression of MCM8 may play critical roles in human cancer development.",MCM8,cancer,84515,D009369
28481876,"As a result, our study showed that copy number increase and overexpression of MCM8 may play critical roles in human cancer development.",MCM8,MCM,84515,84515
28481876,"As a result, our study showed that copy number increase and overexpression of MCM8 may play critical roles in human cancer development.",MCM,cancer,84515,D009369
28481876,"As a result, our study showed that copy number increase and overexpression of MCM8 may play critical roles in human cancer development.",MCM,MCM8,84515,84515
28687665,Mutation of the a-tubulin Tuba1a leads to straighter microtubules and perturbs neuronal migration,a-tubulin,Tuba1a,22142,22142
28687665,Mutation of the a-tubulin Tuba1a leads to straighter microtubules and perturbs neuronal migration,Tuba1a,a-tubulin,22142,22142
28687665,Mutation of the a-tubulin isotype TUBA1A is associated with cortical malformations in humans,a-tubulin,cortical malformations,22142,D054220
28687665,Mutation of the a-tubulin isotype TUBA1A is associated with cortical malformations in humans,a-tubulin,TUBA1A,22142,7846
28687665,Mutation of the a-tubulin isotype TUBA1A is associated with cortical malformations in humans,cortical malformations,a-tubulin,D054220,22142
28687665,Mutation of the a-tubulin isotype TUBA1A is associated with cortical malformations in humans,cortical malformations,TUBA1A,D054220,7846
28687665,Mutation of the a-tubulin isotype TUBA1A is associated with cortical malformations in humans,TUBA1A,a-tubulin,7846,22142
28687665,Mutation of the a-tubulin isotype TUBA1A is associated with cortical malformations in humans,TUBA1A,cortical malformations,7846,D054220
28687665,"In mice carrying a Tuba1a missense mutation (S140G), neurons accumulate, and glial cells are dispersed along the rostral migratory stream in postnatal and adult brains",Tuba1a,S140G,22142,p|SUB|S|140|G
28687665,"In mice carrying a Tuba1a missense mutation (S140G), neurons accumulate, and glial cells are dispersed along the rostral migratory stream in postnatal and adult brains",S140G,Tuba1a,p|SUB|S|140|G,22142
28687665,"Tuba1a mutation led to increased straightness of newly polymerized MTs, and structural modeling data suggest a conformational change in the a/b-tubulin heterodimer",Tuba1a,a/b-tubulin,22142,"22142,22152,53857"
28687665,"Tuba1a mutation led to increased straightness of newly polymerized MTs, and structural modeling data suggest a conformational change in the a/b-tubulin heterodimer",a/b-tubulin,Tuba1a,"22142,22152,53857",22142
28687665,"We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a",Tuba8,a-tubulin,53857,22142
28687665,"We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a",Tuba8,cortical malformations,53857,D054220
28687665,"We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a",Tuba8,Tuba1a,53857,22142
28687665,"We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a",a-tubulin,Tuba8,22142,53857
28687665,"We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a",a-tubulin,cortical malformations,22142,D054220
28687665,"We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a",a-tubulin,Tuba1a,22142,22142
28687665,"We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a",cortical malformations,Tuba8,D054220,53857
28687665,"We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a",cortical malformations,a-tubulin,D054220,22142
28687665,"We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a",cortical malformations,Tuba1a,D054220,22142
28687665,"We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a",Tuba1a,Tuba8,22142,53857
28687665,"We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a",Tuba1a,a-tubulin,22142,22142
28687665,"We show that Tuba8, another a-tubulin isotype previously associated with cortical malformations, has altered function compared with Tuba1a",Tuba1a,cortical malformations,22142,D054220
29045486,Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes,Thiamine,hypoxia inducible factor-1a,D013831,15251
29045486,Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes,Thiamine,hypoxia,D013831,D000860
29045486,Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes,Thiamine,Thiamine deficiency,D013831,D013832
29045486,Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes,hypoxia inducible factor-1a,Thiamine,15251,D013831
29045486,Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes,hypoxia inducible factor-1a,hypoxia,15251,D000860
29045486,Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes,hypoxia inducible factor-1a,Thiamine deficiency,15251,D013832
29045486,Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes,hypoxia,Thiamine,D000860,D013831
29045486,Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes,hypoxia,hypoxia inducible factor-1a,D000860,15251
29045486,Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes,Thiamine deficiency,Thiamine,D013832,D013831
29045486,Thiamine deficiency activates hypoxia inducible factor-1a to facilitate pro-apoptotic responses in mouse primary astrocytes,Thiamine deficiency,hypoxia inducible factor-1a,D013832,15251
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",inflammation,thiamine,D007249,D013831
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",inflammation,alcohol,D007249,D000438
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",TD,thiamine,D013832,D013831
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",TD,alcohol,D013832,D000438
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",thiamine deficiency,thiamine,D013832,D013831
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",thiamine deficiency,alcohol,D013832,D000438
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",impaired mitochondrial function,thiamine,D028361,D013831
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",impaired mitochondrial function,alcohol,D028361,D000438
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",thiamine,inflammation,D013831,D007249
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",thiamine,TD,D013831,D013832
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",thiamine,thiamine deficiency,D013831,D013832
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",thiamine,impaired mitochondrial function,D013831,D028361
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",thiamine,excitotoxicity,D013831,D064420
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",thiamine,alcohol,D013831,D000438
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",excitotoxicity,thiamine,D064420,D013831
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",excitotoxicity,alcohol,D064420,D000438
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",alcohol,inflammation,D000438,D007249
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",alcohol,TD,D000438,D013832
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",alcohol,thiamine deficiency,D000438,D013832
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",alcohol,impaired mitochondrial function,D000438,D028361
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",alcohol,thiamine,D000438,D013831
29045486,"In developed countries, thiamine deficiency (TD) is most often manifested following chronic alcohol consumption leading to impaired mitochondrial function, oxidative stress, inflammation and excitotoxicity",alcohol,excitotoxicity,D000438,D064420
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",oxygen,TD,D010100,D013832
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",oxygen,HIF-1a,D010100,15251
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",oxygen,Hypoxia Inducible Factor-1a,D010100,15251
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",oxygen,hypoxia,D010100,D000860
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",oxygen,ischemia,D010100,D007511
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",TD,oxygen,D013832,D010100
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",TD,HIF-1a,D013832,15251
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",TD,Hypoxia Inducible Factor-1a,D013832,15251
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",HIF-1a,oxygen,15251,D010100
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",HIF-1a,TD,15251,D013832
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",HIF-1a,Hypoxia Inducible Factor-1a,15251,15251
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",HIF-1a,hypoxia,15251,D000860
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",HIF-1a,ischemia,15251,D007511
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",Hypoxia Inducible Factor-1a,oxygen,15251,D010100
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",Hypoxia Inducible Factor-1a,TD,15251,D013832
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",Hypoxia Inducible Factor-1a,HIF-1a,15251,15251
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",Hypoxia Inducible Factor-1a,hypoxia,15251,D000860
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",Hypoxia Inducible Factor-1a,ischemia,15251,D007511
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",hypoxia,oxygen,D000860,D010100
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",hypoxia,HIF-1a,D000860,15251
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",hypoxia,Hypoxia Inducible Factor-1a,D000860,15251
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",ischemia,oxygen,D007511,D010100
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",ischemia,HIF-1a,D007511,15251
29045486,"Consistent with hypoxia/ischemia, TD stabilizes and activates Hypoxia Inducible Factor-1a (HIF-1a) under physiological oxygen levels",ischemia,Hypoxia Inducible Factor-1a,D007511,15251
29045486,"However, the role of TD-induced HIF-1a in neurological injury is currently unknown",TD,HIF-1a,D013832,15251
29045486,"However, the role of TD-induced HIF-1a in neurological injury is currently unknown",HIF-1a,TD,15251,D013832
29045486,"However, the role of TD-induced HIF-1a in neurological injury is currently unknown",HIF-1a,neurological injury,15251,D009422
29045486,"However, the role of TD-induced HIF-1a in neurological injury is currently unknown",neurological injury,HIF-1a,D009422,15251
29045486,"Using Western blot analysis and RT-PCR, we have demonstrated that TD induces HIF-1a expression and activity in primary mouse astrocytes",TD,HIF-1a,D013832,15251
29045486,"Using Western blot analysis and RT-PCR, we have demonstrated that TD induces HIF-1a expression and activity in primary mouse astrocytes",HIF-1a,TD,15251,D013832
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",BNIP3,TD,12176,D013832
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",BNIP3,HIF-1a,12176,15251
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",BNIP3,inflammatory,12176,D007249
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",BNIP3,Noxa,12176,58801
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",BNIP3,MCP1,12176,20296
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",BNIP3,Nix,12176,12177
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",TD,BNIP3,D013832,12176
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",TD,HIF-1a,D013832,15251
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",TD,Noxa,D013832,58801
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",TD,MCP1,D013832,20296
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",TD,Nix,D013832,12177
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",HIF-1a,BNIP3,15251,12176
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",HIF-1a,TD,15251,D013832
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",HIF-1a,inflammatory,15251,D007249
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",HIF-1a,Noxa,15251,58801
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",HIF-1a,MCP1,15251,20296
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",HIF-1a,Nix,15251,12177
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",inflammatory,BNIP3,D007249,12176
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",inflammatory,HIF-1a,D007249,15251
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",inflammatory,Noxa,D007249,58801
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",inflammatory,MCP1,D007249,20296
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",inflammatory,Nix,D007249,12177
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",Noxa,BNIP3,58801,12176
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",Noxa,TD,58801,D013832
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",Noxa,HIF-1a,58801,15251
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",Noxa,inflammatory,58801,D007249
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",Noxa,MCP1,58801,20296
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",Noxa,Nix,58801,12177
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",MCP1,BNIP3,20296,12176
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",MCP1,TD,20296,D013832
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",MCP1,HIF-1a,20296,15251
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",MCP1,inflammatory,20296,D007249
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",MCP1,Noxa,20296,58801
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",MCP1,Nix,20296,12177
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",Nix,BNIP3,12177,12176
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",Nix,TD,12177,D013832
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",Nix,HIF-1a,12177,15251
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",Nix,inflammatory,12177,D007249
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",Nix,Noxa,12177,58801
29045486,"We observed a time-dependent increase in mRNA and protein expression of the pro-apoptotic and pro-inflammatory HIF-1a target genes MCP1, BNIP3, Nix and Noxa during TD",Nix,MCP1,12177,20296
29045486,"We also observed apoptotic cell death in TD as demonstrated by PI/Annexin V staining, TUNEL assay, and Cell Death ELISA",TD,Annexin V,D013832,11747
29045486,"We also observed apoptotic cell death in TD as demonstrated by PI/Annexin V staining, TUNEL assay, and Cell Death ELISA",Annexin V,TD,11747,D013832
29045486,Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD,YC1,thiamine,56878,D013831
29045486,Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD,YC1,TD,56878,D013832
29045486,Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD,YC1,HIF-1a,56878,15251
29045486,Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD,thiamine,YC1,D013831,56878
29045486,Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD,thiamine,TD,D013831,D013832
29045486,Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD,thiamine,HIF-1a,D013831,15251
29045486,Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD,TD,YC1,D013832,56878
29045486,Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD,TD,thiamine,D013832,D013831
29045486,Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD,TD,HIF-1a,D013832,15251
29045486,Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD,HIF-1a,YC1,15251,56878
29045486,Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD,HIF-1a,thiamine,15251,D013831
29045486,Pharmacological inhibition of HIF-1a activity using YC1 and thiamine repletion both reduced expression of pro-apoptotic HIF-1a target genes and apoptotic cell death in TD,HIF-1a,TD,15251,D013832
29045486,These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.,thiamine deficiency,thiamine,D013832,D013831
29045486,These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.,thiamine deficiency,HIF-1a,D013832,15251
29045486,These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.,thiamine,thiamine deficiency,D013831,D013832
29045486,These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.,thiamine,inflammatory,D013831,D007249
29045486,These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.,thiamine,HIF-1a,D013831,15251
29045486,These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.,inflammatory,thiamine,D007249,D013831
29045486,These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.,inflammatory,HIF-1a,D007249,15251
29045486,These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.,HIF-1a,thiamine deficiency,15251,D013832
29045486,These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.,HIF-1a,thiamine,15251,D013831
29045486,These results demonstrate that induction of HIF-1a mediated transcriptional up-regulation of pro-apoptotic/inflammatory signaling contributes to astrocyte cell death during thiamine deficiency.,HIF-1a,inflammatory,15251,D007249
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,AKT,astrogliosis,11651,D005911
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,AKT,mTOR,11651,"2475,56717"
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,AKT,Ca2+,11651,D000069285
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,AKT,KCa3.1,11651,"16534,3783"
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,astrogliosis,AKT,D005911,11651
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,astrogliosis,mTOR,D005911,"2475,56717"
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,astrogliosis,Ca2+,D005911,D000069285
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,astrogliosis,KCa3.1,D005911,"16534,3783"
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,mTOR,AKT,"2475,56717",11651
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,mTOR,astrogliosis,"2475,56717",D005911
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,mTOR,Ca2+,"2475,56717",D000069285
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,mTOR,KCa3.1,"2475,56717","16534,3783"
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,Ca2+,AKT,D000069285,11651
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,Ca2+,astrogliosis,D000069285,D005911
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,Ca2+,mTOR,D000069285,"2475,56717"
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,Ca2+,KCa3.1,D000069285,"16534,3783"
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,KCa3.1,AKT,"16534,3783",11651
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,KCa3.1,astrogliosis,"16534,3783",D005911
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,KCa3.1,mTOR,"16534,3783","2475,56717"
30442153,Ca2+-dependent endoplasmic reticulum stress correlation with astrogliosis involves upregulation of KCa3.1 and inhibition of AKT/mTOR signaling,KCa3.1,Ca2+,"16534,3783",D000069285
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),Alzheimer's disease,intermediate-conductance Ca2+-activated K+ channel,D000544,"16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),Alzheimer's disease,Ca2+,D000544,D000069285
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),Alzheimer's disease,KCa3.1,D000544,"16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),RA,intermediate-conductance Ca2+-activated K+ channel,D005911,"16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),RA,Ca2+,D005911,D000069285
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),RA,KCa3.1,D005911,"16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),reactive astrogliosis,intermediate-conductance Ca2+-activated K+ channel,D005911,"16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),reactive astrogliosis,Ca2+,D005911,D000069285
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),reactive astrogliosis,KCa3.1,D005911,"16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),astrogliosis,intermediate-conductance Ca2+-activated K+ channel,D005911,"16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),astrogliosis,Ca2+,D005911,D000069285
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),astrogliosis,KCa3.1,D005911,"16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),intermediate-conductance Ca2+-activated K+ channel,Alzheimer's disease,"16534,3783",D000544
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),intermediate-conductance Ca2+-activated K+ channel,RA,"16534,3783",D005911
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),intermediate-conductance Ca2+-activated K+ channel,reactive astrogliosis,"16534,3783",D005911
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),intermediate-conductance Ca2+-activated K+ channel,astrogliosis,"16534,3783",D005911
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),intermediate-conductance Ca2+-activated K+ channel,Ca2+,"16534,3783",D000069285
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),intermediate-conductance Ca2+-activated K+ channel,KCa3.1,"16534,3783","16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),intermediate-conductance Ca2+-activated K+ channel,AD,"16534,3783",D000544
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),Ca2+,Alzheimer's disease,D000069285,D000544
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),Ca2+,RA,D000069285,D005911
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),Ca2+,reactive astrogliosis,D000069285,D005911
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),Ca2+,astrogliosis,D000069285,D005911
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),Ca2+,intermediate-conductance Ca2+-activated K+ channel,D000069285,"16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),Ca2+,KCa3.1,D000069285,"16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),Ca2+,AD,D000069285,D000544
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),KCa3.1,Alzheimer's disease,"16534,3783",D000544
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),KCa3.1,RA,"16534,3783",D005911
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),KCa3.1,reactive astrogliosis,"16534,3783",D005911
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),KCa3.1,astrogliosis,"16534,3783",D005911
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),KCa3.1,intermediate-conductance Ca2+-activated K+ channel,"16534,3783","16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),KCa3.1,Ca2+,"16534,3783",D000069285
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),KCa3.1,AD,"16534,3783",D000544
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),AD,intermediate-conductance Ca2+-activated K+ channel,D000544,"16534,3783"
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),AD,Ca2+,D000544,D000069285
30442153,BACKGROUND: The intermediate-conductance Ca2+-activated K+ channel KCa3.1 was recently shown to control the phenotype switch of reactive astrogliosis (RA) in Alzheimer's disease (AD),AD,KCa3.1,D000544,"16534,3783"
30442153,METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining,APP,PS1,"11820,351",5663
30442153,METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining,APP,KCa3.1,"11820,351","16534,3783"
30442153,METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining,APP,AD,"11820,351",D000544
30442153,METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining,PS1,APP,5663,"11820,351"
30442153,METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining,PS1,KCa3.1,5663,"16534,3783"
30442153,METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining,PS1,AD,5663,D000544
30442153,METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining,KCa3.1,APP,"16534,3783","11820,351"
30442153,METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining,KCa3.1,PS1,"16534,3783",5663
30442153,METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining,KCa3.1,AD,"16534,3783",D000544
30442153,METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining,AD,APP,D000544,"11820,351"
30442153,METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining,AD,PS1,D000544,5663
30442153,METHODS: KCa3.1 channels expression and cell localization in the brains of AD patients and APP/PS1 mice model were measured by immunoblotting and immunostaining,AD,KCa3.1,D000544,"16534,3783"
30442153,APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits,APP,memory deficits,"11820,351",D008569
30442153,APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits,APP,PS1,"11820,351",5663
30442153,APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits,APP,KCa3.1,"11820,351","16534,3783"
30442153,APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits,memory deficits,APP,D008569,"11820,351"
30442153,APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits,memory deficits,PS1,D008569,5663
30442153,APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits,memory deficits,KCa3.1,D008569,"16534,3783"
30442153,APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits,PS1,APP,5663,"11820,351"
30442153,APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits,PS1,memory deficits,5663,D008569
30442153,APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits,PS1,KCa3.1,5663,"16534,3783"
30442153,APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits,KCa3.1,APP,"16534,3783","11820,351"
30442153,APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits,KCa3.1,memory deficits,"16534,3783",D008569
30442153,APP/PS1 mice and KCa3.1-/-/APP/PS1 mice were subjected to Morris water maze test to evaluate the spatial memory deficits,KCa3.1,PS1,"16534,3783",5663
30442153,Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro,Fluo-4AM,beta-amyloid,C409648,351
30442153,Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro,Fluo-4AM,Ca2+,C409648,D000069285
30442153,Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro,Fluo-4AM,Abeta,C409648,"11820,351"
30442153,Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro,beta-amyloid,Fluo-4AM,351,C409648
30442153,Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro,beta-amyloid,Ca2+,351,D000069285
30442153,Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro,beta-amyloid,Abeta,351,"11820,351"
30442153,Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro,Ca2+,Fluo-4AM,D000069285,C409648
30442153,Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro,Ca2+,beta-amyloid,D000069285,351
30442153,Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro,Ca2+,Abeta,D000069285,"11820,351"
30442153,Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro,Abeta,Fluo-4AM,"11820,351",C409648
30442153,Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro,Abeta,beta-amyloid,"11820,351",351
30442153,Fluo-4AM was used to measure cytosolic Ca2+ level in beta-amyloid (Abeta) induced reactive astrocytes in vitro,Abeta,Ca2+,"11820,351",D000069285
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,APP,Abeta,"11820,351","11820,351"
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,APP,PS1,"11820,351",5663
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,APP,KCa3.1,"11820,351","16534,3783"
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,APP,AD,"11820,351",D000544
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,Abeta,APP,"11820,351","11820,351"
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,Abeta,PS1,"11820,351",5663
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,Abeta,KCa3.1,"11820,351","16534,3783"
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,Abeta,AD,"11820,351",D000544
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,PS1,APP,5663,"11820,351"
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,PS1,Abeta,5663,"11820,351"
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,PS1,KCa3.1,5663,"16534,3783"
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,PS1,AD,5663,D000544
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,KCa3.1,APP,"16534,3783","11820,351"
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,KCa3.1,Abeta,"16534,3783","11820,351"
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,KCa3.1,PS1,"16534,3783",5663
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,KCa3.1,AD,"16534,3783",D000544
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,AD,APP,D000544,"11820,351"
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,AD,Abeta,D000544,"11820,351"
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,AD,PS1,D000544,5663
30442153,RESULTS: KCa3.1 expression was markedly associated with endoplasmic reticulum (ER) stress and unfolded protein response (UPR) in both Abeta-stimulated primary astrocytes and brain lysates of AD patients and APP/PS1 AD mice,AD,KCa3.1,D000544,"16534,3783"
30442153,The KCa3.1 channel was shown to regulate store-operated Ca2+ entry (SOCE) through an interaction with the Ca2+ channel Orai1 in primary astrocytes,KCa3.1,Orai1,"16534,3783",109305
30442153,The KCa3.1 channel was shown to regulate store-operated Ca2+ entry (SOCE) through an interaction with the Ca2+ channel Orai1 in primary astrocytes,KCa3.1,Ca2+,"16534,3783",D000069285
30442153,The KCa3.1 channel was shown to regulate store-operated Ca2+ entry (SOCE) through an interaction with the Ca2+ channel Orai1 in primary astrocytes,Orai1,KCa3.1,109305,"16534,3783"
30442153,The KCa3.1 channel was shown to regulate store-operated Ca2+ entry (SOCE) through an interaction with the Ca2+ channel Orai1 in primary astrocytes,Orai1,Ca2+,109305,D000069285
30442153,The KCa3.1 channel was shown to regulate store-operated Ca2+ entry (SOCE) through an interaction with the Ca2+ channel Orai1 in primary astrocytes,Ca2+,KCa3.1,D000069285,"16534,3783"
30442153,The KCa3.1 channel was shown to regulate store-operated Ca2+ entry (SOCE) through an interaction with the Ca2+ channel Orai1 in primary astrocytes,Ca2+,Orai1,D000069285,109305
30442153,Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes,protein kinase B,KCa3.1,11651,"16534,3783"
30442153,Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes,protein kinase B,AKT,11651,11651
30442153,Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes,protein kinase B,Ca2+,11651,D000069285
30442153,Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes,KCa3.1,protein kinase B,"16534,3783",11651
30442153,Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes,KCa3.1,AKT,"16534,3783",11651
30442153,Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes,KCa3.1,Ca2+,"16534,3783",D000069285
30442153,Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes,AKT,protein kinase B,11651,11651
30442153,Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes,AKT,KCa3.1,11651,"16534,3783"
30442153,Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes,AKT,Ca2+,11651,D000069285
30442153,Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes,Ca2+,protein kinase B,D000069285,11651
30442153,Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes,Ca2+,KCa3.1,D000069285,"16534,3783"
30442153,Gene deletion or pharmacological blockade of KCa3.1 protected against SOCE-induced Ca2+ overload and ER stress via the protein kinase B (AKT) signaling pathway in astrocytes,Ca2+,AKT,D000069285,11651
30442153,"Importantly, gene deletion or blockade of KCa3.1 restored AKT/mechanistic target of rapamycin signaling both in vivo and in vitro",KCa3.1,AKT,"16534,3783",11651
30442153,"Importantly, gene deletion or blockade of KCa3.1 restored AKT/mechanistic target of rapamycin signaling both in vivo and in vitro",KCa3.1,mechanistic target of rapamycin,"16534,3783",56717
30442153,"Importantly, gene deletion or blockade of KCa3.1 restored AKT/mechanistic target of rapamycin signaling both in vivo and in vitro",AKT,KCa3.1,11651,"16534,3783"
30442153,"Importantly, gene deletion or blockade of KCa3.1 restored AKT/mechanistic target of rapamycin signaling both in vivo and in vitro",AKT,mechanistic target of rapamycin,11651,56717
30442153,"Importantly, gene deletion or blockade of KCa3.1 restored AKT/mechanistic target of rapamycin signaling both in vivo and in vitro",mechanistic target of rapamycin,KCa3.1,56717,"16534,3783"
30442153,"Importantly, gene deletion or blockade of KCa3.1 restored AKT/mechanistic target of rapamycin signaling both in vivo and in vitro",mechanistic target of rapamycin,AKT,56717,11651
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",APP,78-kDa glucose-regulated protein,"11820,351",14828
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",APP,CCAAT/enhancer-binding protein homologous protein,"11820,351",13198
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",APP,RA,"11820,351",D005911
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",APP,glial fibrillary acidic protein,"11820,351",14580
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",APP,PS1,"11820,351",5663
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",APP,AD,"11820,351",D000544
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",78-kDa glucose-regulated protein,APP,14828,"11820,351"
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",78-kDa glucose-regulated protein,CCAAT/enhancer-binding protein homologous protein,14828,13198
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",78-kDa glucose-regulated protein,RA,14828,D005911
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",78-kDa glucose-regulated protein,glial fibrillary acidic protein,14828,14580
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",78-kDa glucose-regulated protein,PS1,14828,5663
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",78-kDa glucose-regulated protein,AD,14828,D000544
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",CCAAT/enhancer-binding protein homologous protein,APP,13198,"11820,351"
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",CCAAT/enhancer-binding protein homologous protein,78-kDa glucose-regulated protein,13198,14828
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",CCAAT/enhancer-binding protein homologous protein,RA,13198,D005911
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",CCAAT/enhancer-binding protein homologous protein,glial fibrillary acidic protein,13198,14580
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",CCAAT/enhancer-binding protein homologous protein,PS1,13198,5663
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",CCAAT/enhancer-binding protein homologous protein,AD,13198,D000544
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",RA,APP,D005911,"11820,351"
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",RA,78-kDa glucose-regulated protein,D005911,14828
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",RA,CCAAT/enhancer-binding protein homologous protein,D005911,13198
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",RA,glial fibrillary acidic protein,D005911,14580
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",RA,PS1,D005911,5663
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",glial fibrillary acidic protein,APP,14580,"11820,351"
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",glial fibrillary acidic protein,78-kDa glucose-regulated protein,14580,14828
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",glial fibrillary acidic protein,CCAAT/enhancer-binding protein homologous protein,14580,13198
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",glial fibrillary acidic protein,RA,14580,D005911
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",glial fibrillary acidic protein,PS1,14580,5663
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",glial fibrillary acidic protein,AD,14580,D000544
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",PS1,APP,5663,"11820,351"
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",PS1,78-kDa glucose-regulated protein,5663,14828
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",PS1,CCAAT/enhancer-binding protein homologous protein,5663,13198
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",PS1,RA,5663,D005911
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",PS1,glial fibrillary acidic protein,5663,14580
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",PS1,AD,5663,D000544
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",AD,APP,D000544,"11820,351"
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",AD,78-kDa glucose-regulated protein,D000544,14828
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",AD,CCAAT/enhancer-binding protein homologous protein,D000544,13198
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",AD,glial fibrillary acidic protein,D000544,14580
30442153,"Consistent with these in vitro data, expression levels of the ER stress markers 78-kDa glucose-regulated protein and CCAAT/enhancer-binding protein homologous protein, as well as that of the RA marker glial fibrillary acidic protein were increased in APP/PS1 AD mouse model",AD,PS1,D000544,5663
30442153,Elimination of KCa3.1 in KCa3.1-/-/APP/PS1 mice corrected these abnormal responses,KCa3.1,APP,"16534,3783","11820,351"
30442153,Elimination of KCa3.1 in KCa3.1-/-/APP/PS1 mice corrected these abnormal responses,KCa3.1,PS1,"16534,3783",5663
30442153,Elimination of KCa3.1 in KCa3.1-/-/APP/PS1 mice corrected these abnormal responses,APP,KCa3.1,"11820,351","16534,3783"
30442153,Elimination of KCa3.1 in KCa3.1-/-/APP/PS1 mice corrected these abnormal responses,APP,PS1,"11820,351",5663
30442153,Elimination of KCa3.1 in KCa3.1-/-/APP/PS1 mice corrected these abnormal responses,PS1,KCa3.1,5663,"16534,3783"
30442153,Elimination of KCa3.1 in KCa3.1-/-/APP/PS1 mice corrected these abnormal responses,PS1,APP,5663,"11820,351"
30442153,"Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice",APP,PS1,"11820,351",5663
30442153,"Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice",APP,KCa3.1,"11820,351","16534,3783"
30442153,"Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice",APP,neuroinflammation,"11820,351",D007249
30442153,"Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice",PS1,APP,5663,"11820,351"
30442153,"Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice",PS1,KCa3.1,5663,"16534,3783"
30442153,"Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice",PS1,neuroinflammation,5663,D007249
30442153,"Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice",KCa3.1,APP,"16534,3783","11820,351"
30442153,"Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice",KCa3.1,PS1,"16534,3783",5663
30442153,"Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice",KCa3.1,neuroinflammation,"16534,3783",D007249
30442153,"Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice",neuroinflammation,APP,D007249,"11820,351"
30442153,"Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice",neuroinflammation,PS1,D007249,5663
30442153,"Moreover, glial activation and neuroinflammation were attenuated in the hippocampi of KCa3.1-/-/APP/PS1 mice, as compared with APP/PS1 mice",neuroinflammation,KCa3.1,D007249,"16534,3783"
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",APP,memory deficits,"11820,351",D008569
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",APP,neuronal loss,"11820,351",D009422
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",APP,PS1,"11820,351",5663
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",APP,KCa3.1,"11820,351","16534,3783"
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",memory deficits,APP,D008569,"11820,351"
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",memory deficits,PS1,D008569,5663
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",memory deficits,KCa3.1,D008569,"16534,3783"
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",neuronal loss,APP,D009422,"11820,351"
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",neuronal loss,PS1,D009422,5663
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",neuronal loss,KCa3.1,D009422,"16534,3783"
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",PS1,APP,5663,"11820,351"
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",PS1,memory deficits,5663,D008569
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",PS1,neuronal loss,5663,D009422
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",PS1,KCa3.1,5663,"16534,3783"
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",KCa3.1,APP,"16534,3783","11820,351"
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",KCa3.1,memory deficits,"16534,3783",D008569
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",KCa3.1,neuronal loss,"16534,3783",D009422
30442153,"In addition, memory deficits and neuronal loss in APP/PS1 mice were reversed in KCa3.1-/-/APP/PS1 mice",KCa3.1,PS1,"16534,3783",5663
30442153,"CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.",memory deficits,KCa3.1,D008569,"16534,3783"
30442153,"CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.",memory deficits,Ca2+,D008569,D000069285
30442153,"CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.",KCa3.1,memory deficits,"16534,3783",D008569
30442153,"CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.",KCa3.1,Ca2+,"16534,3783",D000069285
30442153,"CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.",KCa3.1,neuronal loss,"16534,3783",D009422
30442153,"CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.",Ca2+,memory deficits,D000069285,D008569
30442153,"CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.",Ca2+,KCa3.1,D000069285,"16534,3783"
30442153,"CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.",Ca2+,neuronal loss,D000069285,D009422
30442153,"CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.",neuronal loss,KCa3.1,D009422,"16534,3783"
30442153,"CONCLUSIONS: Overall, these results suggest that KCa3.1 is involved in the regulation of Ca2+ homeostasis in astrocytes and attenuation of the UPR and ER stress, thus contributing to memory deficits and neuronal loss.",neuronal loss,Ca2+,D009422,D000069285
